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This study forms part of an investigation into the possible relevance of the 
lysosomal proteinases, cathepsins B, H, Land D, in cancer cell invasion. In this 
study, the main technique adopted was the Tokuyasu "cryo" method, in which the 
tissues were fixed, frozen and sectioned and labelled using the relevant antibodies, 
which were detected with protein A gold probes. 
In order to implement the Tokuyasu technique, it was necessary to rebuild a knife 
maker, for the production of adequately sharp glass knives, and to modify a sputter-
coater into a glow-discharger, for rendering carbon-coated grids hydrophilic, to 
promote adhesion of hydrated sections. 
This study was directed towards human tissues and peptide antibodies were 
investigated as a means of avoiding isolation of proteins from scarce human tissue, 
and as a means of obtaining antibodies that will target specific regions of proteins of 
interest. Peptide antibodies were also considered promising for studies of 
proteinase trafficking and as immunoinhibiting agents, potentially useful in cancer 
therapy. Various prediction programmes were investigated for their effectiveness 
in predicting whether a given peptide sequence will elicit antibodies that will react 
with the native protein. Successful prediction would increase the success rate of 
peptide antibody production and thus lower the cost. 
Leucocytes were studied as a model of an invasive cell, since they are more readily 
available than tumour cells and serve the purpose during the development of 
methods. In the course of these studies, an optimal protocol for the fixation of 
PMNs was developed, involving lateral fixation of cut sections, that should be 
useful for future studies on these cells. Elastase and cathepsins D and G were found 
on the surface of activated PMNs and could thus playa role in the invasive 
properties of these cells. 
Studies on MCF-IOA "normal" breast epithelial cells and their ras-transformed 
Neo-T counterparts revealed that upon transformation, lysosomes shift from a 
perinuclear position, to a more peripheral position. None of the cathepsins studied 
was found on the cell surface of either the normal or ras-transfected cells , 
suggesting that surface distribution of these enzymes may not be a requirement for 
invasiveness. These studies suggest that immunocytochemical investigation of 
cells, in the process of invading through a barrier membrane, might be profitable in 
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1.1 Tumour malignancy and the metastatic process 
The property that distinguishes malignant tumours from benign tumours is 
largely their ability to invade surrounding tissues and to metastasise to secondary sites 
(Nicolson, 1982; Maciewicz, et al., 1989; Blood and Zetter, 1990). Invasion and 
metastasis are closely related phenomena for, in order to metastasise, the tumour cell 
has to invade surrounding tissue, and penetrate into a blood or lymph vessel, 
whereby it will be transported to another site in the body (Woolley, 1984). At the 
distant site, in turn, the cell must escape through the wall of the vessel to form a new 
metastatic focus (Woolley, 1984). 
Tumour cell metastasis, as sketched out above, seems a relatively simple 
phenomenon, but in fact the mechanism of metastasis has many levels of complexity 
(Liotta, et al., 1986; Gorelik et al., 1988). The heterogeneity of tumours and their 
marked differences in characteristics make it difficult to identify a single metastatic 
phenotype and a single pattern of metastatic behaviour. Certain common features of 
the metastatic cascade which appear to correlate with metastatic potential are, 
however, beginning to emerge (Blood and Zetter, 1990; Condeelis et al., 1992; Lester 
and McCarthy, 1992; Nabi et al., 1992; Turley, 1992). 
Most malignant tumours metastasise via the bloodsteam (Blood and Zetter, 
1990). Upon reaching a critical size, at which passive diffusion of nutrients and waste 
products can no longer occur, metastatic tumours are able to recruit nevy blood vessels, 
to sustain tumour growth, by secreting one of many so-called tumour angiogenic 
factors (Folkman et al., 1981). Tumour cells also lose their cohesive properties 
(Nicolson et al., 1988; Blood and Zetter, 1990) and easily escape into the fragile, highly 
permeable new blood vessels, which infiltrate into the tumour mass in response to 
angiogeniC factors (Nagy et al., 1989; Turley, 1992). 
Once the tumour cells have entered the bloodstream, if they are to establish a 
secondary tumour, they have to evade the tumoricidal cells of the immune system, 
during transit to the secondary site. Metastatic cells accomplish this by mechanisms 
such as alteration in their expression of the class I MHC, a subject reviewed by Gorelik 
et al. (1988). 
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The adherence to and invasion through cultured endothelial monolayers has 
been shown to be enhanced in highly metastatic tumour cells (Kramer and Nicolson, 
1979). Attachment to the target extravasation site requires adherence to specific sites 
on the luminal surface of the vascular endothelium, or selective attachment to the 
capillary endothelium of a preferred target organ (Nicolson, 1988). After induction of 
endothelial cell retraction (Honn et al., 1989), attachment to the subendothelial 
basement membrane is followed by invasion through the type IV collagen, laminin 
and heparin sulphate of the basement membrane (Tryggvason et al., 1987), a process 
requiring the action of hydrolytic enzymes (Liotta et al., 1986). Directional movement 
throu gh the barrier membrane, and growth into the new organ site follows (Liotta 
et al. , 1986). 
With regard to directional movement, metastatic potential has also been 
linked to tumour motility, the greater the motility, the greater the metastatic potential 
(Nabi et al., 1992). Morphological studies of AH66F and Yoshida sarcoma cells have 
shown that these may exhibit pseudopod extensions and leucocyte-like motility 
(Hosaka et al., 1979). Like leucocytes, many tumour cells, induding those of Walker 
256 carcinosarcoma, human A2058 melanoma, HeLa cervical carcinoma, MCF-7 breast 
carcinoma, HT-1080 lung carcinoma, murine B16 melanoma, UV-2237 fibrosarcoma 
and K-1735 melanoma, as well as Nlli-3T3 fibroblasts, have been reported to have the 
potential for chemotactic activation (Marasco et al., 1985; Liotta et al., 1986; Atnip et al., 
1987; Nabi et al., 1990; Silletti et al., 1991). Chemotactic agents have been found to 
range from host serum and extracellular breakdown products (Lam et al., 1981; 
McCarthy et al., 1985; Nabeshima et al., 1986) to cytokines secreted in an autocrine 
fashion by the tumour itself (Liotta et al., 1986; Atnip et al., 1987). A tumour secreted 
cytokine, denoted autocrine motility factor (AMF), has been found to induce both 
random and directed tumour cell migration (Liotta et al., 1986; Atnip et al., 1987; Nabi 
et al., 1990; Silletti et al., 1991). Although the tumours mentioned above are 
predominantly of epitheloid origin, foetal and tumour-derived fibroblasts exhibit 
similar modes of migratory behaviour and have been found to secrete a migration 
stimulating factor (MSF) (Schor et al., 1988). 
Dissociation from the primary tumour and invasion into the bloodstream has 
been associated especially with the chemotactic action of host serum and extracellular 
breakdown products on various tumour cells (Lam et al., 1981; McCarthy et al., 1985; 
Nabeshima et al., 1986). In this part of the metastatic process, i.e. in the chemotactic 
activity of some tumour cells, their attachment to target extravasation sites, and their 
proteolytic enzyme-assisted passage through the basal lamina, tumour cells have been 
3 
found to parallel the behaviour of normal inflammatory cells such as neutrophils 
(PMNs) and macrophages (Savion et al., 1984; Marasco et al., 1985; Blood and Zetter, 
1990). Further, the receptor for urokinase type plasminogen activator has been found 
to polarise the expression of the protease to the leading edge of migrating monocytes/ 
macrophages and to promote degradation of inhibitor complexes (Estreicher et al., 
1990). Such polarised expression of proteinases towards the "invasion front" may 
occur in PMN s and in invasive malignant cells. 
PMNs and monocytes may, therefore, be studied as a model of invasive 
tumour cells, with the advantage that they are more readily accessible. A further 
reason for studying PMNs in the context of cancer, however, is that there is evidence 
that suggests that PMNs may assist in the arrest and extravasation processes of tumour 
cells (Orr and Warner, 1987). B16 and Lewis lung carcinoma cells, have been found in 
contact with PMNs throughout the arrest and extravasation step (Crissman et al., 
1985), and PMNs from rat peritoneum have been found to increase the attachment of 
rat hepatocarcinoma cells to endothelial monolayers (Orr and Warner, 1987). In a 
similar fashion, it has been suggested that, whereas highly metastatic tumours can 
independently degrade the subendothelial extracellular matrix, less aggressive tumour 
cells may follow the invasion path of PMNs, through vessel walls into the 
parenchymal tissue, or may be assisted by the proteinases secreted by these leucocytes 
(Blood and Zetter, 1990). 
Similarly, extracellular matrix destruction at the tumour periphery, due to 
degradative enzymes produced by the host cells, such as neutrophils and monocytes, 
attracted to the tumour site (Dabbous et al., 1986) and migrating vascular endothelial 
cells of the angiogenic process (Kalebic et al., 1983), may assist the primary tumour 
metastatic event, the escape from the primary tumour, or site of origin. 
The proteinases that are involved in leucocyte invasion and the interaction of 
invasive cells, host tissues and leucocytes, was, therefore, of interest in this study. 
Also of interest was whether, in cancer cells and PMN leucocytes, proteinases may be 
associated with the "invasion front" or become associated generally with the external 
membrane, or be released in a controlled directional fashion. 
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1.2 Proteinases and invasion 
Strong evidence indicating that proteinases contribute to the invasive potential 
of metastatic tumours now exists (Sloane et al., 1981; 1982; 1986; 1987; Ryan et al., 1985; 
Rozhin et al., 1987; Tryggvason et al., 1987; Krepela et al., 1987; Keren and Le Grue, 
1988; Qian et al., 1989; Moin et al., 1989; Zucker et al., 1985; Cardozo et al., 1992; Nazeer 
et al., 1992; Wibe et al., 1992). The studies reported in this thesis are one facet of a 
broader study of the role of proteolytic enzymes in invasive and metastatic cancer, and 
of possible immuno-therapeutic approaches that may be used to prevent metastasis 
and eliminate tumourous tissues. In the broader studies, attention is being directed 
largely, although not exclusively, to the so-called cathepsins and, in the studies 
reported here, attention is focused especially on cathepsin B in tumour cells, and 
cathepsin G and elastase in PMNs. PMNs were used mainly as a model of an invasive 
cell and a discussion of these cells and their proteinases will be deferred until 
Chapter 4. 
In normal, non-leucocytic cells cathepsins are lysosomal proteases, having a 
wide range of proteolytic specificities (Barrett and Kirschke, 1981), and playa role in 
the digestion of endocytosed proteins and in the turnover of intracellular protein. 
Lysosomal enzymes are typically glycoproteins that are synthesised, in high molecular 
weight zymogen form, in the rough endoplasmic reticulum and are trafficked, via the 
Golgi apparatus, to the lysosome. In the Golgi apparatus they acquire a M-6-P "address 
label" which is recognised by the M-6-P receptor, which directs them to the lysosome, 
via the late endosome. En route, they are proteolytically processed, from high-
molecular weight pro-forms, to the smaller, mature form. The cathepsin B precursor 
pro-form is processed to the single-chain mature form in the lysosome (Nishimura 
et al., 1988). In keeping with their natural intracellular lysosomal location, the 
mature, lysosomal cathepsins mostly have pH and stability optima of ca. pH 5.6 (Bond 
and Butler, 1987). 
Metastasis of tumours has been linked with the increased activity of cathepsins 
in malignant tumours, identified using classical biochemical techniques (Maciewicz 
et al., 1989; Krepela et al., 1990; Lah et al., 1992a). It is now apparent, however, that the 
measurement of activity alone, is an inadequate approach for assessing metastatic 
potential (Krepela et al., 1989). Correlation between cathepsin B activity and metastatic 
potential, for example, is often of a qualitative rather than a quantitative nature 
(Sloane et al., 1990) as differences in cathepsin B activity in malignant tumours 
appears to be due to differences in regulation at many levels. 
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Alterations in cathepsin B activity may reflect changes in synthesis (Moin et al., 
1989; Qian et al., 1989), activation and processing (Mort and Recklies, 1986; Qian et al., 
1989) and intracellular trafficking and delivery of the cathepsin ( Recklies et aI., 1982a; 
1982b; Mort and Recklies, 1986; Sloane et aI., 1987), resulting in its secretion (Baici and 
Knopfel, 1986) or association with the surface of the invasive cells (Krepela et aI., 1987; 
Sloane et al., 1990). The apparent increased activity of cathepsins in tumour tissues, 
however, may also be the result of impaired natural cathepsin inhibitors, the cystatins 
or "stefins" (Lah et aI., 1989), or a decreased level of these inhibitors in malignant 
tumours (Corticchiato et al., 1992; Lah et al., 1992a). 
An increased expression of the cathepsin B gene in malignant tumours has 
been linked with both increased cathepsin B activity, and with an apparent alteration 
of the intracellular trafficking and subcellular distribution of cathepsin B (Sloane et aI., 
1990), leading to the enzyme being secreted or becoming membrane-bound. It might 
be imagined that, in order to facilitate invasion, the secreted or membrane bound 
forms of cathepsin B must, necessarily, also be active and stable at physiological pH. 
Mature cathepsins are generally reported to be unstable and inactive at physiological 
pH (Koga et al., 1991; Cardozo et aI., 1992) whereas immature, precursor, forms are 
generally regarded as being more stable, though usually inactive (Recklies et al., 1982b; 
1985; Burnette et al., 1983; Buttle and Abrahamson, 1990). 
It is not strictly true that mature and precursor forms of cathepsin Bare 
inactive at physiological pH. In the presence of large protein substrates such as 
laminin, mature cathepsin B is stabilised at physiological pH, so that significant 
enzyme activity is retained for up to 12 h at pH 7.4 (Sloane, et aI., 1990; Moin et al., 
1992). Large protein substrates might thus stabilise secreted mature cathepsin B, or 
mature enzyme generated in situ from intrinsically more stable precursors. 
Precursors of cathepsin B are known to have a greater stability at physiological pH, but 
were reported to be inactive (Mort et aI., 1980). More recently, however, high 
molecular weight forms of cathepsin B from mouse and human mammary tumours 
(Recklies et al., 1982a; 1982b), have been isolated and found to be both stable and active 
at pH 7.2 (Mort and Recklies, 1986). Studies on human cathepsin B from mammary 
tumours (Mort and Recklies, 1986) and from sputa (ButHe et al., 1988) suggest that one 
way in which a stable, active enzyme may be generated is for the pro-piece to become 
"truncated". The pro-enzyme has been found to be activated by such truncation, but 
remains stable, under conditions where the mature enzyme would be rapidly 
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inactivated (Mort and Recklies, 1986; Buttle et al., 1988). The truncated forms have 
molecular weights intermediate between the pro-form and the mature enzyme. 
Osteoclasts involved in bone re-modelling (Eeckhout, 1990) provide a useful 
model of a mechanism whereby mature lysosomal enzymes may function in 
invasion. In this process, intimate contact between the osteoclast and the target tissue 
is required and proteolytic enzymes may be released into a low pH micro-
environment, produced in a pocket formed by the membrane of a closely adherent 
osteoclast and the bone being re-modelled. Similarly, in tumours, mature enzymes 
may be secreted into a compartment between the adherent tumour cell and the 
membrane through which the invasion is to take place. Such pockets have been 
termed "extracellular lysosomes". Breast cancer cell lines have been shown to degrade 
endothelial basement membrane in this way, invasion requiring intimate contact 
between the cancer cell and the target membrane (Yee and Shiu, 1986). A similar 
system may be operative in the normal functioning of macrophages (Silver et al., 1988; 
Delaisse et al., 1984) and in neutrophils (PMNs), moving out of the vasculature to a 
site of infection (Furie et al., 1987). 
Erroneous trafficking, with concomitant aberrant processing of cathepsin B 
seems to be a consistent finding in malignant cells (Mort et al., 1980; 1983; Krepela 
et al., 1989; Pagano et al., 1989; Buttle and Abrahamson, 1990). Lysosomal enzymes, 
secretory proteins and plasma membrane proteins, are synthesised on the rough 
endoplasmic reticulum (RER). After losing their signal peptide, they undergo co-
translational glycosylation of selected Asn residues and glycolytic trimming of these 
oligo saccharides, in the lumen of the endoplasmic reticulum. They are then 
transported to the Golgi stacks where they undergo a variety of post-translational 
modifications, most of which occur at a decreased pH. Oligosaccharides on secretory 
and membrane glycoproteins are processed to sialic aCid-containing complex-type 
units, while most lysosomal enzymes acquire the critical addition of the M-6-P 
recognition Signal, required for trafficking to the lysosome via the Mr 215 000 receptor. 
Lysosomal enzymes, synthesised as pre-pro-zymogen precursors, have the pre- (signal) 
sequence cleaved in the RER, while pro-sequence cleavage is initiated in the pre-
lysosomal compartment and completed in the lysosome. 
The M-6-P receptor recycles between the trans-Golgi stack and the pre-
lysosomal compartment, where an acidic pH causes the release of the bound newly-
synthesised enzyme. The released enzyme is then trafficked in vesicles to the 
lysosome (Brown et al., 1986). A smaller, Mr 46 000, M-6-P receptor recycles between 
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the external membrane of the cell and the peripheral endosomal compartments, not 
via the Golgi apparatus, and is hence not involved in the major lysosomal enzyme 
trafficking pathway (Kornfeld, 1986). 
Bearing the above trafficking scheme in mind, five possible mechanisms that 
could account for the secretion of proteinases of various levels of processing and 
glycosylation may be envisaged: 
i) a mutation in the cathepsin B gene/mRNA itself, affecting trafficking/ 
processing, 
ii) an increase in synthesis of cathepsin B that overwhelms the M-6-P receptors, 
leading to by-passing of the low pH compartments responsible for processing, 
and to default secretion of an unprocessed enzyme, 
iii) an alteration in glycosylation or in phosphorylation that affects the enzyme's 
binding to the M-6-P receptor causing default secretion, 
iv) an alteration in number or regulation of recycling of the M-6-P receptors, 
v) a change in the pH of the lysosomal! endosomal compartments, leading to 
failure of the M-6-P receptor shuttle system. 
Though the mechanisms responsible for the aberrant trafficking and secretion 
of the cathepsins in tumours are still largely unresolved, a pattern seems to be 
emerging. Transformation and dedifferentiation seems to result in the selective 
increase in synthesis of usually one of the lysosomal proteinases. In most cases, there 
also appears to be some alterations in the glycosylation and processing patterns. 
High levels of cathepsin B have been isolated from homogenates of metastatic 
tumours (Maciewicz et al., 1989; Lah et al., 1992b), and increases in mRNA transcripts 
have been observed in most murine and human tumours, relative to normal tissues 
(Achkar et al., 1990; Murnane et al., 1991). No abnormalities in gene sequences coding 
for cathepsin B have, however, been observed (Qian et al., 1991). Gene promotors 
seem normal in B16a tumours (Qian et al., 1991), so the increased cathepsin B levels 
may be ascribed to the increased stability of the larger mRNA transcripts seen in cancer 
tissues Gones and Cole, 1987). Differences in transcript size, due to differences in the 3' 
untranslated regions (UTRs), have been found to have a significant effect on the 
translation efficiency (Kruys et al., 1987) and, coupled with the increased stability of the 
mRNA, may result in increased cathepsin B expression in some tumours. 
Two main sizes of transcript, of ca 2 kb and 4 kb, have been found to 
predominate in most tumours (Capony et al., 1989; Qian et al., 1991), and a 5 kb 
8 
transcript has also been reported (Qian et al., 1991). The 2 kb and 4 kb transcripts are 
apparently not tumour specific but are found in greater amounts at certain stages of 
tumour development: for example, they are reported to be increased 4-fold during 
tumour invasion (Murnane et al., 1991). Some authors associate the 2 kb transcript 
with transformation, rather than with the proliferation of tumour cells (Capony et al., 
1989). 
It might be anticipated that overproduction of a lysosomal enzyme, such as 
cathepsin B, might lead to saturation of the M-6-P receptors, and consequent secretion 
of most lysosomal enzymes by a default secretory mechanism. Studies on 
transformed or tumour cells, however, indicate that the lysosome has a normal 
complement of lysosomal enzymes, even if the synthesis and secretion of one 
lysosomal proteinase is greatly increased. The normal population of lysosomal 
enzymes may be due to an as-yet-undiscovered mode of trafficking of lysosomal 
enzymes to the lysosome (Kornfeld, 1990). With the secretion of a preponderance of 
one enzyme, it is difficult to imagine how a normal population of enzymes in the 
lysosome could result from the recapture and uptake of secreted lysosomal enzymes 
by a cell-surface M-6-P receptor. Mere saturation of receptors is, therefore, unlikely to 
be responsible for the secretion of proteinases. By-passing of the low pH environment 
of the lysosome, due to default secretion could, nevertheless, explain why it is 
precursor enzymes that are secreted. If secretion is by default, then all of the lysosomal 
enzymes should be secreted, though the over-produced enzyme would be secreted in 
the greatest proportion. 
Simple default secretion may only occur in cases where the M-6-P address label 
has not been attached to the lysosomal enzyme during post-translational 
modification, such as occurs in I-cell disease (Kornfeld, 1990). In most cases, uptake 
studies on the secreted enzymes show that they are correctly phosphorylated (Dong 
et al., 1989). Default secretion, therefore, seems most often to be related to a defect in 
the M-6-P receptors. Accumulating evidence points to the involvement of 
disturbances in the cellular pH, due to alterations in the metabolic patterns of 
transformed cells (Pouyssegur et al., 1980). Such pH disturbances may give rise to 
disturbances in M-6-P receptor trafficking and in lysosomal enzyme processing (Brown 
et al., 1986). 
The pH may be shifted in either direction. Studies with cell culture systems 
indica te that changes in extracellular pH are accompanied by parallel shifts in 
intracellular pH Gahde et al., 1989; Tannock and Rotin, 1989). A decrease in pH leads 
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to a shift in the distribution of lysosomes and endosomes to the cell periphery 
(Heuser, 1989), and to the secretion of mature lysosomal enzymes (Krepela et aI., 1989). 
A lower than usual pH in the Golgi and secretory vesicles could result in premature 
dissociation of lysosomal enzymes from the M-6-PRs and in premature (autocatalytic) 
cleavage, resulting in the secretion of mature enzymes. Secretion of mature 
lysosomal enzymes has mainly been demonstrated in cell cultures, however, and may 
be a phenomenon of cell cultures only. 
Conversely, an increase in cellular pH may give rise to the secretion of 
precursor lysosomal enzymes, which is more common (Sloane et al., 1990). An 
increased pH is known to stop the trafficking of M-6-PRs, as M-6-PRs remain in the 
late endosome, unable to dissociate from their bound, newly-synthesised, lysosomal 
proteinases (Brown et aI., 1986). Dissociation does not occur, because this requires a 
low pH environment, and, consequently, recycling of the receptor also does not occur 
(Brown et aI., 1986). This may lead to a receptor shortage and the general default 
secretion of unprocessed precursor proteinases (Achkar et aI., 1990). 
Failure of the acidification of lysosomes and late endosomes, resulting in the 
secretion of precursor lysosomal enzymes, occurs in normal cells, treated with 
lysosomotrophic agents, but has also been observed in hepatocarcinomas, and is 
induced during transformation (Achkar et aI., 1990). Transfection with the ras gene 
has also been shown to increase the pH of the endosome-lysosome system in human 
fibroblasts Giang et aI., 1990). These observations suggest a connection between pH, 
oncogene transfection and secretion of proteinase precursors. 
Defects in the acidification of processing organelles may be due to depletion of 
the ATP required for ATPase-dependent acidification of the lysosome-endosome-
Golgi system, a result of the altered carbohydrate metabolism characteristic of 
malignant tumours. A switch from respiration to aerobic glycolysis is a characteristic, 
with few exceptions, of tumour cells (Pouyssegur et al., 1980), and is closely associated 
with the . malignant phenotype (Weinhouse, 1972; Birnbaum et al., 1987). Aerobic 
glycolysis would yield substantially less ATP, than would respiration through the TeA 
cycle, and this may cause an ATP deficiency. The reason for the change in metabolism 
is unknown, although it has been speculated that it may be due to altered expression 
of certain enzymes (Weinhouse, 1972). 
Paradoxically, although the switch to aerobic glycolysis might occasion a failure 
in acidification of the lysosome-endosome-Golgi system, it appears to lead to a 
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decrease in pH in the immediate extracellular environment, to pH 6.5 to 6.8 (Gullino 
et al., 1965; Jahde et al., 1992). This may be a consequence of the production and 
secretion of lactic acid as the end-product of glycolysis, even in the presence of a 
sufficiency of oxygen Uahde et al., 1992). It is interesting to observe that neutrophils, 
which are naturally invasive cells, also seem to rely mainly on glycolysis for energy, 
though the significance of this in relation to their invasive capability, is unknown. 
In cancer cells, the ATP depletion could also result in the malfunctioning of 
glycosylation steps in the Golgi, and in consequent mis-direction of cellular traffic. In 
transformed murine NIH-3T3 fibroblasts, a high molecular weight precursor form of 
cathepsin L (called MEP - the major excreted protein) has been found to be secreted, as 
a secondary product of the ras oncogene, following Kirsten virus transformation of 
the cells (Mason et al., 1987). Secretion of MEP is primarily due to its low affinity for 
the M-6-P receptor, caused by an alteration in the glycosylation of the M-6-P 
recognition marker. Upon transformation by the ras oncogene, murine NIH-3T3 cells 
becom e invasive (Barbacid, 1987). Again, plausible links can thus be discerned 
between ATP depletion and cell invasion. 
Proteinases associated with malignant tumours are not always secreted, but 
may also be bound to the plasma membrane (Krepela et al., 1987; Sloane et al., 1986; 
1990; Rozhin et al., 1987; Keren and Le Grue, 1988). Some of these may normally be 
membrane-bound enzymes, but which are mis-trafficked in tumours. Examples are 
the lysosome associated membrane proteinase (LAMPS) and the CD631 lysosomal 
proteinase, which are expressed on the cell surface of tumours, especially those 
exhibiting the greatest propensity for metastasis (Heffernan et al., 1989). This suggests 
that there may be a mechanism whereby "lysosomes" and their membranes may, 
under some conditions, become associated with the surface of invasive cells. 
Evidence will be provided in Chapter 4 of this thesis that, in neutrophils, which are 
normally invasive cells, this mechanism might involve fusion of the membrane of 
proteinase-containing organelles with the plasma membrane of the cell (Kobayashi 
and Robinson, 1991). There may be some advantage to an invasive cell in having 
membrane-bound proteinases and this disposition of the proteinases may also explain 
why intimate contact is required between the invading cell and the barrier being 
invaded. 
Most biochemical evidence indicating the involvement of proteinases in 
tumour invasion has been gained from classical biochemical protein isolation 
techniques, in which the tumour mass is homogenised prior to protein isolation or 
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membrane or organelle fractionation (Strauli, 1980; Sloane et al., 1981). Such 
techniques can only give an indication of the total quantity of proteinases present in 
fractions of the tumour mass, relative to that in an equivalent mass of the normal 
tissue. No indication of the source of the isolated proteinases is given; whether these 
arise from infiltrating leucocytes, or from the tumour cells themselves. The form of 
the protease isolated may also not be that which is involved in the invasion process, 
due to exposure to proteases during the homogenisation and isolation procedure. 
Care should, therefore, be taken in the interpretation of data from tissue 
hoinogenates. Similarly, information gained from tumour cell cultures, should be 
interpreted with some care, as cells in culture are extremely sensitive to their 
environment and particularly to the pH of the culture media (Krepela et al., 1989). 
Consequently, in the studies reported here, it was decided to adopt a different 
approach, using the technique of immunocytochemistry. The somewhat ambitious 
original aim of the present project was to establish the precise source and state of 
processing of secreted or membrane-associated proteases and to demonstrate where 
these proteinases occur in invasive cells. Such information, it seemed, would be best 
gained by an immunocytochemical study, at the electron microscope level, of tumour 
tissues and invasive cells. Direct observation, using immunolabelling techniques, 
was considered the most desirable approach, subject to the least error in interpretation. 
1.3 Immuno-electron microscopy 
In principle, immuno-electron microscopy (LE.M.) is simple and the object of 
the immunolabelling technique is to have the biologically specific reaction, between 
an antibody and its specific antigen, expressed in the form of an electron-dense 
material, which can be detected in the electron microscope - fixed at the same place in 
the sample as the antigen is located. 
The first requirement, before an immunocytochemical study can be 
undertaken, therefore, is the aVailability of suitable antibodies which specifically target 
the antigen(s) of interest (Elliott, 1989). In the present study, human tissues were of 
principle interest, so antibodies targeting human antigens were required. A tissue, 
containing the antigen of interest is also required. In the first instance this may be as a 
potential source from which the antigen might be isolated, for the raiSing of 
antibodies. It is not always necessary, however, to isolate human antigens in order to 
raise anti-human antibodies. Alternative strategies are to exploit cross-species 
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immuno-reactivity, whereby antibodies raised against an animal immunogen may be 
used to target the equivalent antigen in human tissue, or to use synthetic pep tides as 
the immunogen. Human tissue is unavoidably required for the LE.M. studies 
themselves but, fortunately, very small amounts of tissue, such as might be available 
from biopsies, are sufficient for this purpose. 
As mentioned previously, the present study is part of a larger study on the 
relevance of proteinases in tumour invasion. In the first few years of this project, 
workers in this laboratory, including the present author, were involved in assembling 
and characteriSing a portfolio of the relevant anti-proteinase antibodies. Three 
different approaches were adopted. Sometimes the proteinase antigen was isolated, 
mostly from animal tissues Gacobs et al., 1989; Pike and Dennison, 1989; Pike, 1991), 
but also from human tissue, where possible (Fortgens, 1991; Coetzer, 1993). An 
efficient second approach was, where possible, to collaborate with workers who had 
already isolated the antigen of interest. In this way, polyclonal anti-human 
cathepsin B antibodies were obtained from Dr D Buttle of the Strangeways Laboratory, 
Cambridge, UK. and polyclonal anti-human elastase was obtained from Dr J Travis of 
the Department of Biochemistry, University of Georgia, Athens, USA. 
A third approach was to prepare peptide antibodies, which are useful in a 
number of unique ways. Peptide antibodies were raised for studies on the processing 
of cathepsin B. In this case, target peptide sequences were chosen from positions in 
the precursor sequence of human procathepsin B. Peptide antibodies were also used 
as a way of obviating the necessity to isolate the target antigen from scarce human 
tissues. By selecting sequences in the active site of the target enzyme, it was hoped 
that these antibodies might also be immuhoinhibitory, and might, because of this, also 
have some potential utility in tumour immunotherapy (Dennison, 1989; Coetzer 
et al., 1991). This aspect will be discussed further in Chapter 3. 
The next requirement for this study was the production of various sizes of 
colloidal gold labels. Colloidal gold labels have become the most popular for electron 
microscopy, due to their regular, unmistakable shape, their electron denSity and the 
fact that colloids can be produced in various sizes. Gold colloids adsorb proteins, such 
as antibodies or protein A, to their surface by non-covalent electrostatic forces 
(Horisberger and Rosset, 1977), in a form in which they remain biologically active. 
ReCOgnition between the immunoglobulin or protein A, bound to the gold probe, and 
the primary antibody, used to probe a tissue section for a particular antigen, is made 
visible in the electron microscope by the presence of the electron-dense gold particle. 
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Different sizes of colloids can be produced by varying the reducing agent used 
to reduce a chloroauric acid solution, and their distinct sizes allow the simultaneous 
detection (Horisberger, 1981; Slot and Geuze, 1985) and quantitation (Slot et al., 1989) of 
a number of antigens. Gold probes may also be used for light microscopy and as a 
sensitive detection system for antigens blotted on nitrocellulose membranes. For this 
purpose, a process of "silver amplification" is used to render the gold label visible to 
the naked eye (Danscher and Norgaard, 1983). Silver is displaced from a solution of 
silver lactate by the metallic gold probe colloid, the displaced silver effectively 
increasing the size of the gold particle to a visible dimension. This provides a 
sensitive alternative to the popular horseradish peroxidase enzyme labelling systems. 
Due to financial constraints, it was necessary to produce and characterise the 
colloidal gold probes in this laboratory (see Chapter 2) and, as this had not previously 
been done here, it was necessary to develop the technique from scratch. The method 
of gold probe production, the particle size and the way in which residual protein 
binding sites on the gold probe are quenched, are reported to have an effect on the 
labelling characteristics of the gold probe and on non-specific interactions between 
tissue components and the gold probe (Birrell et al., 1987). The effect of these various 
factors on the surface charge of the resulting gold probes was investigated as part of a 
study of gold probe production (Elliott and Dennison, 1990), but will not be reported in 
this thesis. Although this study revealed that the production and quenching 
procedures can markedly influence the surface charge of gold probes, the exact nature 
of the interactions between gold particles and proteins remains largely unknown and 
so the origin of non-specific binding is also not properly understood. 
With the antibodies, tissues and gold labels to hand, it becomes necessary to 
optimise the labelling systems, to determine the optimal concentrations and 
proportions of reagents. In the present study it was considered most practicable to 
optimise the labelling systems on normal human tissues, before progressing to studies 
on tumour tissues. The tissues used for this purpose were from human blood or cell 
cultures or were obtained from patients undergoing therapeutic splenectomy. As 
normal human tissues are at an even higher premium than tumour tissues, it is 
perhaps fortunate that only small amounts of tissues were required. In the event, it 
was found that a great deal of methods-development, using normal tissue, was 
required to get the "cryo" immunolabelling system optimised and properly 
operational in this laboratory. This methods-development, a necessary preface to 
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studies on tumour tissues, constitutes the main thrust of the work reported in this 
thesis. 
In any immunolabeUing procedure, the target antigen must be preserved 
through the many processing steps, necessary to get the tissue into a physical form 
suitable for viewing in the electron microscope. Fixation, for example, is aimed at 
preserving the integrity and ultrastructure of tissue, but may result in the antigen 
becoming cross-linked (Hayat, 1986) or denatured (Tokuyasu, 1986), so that it is 
unrecognizable by the antibody. In I.E.M., therefore, preservation of tissue 
ultrastructure becomes of secondary importance and may often have to be sacrificed to 
preserve antigenicity. Various antigens have differing sensitivities to different 
fixation regimes and as a first approach the mildest, least denaturing, conditions are 
sought. Often these are not optimal for the preservation of tissue structure, however, 
and may also not fix all antigens adequately. In this study, preserving the best possible 
ultrastructure, while maintaining antigenicity, proved one of the major problem 
areas. 
After fixation, steps are required to render the tissue rigid enough to allow 
ultramicrotomy sectioning. The conventional approach to this is to embed the tissue 
in a plastic resin. This involves dehydration of the tissue, by solvent substitution, 
infiltration with resin monomer and subsequent polymerisation which, for 
hydrophobic resins, involves heating. Clearly, this is potentially destructive to the 
antigen. So-called "cold-cure" hydrophilic (acrylic) resins (Lowicryl and LR White) 
have been developed, to avoid the denaturing effects of the high temperatures needed 
to cure epoxy resins. Special low temperature refrigerators and ultraviolet globes are 
required to polymerise Lowicryl resins (Glauert and Young, 1989). 
Various other systems have been introduced to overcome the antigen-
denaturing effect of tissue embedding procedures. These include the cryo-fixation and 
freeze-substitution methods in which specimens are ultra-rapidly frozen to the 
vitreous state (Dubochet et al., 1988), and the cell water slowly replaced by solvents and 
resins at low temperatures (Livesey et al., 1990; Jestaitis et al., 1990). These methods 
require expensive equipment, however, which was not available in this laboratory. 
Alternatively, fixed thick sections of tissues may be immunolabelled before 
being resin embedded and sectioned (Priestley and Cuello, 1983). in these so-called 
"pre-embedding" immunolabelling procedures, labelling takes place before the 
damaging effects of tissue processing. These procedures are beset with many 
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problems, however. Penetration of immunoreagents into the thick tissue sections, . is 
one such problem (Priestley and Cuello, 1983). Tissues may be permeabilised, in an 
attempt to promote penetration, but this may cause further antigen-denaturation 
(Robinson, 1985). The subsequent thin sectioning of the pre-embed ding-labelled thick 
sections is also problematic. 
A far better option is the use of cryoultramicrotomy, in which ultra-thin frozen 
sections of fixed tissue are cut on an ultramicrotome to which a freezing apparatus has 
been fitted. In this "ultracryo" -technique, specimens are fixed, cryoprotected against 
ice crystal damage, with sucrose infiltration, and mounted on a stub that is inserted 
into the microtome. The tissue block is rapidly frozen, by plunge-freezing into liquid 
nitrogen, ultrathin sectioned, and the section is collected from the knife-edge in the 
cryochamber on a droplet of sucrose, thawed and immunolabelled in the fully 
hydrated form. The sections are then "sealed" and contrasted with a film of methyl 
cellulose, containing uranyl acetate. This prevents the section from dehydrating in 
the electron beam, and allows the specimen to be viewed in the electron microscope 
in a fully hydrated state -(Griffiths et al., 1983; Tokuyasu, 1980). This so-called 
"Tokuyasu technique" was the main labelling technique used in this study. 
The Tokuyasu technique was chosen as it has two main advantages. The only 
potentially antigen-denaturing step is the fixation and it is, therefore, the method of 
choice for sensitive antigens. It is also rapid. In an optimised system, it is possible to 
fix and process the tissue, section, label and view all in one day. By contrast, 
alternative resin embedding techniques take at least three days before they may be 
labelled and viewed. However, at the outset of this study, the cryoultramicrotomy 
technique was newly-developed and this University did not have a cryoultra-
microtome, nor any of the ancillary equipment necessary for producing the special 
glass knives and grids required. The technique was also not well-established 
elsewhere in South Africa. Consequently, much preliminary equipment- and 
methods-development was required. 
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CHAPTER 2 
MA TERIALS AND METHODS 
21 Introduction 
In this chapter, some of the basic techniques used to prepare and evaluate 
reagents will be described, in general terms. More specific methods will be described 
in the relevant sections of the text. 
Most of the labelling studies reported in this thesis were performed using the 
so-called "Tokuyasu technique" of cryoultramicrotomy and immunolabelling 
(reviewed by Tokuyasu, 1986), which is, perhaps, the mildest, most rapid, means of 
tissue preparation, facilitating the preservation of maximal tissue antigenicity. In this 
technique, fixation of the tissue is the only potentially antigen-denaturing step, and, 
since tissues do not have to withstand the rigours of resin embedding, relatively mild 
fixatives and short fixation regimes may be used. With the Tokuyasu technique there 
is a minimal chance of antigen denaturation, which is especially advantageous in the 
simultaneous study of a number of antigens in the same tissue. 
A necessary preface to immunolabelling studies, is the preparation of knives, 
grids, colloidal gold labels, and tissues. At the outset of the present study, the 
immunolabelling technique was not established in this laboratory and the equipment 
available was not suitable for a study of this nature. Consequently, some of the 
modifications of existing equipment, that were necessary in order to undertake this 
study, will also be described in this chapter. Gold labels are an expensive commodity, 
with a limited shelf life, so techniques for the "in house" production and 
characterisation of gold probes were also established and will also be described here. 
22 Antibody characterisation 
2.2.1 SDS-PAGE 
SDS-PAGE of protein fractions was used in this study to analyse the 
purity of antigens, and as a preface to western blotting of antigens for determination of 
antibody specificities. 
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SOS binds strongly to most proteins in a fixed mass ratio of 1.4:1.0 
(Reynolds and Tanford, 1970), converting them from globular native proteins to 
highly negatively charged rods, the length of which is dependent on their MW. The 
negative charges of the SOS effectively mask the charges of the proteins, giving them 
all similar charge-to-mass ratios. Because of the sieving effect of the gel, the mobility 
of a protein/SOS complex on SDS-PAGE depends on its size only, and hence relates to 
the size of the protein. A standard curve may be constructed by plotting the mobility 
of the protein/SOS complex against the log of the MW of several standard proteins. 
This curve may be used to estimate the MW of an unknown protein from its mobility 
in SOS-PAGE. 
The linear relationship between log MW and mobility breaks down in 
the case of glycoproteins and in proteins constrained by disulfide bridges. It is 
common practice, therefore, to reduce the proteins before SOS-P AGE separation. This 
results in the MW of sub-units (if any) being determined. 
For this study the discontinuous SDS-PAGE system of Laemmli (1970) 
was used on the Hoefer SE250 Mighty Small slab gel unit. 
2.2.1.1 Reagents 
Solution A: Monomer Solution [30% (w Iv) acrylamide, 2.7% 
(w Iv) bis-acrylamide]. Acrylamide (58.4 g) and bis-acrylamide (1.6 g) were dissolved 
and made up to 200 ml with dist.H20 . 
Solution B: 4 x Running Gel Buffer (15M Tris-HCL pH 8.8). Tris 
(36.3 g) was dissolved in approximately 150 ml of dist.H20, titrated to pH 8.8 with HCl 
and made up to 200 mI. 
Solution C: 4 x Stacking Gel Buffer (500mM Tris-HCL pH 6.8). 
Tris (12 g) was dissolved in 150 ml dist.H20, titrated with HCl to pH 6.8 and made up 
to 200 ml. 
Solutions A, B, and C were filtered through Whatman No. 1 
filter paper before use. 
Solution D: 10% (w Iv) SOS. SOS (10 g) was dissolved in dist.H20 
with gentle heating, if necessary, and made up to 100 ml. 
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Solution E: Initiator [10% (w Iv) ammonium persulfate]. 
Ammonium persulfate (0.5 g) was made up to 5 ml just before use. 
Solution F: Tank Buffer [250 mM Tris-HCL 192 mM glycine, 0.1% 
(w Iv) SDS, pH 8.3]. Tris (12 g) and glycine (57.6 g) were dissolved and made up to 
4 litres with dist.H20. Prior to use, 2.5 ml of SDS stock (solution E) was added to 
250 ml for use in the Mighty Small apparatus. 
Solution G: Treatment Buffer [125 mM Tris-HCl. 4% (w Iv) SOS, 
20% (v Iv) glyceroL 10% (v Iv) 2-mercaptoethanoL pH 6.8] . Buffer C (2.5 ml), 10% SDS 
(4 ml) (solution E), glycerol (2 ml) and 13- mercaptoethanol (1 ml) were made up to 
10 ml with dist.H20. 
Stain stock solution [1% (w Iv) Coomassie Blue R-250] . 
Coomassie Blue R-250 (1 g) was dissolved in dist.H20 by magnetic stirring for 1 h at 
room temperature and made up to 100 ml. The solution was filtered through 
Whatman No. 1 filter paper. 
Staining solution [0.125% (w Iv) Coomassie Blue R-250, 50% 
(v Iv) methanoL 10% (v Iv) acetic acid]. Stain stock (62.5 ml) was mixed with 
methanol (250 ml) and acetic acid (50 ml), and the volume was brought to 500 ml with 
dist.H20 . 
Destaining solution I [50% (v Iv) methanoL 10% (v Iv) acetic acid] 
Methanol (500 ml) was mixed with acetic acid (100 ml) and the volume was made up 
to 1 litre with dist.H20. 
Destaining solution II [7% (v Iv) acetic acid, 5% (v Iv) methanol] 
Acetic acid (70 ml) was mixed with methanol (50 ml), and made up to 1 litre with 
dist.H20 . 
Running and stacking gels. Running and stacking gels were 
made up as indicated in Table 1. 
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Table 1. Composition of 12.5% running and stacking gel 
Running Gel (ml) Stacking Gel (ml) 
Monomer solution 6.25 0.95 
Running gel buffer 3.75 
Stacking gel buffer 1.75 
10% SDS solution 0.15 0.07 
Amm. persulfate 0.075 0.035 
TEMED 0.015 0.015 
dist.H20 4.75 4.2 
2.2.1.2 Procedure 
For SDS-PAGE, a Hoefer SE250 Mighty Small apparatus was 
assembled as described by the manufacturer. Aluminium and glass plates, separated 
by two 1.5 mm spacers along each outer edge, were clamped to the electrophoresis pod 
and the apparatus was placed on a clean glass plate. The lower edges of the troughs, 
formed between the aluminium plates and the glass plates, were sealed with molten 
agarose [1% (w Iv), in dist.H20], which was allowed to solidify. The running gel, 
prepared immediately before use, was loaded into the troughs, to within 3.5 em from 
the top of the glass plate, overlaid with dist.H20 and allowed to solidify (approx. 1 h). 
The water was removed and the troughs were filled with stacking gel, into which 10-
or 15-well combs were inserted, to form sample application wells. Once the gel had set 
(about 30 min), the combs were removed, the wells rinsed with dist.H20 and shaken 
dry. 
Tank buffer, containing SDS, was poured into the upper and 
lower electrode compartments. Samples and molecular weight reference standard 
preparations, first diluted in stacking gel buffer (if necessary), and further diluted 1:1 
with treatment buffer, to give a minimum concentration of O.5llg of protein in the 
volume loaded, were boiled (90 sec), cooled, and bromophenol blue tracker dye added. 
Treated samples and reference proteins were loaded into the wells and 
electrophoresed at 18 rnA per gel, until the bromophenol blue reached the bottom of 
the running gel. One gel was used for western blotting, and the other was stained as a 
reference. 
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The reference gel was stained using Coomassie Blue R-2S0 stain 
(4 h), destained in destain I overnight and in changes of de stain II until the 
background was decolourised, and stored in dist.H20 or destain II in zip-sealed bags 
until photographed. 
2.2.2 Western blotting of SDS-PAGE gels 
The specific recognition of KLH-adsorbed peptide-antibodies (Chapter 3) 
and other antibodies to SDS-denatured, whole target enzyme or precursor sequences, 
and potential non-specific reactivity, was assessed by western blotting (Towbin et aI., 
1979; Burnette, 1981) of pure and crude fractions of the target proteins, separated by 
SDS-PAGE (Laemmli, 1970). 
Binding of the primary antibodies to the target antigen, was 
demonstrated using either a peroxidase labelled anti-primary antibody or, if greater 
sensitivity of detection was required, via a biotinylated, anti-primary, secondary 
antibody and the streptavidin-biotin-peroxidase complex. The primary antibody was 
also detected using the more sensitive immunogold or protein A gold and silver 
amplification system (Moeremans et ai., 1984) (see Section 2.3.7), where this procedure 
was deemed necessary. 
2.2.2.1 Reagents 
Tris-glycine blotting buffer. Tris-HCl (27.23 g) and glycine (64.8 g) 
were dissolved in approx. 3.5 litres of dist.H20, AR methanol (900 ml) added and the 
volume made up to 4.5 litres. Just before use, 4.5 ml of 10% SOS was added. 
Tris buffered saline (TBS) [0.02 M Tris, 0.2 M NaCL pH 7.4]. Tris 
(2.42 g) and NaCI (11.69 g) were dissolved in 950 ml of dist.H20, titrated to pH 7.4 with 
HCl and made up to 1 litre. 
Tris wash (TBS-Tween) [0.02 M Tris, 0.2 M NaCL 0.1% (v Iv) 
Tween 20, pH 7.4]. Tris (2.42 g), NaCl (11.69 g) and Tween 20 (1 ml) were dissolved in 
950 ml of dist.H20, titrated to pH 7.4 with HCl and made up to 1 litre. 
Secondary antibodies, antigens and locating agents. Sheep IgG 
was isolated (see Section 3.7.2), and conjugated to HRPO according to the method of 
Hudson and Hay (1980). Biotinylated goat-anti-rabbit IgG and donkey anti-sheep IgG 
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were from Sigma. Streptavidin-biotin-peroxidase complex was from Amersham and 
the Protein A gold and immunogold probes were prepared as described in 
Section 2.3.6. 
Substrate [0.06% (w Iv) 4-chloro-l-napthol in Tris-methanol, 
0.0015% (v Iv) H2lli] . 4-Chloro-l-napthol (0.03 g) dissolved in methanol (10 ml) was 
diluted in Tris buffered saline (2 ml to 8 ml TBS), and H202 [4 III of 35% (v Iv), 
solution] was added immediately before use. 
2.2.2.2 Procedure 
Gloves were worn throughout this procedure, to prevent keratin 
contamination of the reagents and consequent non-specific binding of antibodies 
(Ochs, 1983; Shapiro, 1987). 
SDS-P AGE was carried out in a Hoefer SE250 Mighty Small 
apparatus as described in Section 2.5, separation being effected at 18 rnA per gel. For 
western blots with anti-peptide antisera, up to 15 Ilg of enzyme or crude extract was 
applied per lane. Normally, however, approximately 1 to 5 Ilg of protein was loaded. 
Duplicate gels were run, one gel being used for western blotting, and the other being 
stained as a reference. 
The blotting apparatus was assembled with the buffer-moistened 
nitrocellulose sheet, cut to the size of the gel, placed on the anode side of the gel, with 
both sandwiched between sheets of Whatman No.1 blotting paper and ScotchBrite 
pads. Electrotransfer was effected at 200 rnA for 16 h. The gel was stained (see Section 
2.2.1.2), to check the efficiency of the electrotranfer of protein to the nitrocellulose 
membrane, and the membrane was removed and allowed to dry. 
The strip of nitrocellulose, containing the blotted molecular 
weight marker proteins, was cut from the membrane and stained with 1% aqueous 
Sudan Black. The rest of the membrane was blocked (1 h) using either 5% foetal calf 
serum (Gibco), 10% horse serum or 5% low fat milk powder, each in TBS. The 
membrane was washed in TBS-Tween (3 x 5 min) and the primary antibody, diluted to 
the desired concentration (2 - 10 Ilglml in 0.5% BSA in TBS, unless otherwise 
indicated) was applied for 1 h at room temperature. A control strip incubated with a 
preirnrnune antiserum or IgG preparation, of the same species, was run in parallel at 
the same concentration as the test. 
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Binding of the primary antibody to the target antigen was 
visualised using a sheep anti-rabbit horseradish peroxidase conjugate (1 in 400 in 0.5% 
BSA in TBS) or a biotinylated goat anti-rabbit linker (1 in 500 dilution in 0.5% BSA in 
TBS), followed by an avidin-biotin peroxidase complex (1 in 400 in 0.5% BSA in TBS). 
The strips were washed and substrate applied, until the bands became clearly visible. 
When a sheep primary antibody was used, an anti-sheep linker antibody was 
additionally used between the primary antibody and detection systems. 
23 Tissue preparation and gold labelling reagents 
2.3.1 Buffers 
Phosphate buffered saline (PBS) or Tris buffered saline buffer (TBS) 
were used in immunolabelling protocols and PBS was also used in some fixatives. 
Two versions of TBS were used in labellings in which background or 
non-specific labelling seemed problematic. One, designated IGSS I, had a high salt 
content and contained a detergent, to overcome charge and hydrophobic interactions 
between tissues and labelling reagents. In the second, deSignated IGSS II, a different 
pH was used to overcome non-specificity. The nomenclature originates from their 
original use in immunogold and silver amplification reactions for light microscopy 
(De Mey, 1986). 
For fixation, a HEPES buffer was most often used to avoid the potential 
extraction of cytoplasmic components and some lipids, by phosphate and cacodylate 
buffers (Griffiths, 1993). 
2.3.1 .1 · Reagents 
1 M sodium cacodylate stock solution. Sodium cacodylate (10.7 g) 
was dissolved in 45 ml of dist.H20, titrated to pH 7.2 with sodium hydroxide, and 
made up to 50 ml. For use, the stock solution was diluted to 100 mM, and the pH 
rechecked. 
200 mM (133 mM) sodium cacodylate. A 200 mM (133 mM) 
sodium cacodylate solution was prepared by diluting 10 ml (6.65 ml) of the 1 M 
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sodium cacodylate stock solution to 50 ml with dist.H20. The pH was adjusted if 
necessary. 
400 mM HEPES stock solution. HEPES (100.92 g) was dissolved 
in 900 m1 of dist.H20, adjusted to the required pH (7.2 or 8.0) with NaOH and made up 
to 1 litre. The solution was stored frozen. For use, the buffer was diluted to 200 mM 
and the pH adjusted, if necessary. 
267 mM (200 mM) HEPES. A 267 mM (200 mM) solution of 
HEPES was prepared by diluting 33 ml (25 ml) of 400 mM stock HEPES solution to 
50 ml with dist.H20. The pH was adjusted, if necessary. 
200 mM phosphate buffered saline stock solution, pH 7.2 (lOX 
PBS). NaH2P04.2H20 (13.8 g), NaCl (87.6 g) and KCl (1.86 g) were dissolved in 950 ml 
dist.H20, adjusted to the required pH (7.2 or 8.0) with NaOH, and made up to 1 litre. 
54 mM (20 mM) phosphate buffered saline (PBS). A 54 mM 
(20 mM) solution of PBS (50 ml) was prepared by diluting 13.5 ml (5 ml) of lOX stock 
solution to 50 ml with dist.H20. The pH was adjusted, if necessary. 
10 mM phosphate buffered saline (PBS) . A 10 mM solution of 
PBS was prepared by diluting the lOX stock buffer 1 part to 19 parts with dist.H20 (or, 
when making up fixatives from stock solutions, with the liquid fixatives and 
dist.H20) and the pH adjusted. Unless otherwise stated, when "PBS" is referred to in 
this study, this will be 10 mM PBS, pH 7.2. 
200 mM borate buffer. pH 9.0. Boric acid (12.36 g) was dissolved 
in 950 ml dist.H20, the pH was adjusted to pH 9.0 with NaOH, and the volume made 
up to 1 litre. 
Buffer IGSS 1. Tris base (7.9 g), sodium chloride (25 g) and 
Tween-20 (5 ml) were dissolved in approx. 800 ml dist.H20, titrated to pH 7.4 with 
1 M Hel and made up to 1 litre. 
Buffer IGSS II. Tris base (7.9 g) and sodium chloride (9 g) were 




In this study 8% paraformaldehyde, in HEPES buffer, was mainly used 
to fix tissues as many antigens are sensitive to exposure to even low concentrations of 
glutaraldehyde (Tokuyasu, 1986). Paraformaldehyde is a less cross-linking fixative 
than glutaraldehyde, giving better antigen survival, though generally poorer 
preservation of tissue ultrastructure, except at higher concentrations (Baker and 
McCrae, 1966). Paraformaldehyde, as opposed to commercially prepared formalin or 
formaldehyde, is used as the commercial products contain undetermined amounts of 
impurities, such as methanol and formic acid (Hayat, 1981). 
2.3.2.1 Reagents 
16% Paraformaldehyde stock solution. Para formaldehyde (BOH, 
Poole, England) (16 g) was dissolved in dist.H20 (100 ml), warmed to 60°C and cleared 
with a minimum amount of 1 M NaOH. The solution was stored at -lOoC until 
required. 
8% Paraformaldehyde. 8% solutions of paraformaldehyde, in 
different buffers, were prepared from the 16% paraformaldehyde stock solution, by 
diluting the stock solution with an equal volume of 400 mM HEPES buffer, 200 mM 
sodium cacodylate, or 20 mM PBS (see Section 2.3.1.1). The final pH was checked and 
adjusted, if necessary. 
4% Paraformaldehyde. 4% solutions of paraformaldehyde, in 
different buffers, were prepared from the 16% paraformaldehyde stock solution, by 
diluting one volume of the stock solution with 3 volumes of 267 mM HEPES buffer, 
133 mM sodium cacodylate, or 54 mM PBS (see Section 2.3.1.1). The final pH was 
checked and adjusted, if necessary. 
1 % Glutaraldehyde. 25% Glutaraldehyde (Merck) (1 ml) was 
diluted to 25 ml with PBS, pH 7.2. 
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2% (or 4%) Paraformaldehyde 10.2% glutaraldehyde. 16% stock 
para-formaldehyde [1.25 ml (or 2.5 ml)] and 25% glutaraldehyde (20 lJ.I) were made up 
with 1 ml of lOX stock PBS or 1 M sodium cacodylate stock solution, and 8 ml of 
dist.H20 , the pH adjusted with NaOH or HCl, and a further 1 ml of dist.H20 added. 
2.3.3 "Blocking" agents. 
Attempts to prevent non-specific antibody attachment to the tissue, via 
free aldehyde groups or by charge or hydrophobic interactions, were made using 
gelatin or other "blocking" proteins (Griffiths et al., 1983; Birrell et al., 1987; Behnke, 
1986). These extinguish potential non-specific binding sites. 
All blocking reagents were dispensed in aliquots, sufficient for an 
immunolabelling procedure, and stored frozen (-lOOC) until required. 
2.3.3.1 Reagents 
1% and 5% Bovine serum albumin (BSA). BSA (Boehringer, 
Fraction V) (1 g or 5 g) was dissolved in PBS and made up to 100 ml. 
5% Foetal calf serum. Sterile foetal calf serum (GIBCO) (5 ml) 
was made up to 100 ml with 200 mM HEPES buffer, pH 7.2. 
0.02M glycine in PBS, pH 7.2. Glycine (0.15 g) was dissolved in 
PBS and made up to 100 ml. 
1 % Fish skin gelatin. Fish skin gelatin (Sigma) (0.1 ml) was 
dissolved and made up to 10 ml with PBS. 
2.3.4 Production of gold particles by citrate and tannic acid-citrate 
Gold labels may be produced from colloidal gold particles of different 
sizes, prepared by reducing gold chlorides with various reducing agents (Horisberger, 
1981). Two types of gold labels, "immunogold" and protein A gold probes have 
become the most commonly used, for immunocytochemistry at the electron 
microscope level. The probes are made by adsorption of protein A or 
immunoglobulinS to the surface of gold particles, by non-covalent electrostatic forces, 
forming a protein A gold or "immunogold" probe (Horisberger and Rosset, 1977). 
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Since these two proteins are adsorbed to the gold particles in an undenatured form, 
they continue to bind the primary antibody and act as a bridge between the primary 
antibody and the colloidal gold particle marker. 
Gold probes have many advantages over the potentially diffusable 
reaction products of enzyme labels. The characteristic spherical shape and high 
electron density of gold probes, makes them easy to distinguish from biological 
structures. Their discrete nature and the fact that gold labels or "probes" may be made 
from colloids of different particle sizes, makes gold probes useful for simultaneous 
multiple antigen labelling, and quantitation (Slot and Geuze, 1985). 
Protein A is a staphylococcal protein, of 42 kDa, that binds to the Fc 
portion of IgG molecules of many animal species. This binding is strongest to human, 
rabbit, guinea-pig, swine and dog IgGs (Langone et al., 1978). Binding to IgG from cow, 
mouse and horse is weaker and to IgG from sheep, goat, rat and chickens is 
considerably weaker (Langone, 1982). These IgG species are listed in order of 
decreasing affinity. The present study was performed largely with rabbit antibodies 
and protein A gold probes, the latter being a convenient, universal, reagent. Where 
primary antibodies from other species, such as sheep (which do not react well with 
protein A) were used, a rabbit anti-species specific linker antibody, followed by a 
protein A gold probe was used. 
Protein A, binds to the Fc fragment of a tissue-bound primary antibody, 
in a one-to-one ratio (Slot et al., 1989), whereas more than one immunogold probe 
may bind to a single tissue-bound primary antibody. Immunogold probes, therefore, 
generally give higher labelling signals than protein A gold probes. The inclusion of 
an extra "linker antibody" in the protein A gold labelling system, when, for example, a 
sheep primary antibody is used, has the additional effect of amplifying the protein A 
gold labelling signal, as more than one sec0!ldary antibody can bind to the primary 
tissue-bound antibody. 
Many other factors complicate the direct quantitation of antigens by 
counting the number of tissue-bound gold labels. These may be described under the 
heading, "factors affecting labelling efficiency". Labelling efficiency, the number of 
gold particles observed, divided by the number of antigens known to be present on the 
surface labelled, is usually about 10%, at best (Griffiths, 1993). 
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Labelling efficiency is affected by a number of probe and tissue antigen-
related variables. The size of the gold particle chosen should not be so large that the 
binding of one gold particle precludes the binding of subsequent gold particles in its 
vicinity, a phenomenon known as "steric hindrance". Ina similar fashion 
penetration of gold probes into tissues, to bind antigen-bound primary antibodies, may 
be more of a problem with larger gold probes. Smaller gold probes (2-5 nm), generally 
give a greater labelling density and sensitivity than larger probes (20-30 nm). Smaller 
gold probes (5 to 10 nm) were, therefore, generally used in this study. 
The size and size variation of the colloidal gold particles, used in label 
production, is important when multiple simultaneous labellings, using different sizes 
of gold labels, are carried out. For this reason a method of colloid production which 
produces uniformly sized colloidal particles was sought. The tannic acid-citrate 
method of Slot and Geuze (1985) was used in this study as it produces a uniform 
colloid with a size range from 5 nm to approx. 15 nm, depending on the amount of 
tannic acid added. 
During the formation of colloidal gold particles, nucleation and growth 
of colloidal gold particles are two opposing phenomena. The rate of reduction of the 
chloroauric acid solution, from Au3+ to metallic Au, determines the number of 
nucleation points formed. Particle growth, however, occurs by further condensation 
of Au on the surface of the nuclei. The size or average particle diameter (APD) of the 
particles formed, is, however, inversely proportional to the cube root of the number of 
nuclei formed. Rapid reduction, therefore, gives rise to a larger number of nucleation 
pOints and, consequently, to smaller colloidal particles. 
Tannic acid causes fast reduction, while citrate reacts slowly. In the 
citrate-tannic acid method, various sizes of colloids are produced by varying the 
amount of tannic acid added. At the higher concentration of tannic acid, used for the 
production of the smaller gold probes, reduction is almost exclusively due to the 
tannic acid. Nevertheless, even at lower concentrations of tannic acid, the size of the 
particle appears to be regulated by tannic acid, and the variation in the size of the 
colloid is generally less than 10%, producing a desirably homodisperse colloid, suitable 
for the production of probes for multiple simultaneous immunolabelling regimes 
(Slot and Geuze, 1985). 
The production of colloidal gold probes may be divided into 3 sections: 
production of the colloidal gold particles, determination of the minimum amount of 
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protein required for stabilisation of the particles and finally the production, 
purification, sizing, and testing of the colloidal gold probe. 
2.3.4.1 Reagents 
All reagents must be made in scrupulously cleaned glassware, 
with AR chemicals and highly purified water, preferably produced by reverse osmosis. 
The containers used for the final production of the gold colloid must also be scratch-
free. 
1 % Chloroauric acid solution (HAuCl41. HAuCl4 (Merck, 
Darmstadt) (lg) was dissolved in disLH20, made up to 100 ml, and stored in the dark 
at 4°C, until used. 
1 % Trisoduim citrate . Trisodium citrate.2H20 (Merck, 
Darmstadt) (1.14 g) dissolved in disLH20 and made up to 100 ml, was freshly prepared 
daily. 
1 % Tannic Acid. Tannic acid (Mallinckrodt #1764) (0.1 g), 
dissolved in disLH20 and made up to 10 ml, was freshly prepared daily. 
25 mM K2C03· K2C03 (3.45 g) was diluted with disLH20 (10 ml) 
and filtered through a 0.22 ~ tilter before use. 
2.3.4.2 Procedure 
To make 200 ml of gold sol, two solutions were prepared: 
solution A consisted of dist.H20 (160 ml) and 1% HAuCl4 (2 ml) and Solution B 
consisted of 1% trisodium citrate (8 ml), dist.H20 (32 ml) and a variable amount of 
tannic acid, depending on the size of colloid required (see Table 2). An equal amount 
of K2C03 is added when 1 ml or more tannic acid is used. Solutions A and B were 
separately warmed to 60°C and mixed rapidly, while stirring. Once a red colour is 
formed the solution was heated to . 95°C and cooled on ice. Larger particles (using 
lower concentrations of tannic acid) take longer to form and the red colour can take up 
to 1 h to develop. 
Table 2. Amount of tannic acid to be added per 200 ml of combined 
solutions A and B, to produce the desired size of gold particles. 












2.3.5 Determination of minimum amount of protein for colloid stabilisation 
Optimal adsorption of macromolecules, to the surface of the 
hydrophobic, negatively charged colloidal gold particles, occurs under conditions 
allowing maximal multi-point contact between the macromolecule and the "edge" 
surface of a good particle, which are thought to contain increased Van der Waal's 
forces. Such multipoint contact is favoured by adsorption of minimal amounts of 
stabilising protein, in low ionic strength buffers, at the pI of the protein or at pI + 0.5 
pH units) (De Mey, 1986). 
At the pI of the protein, the protein is predominantly in the 
zwitterionic form, and the interfacial tension maximaL This allows stronger, more 
stable adsorption to the hydrophobic surface of the gold particles. The adsorbed 
protein stabilises the colloid against an electrolyte challenge; at electrolyte levels at 
which the colloid becomes unstable, its colour changes from pink to blue (Geoghegan 
and Ackerman, 1977). The minimum amount of protein required to stabilise a 
colloid, at a particular pH, may be established by titration and electrolyte challenge. 
The lowest amount of protein required to stabilise a set volume of the colloid against 
salt-induced aggregation, at the pI, or slightly to the basic side of the pI of the protein, 
is known as the "minimum stabilisation concentration" for the colloid and the 
particular protein. The "minimum stabilisation concentration" of protein (+ 10 %) is 
then used in the production of the gold probe. 
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2.3.5.1 Reagents 
10% NaCl. NaCl (1 g) was dissolved in dist.H20 (10 ml). 
2 mM Borate buffer. Boric acid (0.123 g) was dissolved in 950 ml 
dist.H20 , adjusted to pH 9.0 with NaOH, and made up to 1 litre. 
Donkey or rabbit anti-sheep IgG. Affinity purified donkey- and 
rabbit anti-sheep IgG (Sigma Chemical Co.) was reconstituted to 0.5 mg/ml and 
dialysed against 2 mM borate buffer. 
Protein A. Protein A (Sigma Chemical Co.) was diluted to 
1 mg/ml with dist.H20. 
2.3.5.2 Procedure 
After high speed centifugation of the proteins, the dialysed IgG 
or protein A, was diluted to 0.2 mg/ml for the 20 run and 0.75 mg/ml for the 5 run 
gold probes, and a dilution series set up, in a Nunc flat-bottomed, high-bond 
micro titre plate, as indicated in Table 3, and mixed by manual agitation. 
The colloidal gold sol was adjusted, with K2C03, to the pI (or just 
above the pI) of the protein and 100 III was added to each well of the micro titre tray 
and mixed by agitation. [For IgGs, pH 8.0 was used (De Mey, 1986) whereas, for 
protein A, pH 6.0 is recommended (Horisberger and Clerc, 1985)]. The adsorption was 
allowed to proceed for 2 min before challenge with 10% NaCl (10 Ill). The plate was 
again agitated, to mix the solutions, and allowed to stand 5 min before the colour 
change was assessed visually. The end point, the highest dilution giving no colour 
change (pink to blue) was assessed and the minimum amount of protein stabilising 
100 III of gold was used to calculate the amount of protein required to stabilise larger 
volumes of sol. 
Table 3. 
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"" The solvent is preferably dist.H20. If the protein is insoluble in this, a low ionic 
strength buffer (less than 10 mM) is used. 
2.3.6 Production and purification of gold probes 
After the addition of the minimal stabilisation concentration of protein, 
residual protein-binding sites on the gold probe may be quenched by the addition of 
excess quenching protein, or polyethylene glycol (PEG). In this study, BSA was 
exclusively used as a quenching agent as PEG was found to be less effective at 
preventing probe aggregation upon centrifugation, leading to a lower yield of probe. 
For the production of protein A gold probes, it is necessary to use globulin-free BSA. 
A one-step glycerol gradient centrifugation procedure is favoured for 
the purification of the probe. The alternative non-gradient method involves 
washing, with buffer, by serial cycles of centrifugation, aspiration of the supernatant 
and resuspension of the pellet. In such a system, the aggregates form a non-mobile 
pellet at the bottom of the tube and the unaggregated, mobile pellet has to be removed 
carefully and rewashed. In the continuous gradient system, the colloid fractionates in 
the gradient on the basis of size, the aggregates passing right through, and the 
unbound proteins are simultaneously removed. 
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2.3.6.1 Reagents 
10% BSA quenching agent for immunogold probes. BSA 
(Boehringer, FractionV) (1 g) was dissolved in about 8 ml of dist.H20, adjusted to 
pH 8.0 with NaOH and made up to 10 ml. The solution was micro-filtered just before 
use, taking care to avoid frothing. 
10% BSA quenching agent for protein A gold probes. BSA 
(Boehringer, FractionV) (1 g) was dissolved in 10 ml of dist.H20, giving a pH of 
approximately 6.8. The solution was micro-filtered just before use, taking care to 
avoid frothing. 
20 mM Tris buffered saline (TBS), pH 8.0. Tris base (2.42 g) and 
sodium chloride (9 g) were dissolved in approx. 800 ml dist.H20, titrated to pH 8.0 
with 1M HCl and made up to I litre. 
20 mM Tris buffered saline containing 0.1% BSA (TBS-BSA), 
pH 8.0. BSA (0.1 g, Boehringer, Fraction V) was dissolved in 100 ml of TBS. 
10% and 30% glyceroL Glycerol (10 or 30 ml) was diluted with 
0.1 % BSA in PBS or TBS-BSA (90 or 70 ml) to make a 10 or 30% glycerol solution, for 
gradient separation of protein A gold probes or immunogold probes, respectively. 
2.3.6.2 Procedure 
The calculated minimal stabilising amount of protein is added 
slowly, while continually and rapidly stirring the pH-adjusted soL After 2 min, 
residual protein-binding sites are quenched by the addition of the appropriate 10% 
BSA solution, to a final concentration of 1 % (globulin-free BSA, in the case of 
protein A gold probes, and pH 8 BSA for the immunogold probes). 
The colloidal gold particles are centrifuged (30 min, 4°C) at the 
speed required to pellet that particular size of colloidal gold particle (Table 4). The 
mobile pellet is suspended in approx. 1 ml of the supernatant and loaded onto a 15 ml 
10~30% glycerol gradient, centrifuged (45 min, 4°C, at the speed indicated in Table 5), 
and the dark red band near the middle of the gradient is collected and stored at 40C. 
Alternatively the protein A gold or immunogold probes are washed twice in 0.1% 
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globulin-free BSA in PBS or 0.1% BSA, respectively, by centrifugation at the speeds 
indicated in Table 4. 
Table 4. Speeds for centrifugation of colloid after minimal stabilisation and 
quenching, for removal of unbound proteins. >I-
Size of particle (nm) Rotor 70 Ti (RPM) X g (r max) 
4 47000 225 000 
5 45000 210000 
6 42000 185000 
7 38000 155000 
8 33000 105000 
9 30000 92000 
10 27000 75000 
12 18000 37000 
14 10000 7000 
>I- If gradient centrifugation is not to follow this step, the pellet is resuspended 
in 0.1 % BSA in PBS or TBS, as indicated above, and recentrifuged as above. 
Centifugation conditions, 30 min,4°C. 
Table 5. Gradient centrifugation purification of colloidal gold probe pellet. 
Size of particle (nm) Rotor SW 40 (RPM) X g (r max) 
4 40000 284000 
5 37000 240000 
6 32000 170000 
7 30000 150000 
8 26000 115000 
9 22000 85000 
10 19000 65000 
12 11 000 20000 
14 5000 5000 
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2.3.7 Characterisation of colloidal gold probes 
Characterisation of the gold probe involves checks on the specific 
binding activity, and the size and size distribution of the harvested probe. Binding of 
the colloidal gold probe to a target antigen can be visualised using the silver 
amplification procedure (Danscher and Norgaard, 1983). This produces an intensely 
black labelling product that makes gold labelling extremely sensitive. Gold labels, 
bound to the antigen, displace metallic silver from soluble silver solutions (e.g. silver 
lactate). In this way, growing shells of precipitated silver surround the gold particles, 
increasing their effective size, and give a visible black-brown colour at the site of 
binding of the gold label. The intensity of the enhancement is controlled by the time 
for which the gold is allowed to displace the metallic silver. 
2.3.7.1 Reagents 
Target and non-target immunoglobulin species. Both target and 
non-target immunoglobulins were diluted in 1 % BSA in PBS to give a final range of 
1 Ilg to approx. 10 ng, in 2 III of blotted target immunoglobulin. 
Membrane blocking solution. BSA (1 g, Boehringer, Fraction V,) 
was dissolved in PBS (100 ml). 
Protein A gold probe diluent. Globulin-free BSA (Sigma) (0.1 g) 
was dissolved in PBS (100 ml). 
Immunogold probe diluent. BSA (Boehringer, Fraction V) (0.1 g) 
was dissolved in PBS (10 ml). 
20 mM Tris buffered saline containing 0.1% BSA (TBS-BSA), 
pH 8.0. BSA (Boehringer, Fraction V) (0.1 g) was dissolved in TBS (100 ml, Section 
2.3.1.1). 
Citrate buffer. pH 3.9. Trisodium citrate (2.35 g) and citric acid 
(2.55 g) were dissolved in 85 ml of dist.H20 . 
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Silver amplification solutions. 
A Hydroquinone (850 mg) was added to 85 ml of citrate 
buffer, pH 3.9. 
B. Silver lactate (110 mg) was added to 15 m1 of dist.H20 and 
protected from light. 
When required, the reagent was prepared by adding A to B (in 
the dark). The silver amplification solution was made immediately before use, in 
scrupulously clean glassware and with high grade dist.H20 . 
5% Sodium thiosulphate. Sodium thiosulphate (5 g) was made 
up in 100 ml of dist.H20. 
2.3.7.2 Procedure 
The colloid was photographed in the electron microscope and 
the size of the particles of the probe measured, to establish the size and size variation 
of the harvested probe. This was carried out by coating a grid with a formvar support 
membrane (Hayat, 1986), and further coating the membrane with 0.1 % polylysine in 
dist.H20. A thin layer of gold sol was allowed to adhere, and was photographed and 
the particles were assessed for size. A size variation of less than 10% was consisdered 
acceptible for multiple labelling procedures. 
The specific binding activity of the probes was also established. A 
0.22 Ilm nitrocellulose membrane was cut to fit a Hoefer Decaprobe apparatus. The 
gasket was laid in position on top of the membrane, on the base of the assembly. A 
dilution series (2 Ill) giving 1 Ilg to approx. 10 ng of target and non-target 
immunoglobulin species was dot-blotting on the membrane and the Decaprobe 
apparatus was assembled. Residual protein-binding sites on the membrane were 
blocked with the membrane blocking solution. 
The gold probes were diluted with protein A gold or 
immunogold probe diluent to a dilution at which the gold probe gives an absorbance 
at AS20 of between 0.05 and 0.1. The relevant diluted gold probe (150 Ill) was added to 
the relevant channel in the Decaprobe, containing the target and non-target dilution 
series. The Decaprobe was rocked gently for 30 min and the unbound gold probe 
washed away with PBS or TBS (for protein A and immunogold probes, respectively), 
with 5 changes of 0.5 ml of buffer over 20 min. The Decaprobe was dismantled and 
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the entire membrane placed in a clean dish and washed thoroughly in 5 changes of 
dist.H20, in 10 min. 
The membrane was placed in the dark, the silver amplification 
reagents applied and the blot developed until the membrane-bound gold is evident 
(approx. 5 min). The silver amplification reaction was terminated by the addition of 
5% sodium thiosulphate (5 min) and the membrane was washed, dried and stored in 
the dark. 
A satisfactory binding activity was given by any probe specifically 
detecting at least 50 ng of the correct target immunoglobulin. 
2.4 The cryoultramicrotomy technique 
The thawed cryosection immunolabelling technique, used in this study, 
embodies cryoultramicrotomy, for embedding and sectioning, and the so-called 
thawed, frozen, ultrathin, section method of Tokuyasu (Tokuyasu, 1986), for 
immunolabelling and viewing in the electron microscope. Together, these constitute 
one of the mildest, quickest, but one of the most technically-demanding of the 
techniques available for immunolabelling. Cryoultramicrotomy demands excellently 
sharp glass knives and special tungsten coating of the knife edge to preserve its 
keenness. Grids need to be specially prepared; formvar and carbon coating has to be 
followed by a cleaning and charge- or hydrophilicity-inducing treatment, to enable 
thawed frozen ultrathin sections to adhere, during the subsequent washing and 
labelling steps. These technical procedures and modification of equipment will be 
described before the treatment and handling of the specimen is described. 
For the thawed cryosection technique, the specimen requires fixation, 
cryoprotection and rapid freezing, before sectiOning, immunolabelling and sealing for 
viewing in the electron microscope. Fixation may be slight, as the tissue does not 
have to withstand harsh treatment, as in resin embedding processes. Fixation (which 
will be discussed in Chapter 4) is the only potentially tissue-damaging technique in the 
Tokuyasu procedure, as labelling and viewing is performed on a fully hydrated 
specimen. Cryoprotection of the tissue is necessary, in order to prevent the damaging 
effects of ice crystal formation, during the freezing process. The tissue blocks should 
be small and frozen very rapidly to the structureless, vitreous state, rather than to a 
hexagonal or cubic crystalline state. This requires cooling at a rate> 105°C/sec, to 
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below -140°C (Dubochet et al., 1988). Plunge-freezing in liquid nitrogen is a 
convenient method for achieving such cooling rates. The frozen tissue block may be 
stored indefinitely in liquid nitrogen for subsequent sectioning. 
In this section, the technicalities of cryoultrasectioning will be considered first; 
knifemaking and the modifications made to an existing commercial knifemaker, will 
be described, followed by a description of the preparation of grids and the modification 
of a sputter-coater, used to render grids hydrophilic, before details of the Tokuyasu 
technique are given. 
2.4.1 Glass knife making and preparation 
A far sharper glass knife than is required for resin sectioning, is a crucial 
requirement for successful cryoultramicrotomy, and this puts more stringent 
demands upon the knife-making instrument. Most existing knifemakers were 
designed to make glass knives for resin sectioning and, without modification, have 
proved to be inadequate for making knives for cryoultramicrotomy. 
The principles of knife making for cryoultramicrotomy have been 
discussed by Griffiths et al. (1983). A glass knife is made by first cutting 25 x 50 mm 
rectangles from a strip of glass (5 x 25 x 400 nun) and then bisecting the rectangles to 
make two squares from each. The reason for adopting this approach is so that, when 
the final break is made, there will be equal weights of glass on either side of the 
fracture, resulting in accurate breaks, with the fracture plane at right-angles to the 
surface of the glass. Finally, the cutting edge is produced by making a diagonal score 
line across the 25 nun squares and applying a tensile stress across the score. 
The sharpness of the cutting edge is determined by how close the break 
comes to passing through the two opposite comers of the glass squares - a theoretical 
ideal would be for the fracture to pass accurately through the comers, bisecting them at 
45°. In practise, the fracture veers away from the corner. How close it comes to the 
comer may be judged by measurement of the width (w) of the counter-piece, which 
should be less than 0.1 mm in a satisfactory glass knife (Griffiths et al., 1983) (Fig. 1). 
Figure 1. 
a 
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Making glass knives by fracture of a 25 mm square of glass. 
a, the score line and a theoretical break line. 
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b, the nearness of the break to bissecting the opposite comers of the glass and hence 
the sharpness of the knife, is indicated by the thickness (w) of the counter-piece 
edge, or complementary face (CF) in an actual break line (from Griffiths et aI., 
1983). 
Without modification, our LKB 7801B KnifeMaker was found to be 
incapable of reproducibly making knives acceptable for cryoultramicrotomy. The 
reason for the irreproducibility was found to be largely the accumulative effect of a 
number of manufacturing tolerances, and/or wear, in the clamping head and cutter 
wheel holder assembly (see Fig. 4) which, together, allowed the cutter to move 
sideways over a distance of 0.34 mm. With this amount of play in the mechanism, 
cutting to within 0.1 mm of the corner was largely a matter of chance. The 
modifications, described below, made to improve the accuracy of the mechanism, as 
well as other modifications, led to a marked improvement in the reproducibility of 
knifemaking, and a corresponding increase in the proportion of acceptable knives 
produced (at least a 100% improvement in the successs rate). 
2.4.1.1 Modification of LKB 7800 series KnifeMaker 
The KnifeMaker was first modified according to Stang (1987) 
(Fig. 2). This involved manufacture of the aluminium T-shaped holder, and 
machining of the "38" cam lobes, of the scoring selector (Fig. 3) to reduce the score 
length to 12 mm. This 12 mm score was used for all glass pieces, including long 
pieces. In addition, the following modifications were made:-
Figure 2. 
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An LKB 7800 series KnifeMaker incorporating the I-piece modification of Stang (1987) . 
The front glass holder, guide plate, guide rings, damper lever and pads shown in Fig. 3a 
are replaced by the I-piece. 
a) The play between the cutter wheel and the cutter wheel holder bracket was 
eliminated by removing the cutter wheel and bending the side plates of the cutter 
wheel holder bracket inwards, by about 0.01 mm at a time, until only a very slight 
interference fit was perceptible, between the cutter wheel and the holder bracket, but 
which nevertheless still allowed free rotation of the cutter wheel. 
b) Similarly, the play between the cutter wheel holder and the cutter wheel holder 
bracket (LKB part No. 24-10 688) (originally 0.06 mm) was eliminated by bending the 
side plates towards each other, by about 0.01 mm at a time, wltil only a very slight 
interference fit was perceptible (Fig. 3). 
c) The play (originally 0.11 mm) between the cutter wheel holder bracket and the 
scoring shaft was eliminated by machining a recess 1.3 mm (deep) x 6.5 mm x 15 mm 
into the cutter wheel holder bracket and inserting a beryllium copper spring, 0.5 mm 
thick, bent to form two lines of contact with the scoring shaft, for extra stability 
(Fig. 4a). This spring must not press too firmly against the scoring shaft, or the cutter 
wheel holder bracket will not retract after leaving the cam. 
19. Operation Instructions 
20. Angle setting plate 
21. Guide plate 
22. Front glass holder 
22a. Guiding rings '. 
23. Locking screw for (22) . 
23a. DPA-Iever (lever for 
Damping Pressure Ad-
justment) 
23b. Damping pad 
24. Locking screw for (25) 
25. Front dial 
26. Breaking pins 
27. Centre line 
28. Rear glass holder 
29. Arresting stud for 25 rT'!m 
glass strips width 
29a. Arresting stud for 38 mm 
glass strips width 
30. Foundation block (silumin-
gamma) 
31. Disengage knob 
32. Cutter wheel 
holder (see fig. 8). 
33. Screw for adjusting 
scoring pressure " 
34. Cutter wheel (sintered 
tungsten carbide) " 
35. Shaft for cutter 
wheel 
36. Locking pin 
37. Bracket for (32) 
38. Guide for (15) 
39. Allen wrench for 
adjusting scoring 
pressure 
40. Screws for (20) 
I 
YJ/ 
1. fork used to remove the 
·.glass knives from the 
apparatus 
2- Locking lever 
3. Shaft 
4. Adjusting sleeve for (8) 
5. Bracket 
6. Set screw for (4) 
a 
b 
7. Cover screw for (6) 
8. Clamping head 
9. Locking screw for (28) 
10. Support studs 
11. Locking screw for (12) 
12. Rear dial 
13. Score selector 
14. Cover plate 
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14a. Dot (marking 200 mm 
strip length) 
15 . . Scoring shaft with cutter 
wheel 
16. Support plate for glass 
strip 
17. Locking knob for (21) 
18. Breaking knob 
Figure 3. Components of LKB 7800 series KnifeMaker (from 
manufacturer's pamphlet). 
a shows the components of the unmodified knifemaker 
b shows a view of the underside of the clamping head, 
showing the cutter wheel and the scoring shaft, and 





Modifications to the LKB 7800 series KnifeMaker. 
a, The beryllium copper spring inserted to eliminate play between the cutter wheel 
holder bracket (LKB Part No. 24-10 688) and the scoring shaft . 
The arrows indicate the two lines of contact between the spring 
and the scoring shaft. 
b, The holes drilled and tapped into the clamping head to accommodate 
grubscrews . 
The arrows indicate the position of the holes accommodating teflon plugs and 
grubscrews that eliminate play between the scoring shaft and the clamping 
head. 
d) The play (originally 0.06 mm) between the scoring shaft and the clamping head 
was eliminated by drilling two 2.5 mm holes, into the clamping head (Fig. 4b), and 
tapping these with a 3 mm 1.5.0. thread. Small teflon plugs were inserted into the 
holes, followed by grubscrews that were tightened to an extent which just allowed free 
travel of the scoring shaft. 
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e) The breaking pins, which apply the breaking force to the glass, were removed, 
smoothed in a lathe with fine water paper and buffed to a polished finish. 
f) The play between the scoring shaft guide (Fig. 3, item #38) and the scoring shaft 
itself (Fig. 3, item #15) was eliminated by bending the outer "forks" of the scoring shaft 
guide outwards, a small amount, until a slight interference fit was achieved in the 
scoring shaft groove. 
The angle at which the glass breaks, which should be 90° to the 
glass surface, is determined by the exact positioning of the cutter wheel scoring edge 
over the domed breaking pins. Consequently, it is necessary that the the cutter wheel 
is accurately centralised and locked between the support studs to ensure that the score 
is directly over a line joining the axes of the breaking pins. The holes in the scoring 
shaft guide are larger than the screw diameters and so the position of the scoring shaft 
guide can be altered. Movement of the scoring shaft guide causes rotation of the 
scoring shaft and consequential lateral displacement of the cutter wheel. The 
necessary adjustment can be made, without waste, by test breaks while cutting the 
glass strips into 50 x 25 mm rectangles. If the cutter wheel is off centre, the glass will 
not fracture at right angles to the plane of the glass. If this is so, the shaft guide screws 
may be loosened slightly, the shaft guide plate moved in the appropriate direction to 
compensate, and the screws retightened. Further test cuts may be made and small 
corrections made by loosening the shaft guide screws, tapping the plate left or right 
and retightening the screws. This procedure is repeated until the break in the test 
piece is true and vertical. When the cutter wheel is properly centred, the KnifeMaker 
will break optimal knives, with cutting edges at right angles to the plane of the glass. 
Conversely, if the cutter wheel is off-centre, the resulting knives will have sub-
optimal, out-of-square cutting edges. Proper adjustment in this respect greatly 
improves the accuracy of knife breaking. 
Accurate and reproducible positioning of the glass pieces is also 
important. The rear and front glass holders have tongues which slide in slots in the 
base of the KnifeMaker. On our KnifeMaker the clearance, between the tongues and 
the slots, was about 0.11 mm, which enabled each glass holder to move left or right by 
about 0.08 mm, and this affected the reproducible positioning of the glass. The play 
was consequently eliminated, by peening the end of each slide tongue on the inner 
side and filing the raised section to a slight interference fit, using a #4 needle file. 
While this approach proved adequate, the same effect might be better achieved by the 
use of appropriately inserted captive balls and springs. 
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In addition to the modifications and adjustments to the 
KnifeMaker itself, it was found to be necessary to orientate the glass strips and glass 
pieces in the KnifeMaker in a specific manner. The glass strip should be orientated on 
the KnifeMaker with the scored long edge break downwards and the clean break edge 
upwards. When using 25 mm strips, the strip is first cut into 25 x 50 mm rectangles, 
marked as shown in Fig. Sa with a felt-tipped pen and cut into two 25 mm squares. 
The resulting squares are orientated in the Knife Maker, for breaking, as shown in 
Fig. 5b. It is important to check that the glass strips used have consistent dimensions: 
this was not true of glass strips from all manufacturers. 
Figure 5. 
b 
~~_ break line 
Orientation of glass blocks for cutting 450 knives, from 25 mm strip. 
a Marks are made on the glass rectangle as shown, using a felt-tipped 
pen, before it is cut into 25 mm squares. 
b The 25 mm squares are oriented as shown, before being broken into 
knives. 
2.4.1.2 Tungsten coating of glass knives 
score line 
The keenness of the knife edge is maintained indefinitely in 
storage and the life of the edge conSiderably prolonged by coating the knife with a thin 
layer of tungsten metal (Roberts, 1975). 
Freshly made knives were placed in an Edwards E306A high 
vacuum coater and tilted such that the line from the filament source to a knife edge 
bisected the cutting angle of the knife, allowing deposition of the metal film on both 
faces of the knife Simultaneously. A 25 mm length of 0.5 mm pure tungsten wire, 
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bent to form a "v" -shaped filament, was mounted at a distance of 8 - 10 cm from the 
cutting edge of the glass knife. The pressure in the vacuum coater was reduced to 
5 x 10-5 Torr, and the filament was cleaned by briefly heating, with a guard in place 
between the knives and the filament. The guard was removed and the tungsten was 
evaporated onto the cutting surface of the knives, by increasing the current through 
the filament to 80 - 90% of the value of Z, for 3-5 min (Z being the current which melts 
a filament of the same length). Coated knives were removed and stored in a 
container, stuck down at the base with double-sided tape. 
2.4.2 Preparation of grids for cryoultramicrotomy sectioning 
Before use, the 100 mesh hexagonal grids are coated with a support layer 
of formvar which, in tum, is coated with a thin layer of carbon (see Section 2.4.2.3). 
The carbon layer is hydrophobic in character and requires "activation", by the process 
of glow-discharging, to render it hydrophilic so that hydrated sections will easily stick 
to the grid. 
In the process of glow-discharging, the grid is placed in a vacuum, 
between two electrodes, in a position corresponding to the so-called Crookes' space, a 
dark zone in the purplish glow that occurs when a high voltage DC glow-discharge is 
set up between the electrodes (Benada and Pokorny, 1990). In the Crooke's dark space 
the high velocity electrons have a cleaning effect, decomposing adsorbed hydrocarbon 
molecules (Holland, 1960) and imparting a negative charge to the surface of the carbon 
layer, to which proteins will adhere (Benada and Pokorny, 1990). 
In order to effect activation of grids by glow-discharging, a Polaron 
sputter-coater was modified, as described below, using the information provided by 
Benada and Pokorny (1990) as a guide. 
2.4.2.1 Modification of sputter coater 
In both the original modification of Benada and Pokorny (1990) 
and our modification, the top plate assembly, with annular target, and the specimen 
support, of the Polaron E 15000 series sputter-coater unit, were replaced. In the 
modification of Benada and Pokorny (1990) the aluminium lid was replaced by a 
Perspex (Plexiglass) lid, a. stainless steel spacer and an aluminium disc anode. In our 
model the aluminium lid was retained, and insulation was achieved by the use of a 
PTFE spacer (20 x 40 mm o. d.) and a Perspex insulating shield. The insulating shield 
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(2 mm thick x 130 mm diameter) was placed behind the cathode (6 mm thick x 90 mm 
diameter), between it and the aluminium lid, to obviate flash-over (Fig. 6). 
In our modification the original lower plate was replaced with a 
larger anode (6 mm thick x 89 mm diameter) and a PVC support made of 3 mm wall-
thickness tubing (63 mm o. d. x 28 mm) covered with a nylon (20 mesh) support grid, 
at one end. The support is placed on top of the anode electrode, to lift the grids into 
the Crooke's dark space. The electrodes, located 40 mm apart, were attached to the 
built-in power supply, capable of delivering at least 800 kV, the lowest voltage 
required to strike the plasma when the chamber is evacuated. The chamber 
(originally filled with air) requires evacuation to at least 1.5 Torr before the plasma 
will strike. 
The higher the voltage and amperage used in the glow-
discharging process, the more damaging the action of the electrons to the formvar 
film. Optimisation procedures, varying these parameters and checking the induced 
hydrophilicity, by checking the water-wettability of the surface of the grids, and 
examination of the formvar grid surface for damage, using scanning electron 
microscopy, indicated that adequate glow-discharging may be achieved at 800kV, 
16 rnA for 10 sec. Newly prepared, carbon-coated formvar grids were treated in this 
way before the grids were used as supports for thawed cryoultramicrotomy sections. 
a b 
Figure 6 Diagram showing the key modifications of the Polaron sputter coater. 
a ~strument with glass chamber removed and lid open. 
b LId closed and glass chamber in position. 
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2.4.2.2 Formvar grid preparation 
Formvar (0.2 g) was dissolved in absolute alcohol (100 ml) and 
stored in an air-tight container. A dish (approx. 20 cm diameter x 40 mm deep) was 
completely filled with dist.H20. A cleaned glass slide is completely dipped into the 
formvar, drained briefly and allowed to dry. The dried formvar film was loosened 
around the edges of the slide, with a blade, and floated off onto the surface of the 
water. Copper grids (100 mesh, hexagonal) were placed, shiny side up, on the floating 
film. The film was recovered from the surface of the water, using a circular, 
downward scooping action, through the water, bringing the grids up out of the water 
with the film, covering the dull surface, uppermost on a square piece of wire mesh or 
a glass slide. The film-covered grids were allowed to dry before being carbon-coated 
and glow-discharged. 
2.4.2.3 Carbon-coating and glow-discharging of grids 
Grids were coated with a thin layer of carbon from a graphite 
source rod in an Edwards E306A high vacuum coater. At a vacuum of 10-5 Torr, the 
variable transformer is adjusted until the evaporation point of carbon is reached, and 
evaporation is maintained for 10 secs. The thickness of the carbon deposit may be 
judged from a piece of white paper inserted under the grids before the coating 
procedure. This should show a faint shadow around the wire mesh or glass 
supporting the grids. 
The grids were rendered hydrophilic by placing them in the 
modified sputter coater (see Section 2.4.2.1), under a vacuum of approx. 0.5 Torr and 
discharging a current of 16 mAmps for 10 secs. The vacuum was broken and the grids 
removed and stored in a petri dish for use. 
2.4.3 The "Tokuyasu" thawed cryosection technique 
The Tokuyasu thawed frozen hydrated section technique, involves 
tissue fixation, trimming, cryoprotection, mounting on a stub for insertion into the 
cryoultramicrotome, rapid freezing in liquid nitrogen and sectioning before 
immunolabelling (Griffiths et al., 1983; Tokuyasu, 1986; Griffiths, 1993). The related 
technique of embedding of cells in gelatin, before trimming, cryoprotection, freezing-
and-sectioning of tissue blocks, immunolabelling, and contasting-and-sealing of the 
section for viewing in the electron microscope, is also described in this Section. 
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The fixatives used in this study are described in Section 2.3.2 and the 
fixation protocols, being antigen-specific, are described in Chapter 4. 
Infusion of cryoprotectants such as sucrose, containing polyvinyl 
pyrrolidone (PVP) or polyvinyl alcohol, into chemically fixed specimens, before 
freezing, has been claimed to give superior sectioning plasticity to frozen tissue 
(Tokuyasu, 1989). Infusion with sucrose (2.1 - 2.3 M), however, generally provides 
adequate sectioning plasticity for ultrathin sectioning, at temperatures of between -80° 
to -110°C. Higher concentrations of sucrose make the block relatively brittle at 
sectioning temperatures below -120°C, whereas infusion with lower concentrations of 
sucrose causes the blocks to be harder but more brittle. In this study 2.lM sucrose was 
used as a cryoprotectant and the cutting temperature was -100°C. 
2.4.3.1 Reagents 
2.1 M Sucrose in PBS, pH 7.2. AR grade sucrose (71.8 g) was 
dissolved and made up in 100 ml PBS, pH 7.2. 
2.3 M Sucrose in PBS, pH 7.2. AR grade sucrose (78.7 g) was 
dissolved and made up in 100 ml PBS, pH 7.2. 
10% Gelatin for embedding cells. Microbiological grade gelatin 
(Merck, Darmstadt) (10 g) was added to 100 ml boiling dist.H20, heated to dissolve and 
chilled rapidly on ice. Chilled dist.H20 was poured on top of the gelatin and left 
overnight at 4°C. The dist.H20 was decanted and the gelatin aliquotted and stored at 
4°C. 
3% Aqueous uranyl acetate. Uranyl acetate (3 g) was dissolved in 
dist.H20 , made up to 100 ml and stored in the dark. This solution was made up freshly 
every 2 months. 
2% Methyl cellulose. Methyl cellulose (25 centipoises, Sigma 
M6385) (2 g) was added to dist.H20 (100 ml) and left to dissolve for a few days at 40C 
before centrifugation at high speed (185 000 x g, 1 h,4°C). The supernatant was stored 
at 4°C for up to 4 weeks. 
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0.3% Uranyl acetate/Methyl cellulose contrasting-and-sealing 
reagent. Immediately before use (within 15-30 min of use) methyl cellulose (9 parts) 
was mixed with 3% uranyl acetate (1 part) and stored on ice until required. 
2.4.3.2 Procedure 
After fixation (see Chapter 4), tissues were trimmed to approx. 1 x 
1 x 1 mm, to give a trapezoid shaped surface to be sectioned, cryoprotected by 
infiltration with 2.1 M sucrose (15 - 30 min, depending on the size of the tissue block) 
and mounted on a stub, for insertion into the microtome. Excess sucrose was 
removed from around the block, and the block was frozen by plunge-freezing. The 
block was also agitated in liquid nitrogen (-190°C) to ensure a maximal rate of heat 
exchange and cooling, and was stored in liquid nitrogen for use. 
Non-adherent cells, such as leucocytes, require embedding to 
keep them together during cryoprotection. In such cases, residual reactive aldehyde 
fixative was quenched by washing the cells in 0.02 M glycine in PBS (PBS-glycine), in 
an Eppendorf tube. Excess PBS-glycine was removed and a few drops of warm, liquid 
gelatin (at approx. 30°C) was added and allowed to infiltrate for up to 15 min at the 
lowest temperature at which the gelatin remained liquid. Excess gelatin was removed 
and the gelatin-embedded block was set by cooling on ice. The gelatin block was 
trimmed and cryoprotected, mounted, frozen and stored as before. Inadequate 
infiltration of sucrose, during cryoprotection, results in an opaque block, indicative of 
the presence of cubic or hexagonal ice. Such a block crumbles upon sectioning and is 
thus impossible to section. 
Each specimen for sectioning was transferred to a pre-cooled 
(-100°C) cryoultramicrotome chamber of an RMC MT6000XL ultramicrotome, fitted 
with a CR2000 cryo attachment, and allowed to equilibrate. Sectioning was performed, 
using a tungsten-coated knife, at a block and knife temperature of -100°C and a cutting 
speed of less than 1 nun/ sec. Sections are manipulated off the knife-edge with an 
eyelash attached to the end of a wooden applicator stick, and collected on a droplet of 
2.3 M sucrose, in a 1 nun nichrome wire loop. The droplet is brought in to the 
chamber quickly enough for the sucrose still to be liquid, when the loop approaches 
the knife, from which the sections are gathered. As the loop is brought within 1 nun 
of the sections on the knife, the sections "jump" onto the sucrose and adhere to the 
underside of the drop. If the droplet, used to retrieve the sections, freezes before the 
loop is withdrawn from the chamber, the sections do not flatten out, and remain 
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wrinkled. If the loop is withdrawn quickly enough, the section and sucrose thaw, and 
the section flattens out on the droplet of sucrose. 
As the droplet of sucrose is brought out of the chamber, carrying 
the section(s), and is placed in contact with a glow-discharged grid, the section(s) 
adhere(s) avidly to the surface of the grid. The grid and section are lifted, with the 
loop, on the drop of sucrose, and the grid is floated off, section-side-down, onto PBS in 
a 35 mm Petri dish. Sections are kept on PBS until labelled. 
Immunolabelling was performed by incubation of the grid, 
section-side-down on droplets of reagents on Parafilm. Grids were transferred from 
reagent to reagent with a 1 mm nichrome wire loop. (Loop carryover causes a 
dilution factor in the final concentration of antibody, used in labelling, therefore, the 
same loop should be used in all labellings subsequent to labelling optimisation). 
Various blocking procedures were used, before immunolabelling. Sections were 
blocked in 0.02 M glycine in PBS, 10% foetal calf serum, 1% BSA in PBS or 1% fish skin 
gelatin (Section 2.3.3) for between 15 to 30 min, and unless stated otherwise, exposed 
(1 h, RT) to primary antibody (10 Ill, diluted in 1% BSA in PBS or 5% foetal calf 
serum), washed in 50 III changes of PBS (6 x 20 min), treated for 30 min with secondary 
antibody or protein A gold probe (10 Ill), washed as before, and fixed in 1% 
glutaraldehyde in PBS (5 min). The sections were washed on dist.H20 (4 changes, total 
time, 5 min) and counterstained in 0.3% uranyl acetate/methyl cellulose, by 
transferring quickly through two changes of this reagent and incubating on a further 
50 III drop, on ice (10 min). 
Finally, the grids were removed from the uranyl acetate/methyl 
cellulose medium, on drops of this reagent suspended from a nichrome wire loop (of 
3-3.5 mm diameter, just slightly larger than the grid). Excess medium was removed 
with fiber-free filter paper, leaving the grid supported in the loop by a thin layer of 
medium. The final residual support film should dry to give a gold-blue interference 
colour. The thickness of the film is critical with respect to both contrast and fine 
structure preservation. Should the film break or be too thin, the section will be 
exposed and irrevocably damaged due to drying artefacts. If too thick, depending on 
the final thickness of the film, illumination problems will be experienced in the 
electron microscope, as the beam passes through the film less easily. 
Once the uranyl acetate/methyl cellulose film dries, the grid 
must be carefully removed, without tearing away the sealing layer covering the 
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section, by piercing the film between the loop and the outer periphery of the grid. The 
grid was viewed in a Jeoll00CX transmission electron microscope, at 100 kV. 
25 LR White resin embedding 
Recognition of the cathepsin B antigen, by the anti-human liver cathepsin B 
antibody, appears to require a harsh tissue embedding procedure, to denature the 
antigen. The dehydration and embedding procedure involved in processing tissues 
for LR White resin embedding, seemed to promote denaturation sufficiently to permit 
labelling for cathepsin B. 
LR White is a hydrophilic, methacrylate resin which polymerises at 50°C, in 
the absence of oxygen. It can tolerate dehydration to only 70% and generally is 
preferable to epoxide and polyester resins, as it is less damaging to tissue antigens. The 
hydrophobic epoxide and polyester resins require "etching" with strong alkalis or 
H202, to introduce hydrophilic groups into the resin. They also require heat 
polymerisation at 70°C for 48 h and absolute dehydration; features that would be 
potentially damaging to the survival of many antigens. The LR White resin offers a 
compromise. It is inferior to the hydrophilic Lowicryl resins, in that it tends to be 
unstable in the electron microscope beam and gives rise to polymerisation artefacts, 
but it requires none of the specialised equipment required for Lowicryl resin 
embedding, such as low temperature refrigeration and UV light sources, to effect 
polymerisation. 
LR White polymerisation can be promoted by the addition of a catalyst, or 
allowed to occur spontaneously at 50°C. Catalyst-induced polymerisation, is 
exothermic and gives rise to marked tissue distortion due to uneven heating. When 
polymerisation is allowed to occur spontaneously in gelatin capsules (an oxygen-free 
environment) at 50°C, however, tissue morphology is adequately preserved. This 
procedure was, therefore, used in preference. 
2.5.1 Fixation 
Tissue blocks were variously fixed (see Section 2.3.2 and Chapter 4). 
Sl 
2.5.2 Dehydration and embedding 
2.S.2.1 Reagents 
25%, 50% and 70% alcohol. Absolute alcohol (25, 50 and 70 ml) 
was made up to 100 ml with dist.H20, in each case. 
LR White resin. LR White resin was obtained from Wirsam 
Scientific, South Africa. 
Uranyl acetate. Uranyl acetate (1 g) was dissolved in dist.H20 
(SO ml), solubility being assisted by the addition of 9S% ethanol (1 ml). Uranyl acetate 
is light sensitive and should be kept out of the light, and stored at 4°C. 
Lead citrate. Lead nitrate (1.33 g) and trisodium citrate.2H20 
(1.76 g) were added to freshly boiled and cooled double dist.H20 and shaken 
continuously for 1 min, then intermittently for 30 min. NaOH (8 ml of freshly made 
1 M solution) was added to clear the milky solution. The solution was adjusted to 
50 ml with freshly boiled and cooled double dist.H20 and stored in the refrigerator in 
an air-tight container, in a foil wrapper. 
2.5.2.2 Procedure 
Fixed (see Chapter 4) human splenic tissue blocks (approx. 2 x 2 x 
2 mm) were dehydrated through 25% and 50% alcohol (15 min each), followed by two 
changes of 70% alcohol (1 h each). Tissue blocks were transferred to increasing 
amounts of LR White in ethanol (1:1 for 30 min; 2:1 for 20 min) and into pure LR 
White (60 min) followed by overnight in a further change of resin (Newman et al., 
1983). 
Each tissue block was transferred to a gelatin capsule. The 
capsule was completely filled with resin and polymerisation effected at SO°C for 24 h. 
Blocks showing any sign of softness were reincubated for a further 24 h. The gelatin 
capsule was removed and the block trimmed and mounted on a stub and sectioned on 
an RMC MT 6000XL ultramicrotome. Sections with a gold (60-70 nm thick) or silver-
gold (50-60 nm) interference colour were collected on 200 mesh copper or nickel grids, 
and allowed to dry overnight before immunolabelling. 
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Immunolabelling was performed by incubation of the grid, section-side-
down on droplets of reagents on Para film. Transfer of grids from reagent to reagent 
was effected with a 1 mm nichrome wire loop. Sections were blocked in 0.02 M 
glycine in PBS, 10% foetal calf serum, 1% BSA in PBS or 1% fish skin gelatin (Section 
2.3.3) for between 15 to 30 min, arid unless stated otherwise, exposed (1 h, RT) to 
primary antibody (10 Ill, diluted in 1% BSA in PBS or 5% foetal calf serum), washed in 
50 III changes of PBS (6 x 20 min), treated for 1 h with secondary antibody or protein A 
gold probe (10 Ill) and washed as before. The sections were washed in a jet of dist.H20 
and counterstained on a droplet of uranyl acetate (10 min). This was followed by jet 
washing in dist.H20 and incubation on droplets of lead citrate (10 min) in a closed 
petri dish, into which pellets of NaOH have been placed to remove C02. The grids 
were finally jet washed in a stream of dist.H20, dried and viewed in a Jeol 100CX 
transmission electron microscope, at 80 kV. Specific details of immunolabelling 
procedures are given in Chapters 4 and 5. 
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CHAPTER 3 
PRODUCTION AND CHARACTERISATION OF PEPTIDE. AND POLYCLONAL 
ANTIBODIES 
3.1 Introduction 
At the time when this study was initiated, no comprehensive study had yet 
been undertaken to substantiate unequivocally the involvement of any specific 
proteinase in the invasion process, using the direct immunocytochemical approach. 
Abnormally high levels of cathepsin B, as well as unusual, secreted, high molecular 
weight forms of this enzyme, have, however, been demonstrated in a number of 
human and animal tumours, using classical biochemical fractionation techniques 
(Sloane et aI., 1987; 1990). The increased amounts of intra- and extracellular 
cathepsin B (Sloane et aI., 1981; 1982; Rozhin et aI., 1990), increased number of 
cathepsin B mRNA transcripts (Murnane et aI., 1991), and the association of 
cathepsin B with the plasma membrane (Sloane et aI., 1986; 1987; Erdel et aI., 1990) 
have also been correlated with tumour metastatic potential. In the present 
investigation, therefore, the aim was primarily to substantiate the validity of 
extrapolations, from biochemical isolation procedures to invasive potential, by 
exploring the distribution of cathepsin B in invasive cells, using 
immunocytochemistry. In principle, either conventional polyclonal or peptide 
antibodies could be used for this purpose. 
Peptide antibodies (Bulinski, 1986) are polyclonal but are directed at a particular 
peptide sequence, usually consisting of from six to twenty amino acids, selected from 
the protein primary structure. A peptide, corresponding to the so-called "target" 
sequence, is synthesised and used to raise peptide antibodies which, ideally, will 
subsequently recognise and react with the target sequence in the native protein. The 
fact that the target sequence can be selected, gives peptide antibodies a particular 
utility, which has been exploited for several different purposes in the present study. 
For the immunocytochemical localisation of cathepsin B, peptide antibodies 
have a potential advantage over conventional antibodies. Most polyclonal antibodies 
against mature cathepsin B, raised in laboratory animals, only recognise the denatured 
form of the enzyme (Barrett, 1977; Graf et al., 1981; Wardale et aI., 1986). The 
cryoultramicrotomy approach, selected for this study partly because of its speed, is also 
particularly mild. This favours the survival of labile antigens and is, consequently, an 
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advantage in most cases. In the specific case of cathepsin B, however, the enzyme may 
be insufficiently denatured to be recognised by polyclonal antibodies; this is discussed 
more fully in Chapter 4. Peptide antibodies, targeting a linear sequence of amino 
acids, however, may recognise the protein in either its native or denatured forms, 
depending upon the accessibility of the peptide sequence in the structure of either 
form, and may, therefore, be more suited to the immunocytochemical localisation of 
cathepsin B in cryoultrasections. 
Peptide antibodies are also potentially useful for labelling studies designed to 
locate and identify precursor forms of cathepsin B. Various high molecular weight 
forms of procathepsin B, presumably processing intermediates, have been identified 
(Mort et al., 1983; Mort and Recklies, 1986; Buttle et al., 1988; Buttle and Abrahamson, 
1990). Many of these high molecular weight intermediates are secreted, for example by 
lactating mouse and rat mammary glands (Recklies et al., 1985), mammary tumours 
(Recklies et al., 1982a) and malignant human breast tumour explants (Mort et al., 1980) 
and have been found in the ascitic fluid of patients with neoplasia (Mort et al., 1983). 
These secreted high molecular weight forms of cathepsin B exist in three different 
states: fully active, partially active and latent, the active enzyme being secreted to a 
greater degree by malignant than non-malignant tumours (Mort and Recklies, 1986). 
These forms are stable at alkaline or neutral (physiological) pH and may be most 
relevant in tumour invasion, especially as they are resistant to inhibition by the 
proteinase inhibitor, u2-IIlacroglobulin (Mort and Recklies, 1986) and have a decreased 
tendency to be inhibited by cystatins, their natural inhibitors (Buttle et al., 1988). This 
is in marked contrast to the mature enzyme which is labile at physiological pH and 
would, therefore, probably be inactive if secreted, and would also be more subject to 
inhibition. 
The peptide antibody approach also offers a unique way of studying the 
properties and distribution of intermediately processed forms of cathepsin B. 
Cathepsin B, like most proteinases, is synthesised in a pre-pro- precursor form. The 
Mr of procathepsin B, after cleavage of the pre- (signal) peptide, is calculated, from its 
cDNA, to be 35 900, and measured to be 40 000 in its glycosylated state (Chan et al., 
1986). The "latent" and active high molecular weight forms of cathepsin B, found in 
cell cultures of tumour explants and cancer cells (Mort and Recklies, 1986), were found 
to have a roughly corresponding molecular weight (Mr 33000) after deglycosylation. 
A similar, high molecular weight, active, form of cathepsin B, stable to alkali 
pH, has been found in sputum (Buttle and Abrahamson, 1990). Sputum cathepsin B 
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appears to have a molecular weight intermediate to that of the entire procathepsin B 
precursor sequence (Mr 35900 from the cDNA sequence) and the mature form of the 
enzyme [Mr 27 600 for the human liver enzyme, on the basis of the amino acid 
sequence (Ritonja et ai., 1985)]. For this reason, it has been speculated that this variant 
may be a procathepsin B intermediate, which has retained only the C-terminal portion 
of the pro cathepsin B sequence, to give a "truncated form" of procathepsin B (Buttle 
et ai., 1988; Buttle and Abrahamson, 1990). In order to investigate the relative 
distribution, and hence the relevance of such cathepsin B variants, in tumours and 
invasive cells, peptide antibodies which would recognise either the entire 
procathepsin B or the "truncated" form, were raised. To do this, target peptide 
sequences were selected from positions "early" and "late" in the pro-peptide sequence. 
In addition to the use of anti-cathepsin B antibodies in immunolocation 
studies, it was decided to take a longer-term view and consider what may be done, by 
way of therapy, if the immunocytochemical studies were to reveal that cathepsin B 
was, in fact, involved in tumour invasion. In this regard, it was considered that, by 
judicious choice of a target peptide, one might be able to elicit peptide antibodies 
which, upon reaction with the intactenyzme, would block its activity. Such an 
approach, using immuno-inhibitory peptides antibodies, could be envisaged to lead to 
immunotherapies of two types; passive immunotherapy, where administration of the 
antibody itself could be used to block invasion, and active immunotherapy, where the 
target peptide may be used as a "vaccine", able to induce production of the protective 
antibodies by the patient's own immune system. Although this approach is 
conceptually simple, there are many practical problems which would have to be 
addressed, not least the problem of autoimmunity and that of accessibility of the 
antibody to the invasion front. Nevertheless, this approach was considered to have 
sufficient potential to warrant preliminary investigation here. Consequently, in this 
study, peptide antibodies against mature cathepsin B were selected for their potential 
in two respects, for immunocytochemistry and for enzyme immunoinhibition, as this 
was considered the most cost-effective approach. 
The ultimate aim of the immunolabelling studies undertaken was to 
determine the relevance of precursor and mature forms of cathepsin B, as well as 
other enzymes, in the invasion process of human tumours. Early on it was realised, 
however, that a great deal of preliminary methods-development work was necessary, 
as none of the required methods were extant in this laboratory, nor indeed at the 
University of Natal, at that time. For the purposes of methods-development, a readily 
accessible model of a human invasive cell was required and for this purpose it was 
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decided to use human leucocytes, especially neutrophils and monocytes. Also, since it 
was intended that mainly human tissues were to be studied, peptide antibodies were 
raised against human sequences. For the limited investigation undertaken, the 
antibodies that were deemed necessary, were antibodies to cathepsin B (both to the 
full- and truncated precursors, and to mature cathepsin B); to cathepsin D, a marker 
enzyme for lysosomes; to the major neutrophil proteinases, elastase and cathepsin G, 
and to the neutrophil granule marker enzymes, lactoferrin and myeloperoxidase. 
3.2 Polyclonal antibodies against whole proteins 
Rabbit antibodies against sheep IgG and chicken IgY, and against mature 
cathepsin D, were raised in this laboratory from PEG precipitates of sheep IgG and 
chicken IgY (Polson et al., 1985), and from purified antigens from human; porcine and 
bovine splenic tissue Gacobs et al., 1989), by Theresa Coetzer and Philip Fortgens, ' 
respectively. Sheep antibodies, raised and affinity purified against mature human 
liver cathepsin B, were provided by Dr D. Buttle, Strangeways Research Laboratory, 
Cambridge, UK, and rabbit anti-human leucocyte elastase antibody was supplied by Dr 
J. Travis, Department of Biochemistry, University of Georgia, Athens, GA. The anti-
cathepsin G, lactoferrin and myeloperoxidase antibodies were from Serotec Ltd, 
(Oxford, England), Sigma Chemical Co. (St Louis, Mo.) and Dakopatts (Glosstrup, 
Denmark), respectively. 
3.3 Peptide selection for production of antibodies against pro- and mature 
cathepsin B 
Two peptides in the sequence of human procathepsin B (residues 17-79, 
numbered from the prepro- amino terminus), were chosen, one from the amino-
terminal end of the procathepsin B sequence, residues 22~36 (denoted ppB22-36), and 
one from the C-terminal end, residues 64~77 (denoted ppB64-77) (Fig. 7). These were 
selected to represent the complete and the "truncated" forms of the pro-sequence, 
respectively (Buttle et al., 1988; Buttle and Abrahamson, 1990). The "truncated" 
sequence would, presumably consist of about 50% fewer pro-sequence residues, the 
residues being removed from the amino-end of the pro-sequence. Pep tides 
representing these two sequences were synthesised by Dr G. Knight' of Strangeways 
Research Laboratories, Cambridge. 
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The chosen sequences of the human cathepsin B were compared with the 
corresponding mouse sequences, to assess the likelihood of cross-species reactivity 
between the anti-human sequence antibodies produced and mouse cathepsin B (Chan 
et al., 1986) (Fig. 7). Such cross-reactivity would be useful for envisaged studies on the 
BL16-BL6 mouse melanoma cell line. In the case of ppB22-36, 11/15 residues are 
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Figure 7. Human and mouse procathepsin B sequences showing selected peptide sequences 
ppB22-36 and ppB64-77. 
Bold, underlined sequences represent human sequences chosen for synthesis. Those 
underlined with a broken line represent mouse residues homologous to those from the 
selected human sequence (from Chan et aI., 1986). 
The procathepsin B sequence is too short to allow much latitude in the 
selection of target peptide sequences on the basis of the commonly-used criteria of 
hydrophilicity and flexibility (Figs. 8 and 9). Sequence ppB64-77 is more hydrophilic 
than sequence ppB22-36 which has both hydrophilic and hydrophobic character (Fig. 8) 
(Hopp and Woods, 1981; 1983). Both pro-sequence peptides selected were sequences 
showing peaks of flexibility (Fig. 9). 
In the mature enzyme, target sequences were similarly selected by 
consideration of hydrophilicity and segmental mobility (flexibility) (Figs 8 and 9), and 
by inspection of the published 3-D structure of the analogous enzyme, papain (since at 
the time the 3-D structure of cathepsin B had not been published). The 3-dimensional 
structures of cathepsins B, Hand L were deduced, from amino acid sequence 
information, to be comparable to that of papain (Kamphuis et al., 1985; Dufour, 1988), 
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Hydrophilicity plot of the human preprocathepsin B sequence (Hopp and Woods, 
1981; 1983). 
The bold lines indicate the four peptides, ppB22-36, ppB64-77, B13-22 and BI92-201, 
selected from the sequence of procathepsin B. The prepro-sequence contains 79 
residues, which must be subtracted from the preprocathepsin B residue numbers 
indicated, to obtain the residue numbers in the mature enzyme. 
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Flexibility plot of the human preprocathepsin B sequence (Westhof et al., 1984). 
The bold lines indicate the four pep tides, ppB22-36, ppB64-77, B13-22 and BI92-201, 
selected from the sequence of preprocathepsin B. 
so the 3-D structure of papain, as published by Wolthers et al. (1970), was used in the 
choice of peptide. Consideration of the 3-D structure was necessary in the choice of 
peptide to raise antibodies having a high probability of being immunoinhibitory. In 
order to elicit immunoinhibitory antibodies, the peptide sequence should be accessible 
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to antibody binding and should also involve the substrate-binding cleft, and preferably 
some active site residues. 
The numbering of papain's residues and the alignment of the equivalent 
residues in cathepsins B, Hand L is slightly different in different publications 
(Wolthers et al., 1970; Kamphuis et al., 1985; Dufour, 1988; Musil et al., 1991; 
Wiederanders et al., 1991), but for ease of reference the 3-D structure and the 
numbering of papain according to Wolthers et al. (1970), will initially be used (Fig. 10). 
The selected residues will then be converted to the equivalent numbering of papain 
and cathepsin B, as given by Musil et al .. (1991), and aligned with equivalent residues 
of cathepsins H and L according to Wiederanders et al. (1991), using the papain 
numbering of Musil et al. (1991) (Fig. 11). 
Figure 10. 
Sequence 1 
3-D structure of papain (from Wolthers et al., 1970). 
The three target sequences for peptide synthesis (sequences I, 2 and 3) are within the 
active site deft, which runs roughly vertically across the centre of the papain structure. 
Large arrow, active site His-159; small arrow, active site Cys-25. 
Inspection of the 3-dimensional structure of papain (Fig. 10), reveals three 
potential target peptide regions, for raising antibodies with the required properties. 
The three choices were, either from an accessible loop of amino acids containing the 
active site histidine (residues 150-7161 of the mature papain enzyme, designated 
"sequence I"), from a helical sequence around the active site cysteine at position 25 
(designated "sequence 2") and a hinge region (residues 9-719, designated "sequence 3", 
just preceding the active site cysteine sequence) (Fig. 10). 
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Of these three potential choices, only two peptides were considered suitable. 
Sequence 1, containing the active site histidine, appeared to be a suitable choice for the 
production of peptide antibodies against a specific cathepsin, as there is no inter-
cathepsin sequence homology in this region (Wiederanders et al., 1991, and Fig. 11). 
Human cathepsin B: Q H V T G EMMGGHAV (res 192-201) 
Human cathepsin H S C H K T PDKVNHAV (res 149-161) 
Human cathepsin L: E P D C S SEDMDHGV (res 153-165) 
Papain 
Figure 11. 
F V G P C GNKVDHAV 
Comparative sequences for cathepsins B, Hand L containing the active site histidine 
(Sequence 1). 
Alignment has been made according to the histidine residue (bold) using the residue 
equivalents of Wolthers et al., (1970) but the numbering and sequence of cathepsin B 
as given by Musil et al., (1991) and of cathepsin Hand L as given by Wiederanders 
et al. (1991). [The numbering of res . 150 - 161 of papain, according to Wolthers et al., 
(1970) is given as res. 149 -161 by Musil et al. (1991)]. Chosen sequences are indicated by 
underlining. 
Residues in sequence 2 (Fig. 10) are, however, highly conserved (Dufour, 1988, 
Wiederanders et al., 1991), so that antibodies raised against peptides in this region 
would probably be non-discriminating. This region is also a-helical and the 
discontinuous strip-of-helix epitope may be more difficult to model than a simple 
linear epitope. All these factors made sequence 2 an unsuitable choice. 
The choice of peptide sequence for the production of immunoinhibitory 
antibodies to cathepsin B, was, therefore, between sequence 1 and sequence 3. This 
study was, however, part of a group study (subject to economic constraints) on 
immunoinhibitory peptide antibodies. Sequence 3 was an unsuitable choice for 
cathepsin L, due to high sequence homology in this region between cathepsins L and 
H (Ritonja et al., 1988), but the cathepsin B sequence was different from both the 
cathepsin L and H sequences in this region. Sequence 3 was, therefore, chosen for the 
production of anti-cathepsin B antibodies, while sequence 1 was selected for the 
production of the anti-cathepsin L antibodies. Due to the similarity in structure of the 
different cathepsins (Dufour, 1988), the decision to choose sequences from different 
peptide sequences within the 3-D structure, for the production of the anti-cathepsin B 
and L peptide antibodies, was taken in order to potentially maximise the information 
gained from the experiments. 
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Selection of sequence 3 (residues 9-719, Fig. 10) as a target for the production of 
immunoinhibitory anti-cathepsin B antibodies, was considered a potentially good 
choice. The sequence is near to the active site cysteine (residue 25), an important 
region for enzyme activity, as judged by the sequence conservation in this region 
(residue 23-733) and yet has a reasonably high hydrophilicity (Fig. 8) and segmental 
mobility profile (Fig. 9), suggesting it would be immunogenic. Antibodies binding to 
this peptide sequence could also potentially occlude the active site cleft (Fig. 10) and 
thus immunoinhibit the enzyme. Papain residues 9-719 (Wolthers, 1970) correspond 
to papain residues 10-718, according to Musil et al. (1991), and residues 13-722 in 
mature human cathepsin B (Chan et al., 1986; Musil et al., 1991). The selected peptide 
was consequently denoted B13-22. 
Figure 12. 
Human: w p 0 CPT IKE I R D Q G S C 
Mouse: 
Residues 13-22 of human liver cathepsin B chosen for the production of a potentially 
immunoinhibitory antibody (Sequence 3). 
The equivalent mouse sequence is given below, with residues common to those chosen 
from the human sequence underlined (Chan et al., 1986; Musil et a/., 1991). 
Mouse cathepsin B has 8/10 residues in common with human cathepsin B in 
the B13-22 peptide, indicating a fairly high probability of useful cross-reactivity 
(Fig. 12). 
As detailed below, in practice the peptide B13-22 proved unsuccessful in 
eliCiting antibodies capable of recognising and inhibiting the activity of mature 
cathepsin B, whereas antibodies against sequence 1 proved successful in both respects 
for cathepsin L (Coetzer et al., 1991) and H (Coetzer, 1993), and were subsequently used 
in labelling studies (see Chapter 5). Consequently, in a second round of peptide 
synthesis, sequence 1 was selected as a target for raising potentially immunoinhibiting 
peptide antibodies against human cathepsin B (Fig. 10). The selected peptide, denoted 
BI92-201 (Fig. 13), was compared with that of mouse cathepsin B (Chan et al., 1986). In 
peptide B192-201, 6/10 residues, in a continuous stretch, are identical, so that cross-
reactivity is again at least possible. 
Figure 13. 
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Human: Y Q V T GEM M G G m~ R L G W G 
Mouse: YKHEAGDMGGmAIRILVWG 
A peptide sequence of human and mouse cathepsin B (Sequence 1) showing the 
chosen human sequence B192-201 and the equivalent mouse sequence (Chan et aI., 
1986). 
The bold underlined sequence represents the sequence chosen for synthesis, and that 
underlined with a broken line, represents mouse residues identical to those selected 
from the human sequence. The active site histidine is indicated. 
3.4 Peptide synthesis 
The procathepsin B peptides, ppB22-36 and ppB64-77 (Fig. 7), were synthesised 
by Dr G. Knight, of Strangeways Research Laboratory, Cambridge, UK. An extra 
glycine and cysteine residue was added to both C-termini to facilitate conjugation via 
the cysteine residue at the carboxyl end of the peptide, using the heterobifunctional 
cross-linking reagent, NHS-bromoacetate. The N-terminal serine of ppB22-36 was 
acetylated in order to "block" the charge on this residue, which is not present in the 
protein. 
The two peptides, B13-22 and B192-201, selected from the mature human liver 
cathepsin B sequence, were custom synthesised by Multiple Peptide Systems, San 
Diego, CA. B13-22 was synthesised with an additional cysteine residue added to the 
carboxyl end of the peptide and an a-amino butyric acid residue was substituted for 
the existing cysteine. This was done to allow conjugation via the added carboxy-
terminal residue, rather than the existing cysteine, using m-maleimidobenzoyl-N-
hydroxysuccinimide (MBS). The N-terminal amino acid was acetylated only in the 
case of B13-22, as it was intended that conjugation of this peptide should be effected 
via the C-terminus. In the case of B192-201, this was not done as the N-terminal 
residue was required for coupling, using glutaraldehyde. 
The second peptide, B192-201, was also synthesized with alkylation of the two 
methionine residues and an amide on the carboxyl terminus of the peptide. The 
modification of the methionine residues was designed to block these reactive sites 
during synthesis and coupling procedures, while the addition of an amide group 
blocks the negatively charged carboxyl group and makes the peptide mimic the 
situation in a protein more closely (Multiple Peptide Systems technical bulletin). 
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3.5 Peptide (carrier protein conjugation 
3.5.1 Procathepsin B peptide-carrier protein conjugation 
The procathepsin B peptides (ppB22-36 and ppB64-77) were conjugated 
to keyhole limpet haemocyanin (KLH), via the amino groups of the KLH and the 
cysteine residues added to the carboxyl ends of the pep tides, using the 
heterobifunctional cross-linking reagent, NHS-bromoacetate in a modification of the 
procedures of Davies et al. (1988) and Bematowvicz and Matsueda (1986), as reported 
below. The peptide ppB22-36 was conjugated to KLH in a molar ratio of approximately 
1:39 and the antibody raised (using intramuscular injections of 400 Ilg of peptide, into 
each of two rabbits) by Dr D. Buttle, Strangeways Research Laboratory, Cambridge, UK. 
This antibody was supplied as a non-affinity purified, uncharacterised, IgG fraction. A 
similar conjugation and inoculation procedure was used by the present author for the 
peptide ppB64-77. 
3.5.1.1 Reagents 
KLH and N-hydroxysuccinimidyl (NHS-) bromoacetate were 
obtained from Sigma. Dimethyl formamide (DMF), originally from Holpro, was 
obtained from the Natal Institute of Irrununology, where it had been redistilled. The 
DMF was tested for free amines (Sanger, 1945) and stored over a molecular sieve. 
Reduction buffer A [0.02 M sodium phosphate buffer, 8 M urea, 
pH 8.0,]. NaH2P04.H20 (0.675 g) and urea (120.1 g) were dissolved in 225 ml of 
dist.H20 , titrated to pH 8.0 with NaOH and made up to 250 ml. 
Buffer B [0.1 M potassium phosphate buffer. 1 mM EDTA, 
0.02% NaN3, pH 7.0]. KH2P04 (13.61 g), Na2EDTA (0.372 g) and NaN3 (0.2 g), were 
dissolved in 950 ml dist.H20, titrated to pH 7.0 with NaOH, and made up to 11itre. 
Buffer C [0.05 M sodium acetate buffer. pH 4.0]. Glacial acetic acid 
(1.43 ml, ~ =1.05) was added to 450 ml dist.H20, titrated to pH 4.0 with NaOH and made 
up to 500 ml. 
Buffer D [0.02 M sodium phosphate buffer. pH 7.0]. 
NaH2P04·H20 (0.675 g) was dissolved in 225 ml of dist.H20, titrated to pH 7.0 with 
NaOH and made up to 250 ml. 
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3.5.1.2 Procedure 
Reduction of the peptide ppB64-77 (8 mg) (4.94 x 10-6 moles, 
assuming an Mr of 1617), solubilised in reduction buffer A (0.27 ml), was effected by an 
almost equimolar amount of dithiothreitol (DIT) (7.33 x 10-4 g, 4.76 x 10-6 moles), at 
pH 8.0 (Cleland, 1964). After overnight reduction at room temperature, the peptide 
mixture (0.27 ml) was desalted into buffer C, pH 4.0, using a column of Sephadex G-I0 
(4 x 0.9 cm i.d.). The degree of reduction and concentration of peptide eluted at V 0 was 
determined using the Ellman's Test (Sedlak and Lindsay, 1968), the number of moles 
of sulfhydryls, calculated from the extinction coefficient of Ellman's reagent, being 
equated to the equivalent weight of the peptide in 1 ml of eluate. Removal of urea 
was checked using the Berthelot reaction (Vadey, 1967). 
Bromoacetylation of KLH was effected as follows: KLH (30 mg 
dissolved in 2 ml of buffer B) was extensively dialysed against buffer B, centrifuged to 
remove any large aggregates (10000 x g, 10 min, RT) and cooled on ice to 4°C. NHS-
bromoacetate (10.6 mg) in amine-free DMF (166 Ill), was added drop-wise, with 
stirring, the solution was allowed to warm to room temperature, over a period of 
30 min, recooled on ice and a further amount of NHS-bromoacetate (10.6 mg in 166 111 
DMF) was added and treated as before. The bromoacetylated KLH was desalted in 
buffer D on a Sephadex G-2S column (26.8 x 1.5 cm i.d.), and the concentration and 
recovery of bromoacetylated KLH was approximately calculated using the absorbance 
readings of the recovered protein at 280 nm and an extinction coefficient previously 
established for this KLH (A280 of a 1 mg/ml solution = 1.47). This allowed the 
calculation of the amount of bromoacetylated KLH to be added to the reduced peptide. 
Bromoacetylated KLH (approx. 8 mg ) (4 x 10-8 moles) in 1.3 ml 
buffer D was added to the reduced cysteine residues in the peptide (2 mg) (1.23 x 10-6 
moles) in 300 III of buffer C, in a molar ratio of ca. 1:30 of KLH to peptide. The peptide 
was added to the bromoacetylated KLH, stirred for 2 h at room temperature, and the 
KLH-peptide conjugate was re-applied to the Sephadex G-2S column (26.8 x 1.5 cm. i.d.) 
and eluted in buffer D. 
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3.5.1.3 Results 
The degree of reduction and concentration of peptide, eluted at 
Vo after reduction with DIT, was 99% and 6.4 mg/ml, respectively. 
The concentration of bromoacetylated KLH recovered in the 
pooled fractions of the eluted peak was roughly assessed to be 6 mg/ml. A total 
amount of approx. 8 mg of bromoacetylated KLH was added to 2 mg of the peptide; a 
mass ratio of 4:1 or a molar ratio of 1:30 of KLH to peptide. From the calculated 
amount of bromoacetylated KLH re-applied to the ' column and the absorption, at 
280 nm, of the single eluted peak, the recovery of KLH was estimated to be 94% (7.5 mg 
from 8 mg applied) and the eluted conjugate concentration, 2.7 mg/ml KLH. This 
gives a concentration of 0.54 mg/ml of conjugated peptide, assuming 100% coupling 
efficiency, or 0.12 mg/ml of peptide at a 22% coupling efficiency previously reported by 
Bematowvicz and Matsueda (1986). 
As the desired inoculation dosage for each of two rabbits was 
100/.1g peptide, 195 /.11 of conjugate (equivalent to 102 /.1g peptide, at 100% conjugation, 
or 20 /.1g, at a 22% coupling efficiency) was used per rabbit. 
3.5.2 Mature cathepsin B peptide-carrier protein conjugation 
Pep tides B13-22 and B192-201 were conjugated using two different 
conjugation procedures (the MBS and glutaraldehyde methods) and two different 
carrier proteins (KLH and ovalbumin). Using MBS, BI3-22 was conjugated, to free 
amino groups in KLH, via the added cysteine residue, using a modification of the 
method of Robertson and Lui (1988). BI92-201 was conjugated to ovalbumin, using 
glutaraldehyde (Briand et al., 1985). These different approaches reflect an evolution of 
opinion in this laboratory, an evolution which was partly influenced by the results of 
the present study. 
3.5.2.1 Reagents 
M-maleimidobenzoyl-N-hydroxysuccinimide (MBS) was from 
Sigma and glutaraldehyde [25% (m/v), E.M. grade] was from Merck. 
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Buffer A [0.02 M sodium phosphate buffer. pH 8.0] . 
NaH2P04.H20 (0.276 g) was dissolved in 950 ml of dist.H20, titrated to pH 8.0 with 
NaOH, and made up to 1 litre. 
Buffer B [0.05 M sodium acetate buffer. pH 4.0]. Glacial acetic acid 
(2.86 ml) was added to 950 ml of dist.H20, titrated to pH 4.0 with NaOH, and made up 
to 1 litre. 
Buffer C [0.1 M sodium phosphate buffer, pH 7.0]. NaH2P04.H20 
(13.8 g) was dissolved in 950 ml of dist.H20, titrated to pH 7.0 with NaOH, and made 
up to 1 litre. 
Buffer D [0.1 M sodium phosphate buffer, pH 6.5]. NaH2P04.H20 
(1.38 g) was dissolved in 95 ml of dist.H20, titrated to pH 6.5 with NaOH and made up 
to 100 m!. 
Buffer E [0.1 M sodium phosphate buffered saline, pH 7.2]. 
NaH2P04·2H20 «1.15 g), NaCl (8 g), KCI (0.2 g) and KH2P04 (0.2 g) were dissolved in 
950 ml dist.H20, titrated to pH 7.2 with NaOH, and made up to 1 litre. 
3.5.2.2 Procedure 
The MBS coupling procedure requires reduction of any oxidised 
cysteine residues before the peptide conjugation. Peptide B13-22 (8.1 mg) (6.92 x 10-6 
moles, assuming molecular weight 1169) was dissolved in buffer A (0.3 ml), and 
reduced (1 h, RT) by the addition of an approx. 10% molar excess of DTT (1.17 mg) 
(7.59 x 10-6 moles) (Cleland, 1964). The peptide mixture (0.3 ml) was desalted into 
buffer B, using Sephadex G-I0 (4 x 0.9 cm i.d.). The number of moles of reduced 
cysteine residues (and hence number of moles of peptide) available for conjugation in 
the peptide eluate peak (0.5 ml) was determined using the Ellman's Test (Sedlak and 
Lindsay, 1968). 
The maleimide group was incorporated into KLH, following the 
method of Robertson and Lui (1988). KLH was extensively dialysed against buffer C 
and centrifuged (10 000 x g, 10 min, RT) to remove large aggregates. MBS (3.7 mg) 
(1.18 x 10-5 moles in 0.58 ml of amine-free DMF) was added to KLH (30 mg in 1.5 ml 
buffer C) and allowed to react, with stirring, for 1 h. The resulting mixture (2.0 ml) 
was applied to a Sephadex G-25 column (4.7 x 1.6 cm i.d.) and eluted with buffer D. 
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The total number of maleimide groups introduced was calculated by taking an aliquot 
of the KLH-MBS conjugate (30 Ill), adding a known amount of mercaptoethanol (2 Ill, 
9 nmoles) and relating the number of free sulfhydryls consumed (determined using 
the Ellman's test) to the number of MBS groups introduced, and relating this to the 
total volume of the KLH-MBS eluted in the Sephadex G-25 peak (2.4 ml) (Kitagawa 
and Aikawa, 1976). 
The peptide (0.5 ml, containing 4.375 x 10-6 moles reduced 
cysteine residues, equivalent to 5.02 mg of peptide) was added to the KLH-MBS 
conjugate (2.4 mI, containing 7.08 x 10-6 moles of MBS residues). The mixture (2.9 ml) 
was allowed to react for 3 h at room temperature, while stirring, and 2.6 ml was 
subsequently applied to Sephadex G-100 (9.6 x 1.5 em Ld.), equilibrated with buffer C. 
The elution profile was monitored at 280 nm and two peaks were identified. The 
major peak contained the KLH-MBS-peptide (5.8 ml), and the second peak (9.3 ml) 
contained free peptide. 
The second peptide, B192-201, was conjugated in this laboratory, 
in parallel with other peptides, by Theresa Coetzer, using the method of Briand et al. 
(1985). Ovalbumin (25 mg) (0.55 x 10-8 moles) in 1.1 ml buffer E was extensively 
dialysed against buffer E and centrifuged (10 000 x g, 10 min, RT). Peptide (5 mg) (0.5 x 
10-7 moles of peptide, assuming an Mr of 1002) was dissolved in the supernatant, 
giving a molar ratio of 9.09:1, peptide:ovalbumin. Glutaraldehyde [568 III of a 25% 
solution (Merck, E.M. grade, d = 1.06)] was added dropwise over 5 min, with constant 
stirring. After reaction for 1 h, at room temperature, sodium borohydride (1 mg/ml) 
was added to terminate the reaction, and the conjugate was dialysed extensively 
against buffer E. The final volume of conjugate was 7.7 mI, so the concentration of 
peptide was estimated at approximately 324 Ilg/ml, assuming a 50% coupling 
efficiency. 
3.5.2.3 Results 
The amount of reduced B13-22 peptide added to the MBS-
derivatised KLH and the number of MBS groups introduced into the KLH, were 
estimated, using the Ellman's test, as being 4.375 x 10-6 moles reduced cysteine 
residues (equivalent to 5.02 mg of reduced peptide), and 7.08 x 10-6 moles of MBS 
residues, respectively. By relating the number of MBS groups to the original amount 
of KLH derivatised, it was estimated that the MBS groups would be contained in 
18.9 mg of KLH (9.45 x 10-8 moles). The coupling molar ratio would, therefore, have 
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been 1:44, KLH to peptide. The ratio of MBS to peptide groups allowed to react was 
1:1.5. The low coupling efficiency estimated (59%), however, indicated that final 
coupling was possibly of the order of 23:1 peptide to KLH. This coupling efficiency 
result was confirmed using the micro-biuret assay (ltzhaki and Gill, 1964). Of the two 
peaks identified after the final conjugation step, the second peak (9.3 ml) was 
estimated to contain 2.0 mg of free peptide, indicating 60% conjugation (i.e. the 
conjugate peak contained 3.02 mg peptide in 5.8 ml = 0.52 mg/ml). It was, therefore, 
calculated that 400 III of conjugate (equivalent to 200 Ilg of peptide) should be used per 
rabbit for the production of antibodies. 
The efficiency of coupling of the B192-201 peptide to ovalbumin, 
using the glutaraldehyde procedure was not estimated, but was assumed to be about 
50% (a ratio of approximately 4.50:1 peptide to ovalbumin, giving a concentration of 
324 Ilg/ml of peptide). Inoculation of 330 III of conjugate (equivalent to approx. 100 Ilg 
of peptide) was estimated to be required per rabbit. 
3.6 Inoculation protocols for antibody production 
Antibodies were raised in rabbits, two rabbits being inoculated with each 
immunogen. The inoculation protocol used for all peptide conjugates is summarised 
in Table 6. The indicated dose of conjugate was triturated 1:1 with Freund's Complete 
or Incomplete adjuvant (Dileo), to form a stable emulsion, and injected intradermally 
in at least two sites, at the intervals indicated in Table 6. 
Free, unconjugated, peptides were also used as immunogens in two cases. In 
the first case, the protocol of Richardson et al. (1985) was used. In the case of the first 
mature cathepsin B peptide (B13-22), an inoculation regime as given above (Table 6) 
was adopted, except that the final inoculations at 13, 28 and 30 weeks, were with free 
peptide. In the case of peptide B192-201, 0.5 mg of free peptide in 1 ml PBS, was 
emulsified with an equal volume of either complete or incomplete Freund's adjuvant 
(used alternately, the first inoculation being with complete adjuvant) and 1 ml of the 
preparation (250 Ilg of peptide) was injected subcutaneously into two sites on the back 
of the neck of each rabbit. A greater amount of free peptide was inoculated to 
compensate for the antiCipated multiple conformations that the peptide could pOSSibly 
adopt, due to the lack of constraint on conformation otherwise imposed by 
conjugation procedures (Todd et al., 1982). 
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Table 6. The inoculation protocol used to raise anti-cathepsin B peptide antibodies. 
( 
Weeks Freund's Adjuvant Site Dose 




2 Incomplete Ld. As previous 
3 Bleed 
6 Incomplete Ld. As previous 
8 Bleed 
10 Incomplete Ld. As previous 
none . f l.v. 1 mg free peptide 
12 Bleed 
a intradermal injection into skin at the back of the neck of rabbit 
b procathepsin B peptide (ppB22-36) 
c procathepsin B peptide (ppB64-77) 
d first mature cathepsin B (BI3-22) 
e second mature cathepsin B (BI92-201) 
f intravenous injection into marginal ear vein (Richardson et al., 1985) 
used only with the first mature cathepsin B peptide (BI3-22). Inoculation 
of free peptide again at 13, 28 and 30 weeks, with bleeds two weeks after. 
3.7 Assessment of immune response. and antibody purification 
Antibody response and recognition of the peptide sequence was generally 
monitored using whole antisera and the ELISA procedure (Coetzer et al., 1991). 
3.7.1 ELISA procedure for assessment of antibody recognition of peptide and 
enzyme 
ELISA assays against the peptide and the mature enzyme, were 
conducted in a similar fashion, using whole sera, before the removal of antibodies 
directed at KLH carrier molecules, as detailed below. 
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3.7.1.1 Reagents 
Phosphate buffered saline pH 7.2 (PBS). NaH2P04.2H20 (1.15 g), 
NaCl (8 g), KCl (0.2 g), KH2P04 (0.2 g), were dissolved in 950 ml dist.H20, titrated to 
pH 7.2 with NaOH, and made up to 1 litre. 
PBS-Tween. Tween 20 (1 ml) was made up to 1 litre with 
PBS. 
Blocking solution [0.5% (w Iv) bovine serum albumin in PBS] 
(PBS-BSA). BSA (0.5 g) was dissolved in 100 ml PBS. 
150 mM citrate-phosphate buffer. pH 5.0. Citric acid solution 
(21.0 gil) was titrated to pH 5.0, with a solution of NaH2P04.2H20 (35.6 gil). 
ABTS substrate [0.5% 2,2'-azino-di(3-ethyl)benzthiozoIine in 
150 mM citrate buffer, pH 5.0, containing 0.0015% H2Q21. ABTS (7.5 mg) and H20 2 
(7.5 Ill, added immediately before use) were dissolved in 150 mM citrate-phosphate 
buffer, pH 5.0 (15 ml). This provides sufficient reagent for one ELISA plate. 
50 mM carbonate buffer. NaHC03 {0.21 g) was dissolved in 45 ml 
of dist.H20, titrated to pH 6.0 with HCI, and made up to 50 ml. 
Stopping buffer [150 mM citrate-phosphate buffer containing 
0.1 % NaN31. NaN3 (0.1 g) was dissolved and made up to 100 ml in 150 mM citrate-
phosphate buffer. 
3.7.1.2 Procedure 
Nunc High Bond Immunoplate wells were coated with antigen 
(150 III of peptide in PBS, pH 7.2, or enyzme in 50 mM carbonate buffer, pH 6.0) 
overnight at room temperature, diluted to give a final optimal coating (ppB22-36, 
ppB64-77, and B192-201, 21lg; B13-22, 5 Ilg and whole cathepsin B, 1Ilg). Wells were 
blocked with BSA (200 III of PBS-BSA, 1 h, 37°C), and washed 3X with PBS-Tween. 
Dilutions of primary antiserum (l00 Ill, in PBS-BSA) were added and incubated for 2 h 
at 37°C. 
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After washing 3X in PBS-Tween, a sheep anti-rabbit-IgG 
horseradish peroxidase conjugate (120 I.tl in PBS-BSA) was added and incubated 
(30 min, 37°C). The plate was again washed 3X in PBS and ABTS substrate (150 JlI) was 
added, incubated for 15 min, and the A405 measured using a Bio-Tek EL307 plate 
reader. 
3.7.1.3 Results 
Some differences were observed in the responses to inoculation 
protocols using conjugated peptide followed by free peptide, as used to raise the B13-22 
antisera (Fig. 14, graphs a & b), or inoculation with conjugated or free peptides alone 
(each used throughout the inoculation protocol), as used with peptide B192-201 
(Fig. 14, graphs e & f, and c & d, respectively). All inoculation regimes elicited 
responses which differed in duplicate experimental animals but all produced antisera 
which recognised their respective free pep tides coated to ELISA plates (Fig. 14). In the 
case of the B13-22 peptide, where conjugated peptide was followed by free peptide, an 
initial decrease in level of response was seen in the rabbit that responded best to 
inoculation with conjugated peptide (Fig. 14, rabbit 1b) while the rabbit that responded 
the least to the conjugated peptide showed an increasing response to inoculation with 
free peptide (Fig. 14, rabbit 1a). 
Assays for the recognition of mature cathepsin B, coated to 
ELISA plates at pH 6.0, were only performed for peptide B13-22 antiserum, but no 
recognition of the native protein was observed in this case (results not shown). 
3.7.2 Isolation of IgG fraction 
The IgG fraction was separated from rabbit serum using the method of 
Polson et al. (1964). 
3.7.2.1 Reagents 
10 mM borate buffer. pH 8.6. Boric acid (2.16 g), NaCl (2.19 g), 
NaOH (0.2 g) and HCI (0.62 ml of 37% solution) were dissolved in 950 ml dist.H20. 
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Response curves showing recognition of coated free peptides by antibodies. 
Response curves of:- a and b, two rabbits (rabbits 1a and 1b) inoculated intradermally with 
200 Ilg KLH-conjugated 813-22 peptide, followed by one inoculum of 1 mg of free peptide 
into the marginal ear vein (Note that the Y-axis in a is expanded 5X and in b is expanded 
2X); c and d, two rabbits (2 and 3) inoculated with 100 Ilg of ovalbumin-conjugated 8192-201 
peptide; e and f, two rabbits (3 and 4) inoculated with 250 Ilg of free 8192-201 peptide. 
8 = preimmune; X = 3-week; • = 5-week; • = 8-week; () = 12 week; A = 14-week; 
• = 17-week; • = 3O-week; 0 = 32-week 
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0.1 M sodium phosphate buffer pH 7.6. NaH2P04.H20 (1.4 g) and 
NaN3 (0.01 g) were dissolved in 95 ml of dist.H20, titrated to pH 7.6 with NaOH and 
made up to 100 m!. 
3.7.2.2 Procedure 
One volume of serum was diluted with two volumes of borate 
buffer and polyethylene glycol (PEG) (Mr 6 OOO) was added slowly, while stirring, to a 
final concentration of 14% (w Iv). The mixture was centrifuged (12 000 x g, 10 min, 
RT) and the pellet re-dissolved in the original volume of 0.1 M sodium phosphate 
buffer, pH 7.6. PEG was again added slowly to a final concentration of 14% (w Iv), 
allowed to dissolve, and the solution was again centrifuged (12 000 x g, 10 min, RT). 
The pellet, containing the rabbit IgG, was dissolved in half the original serum volume 
of 0.1 M sodium phosphate buffer, pH 7.6, and stored at 4°C. 
3.7.3 Removal of KLH antibodies 
Contaminating antibodies, generated against the KLH carrier molecules 
of the peptide-KLH conjugate, are known to cause cross-reactivity to a large number of 
epitopes. The anti-B13-22, ppB22-36 and ppB64-77 IgG fractions were consequently 
affinity purified, the unwanted anti-KLH antibodies being removed by adsorption to a 
KLH-derivatised Sepharose-4B affinity colunm, prepared by the method of March 
et al. (1974). 
3.7.3.1 Reagents 
2 M sodium carbonate. NaC03 (21.19 g) was dissolved in 
dist.H20 and made up to 100 m!. 
Wash A [200 mM NaHCOJ, pH 9.61. Na2C03.H20 (12.4 g) and 
NaHC03 (8.4 g) were each dissolved in dist.H20 and made up to 500 mI. The Na2C03 
solution was titrated against the NaHC03 solution (lOa ml) to pH 9.6. 
Wash B flOO mM sodium bicarbonate buffer, pH 9.2]. 
Na2C03·H20 (0.25 g) and NaHC03 (0.84 g) were each dissolved in dist.H20 and made 
up to 200 ml. The Na2C03 was titrated against the NaHC03 (100 ml) to pH 9.2. 
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Coupling buffer [100 mM sodium bicarbonate, 500 mM NaCL 
pH 8.3]. Na2C03.H20 (5.3 g) and NaHC03 (4.2 g) were each dissolved with NaCl (14.61) 
in dist.H20 and made up to 500 ml. The Na2C03 solution was titrated against the 
NaHC03 solution (250 ml) to pH 8.3. 
Keyhole limpet haemocyanin (KLH) (5 mg/ml). KLH (50 mg) 
was dissolved in coupling buffer (10 ml), centrifuged (10 000 x g, 15 min, RT) (to 
remove aggregates) and the absorbance read for later use in calculating coupling 
. . 1 mg/ml H) effiCIency (E2BO nm = 2.0 for KL . 
Blocking agent [1 M ethanolamine-HCL pH 8.0]. Ethanolamine 
(6.06 ml) was diluted in 80 ml dist.H20, titrated to pH 8.0 with HCI and made up to 
100 ml. 
Wash C [100 mM sodium acetate, 500 mM NaCl, pH 4.0]. 
Acetic acid (5.72 ml) and NaCl (14.6 g) were dissolved in 450 ml dist.H20, titrated to 
pH 4.0 with NaOH and made up to 500 ml. 
Chromatography buffer [20 mM sodium phosphate, 500 mM 
NaCL pH 7.4]. NaH2P04 (1.38 g), NaCl (14.61 g) and NaN3 (0.1 g) were dissolved in 
450 ml dist.H20, titrated to pH 7.4 with NaOH and made up to 500 ml. 
Elution ''buffer'' [3.5 M potassium isothiocyanate]. KSCN (34.0g) 
was dissolved in 100 ml dist.H20. 
3.7.3.2 Procedure 
Sepharose-4B (10 ml of packed gel) was washed in a Buchner 
funnel, on a Whatman No 1 filter paper disc, with 150 ml dist.H20, transferred to a 
small beaker, allowed to settle and the supernatant removed. Dist.H20 (10 ml) and 
2 M Na2C03 (20 ml) were added to the gel, and the mixture was placed on ice, in a 
fume hood, and mixed gently until the temperature decreased to 4°C. The rate of 
stirring was increased and 1 M CNBr solution in acetone (2 ml) was added as rapidly as 
possible. 
The gel mixture was stirred rapidly for not longer than 90 min, 
transferred to a Buchner funnel and washed with dist.H20 (100 ml), wash A (100 ml) 
and wash B (100 ml). During washing, the gel must be stirred gently with a glass rod 
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to prevent it from "caking" during filtration, especially during the initial washing 
step, as the gel tends to become sticky in the final stages of activation, unless the 
activating agent is quickly and uniformly removed. The activated gel was washed 
with excess coupling buffer, transferred to a glass bottle and allowed to settle. Excess 
coupling buffer was removed, and the KLH in coupling buffer (5 mg/m!, 10 ml) was 
added to the suspension and mixed, end-over-end, for 14 h at 4°C. 
The gel was ' allowed to settle and the excess coupling buffer, 
containing any unbound KLH, was removed and kept. The absorbance at 280 nm of 
the supernatant, determined against a coupling buffer blank, was compared with the 
absorbance of the original KLH solution, and the coupling efficiency calculated by 
difference. 
Blocking agent (10 ml) was added to the remaining gel and the 
slurry was mixed, end-over-end, for 2 h at room temperature, to block the remaining 
reactive groups. The gel was washed on a Buchner funnel, alternately with coupling 
buffer and low pH buffer, wash C, to ensure that no free ligands remain iOnically or 
non-covalently linked to the gel or ligand. The gel was finally washed and stored in 
chromatograhy buffer (4°C). 
The Sepharose-4B affinity resin was packed into a column (5.3 x 
0.5 mm i.d.) and washed with chromatography buffer (3 column vols), elution 
"buffer" (1 column vol, to elute any loosely bound KLH) and again with 
chromatography buffer (3 column vols). IgG (3-5 mg, in 0.5-0.6 ml of chromatography 
buffer) was applied to the column and eluted with chromatography buffer. The break-
through peak, being the desired IgG fraction, was collected, while the contaminating 
KLH antibodies were eluted with elution "buffer" (1 column vol.). The resin was 
subsequently washed and stored in chromatography buffer. 
3.7.3.3 Results 
Judged using the ELISA technique, levels of contaminating anti-
KLH antibodies in the break-through peak appeared to be very high, even after 
successive purification steps, and with very little IgG loaded. When assayed using a 
dot blot system, however, the KLH -binding activity apparently disappeared after two 
passages of the IgG fraction through the column. 
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3.8 Antibody characterisation 
3.8.1 Western blotting of SDS-PAGE gels 
Western blotting was done as described in Chapter 2. 
3.8.1.1 Reagents 
Secondary antibodies, antigens and locating agents. Sheep IgG 
was isolated (section 3.7.2) and conjugated to HRPO according to the method of 
Hudson and Hay (1980). Biotinylated goat-anti-rabbit IgG and donkey anti-sheep IgG 
were from Sigma. Human liver cathepsin B, affinity purified anti-human liver 
cathepsin B antibodies and crude preparations of mucoid and purulent sputa were 
provided by Dr D. Buttle, Strangeways Research Laboratory, Cambridge, UK. Human 
leucocyte elastase was from Dr J. Travis, Department of Biochemistry, University of 
Georgia, Athens, GA. Recombinant human procathepsin B, recombinant human 
cathepsin B, isolated human liver cathepsin B and a second affinity-purified anti-
human liver cathepsin B antibody were from Dr 1. Mach, Zentrum fUr Angewandte 
Genetik, Universitat fUr Bodenkultur, Vienna, Austria. Streptavidin-biotin-
peroxidase complex was from Amersham and the Protein A gold and immunogold 
probes were prepared as described in Chapter 2. 
3.8.1.2 Procedure 
For the evaluation of anti-pro cathepsin B peptide antibodies, and 
anti- (mature) human liver cathepsin B, three (purported) sources of procathepsin B 
were used. Firstly, a neutrophil fraction, containing monocyte/macrophages, and 
hence also cathepsin B (Burnett et al., 1983; Crocker et al., 1984) and presumably its 
pro-forms, was used. Secondly, mucoid and purulent sputa, reported to contain the 
whole (Mr 40 000) and truncated (Mr 37 000) forms of procathepsin B, respectively 
(Buttle et al., 1988), were used. Finally, and arguably most definitively, the antibodies 
were evaluated by probing electroblots of recombinant procathepsin B and mature 
cathepsin B molecules, expressed in yeast. 
77 
3.8.1.3 Results 
The characterisation of the ppB22-36 and ppB64-77 peptide 
antibodies proved to be problematic, due mainly to the difficulty in finding a suitable 
source of procathepsin B. Crude leucocyte fractions did not show any bands of 
reactivity with anti-mature liver cathepsin B antisera, used at a level of 20 Ilg / ml, 
even when the leucocyte fractions were loaded in excess of 15 llg per lane, and a 
sensitive immunogold or protein A gold method, with silver amplification, was used 
(Fig. 15, blot B, lanes a and b, and blot D lanes a and b, respectively). Such overloading 
of protein caused non-specific targeting of some bands on these blots, with similar 
non-specific bands being seen in the IgG controls used at the same concentration as the 
anti~athepsin B antibody (Fig. 15, blots A and C, lanes a and b). 
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B C D 
Western blots of leucocyte fractions and human liver cathepsin B. 
Western blot of a 12.5% reducing SDS-PAGE separation. Approx . 15 jlg of crude 
lymphocyte (lane a), and neutrophil fraction (lane b), and human liver cathepsin B 
(1 jlg) (lane c), were loaded. A and C were treated with a pre-immune IgG preparation 
(20 jlg/ml), while Band D were treated with a sheep anti-human liver cathepsin B IgG 
preparati~n (20 jlg/ml), and probed with a rabbit anti-sheep gold probe (blots A and B) 
or a protem ~-gold pro~e (after the use of a rabbit anti-sheep linking antibody) (blots C 
and D), and silver amplIfied. The anti-cathepsin B antibody located bands at M 57000 r , 
40 000,27000,25000 and 20 000. 
Figure 16. 





Reducing SDS-PAGE reference gel (12.5%) for blots of lymphocyte and neutrophil 
fractions and human liver cathepsin B (Fig. 17) . 
Gel shows · electrophoretic pattern for the lymphocyte fraction (lane a) and the 
neutrophil fraction (lane b) (15 flg), human liver cathepsin B (1 flg) (lane c) and 
molecular weight markers BSA, Mr 68 000, ovalbumin, Mr 45 000, carbonic anhydrase, 
Mr 29 000, lysozyme, Mr 14000 and insulin, Mr 6000. (lane d) . 
Although only a single band (Mr 27 000) of human liver 
cathepsin B was seen on SDS-P AGE gels loaded with 1 Jlg of human liver cathepsin B 
(Fig. 16), blots probed with the anti-human liver cathepsin B, followed by an 
immunogold or protein A-gold probe, with silver amplification, indicated the 
presence of trace amounts of approx. Mr 57 000, 40 000, 25 000 and 20 000 forms of 
cathepsin B, in addition to the Mr 27 000 mature form (Fig. IS, blots B and D, lane c). 
The Mr 57 000 form was possibly a dimer and the Mr 25 000 and 20 000 forms, minor 
products of autocatalytic processing. Different gold probes were used to check whether 
any of the bands may be due to intrinsic non-specificity in either of the gold probe 
systems. Subsequently, a peroxidase system was used, and the western blot results for 
the lymphocyte, neutrophil and human cathepsin B fractions, were verified (Fig. 17). 
The Mr 40 000 form was considered to possibly be the pro-form of 
cathepsin B, and hence the human liver preparation potentially provided a source of 
precursor for blots using the anti-ppB22-36 and ppB64-77 antisera. However, when the 
amount of human cathepsin B and leucocyte fractions loaded into each well for SDS-
PAGE was increased to 15 Jlg or more, to increase the amount of putative 
procathepsin B blotted, bands were targeted in a manner which could not be due to the 
expected targeting of the anti-ppB22-36 (Fig. 17, blot A) and which was, therefore, most 
likely due to non-specific interactions. [The ppB64-77 antiserum gave no labelling of 
the leucocyte and human liver cathepsin B fractions (results not shown)] . Similarly, 
mucoid and purulent sputa, which have been reported to contain whole and 
• 
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truncated forms of procathepsin B (Buttle et al., 1988), also gave a pattern of 
inexplicable, non-specific binding effects (e.g. Fig. 18). 
Figure 17. 
a b c 
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Western blot of lymphocyte and neutrophil fractions and human liver cathepsin B. 
a and d, lymphocyte fraction; band e, neutrophil fraction (loaded in excess of 15 Ilg 
protein); c and f, human liver cathepsin B (151lg of protein/well) . Blot A was probed 
with anti-ppB22-36 IgG (lOOllg/ml) and blot B with anti-human liver cathepsin B 
(10 Ilg/ml), and labelling detected with sheep anti-rabbit HRPO. 
In an attempt to find a more defined and suitable source of 
procathepsin B, a collaboration was established with Dr J. Glossl, and his (then) 
student, Lukas Mach, of the Zentrum fur Angewandte Genetik, UniversiUit fur 
Bodenkultur, Vienna, Austria. These workers had available, mature cathepsin B, 
isolated from human liver, as well as mature and procathepsin B, expressed in yeast, 
and, in exchange for samples of the anti-ppB22-36 and anti-B64-77 peptide antibodies, 
Lukas Mach agreed to do western blots of their cathepsin Band procathepsin B 
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Western blot of reducing 12.5% SDS-PAGE of mucoid and purulent sputa, and human 
liver cathepsin B. 
Lane a, human cathepsin B (15 mg/ml); lane b, a crude fraction of purulent sputum; 
lane c, a crude fraction of mucoid sputum. Probed with; A, anti-human liver cathepsin 
B (10 )lg/ml); B, anti-ppB64-77 (200 )lg/ml); C, anti-ppB22-36 (200 )lg/ml); D, pre-
immune IgG (200 )lg/ml). Targeting of antibodies was located using the streptavidin-
biotin -peroxidase system. 
a b c d 
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Reducing 50S-PAGE reference gel (12.5%) for blot shown in Fig. 18. 
Lane a, Human liver cathepsin B (15 )lg/ml); lane b, purulent sputum; lane c, mucoid 
sputum; lane d, molecular weight markers, BSA Mr 68 ODD, ovalbumin Mr 45 DOD, 
carbonic anhydrase Mr 29 ODD, lysozyme Mr 14 ODD. 
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The anti-ppB22-36 antibody reacted strongly with recombinant 
procathepsin B (Fig. 20, blot A, lane a), but not with the mature recombinant or 
mature isolated human liver cathepsin B (Fig. 20, blot A, lane b and c, respectively). 
The anti-ppB64-77 antibody did not recognise isolated mature human liver 
cathepsin B (Fig. 20, blot B, lane c), reacted extremely weakly with the recombinant 
human pro-enzyme (Fig. 20, blot B, lane a) and weakly with the recombinant mature 
enzyme (Fig. 20, blot B, lane b). All three forms of cathepsin B were recognised by the 
anti-human liver cathepsin B antisera (Fig. 20, blot C, lanes a, b and c). 
The reaction of the anti-ppB22-36 peptide antibody was as 
anticipated. Similarly, the reactivity of the anti-ppB64-77 peptide antibody with the 
recombinant procathepsin B (entire sequence), was as anticipated. The weak reactivity 
with the recombinant mature cathepsin B and lack of reactivity with the mature liver 
cathepsin B may be explained by the fact that recombinant mature cathepsin B 
contains an N-terminal extension of, probably, six residues, after autocatalytic cleavage 
of procathepsin B, by cathepsin B itself (Hasnain et a/., 1992a). In the yeast this 
sequence remains, whereas, in mammalian cells, this extension seems to be removed 
by sequential exopeptidolytic trimming, possibly by cathepsin C (Hasnain et a/., 1992a). 
The epitope recognised by the anti-ppB64-77 antibody is, therefore, possibly comprised 
of only 5 amino acids, residues 73-77 (the difference between the C-terminal extension 
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Western blots of recombinant procathepsin B, recombinant mature human 
cathepsin B and mature isolated human cathepsin B. 
a, recombinant yeast procathepsin B (0.5 ).l.g); b, recombinant mature human 
cathepsin B, from yea~t (0.5 ).l.g), .c, isolated mature human liver cathepsin B (0.5 ).l.g). 
Blots were probed Wlth; A, antt-ppB22-36; B, anti-ppB64-77; C, anti-human liver 
cathepsin B (all at 2-5 ).l.g/ml), and visualised using the streptavidin-biotin-peroxidase 
system. 
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As the reactivity of the anti-ppB64-77 antibody was extremely 
weak, this, unfortunately, precluded studies into the presence of the stable, truncated, 
form of procathepsin B in cancer and normal cells. The success of the ppB22-36 
antibody, however, meant that this could be applied to the detection of procathepsin B 
(see Chapters 4 and 5). 
With regard to peptide antibodies to mature cathepsin B, it was 
found that IgG fractions from different rabbits reacted differently with respect to their 
recognition of human liver cathepsin B in reducing SDS-P AGE blots (Table 7). 
Table 7. Recognition of whole mature cathepsin B by anti-peptide antibodies 
in reducing SDS-P AGE western blots. 
Recognition of 
Rabbit Number Inoculate Cath B in SDS-P AGE 
blots by corresponding 
antibody 
lA KLH-conjugated B9-19 -
IB KLH-conjugated B9-19 -
2 Free BI92-201 -
3 Free BI92-201 + 




The IgG fractions that reacted positively, varied in their response 
to different bands in the human cathepsin B (Fig. 21). The IgG fractions from rabbits 3 
and 4 targeted the heavy chain of mature cathepsin B, at ca . Mr 26 000 and a dimer 
form at ca. Mr 57 000, while that from rabbit 5 targeted all of the components of 
mature cathepsin B (Fig. 21). The reactivity of these peptide antibodies was as expected 




a b c d 
Western blot of 12.5% SDS-PAGE gel of human liver cathepsin B, probed with the 
antisera from different rabbits inoculated with the B192-201 peptide. 
Human liver cathepsin B (2Ilg/ml) was loaded and probed with IgG (100 Ilg/ml): blots a 
and h, IgG from rabbits 2 and 3, respectively, inoculated with free Bl92-201 peptide; 
blots c and d, IgG from rabbits 4 and 5, respectively, inoculated with B192-201 
conjugated to ovalbumin. 
The anti-human leucocyte elastase IgG fraction, targeted the 
Mr 28 000-30 000 doublet in purified fractions of human leucocyte elastase, (Fig. 22), 
but failed to recognise elastase in crude homogenates of density gradient-separated 
leucocyte fractions (result not shown). Since neutrophils contain large amounts of 
elastase, this failure could be ascribed to non-optimal Ab / Ag ratios in the western blot. 
However, at all ratios tested, the homogenates gave either no labelling or, at higher 
Ab levels, generally non-specific labelling. This seems to reflect a peculiar property of 
the leucocyte homogenate as the anti-elastase antibody subsequently gave specific 
immunolabelling of cell sections (Chapter 4). 
The rabbit anti-human cathepsin D sera recognised the Mr 48 000, 
Single-chain form in crude fractions of human leucocyte homogenates, and the 
Mr 48 000 single-chain and Mr 30 000 two-chained form of human cathepsin D, in 
purified fractions of human cathepsin D (Fig. 23, blots A and B), whereas no 
equivalent targeting was seen with pre-immune IgG (result not shown), used at the 
same concentration. In crude leucocyte homogenates, an additional doublet at approx. 
Mr 15 000 was seen; this could represent the light chain of the two-chained form of 





Western blot of 12.5% reducing SDS-PAGE gel of human leucocyte elastase. 
Human leucocyte elastase (7.5 )lg/ml) was separated by SDS-PAGE, electroblotted and 
probed with rabbit anti-human elastase and pre-immune IgG (86 )lg/ml). Labelling 
was visualised with a sheep anti-rabbit HRPO conjugate. Pre-immune IgG gave no 





Western blots of 12.5% reducing SDS-PAGE gel for the characterisation of rabbit anti-
human cathepsin D antibodies. 
A, a crude homogenate of human neutrophils (5 )lg per well); B, a purified fraction of 
human spleen cathepsin D (5)lg per well). Blots were probed with a rabbit anti-human 
cathepsin D antiserum (1 in 40 dilution) and visualised with a sheep anti-rabbit HRPO 
conjugate. 
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The chicken anti-porcine cathepsin D showed a similar pattern 
of labelling, strongly targeting the Mr 48 ODD, single-chain form and the Mr 30 000 
heavy chain form in the purified fraction from porcine spleen and the corresponding 




Figure 24. Western blots for the characterisation of chicken anti-porcine cathepsin D antibodies. 
A, a crude homogenate of porcine spleen (5 Ilg per well); B, a purified fraction of 
porcine cathepsin D (5 Ilg per well). Blots were probed with a chicken anti-porcine 
cathepsin D antiserum (188 Ilg/ml) and visualised using a rabbit anti-chicken 
antiserum (1 in 240 dilution), followed by a sheep anti-rabbit HRPO conjugate (1 in 400 
dilution). 
3.8.2 Immunoinhibition assays 
The anti-mature cathepsin B antibodies, anti-B13-22 and anti-Bl92-201, 
were tested for their recognition of the active enzyme, especially for immunolabelling 
studies in .the "cryo" system, where antigens tend not to be denatured, and as an 
indication of the possible use of such antibodies for anti-proteinase immunotherapy 
of cancers. 
3.8.2.1 Reagents 
Assay buffer [352 mM KH2ffi4, 48 mM Na2HP04, 4 mM 
Na2EDTA, 0.02% (m/y) NaN3, 8 mM Cysteine.HC}' pH 6.0]. KH2P04 (23.95 g), 
Na2HP04·2H20 (4.27 g), Na2EDTA.2H20 (0.75 g) and NaN3 (0.1 g) were dissolved in 
450 ml of dist.H20, adjusted to pH 6.0 with NaOH and made up to 500 ml. Prior to the 
assay, cysteine.HCl (0.007 g) was added to 5 ml of buffer. 
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1 mM substrate stock solutions. Z-Arg-Arg-NHMec (1.1 mg) was 
dissolved in DMSO (1.5 ml), aliquotted and stored at 4°C. 
20 blM substrate solutions. Substrate stock solution (0.1 ml) was 
diluted to 5 ml with dist.H20 . 
Brij 35 diluent [0.1% (m/v) Brij 35]. Brij 35 (0.1 g) was made up 
to 100 ml with dist. H20. 
Antibody diluent. Tween 20 was added to assay buffer 
(containing no cysteine.HCl) to 0.1% (v Iv). 
3.8.2.2 Procedure 
Assays for the immunoinhibition of cathepsin B were carried 
out using the synthetic substrate Z-Arg-Arg-NHMec, as described by Barrett (1980). 
Immunoinhibition of cathepsin B by antibody preparations was assayed by continous 
monitoring of the cleavage of Z-Arg-Arg-NHMec. Human cathepsin B (150 ng) was 
diluted to 500 III in 0.1 % Brij 35, and the relevant IgG preparation was added at 2 mg-, 
1 mg-, or 0.5 mg/ml, in antibody diluent (500 Ill). The mixture was incubated at 40°C 
for 15 min, and an aliquot (500 Ill) was removed and activated with assay buffer, 
containing 8 mM cysteine (250 Ill), for 1 min. Z-Arg-Arg-NHMec substrate (250 III of 
20 11M) was added, and the increase in fluorescence was monitored for 5 min at 40°C 
in a temperature controlled cell in a Hitachi Model F-2000 spectro-fluorimeter, with 
excitation at 370 nm and emission at 460 nm. The slope of the linear increase in 
activity, in the presence of the different IgG preparations, was calculated, and the 
percentage inhibition was expressed in comparison to the slope in the presence of 
non-immune IgG at the same concentration. The inhibition of enzyme activity by the 
antibodies was expressed as a percentage of the activity in the presence of non-
immune rabbit IgG. Continuous monitoring of substrate hydrolysis established, using 
minimal amounts of enzyme, whether a particular antibody preparation was 
immunoinhibitory and whether optimal conditions prevailed for the duration of the 
assay, such as the amount of substrate available. 
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3.8.2.3 Results 
The peptide antibody IgG fractions against peptide B13-22 showed 
no effect on enzyme activity (results not shown). By contrast, all IgG preparations 
from rabbits inoculated with ovalbumin-conjugated, or free peptide BI92-201, showed 
slight activation (approx. 10%) of human liver cathepsin B, rather than an immuno-
inhibitory effect (results not shown). None of the anti-cathepsin B peptide antibodies 
were, therefore, suitable for studies on the immunoinhibition of invasion. 
3.9 Discussion 
Proteins or peptides may be "immunogens", i.e. structures which elicit an 
immune response, leading to the production of antibodies, and/or "antigens", i.e. 
structures which react with the antibodies produced. In the case of whole proteins, the 
protein molecule is usually both immunogenic · and antigenic, and the distinction 
between these terms becomes of academic interest only. The same may not hold for 
peptides, and peptide antibodies intended to react with whole proteins. 
So-called "peptide antibodies" are raised by choosing a peptide sequence of ca. 
10 amino acids from the primary amino acid sequence of the protein of interest, 
synthesising the peptide and using this to inoculate an animal, either in the form of a 
conjugate with a carrier molecule or as the free peptide. The resulting peptide 
antibodies invariably react with the peptide itself, i.e. they are invariably "peptide-
reactive", but they mayor may not react with the protein of interest, i.e. they mayor 
may not be "protein-reactive". The protein-reactivity, moreover, may be specific for 
the native protein or for more or less denatured forms of the protein. 
A major challenge in peptide antibody technology is to be able to predict, in 
advance, whether a given peptide will elicit protein-reactive antibodies, especially 
against the native protein, since these antibodies would be the most useful. The 
terminology in this field is not well developed and so, for economy of expression in 
this thesis, the term "protein antigenic" will be used to describe a peptide which elicits 
protein-reactive peptide antibodies. The term "peptide antigenic" will be used for 
peptides which elicit peptide antibodies able to recognise the peptide, but not 
necessarily the protein from which the peptide was selected. Predictive methods are, 
therefore, largely aimed at the identification of "protein antigenic" pep tides. 
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During the raising and characterisation of specific antisera, three aspects of the 
immune response should be borne in mind. Firstly, protein molecules or peptide 
sequences are only antigenic if matched by a complementary recognition paratope 
(antigen-binding site) of an antibody that arises from the pool of immunoglobulin-
producing cells, in the inoculated animal (Van Regenmortel, 1986; Larsson, 1988a). 
Secondly, injection of a foreign substance into an animal, induces the proliferation of -
and antibody production by - a particular subset clone of lymphocytes, producing 
antibodies with a "best fit" paratope (Larsson, 1988a). Thirdly, since the subset clone 
selection is on the basis of the "best fit possible," the precision of "fit", or 
complementarity, between the paratope and epitope can vary considerably and hence 
binding of similar-but-different epitopes may occur, though usually with different 
avidities (Van Regenmortel, 1986). This fact can give rise to considerable differences 
in apparent specificity or non-specificity of antigen recognition, given that many 
epitopes are similar, and may explain the recognition or non-reCOgnition of different 
epitopes by antibodies diluted to different extents. 
Westhof et al. (1984) and Tainer et al. (1984) found that antibodies preferentially 
bind to protein regions with a high degree of mobility or fleXibility. The mobility of 
the antigenic region may facilitate the binding of an antigen to an antibody which does 
not posses an ideal complementary paratope. This may occur as highly mobile regions 
of antigens stand a better chance of selecting a clone producing antibodies, by adopting 
a conformation which fits the paratope (Westhof et al., 1984). For recognition, 
therefore, not only are the residues comprising the epitope (the peptide sequence) 
important, but so too is the conformation or potential conformations that the epitope 
may adopt. 
Generally, approaches which have endeavoured to identify "protein antigenic 
peptides" on the basis of primary structure have been found to be less successful than 
those based on 3-D information and X-ray data (Stern, 1991). This is because most anti-
native protein antibodies recognise assembled topological determinants and these are 
difficult to predict using only primary sequence data (Margalit et ai., 1987). The 
conformation dependence of epitope recognition explains how easy it is to alter, create 
or destroy the epitope by treatments that alter the conformation of the target antigen. 
Where the conventional preparation of anti-protein antibodies involves the injection 
of a conformationally restricted form of the protein molecule, anti-peptide antibodies 
are produced using a conformationally less restricted synthetic peptide. It is estimated 
that pOSSibly as few as one in 104 or 105 peptides retain the conformation recognisable 
to an antibody raised against the native protein (Todd et ai., 1982). POSSibly for this 
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reason, many peptide antibodies do not recognise, or react only weakly with, their 
target sequences in whole proteins (Palfreyman et al., 1984; Tanaka et al., 1985). 
Many methods, based on assumptions on the nature of the immune response 
and antigenicity, and based on primary sequence data, have been proposed for the 
predictive identification of protein antigenic peptide sequences (Hopp and Woods, 
1981; 1983; Atassi, 1984; Palfreyman et al., 1984; Tainer et al., 1984; Westhof et al. 1984; 
Parker et al., 1986; Van Regenmortel, 1989; Stern 1991). The aim of all of these 
methods is to facilitate the selection of linear antigenic peptide sequences, usually on 
the basis of a physical property, that has been found to predispose parts of a protein 
sequence to constitute a protein antigenic epitope, when the whole protein molecule 
is injected into an animal. 
At the commencement of this study, 3-D structural information, on 
cathepsin B itself, was not available, and potentially protein antigenic peptide 
sequences were selected by extrapolation from the 3-D structure of papain, and on the 
basis of the hydrophilicity, mobility and accessibility of the target peptide (Hopp, 1989; 
Van Regenmortel, 1989). Hydrophilicity provides an indication that the peptide 
sequence chosen occurs on the outer aspect of a protein, where it should be accessible 
to antibody binding (Hopp and Woods, 1981). Mobility parameters (Tainer et al., 1984; 
Westhof et al., 1984; Van Regenmortel, 1989) have been found to correlate well with 
the successful choice of peptides for the production of peptide antibodies (Stern, 1991), 
the more mobile residues proving the most protein antigenic (Tainer et al., 1984; 
Westhof, et al., 1984). Hydrophilicity (Hopp and Woods, 1981; 1983; Fraga, 1982; Kyte 
and Doolittle, 1982) and acceSSibility programmes (Chothia, 1976; Janin, 1979; Novotny 
et al, . 1986) have, however, been found to correlate poorly (Stern, 1991). 
Most hydrophilicity (Hopp and Woods, 1981;1983; Kyte and Doolittle, 1982) and 
mobility predictive programmes (Karp Ius and Schultz, 1985), are based on protein 
primary sequence and are designed to make predictions for proteins for which only 
the primary sequence is known. The Hopp and Woods (1981) programme is reported 
(Van Regenmortel and de Marcillac, 1986) to correlate less favourably with protein-
antigenicity, than hydrophilicity predictions using HPLC methods (Parker et al., 1986), 
but was used in this study because the programme was readily available. Mobility 
measurements using X-ray crystallographic temperature information (Tainer et al., 
1984), and the less favoured Karplus and Schultz (1985) programme, could similarly 
have given superior protein-antigenic reactivity predictions to that given by the 
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programme of Westhof et al. (1984) (Van Regenmortel, 1986; Stern, 1991) but these 
programmes were also not available at the time of selection of peptide sequences. 
Subsequent to the selection of the four peptides used in this study, various 
additional predictive programmes were obtained, for the analysis of primary structure 
sequence data for hydrophilicity (Kyte and Doolittle, 1982; Parker et al., 1986), flexibility 
(Karplus and Schultz, 1985), antigenicity (Welling et al., 1985) and accessibility 
(Chothia, 1976; Janin, 1979; Novotny et al., 1986). This provided the opportunity for a 
retrospective analysis of the sequence of procathepsin B and an assessment of the 
accuracy of the programmes' predictions. Only the antigenicity prediction of Welling 
et al. (1985) (Fig. 25) and the accessibility plot of Chothia (1976) (Fig. 26) appeared to 
correlate with the results obtained for the "protein antigenicity" of the four peptides 
chosen for the present study. 
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Antigenicity plot of the human preprocathepsin B sequence (Welling et al., 1985). 
The bold lines indicate the four peptides, ppB22-36, ppB64-77, B13-22 and BI92-201, 
Selected from the sequence of procathepsin B. The prepro-sequence contains 79 
residues, which must be subtracted from the preprocathepsin B residue numbers 
indicated, to obtain the residue numbers in the mature enzyme. 
The Welling predictive programme uses the calculated relative occurrence of 
each amino acid in the sequences of known antigenic regions of 20 proteins and 
compares this with the primary sequence of the unknown protein to predict antigenic 
epitopes. If peaks occurring above the zero base line are taken as "protein antigenic" 
regions, and recognition of proteins in western blots is taken as "protein reactivity", 
then the Welling antigenicity plot correctly predicts the success of the three "protein 
antigenic" peptides (ppB22-36, ppB64-77 and B192-201) and the lack of protein 
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antigenicity of peptide BI3-22 (though, it must be admitted, that BI92-201 appears to 
barely meet the criterion). 
The overall trend of these results is also reflected by the accessibility plot of 
Chothia (1976), in which only pep tides producing peaks greater than 0.5 on the 
accessibility scale produced protein reactive antibodies. This may indicate that the lack 
of protein recognition, of the B13-22 antibody, was on account of the lack of 
accessibility of the target peptide in the whole molecule (as seems to be the case from 
the 3-D structure of cathepsin B, as discussed below). 
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Accessibility plot of the human preprocathepsin B sequence (Chothia, 1976). 
The bold lines indicate the four peptides, ppB22-36, ppB64-77, B13-22 and B192-201, 
selected from the sequence of procathepsin B. The prepro-sequence contains 79 
residues, which must be subtracted from the preprocathepsin B residue numbers 
indicated, to obtain the residue numbers in the mature enzyme. 
In this study, the hydrophilicity plots of Hopp and Woods (1981) (Fig. 8) and of 
Parker et al., (1986) (not shown) and the segmental mobility plots of Westhof et al. 
(1984) (Fig. 9) and of Karplus and Schultz (1985) (Fig. 27), seem to indicate that neither 
hydrophilicity or segmental mobility per se are reliable indicators of protein-
antigenicity. One common feature of the protein-antigenic peptides (ppB22-36, 
ppB64-77 and BI92-201), however, is that they all contain at least some hydrophobic 
residues; the peptide ppB64-77 that produced the more weakly reacting anti-peptide 
antibodies, containing the fewest hydrophobic residues (Fig. 8). 
Although, as discussed above, flexibility favours immunogenicity, in this study 
the flexibility plot of Karplus and Schultz (1985) seems to indicate that some 
immobility of amino acid residues in the peptide favours protein antigenicity (Fig. 27). 
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Segmental mobility plot of the human preprocathepsin B sequence (Karplus and 
Schultz, 1985). 
The bold lines indicate the four peptides, ppB22-36, ppB64-77, B13-22 and B192-201, 
selected from the sequence of procathepsin B. The prepro-sequence contains 79 
residues, which must be subtracted from the preprocathepsin B residue numbers 
indicated, to obtain the residue numbers in the mature enzyme. 
The presence of some hydrophobic residues and limited peptide flexibility may 
be important in restraining the peptides in a specific conformation. The conformation 
adopted by a peptide upon inoculation may be biased by the presence of such 
hydrophobic residues or by other restraining residues, such as proline (Lerner et al., 
1981) or disulfide bonding within the chosen sequence, which would predispose the 
peptide to adopt a particular conformation. Analysis of the properties of the peptide 
antibodies raised during this study, seems to indicate that the successful raising of 
protein reactive peptide antibodies may correlate with the peptides' propensity to 
adopt specific conformations, due to restraining hydrophobic domains. The possibility 
that the peptides were adopting helper T-cell binding site conformations (Cornette 
et al., 1989) was, therefore, investigated. 
T -cell presented pep tides are reported to be generally amphipathic sequences 
comprised of hydrophobic and hydrophilic domains (Mouritsen et al., 1991) or a-
helices (Delisi and Berzofsky, 1985). Peptides with amphipathic properties, due to 
regularly spaced hydrophobic residues, tend to fold into a-helical-like structures on a 
hydrophobic surface (DeLisi and Berzofsky, 1985), such as the membrane of an 
antigen-presenting macrophage. The helix-like conformation may be promoted by 
progreSSive anchoring of the regularly-spaced hydrophobic side chains into a lipid 
bilayer, at successive turns of the peptide, assisted by hydrogen bonding along the 
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peptidyl backbone (Lu et al., 1991). Membrane adsorption may be a step in the transfer 
of pep tides to major histocompatibility complex (MHC) molecules (Berzofsky et al., 
1987). The recurring hydrophobic residues would form a longitudinal hydrophobic 
strip along the helix which could promote its binding to the hydrophobic floor of a 
scavenging transfer molecule or to an MHC molecule's antigen-binding site. Either as 
a helical configuration per se or within a protective structure, the peptide might be 
relatively resistant to further proteolytic attack during antigen processing and hence 
may survive as a presented epitope. The potential amphiphilic helical configuration 
of T-cell-presented peptides might, thus, reflect selection at a scavenging/transfer step 
in antigen processing, rather than coiling as a helix within the antigen binding site (Lu 
et ai., 1991). Transfer is perhaps via the surface of an antigen presenting macrophage 
(together with the 1a receptor) to the T-cell, as free peptide apparently does not cause 
stimulation in the absence of macrophages (Margalit et ai., 1987) 
The T-cell receptor sees only a relatively small segment of protein, after the 
appropriate cleavage, and! or unfolding (Berzofsky, 1985). Thus the experimental 
modelling approach can be focussed on peptides and short segments of proteins 
without consideration of protein tertiary structure (Margalit, et aI., 1987). X-ray 
analysis of T-cell sites has revealed that only a limited number of sites are seen by T-
cells after immunisation. In order to assess whether any of the chosen pep tides could 
pOSSibly have the propensity to fold into an a-helix and form such an epitope, the 
"amphipathic helix algorithm" of Margalit et al. (1987), was applied. The computer 
programme (AMPHI), based on this algorithm, predicted 18 out of 23 T-cell antigenic 
sites correctly (78% correct prediction) in the study by Margalit et ai. (1987). 
This programme identified all of the protein-antigenic peptide sequences, in 
the present study, as T-cell binding sites. Most of the unsuccessful peptide, BI3-22, was 
identified as an amphipathic region but not as a T-cell binding site. Four amino acids 
of the peptide ppB22-36 (residues 29~32) and two regions of peptide B192-202 (residues 
194~197 and 199~202) were identified as pattern 1 T-cell binding sites (i.e. the pattern, 
(charged or Gly) - hydrophobic - hydrophobic - (hydrophobic or Pro) -(polar or Gly). 
Residues 71~75 of the procathepsin B sequence, ppB64-77, were recognised as a 
pattern 2 T-cell binding site [i.e. (charged or Gly)-hydrophobic-(hydrophobic or Pro)-
(polar or Gly)] though the pattern in the peptide is actually, Gly-Pro-Pro-Lys. 
There is no doubt that a consideration of the topology of the target peptide 
sequence in the whole protein is also important. The fact that the peptide antibody 
against the sequence B13-22 did not recognise the native protein may be due to the 
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topological position of this sequence within the cathepsin B molecule. On the other 
hand, the success of the peptide ppB22-36, may be attributed to the fact that it occurs on 
an accessible loop which occludes the active site, as hypothesised by Mort and Recklies 
(1986). This peptide occurs on an exposed, flexible region, on the external aspect of the 
procathepsin B molecule, where it is easily accessible to antibody binding. The overall 
mobility of the ppB22-36 peptide is lower, however, than the less successful anti-
ppB64-77 peptide, showing that mobility alone may not be a reliable criterion for the 
selection of protein antigenic pep tides. 
For the choice of a peptide sequence for the production of anti-mature 
cathepsin B reactive- and, hopefully, immunoinhibitory peptide antibodies, 
knowledge of the actual 3-D topology of cathepsin B is essential. The structure, 
published by Musil et al. (1991), revealed that the overall folding pattern of 
cathepsin B, and the arrangement of the active site residues, is similar to that of the 
related cysteine proteinases papain, actinidin and calotropin D. A few large insertion 
loops, however, appear on the outer surface of cathepsin B, changing the properties of 
the molecule and make alignment of equivalent sequences in the different 
proteinases problematical. Figure 28 shows the structure of cathepsin B (bold), 
superimposed on the structure of papain (fine lines). The model of the cathepsin B 
molecule (Fig. 28) is rotated by 45°, around the x-axis, relative to the structure of 
papain (Fig. 10). 
Figure 28. The 3-D structure of cathepsin B, compared to that of papain. 
(from Musil et al. 1991) 
A stereo image m~y ~e created by viewing the centre and right images through a 
stereoscope or by vlewmg the left and centre images with unaided eyes, using proximal 
convergence (Wood, et aI., 1981) 
Two of the insertion loops occur in exactly the regions of both of the mature 
cathepsin B peptides selected for syntheSis. Peptide B13-22 occurs on one of the 
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insertion loops (sequence 16-19, according to the cathepsin B numbering of Musil 
et al., 1991), and in this region cathepsin B has no residues in common with papain 
(Table 8). 
Table 8. Alignment of cathepsin B and papain1 (From Musil et al., 1991). 
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INon-equivalent papain residues given in lower case. 
The lack of conserved residues, suggests that the sequence B13-22 may be 
unimportant in the enzymatic activity of cathepsin B, and hence may not be a good 
choice of peptide for the production of immunoinhibitory antibodies. Such a view is 
reinforced by an examination of the position of the residues 13~ 22 in the 3-D 
structure of cathepsin B (Fig. 28), which reveals that this sequence is occluded by the 
extra loop in cathepsin B, comprised of residues 108 to 125. Whereas the presumed 
equivalent sequence (sequence 3) in the papain structure appeared to be accessible to 
antibody binding (Fig. 10), in the actual 3-D structure of cathepsin B (Fig. 28), residues 
13~22 seem to lie buried in the active site cleft, where they are inaccessible to antibody 
binding. This could explain why peptide antibodies targeting this sequence were not 
protein reactive. 
By contrast, peptide B192-201, in both the speculated position (sequence 1) from 
the structure of papain (Fig. 10) and in the actual structure of cathepsin B (Fig. 28), 
96 
occurs on an exposed loop, part of which (Met-196-7His-199) makes up the active site 
cleft on the right-hand side (Fig. 28). The fact that residues 192-7201 are apparently 
more accessible to antibody binding, than residues 12-722, possibly accounts for the 
success of this peptide in eliciting antibodies to the native and SDS-denatured protein. 
Mobility, hydrophilicity, and topological characteristics are all favourable and endorse 
the success of this peptide. 
It was surprising, therefore, that antibodies raised against Bl92-201 were not 
immunoinhibitory, as were antibodies to the equivalent sequences in cathepsin L 
(Dennison and Pike, 1991) and cathepsin H (Coetzer, 1993). This may reflect 
differences in the catalytic mechanisms of these cathepsins, but it may be noted that 
the sequence B192-201 is particularly inflexible in cathepsin B (Fig. 9), and this may 
have some bearing on the lack of immunoinhibitory properties. Because these 
antibodies were not immunoinhibitory, studies on the immunoinhibition of 
invasion were temporarily suspended. 
Since the target peptides chosen were unsuccessful in eliciting 
immunoinhibitory antibodies, it might be asked whether, in the light of newer 
information, another peptide may be selected. Site-directed mutagenesis studies of 
His-ll1 (Hasnain et al., 1992b) have shown the importance of this residue in the 
endopeptidase activity of cathepsin B. The 18-amino acid, internally disulfide-bonded 
loop that contains His-111 and that partially occludes the binding cleft of cathepsin B, 
therefore, appears to be a target region that warrants further study in the search for 
antibodies capable of immunoinhibiting cathepsin B. 
Besides the many considerations which bear on the choice of a peptide 
sequence, the way in which the synthetic peptide is presented to the immune system 
can also have a significant influence on the outcome. At the outset of this study, 
"conventional wisdom" was followed and conjugates of the pep tides with KLH were 
used to inoculate test animals. Largely through personal contacts with Dr Atassi, of 
Texas, and Dr Sylvianne Muller, of Strassburg, however, workers in this laboratory 
subsequently became aware of the efficacy, and reported advantages, of inoculation 
with free peptides. 
There seems no doubt that free peptides can be as immunogenic as conjugated 
pep tides, judged by the almost equal response seen in ELISA systems (though 
admittedly a higher dose of peptide was used in the case of the free peptide). The free 
pep tides, however, must elicit a greater number of conformation-specific antibody 
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types, in an experimental animal. In the present study, the recognition of whole or 
SDS-denatured, blotted proteins, treated with an equivalent concentration of antibody 
elicited with the free or conjugated peptide, gave a much weaker reaction in the case 
of the free peptide, though judged with an ELISA the response is apparently the same. 
The conjugation procedure possibly helps to restrain the conformations adopted by 
the peptide, after inoculation (Van Regenmortel and de Marcillac, 1986). 
Conjugation to carrier proteins can cause problems of non-specificity (Briand 
et al. , 1985), and in this study removal of anti-KLH antibodies was problematic. 
Measurement of the initial immune response to inoculation, where KLH was used as 
a carrier molecule, revealed that anti-KLH antibodies, in control wells, gave far greater 
absorbance values than those recorded against the coated free peptide. Even 
subsequent to repeated KLH affinity purification of IgG fractions, the absorbance 
values still reflected this trend. This is unsatisfactory, especially if the antibodies are to 
be used for immunolocation studies, as there is always the possibility that anti-KLH 
antibodies could ' cross-react with the target peptide, and/or with unrelated peptides. 
Anti-KLH antibodies are, in fact, known to give non-specific reactions as they cross-
react with a large number of different proteins (Dr D. Buttle, pers. comm.). Such 
observations led to the discontinued use of KLH as a carrier protein, and extra efforts 
to ensure the specificity of antisera using western blotting. 
Many opinions have been voiced on what constitutes a "specific antibody" 
(Pool et al., 1983; De Mey, 1986; Van Leeuwen, 1986; Larsson, 1988a). In the light of the 
experience gained in raising peptide and polyclonal antibodies and using these in 
immunocytochemical studies, however, the author has come to the view that 
specificity is best judged by a number of different systems and labelling preferably 
confirmed by verification of the presence of the target antigen by classical biochemical 
or histological techniques. If this is not possible, preliminary western blot 
experiments give a good indication of the specificity of the antibody, but most weight 
should be given to the results of test and control experiments obtained in the system 
in which the antibody is to be used. 
All antibodies used in the present study were checked for labelling specificity, 
using western blotting against crude and purified fractions of the target antigen. This 
was found to be the most reliable method for optimising the antibody dilutions to be 
used in immunolabelling procedures, for checking for the presence of contaminating 
antibodies, and for checking for cross-reactivity to antigens present in crude extracts of 
target tissue proteins. It must be noted that for western blots to yield useful 
98 
information, the IgG fraction dilution has to be optimal and an optimal protein 
loading must be used. For testing cross-reactivity, it is normal to load the gels with 
10-7100-fold the optimal amount of antigen (Larsson, 1988a). To assess non-specific 
antibody interactions due to the use of too much blotted protein or the use of too-
concentrated an antiserum, it was found advantageous to use only IgG fractions and to 
use a pre-immune IgG control at the same concentration as that used for the test blot. 
This gave some confidence in results when it was known that antibodies were being 
used at considerably higher levels than would normally be used. The antibodies 
mentioned in this chapter, except anti-B13-22, were judged to be biochemically specific, 
using the western blotting criterion, and were, therefore, considered to be potentially 
suitable for use in immunolocation studies, described in Chapters 4 and 5. 
3.9.1 Summary 
In summary, the following points have emerged from the studies 
reported in this chapter:-
i) Choice of peptide sequences for the production of peptide antibodies is best made 
from 3-D structural data, which allows the selection of exposed regions on the 
protein surface, most likely to be "seen" by the immune system. 
ii) Predictions of potentially "protein-reactive" sequences, from primary sequence 
data only, are best made using the Chothia accessibility plots (Chothia, 1976), the 
Welling antigenicity prediction programme (Welling et al., 1985) or the T-cell 
epitope predicting programme (Margalit et al., 1987) (and possibly best by 
combining the results of all three programmes). 
iii) For protein-reactive peptide antibodies the flexibility plot of Karplus and Schultz 
(1985), indicates that some non-mobility in the chosen peptide sequence is 
desirable. The Hopp and Woods (1981) plot, indicates that a hydrophobic region 
in the peptide sequence is useful and this is confirmed by the apparent success of 
the T-cell epitope selection programme. 
iv) Free peptides are immunogenic, but appear to elicit weakly protein-reactive 
antibodies. Peptides conjugated with ovalbumin gave the best antibodies. 
v) Antibody speCificity may be tested primarily in an overloaded western blot 
system, using the highest concentration of antibody possible, and controlling the 
results using a pre-immune IgG, at the same level of antibody as the test. (As a 
secondary, or alternate, test of specificity, the antibody must give labelling of the 
organelles known, from biochemical analyses, to contain the antigen. A pre-
immune IgG preparation (at the same level used for the test antibody) substituted 
into the labelling regime, must give a negative result). 
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Of the peptide antibodies raised, only the anti-procathepsin B (anti-
ppB22-36) and anti-B192-201 antibodies were potentially applicable to immuno-
cytochemical studies. No immunoinhibitory antibodies were produced. 
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CHAPTER 4 
LEUCOCYTES AS MODEL SYSTEMS OF INVASIVE CELLS 
4.1 Introduction 
4.1.1 Leucocyte and tumour cell invasion 
Many parallels exist between the invasive behaviour and physiological 
processes of tumour cells and those of polymorphonuclear leucocytes (PMNs), 
monocytes and macrophages of human peripheral blood. In the process of moving 
into and out of blood vessels - a key step in the successful establishment of metastases 
- the tumour cell must traverse interstitial stroma and subendothelial basement 
membrane. Similarly, during extravasation, the blood phagocytes must traverse the 
same barriers to reach inflammatory tissue sites. In both cases, this requires adhesion, 
degradation of the extracellular matrix and locomotion (Terranova et al ., 1986; 
Condeelis et al., 1992). 
In the case of the tumour cell, the ability to degrade the extracellular 
matrix correlates strongly with the tumour's metastatic potential (Liotta and Stetler-
Stevenson, 1989). Thus, highly metastatic tumours are capable of releasing a variety of 
degradative enzymes, such as cathepsin B, plasminogen activator, heparin sulphate 
endoglycosidase, type IV collagenase and elastase (Yusa et al., 1989). A similar subset 
of proteinases must be involved in the invasive activities of blood phagocytic cells. 
The two proteinases most likely to be involved in the invasive activity of PMNs are 
the dominant neutral proteinases, elastase and cathepsin G. These proteinases have 
been shown by several previous studies to mediate degradation of basement 
membrane components (Heck et al., 1990). Elastase has, moreover, been associated 
with mouse mammary tumour cells (Grant et al., 1990) and other human breast 
carcinoma cell lines (Kao and Stem, 1986). Elastase is also the only neutral proteinase 
capable of degrading insoluble elastin, a structural component of elastic tissues such as 
blood vessels, skin, lung and breast tissues (Grant et al., 1990). In monocytes/ 
macrophages the acidic proteinases, cathepsins B (Ward et al., 1990) or D (Bever et al., 
1989), may be most relevant in this context. 
Many factors that are chemotactic for metastatic tumour cells (Yusa 
et al., 1989), monocytes (Senior et al., 1982) and PMNs (Blood and Zetter, 1990), are 
fragments of extracellular matrix molecules produced by proteolytic activity. 
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Chemotaxis (movement towards a chemotractant through a concentration gradient) is 
commonly mediated by binding of the chemotractant to a receptor (Zimmermann 
et al., 1988) and there is evidence that some receptors, such as that for the chemotactic 
peptide N-formyl-L-methionyl-Ieucyl-phenylalanine (fMLP) are common to both 
PMNs and the cells of some tumours, such as Walker 256 carcinosarcoma (Marasco 
et al., 1985). 
Chemotactic stimulation of PMNs results in a change in the shape and 
polarisation of the granules towards the direction of movement (Zimmermann et al., 
1988). Similarly, chemotactic stimulation of tumour cells (for example, by binding of 
autocrine motility factor to its receptor) initiates the redistribution of some receptors 
towards the "leading edge" and the extension of pseudopodia (Nabi et al., 1992). In 
cancer cells, exocytosis of membraned vesicles at the leading edge has been suggested 
to supply membrane for extension of the leading edge, as well as generating the force 
for cell locomotion (Bretscher, 1984). Similar principles may apply in the case of 
PMNs and monocytes. Moreover, if exocytosis of protease-containing vesicles occurs, 
the proteases may assist the invasive movement of such cells. Elastase receptors have 
been biochemically demonstrated to relocate to the surface of activated PMNs 
(Dwenger et al., 1986). 
Diapedesis (or movement through a barrier), on the other hand, 
appears to involve tumour cell receptor-mediated adhesion and Signalling, and 
motility, all of which appear to be closely linked phenomena (Lester and McCarthy, 
1992). Some adhesion receptors, such as that to laminin, which may assist in adhesion 
to basement membranes, have been identified in neoplastic cells, PMNs and 
monocytes (Huard et al., 1986; Liotta et al., 1986; Mercurio and Shaw, 1988; Terranova 
et al., 1983; 1986). The 67 kDa laminin receptor, is the dominant laminin-binding 
protein in PMNs and macrophages (Huard et al., 1986; Mercurio and Shaw, 1988), and 
is elevated in PMNs by inflammatory agonists such as PMA and fMLP (Yoon et al., 
1987). High levels of this laminin receptor are also expressed in oncogenically 
transformed cells (Hand et al., 1985; Yow et al., 1988), suggesting that increased 
adhesion to basement membranes is a characteristic of neoplastic transformation, and, 
in the case of the activated PMN also, is necessary for invasion. 
Invasion, after attachment to the basement membrane, involves 
proteolytic degradation of the extracellular matrix components and diapedesis. The 
proteases involved in such proteolytic and invasion processes are still unknown. It is 
also not known whether the proteinases become attached to or associated with the 
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surface of the invading cell, as indicated by some biochemical studies (Krepela et al., 
1987; Sloane et al., 1990), or whether the cells themselves attach to the basement 
membrane and form a "pocket", into which proteases are discharged, by intimate 
association between the basement membrane and the invading cell, as occurs in 
osteoclasts (Eeckhout, 1990). 
Attempts to reveal which protease(s) are involved in these processes have been 
made, using invasion models and employing chemotactic agents and specific 
proteinase inhibitors (Taylor et al., 1981; Territo et al., 1984; Furie et al., 1987). In these 
systems, tumour cells and PMNs are stimulated to invade through a membrane 
analogous to a basement membrane, and the inhibitory effects of incorporation of 
specific inhibitors observed. Such investigations suffer from a number of short-
comings, arising from two main sources: the penetration of the proteinase inhibitors 
to the site of action of the proteolytic process (Furie et al., 1987; Milks et al., 1983), and 
the fact that, once a proteinase has bound to its target substrate, proteinase inhibitors 
are largely ineffectual in preventing proteolysis (Johnson and Varani, 1981; Campbell 
et al., 1982). A final complication in studies on PMNs is that some proteinase 
inhibitors, such as aI-proteinase inhibitor, have been found to be inactivated by 
oxidants generated by neutrophils (Carp and Janoff, 1980; Weiss and Regani, 1984). A 
better approach might be to observe directly the invading cells, using immuno-
cytochemistry. 
4.1.2 The fixation problem 
The main focus of the present immunocytochemical study, was to 
establish whether cathepsin B, one of the main proteinases found in monocytes 
(Ward et al., 1990) or elastase and cathepsin G, the major proteinases found in PMNs, 
could become associated with the surface of activated monocytes or neutrophils, 
respectively, providing a means by which such chemotactically activated cells may be 
assisted to invade through barrier membranes, as seen in vivo and indirectly 
indicated by some biochemical studies (Dwenger et al., 1986; Sloane et al., 1990). 
The first consideration and the major challenge associated with this 
study was the choice and optimisation of the fixation procedure. For most 
immunocytochemical studies, a primary requirement is that fixation should 
immobilise the target antigen, i) where it occurs in the tissue, ii) in a form in which 
antigenicity is retained, and iii) in a form accessible to the labelling antibody and other 
immunolabelling reagents (Tokuyasu, 1986). A secondary requirement is that, for 
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electron microscopy studies, the fixative should preserve adequate tissue 
ultrastructure to allow the recognition of the subcellular organelles, while producing 
minimal structural distortions and fixation artefacts. Further tissue processing or 
embedding procedures should, similarly, not destroy or mask the antigen. 
In the present study, the preservation of antigenicity of the two main 
target antigens for immunolabelling, cathepsin B and elastase, was of primary 
importance. As the simultaneous identification of granule populations, using 
labelling of "marker enzymes", was required, a fixation and embedding regime that 
would allow the labelling of the maximum number of tissue antigens, in a single 
human tissue or blood sample, was sought. The unpredictable variation in the 
sensitivity of antigens, to fixation conditions, however, often necessitates the 
sacrificing of some ultrastructural detail, for the preservation of tissue antigenicity. 
Adequate fixation was consequently accepted, and for most of the 
studies undertaken, paraformaldehyde (PFA), the least denaturing fixative to a wide 
variety of antigens, was chosen. PF A has low antigen-denaturing properties, but, at 
physiological pH, it crosslinks tissue residues slowly and produces poor ultrastructure. 
For electron microscopy, such a weak fixative could only be used in conjunction with 
the cryoultramicrotomy system of immunolabelling. In this system, tissues or cells 
are only subjected to mild post-fixation tissue processing procedures. Tissues are 
frozen prior to sectioning, instead of being embedded in resins, hence obviating the 
potentially antigen-denaturing and tissue-damaging steps of resin embedding. The 
"Tokuyasu cryoultramicrotomy technique" was the main tissue processing and 
sectioning technique adopted for this study. 
At physiological pH, PFA was found to be ineffective in fixing elastase 
in azurophil granules. Extraction and translation of azurophil granule contents has 
proved a major problem in many studies, using different fixation regimes (Hibbs and 
Bainton, 1989; Damiano et al., 1986; Cramer et al., 1985; Robinson, 1985). This problem 
prompted an ongoing investigation, throughout the present study, of ways in which 
the efficacy of PFA fixation could be improved. Demands on the fixation regime are 
even more rigorous when dealing with activated PMNs, where granule membranes 
are considerably more fragile than in unactivated cells and containment of granule 
contents is consequently more difficult. Investigations of fixation methods were, 
therefore, conducted using both chemotactically activated and non-activated cells. 
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Attempts to do double labelling, after cryoultramicrotomy, led 
fortuitously to the discovery of the benefits of post-labelling fixation, for the 
improvement of tissue ultrastructure and antigen immobilisation, and to the 
discovery of the beneficial effect of further, prelabelling, fixation of the sections (lateral 
fixation). This also provided a novel method for varying the "effective" PFA fixation 
of a single specimen. 
Whereas labellings for most antigens required mild fixation and the use 
of cryoultramicrotomy, immunolabelling of cathepsin B proved to have unique 
requirements. Polyclonal antibodies to human liver cathepsin B only recognise 
cathepsin B in the denatured form. Cryoultramicrotomy and PFA fixation, therefore, 
proved to be insufficiently denaturing at physiological pH to promote the recognition 
of cathepsin B by the antibody. It consequently became necessary to explore different 
fixation and embedding approaches in the hopes of finding a system suitable for 
cathepsin B, but which would allow the simultaneous labelling of other antigens of 
interest. 
4.1.3 Activation of leucocytes 
Activation studies were designed to test the hypothesis that elastase and 
cathepsin G, and cathepsin B, may become associated with the surface of activated 
PMNs and monocytes/macrophages, respectively. Difficulties were encountered in 
these study, however, due to the loss of PMN and monocyte/macrophage fractions by 
their adherence to the surface of tubes used in the isolation procedure, and because of 
the reactive nature of the PMNs and the monocytes themselves. For this reason, 
different density gradient isolation procedures were used and, to obviate the effects of 
cell isolation procedures, some studies were also performed on leucocytes in situ in 
splenic tissues. 
PMNs are easily activated by substances present in the materials used to 
form density gradients, and appear to have different fragilities in different isolation 
procedures (Haslett et al., 1985). "Monocytes" are also easily activated during cell 
fractionation procedures, either by adherence to surfaces or by exposure to 
contaminating extracellular matrix proteins (Dougherty and McBride, 1989). In the 
monocyte, this activation triggers morphological, biochemical and functional changes, 
as the cell becomes the more phagocytically active derivative, a "macrophage". 
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Unfortunately, the term "monocyte" is loosely used to describe a very 
heterogeneous group of cells which, upon activation, become even more difficult to 
classify on morphological grounds (a fact not fully appreciated at the commencement 
of this study). Classification of these phagocytes is still a topic of some dispute, but is 
generally carried out by immunolabelling of surface markers (Dougherty and McBride, 
1989; Hogg, 1989). In this study, classification was made on morphological grounds, on 
the basis of descriptions in recent review texts (Van Furth, 1986; Dougherty and 
McBride, 1989; Kamperdijk et al., 1989; Strachura, 1989) (Section 4.2), and by labelling 
for marker enzymes. 
Finally, to confirm labelling results obtained in the preliminary 
cryoultramicrotomy studies on monocyte/macrophage cells, some fluorescent 
microscopy studies were performed on the U937 promonocytic cell line. These cells 
were differently treated to induce terminal differentiation into PMNs or monocytoid 
cells, respectively, in order to confirm cathepsin D and B labelling results observed in 
isolated PMNs and monocytes. Labelling for these antigens and the M-6-P receptor 
were also performed to establish reliable "marker(s)" of differentiation to the 
monocyte (by their presence), or to the PMN phenotype (by their absence), in the U937 
cells. Such a "marker", it was thought, could also possibly aid identification of such 
cells in peripheral blood for future studies. 
4.2 Morphological identification of peripheral blood PMNs and monocyte! 
macrophages 
The identification of cells on morphological grounds only, proved quite a 
challenge. Not only is the classification of the different monocyte-like cell types the 
subject of some dissent, but ultrastructural detail, required for the identification of the 
cell type, was often compromised by the fixation protocol used. 
Identification of PMNs and their precursors is facilitated by the segmentation 
and granularity of the nucleus. In cells that have been sectioned, however, 
information on the segmentation of the nucleus may not always be available, due to 
the orientation of the cell upon sectioning. Similarly, nuclei which are not segmented 
may appear to be so, if the "thickness" of the nucleus varies within the plane of 
sectioning. 
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A PMN matures from a promyelocyte, with a single round nucleus, to a 
myelocyte, and then to a metamyelocyte [or band or stab forms (PS), Plate I, Fig. 2], the 
nucleus becoming progressively more eccentric and lobulated. Finally the nucleus 
becomes polylobulated, the more mature PMN having a greater number of nuclear 
lobes (normally from 3-5), and a greater amount of cytoplasm, containing 
progressively fewer granules (Plate I, Fig. 1). Usually only the metamyelocyte and 
PMN form are present in the peripheral blood, with occasional myelocytes being 
found (Hayhoe and Flemans, 1980). 
Non-activated PMNs are generally round, with an even distribution of 
granules. Activated PMNs exhibit polarisation of granules towards the direction of 
chemotaxis and leave behind a trailing "tail" of cytoplasm (Zimmermann et al., 1988) 
(Plate I, Fig. 1). 
Monocytes arise in the bone marrow as monoblasts and promonocytes. They 
remain in the bone marrow very briefly before entering the circulation for up to ca. 
4 days. They subsequently migrate into the tissues, where differentiation and 
maturation into macrophages occurs as a result of environmental stimulae. 
Monocytes display remarkable heterogeneity in ultrastructure, cytochemistry, and 
peroxidase activity, the latter being used for classification of developmental stage and 
activation status (Van Furth, 1986; Kamperdijk et al., 1989; Dougherty and McBride, 
1989; Strachura, 1989). 
One of the main cell types with which monocytes may be confused are the 
dendritic cells (Des), a distinct group of antigen presenting cells which playa role, in 
the presentation of antigens to resting T lymphocytes, as highly efficient stimulators of 
primary responses (MacPherson, 1989). Des show irregular outlines with an eccentric, 
elongated, often lobulated, nucleus and a nucleus/cytoplasm ratio of 1:2 in peripheral 
blood (Kamperdijk et al., 1989). The plasma membrane is always irregular, some cells 
possessing moderately smooth surface lamellipodia while others possess blunt 
pseudopodia of varying length. (Kamperdijk, 1989). Often the nucleus is reniform 
with many indentations and sometimes it has a nucleolus. The karyoplasm is 
euchromatic with condensations at the nucleus edge and the cytoplasm contains 
mitochondria and some strands of rough and smooth endoplasmic reticulum (ER) 
(see Plate I, Figs 3 and 4). Des often contain vacuoles, especially near the cell surface 
(Plate I, Figs 3 and 4 ), but they are non-phagocytic (Kamperdijk, 1989). 
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Monocytes represent about 5% of the leucocyte population, and show marked 
endocytic and phagocytic activity, such activity increasing with differentiation from 
the monoblast to macrophage forms (Strachura, 1989) (see Plate I, Figs 1 and 2). 
Monocytes generally have a horseshoe nucleus and faint azurophilic granules which 
contain myeloperoxidase (Beelen et al., 1989). Their nucleus has heterochromatin 
(denser chromatin) towards the margins and the cell has a few lamellipods, subsurface 
vacuoles and a nucleus/cytoplasm ratio of approximately 1:1. They have a lower 
content of rough endoplasmic reticulum (RER), coated vesicles and lysosomes than 
macro phages (compare Plate 10, Figs 1 and 2 with Plate 13, especially Fig. 4). 
Monocytes stain for esterase-l and acid phosphatase throughout the cytoplasm, 
whereas in Des acid phosphatase is located in a central area near the nucleus. As 
monocytes mature, the peroxidase content of their granules decreases, and as they 
differentiate into macrophages, it disappears altogether (Strachura, 1989). A large 
increase in cytoplasm occurs upon cell activation and transformation into a tissue-
specific macrophage, morphology being thereafter determined by external stimulae 
(Beelen et al., 1989). Descriptions of the morphology of in vitro activated and 
differentiated monocytes (macrophages) are sketchy, except for a few descriptions that 
monocytes increase in size, the cytoplasm to nuclear ratio, membrane ruffling, and the 
number of cytoplasmic granules and lipid inclusions increaSing simultaneously 
(Dougherty and McBride, 1989). 
In the case of macrophages, therefore, identification is not Simple. In this 
study, the greatest difficulty was experienced in differentiating metamyelocytes 
(immature PMNs) (Plate I, Fig. 2) from monocytes and fully activated macrophages 
(Plate I, Fig. 2 and Fig. I, respectively). These cells contain numerous morphologically 
similar granules and similar horseshoe-like nuclei and the only differences seem to be 
in the type and quantity of specific marker enzymes present, in the size of the celt and 
the number of mitochondria present (Plate 1 and Plate 13, Fig. 4). If the fixation 
procedure does not preserve the morphology of mitochondria, then the usefulness of 
this distinguishing feature is diminished. 
In this study, a source of frustration was that serial sectiOning was not possible 
using cryoultramicrotomy, so identifications could not be confirmed by further 
labellings of marker enzymes on replicate sections. Also, serial sectioning is required 
to determine the true size of the cell. 
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4.3 Methods used in the study of peripheral blood leucocytes 
Certain methods which were commonly used in the study of PMNs and 
monocytes are reported in this section. These include gradient fractionation 
techniques and cell activation protocols. 
4.3.1 Gradient separation of PMNs and monocytes 
Various density gradient media and many procedural approaches have 
been advocated for the separation of leucocyte fractions by differences in density (e.g. 
Boyum, 1968; English and Andersen, 1974; Segal et al., 1980; Jepsen and Skottun, 1982; 
Haslett et al., 1985; McFaul, 1990). Cell density differences are small, with densities 
being typically between 1.05 and 1.10 gil (Miller, 1986). For this reason, no density 
gradient procedure can ensure absolute separation of the leucocyte populations. 
Typically, lymphocytes are most easily separated from granulocyte (PMN and 
monocyte) fractions. Separation of monocytoid cells and PMNs was found to be 
impossible, due to the heterogeneity of cell densities and differences in the 
morphologies of cells classified as monocytes. 
Separation protocols generally fall into two groups, those based on 
Ficoll, a sucrose polymer preparation (Boyum, 1968) and those based on Percoll, a PVP-
coated colloidal silica preparation (Dettman and Wilbur, 1979). Most other media are 
modifications of the Ficoll medium, which include density enhancing additives, such 
as sodium diatrizoate (known as "Isopaque" or "Hypaque") in the "Ficoll-Hypaque" 
discontinuous density gradient system of English and Andersen (1974). 
Two requirements of density gradient media are that they are non-toxic 
to cells and have a high molecular weight. A common problem is that gradient 
forming materials may form significant tonicity gradients also (Miller, 1986). High 
relative molecular mass preparations often contain large quantities of salt impurities, 
so cells moving into media of a higher density, also move into regions of higher salt 
tOnicity. Osmotic forces may cause cell shrinkage, thereby increasing cell density and 
causing cells to move straight through the gradient, to pellet on the bottom of the tube 
(Miller, 1986). Ficoll gradients are not isotonic at high concentrations of Ficoll, 
probably due to interactions of Ficoll with water (Williams et al., 1972). Ficoll also 
tends to enhance cell aggregation, particularly with increasing cell load (Miller, 1986). 
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Colloidal silica separation media have the principal advantage that high 
densities can be achieved with very little increase in tonicity or viscosity, and without 
inducing cell aggregation (Miller, 1986). Colloidal silica, however, is toxic. This may 
be overcome by the incorporation of a polymer of relatively high molecular mass, 
such as PVP (Dettman and Wilbur, 1979). Perc oIl (Pharmacia) consists of silica 
particles, coated with PVP and, in this study, it was found to be a superior medium for 
cell separation. 
Density gradient cell separation media have been shown to have 
various effects on cell functions. Increased expression of C3b receptors by PMNs has 
been observed (Fearon and Collins, 1983) and modulation of multiple PMN functions 
by trace concentrations of bacterial lipopolysaccharide, have been reported (Haslett 
et al., 1985). These authors report that cells isolated by the Ficoll-Hypaque method, 
showed spontaneous shape change, reduced chemotactic responsiveness, and 
increased production of lysosomal enzymes upon subsequent stimulation with fMLP, 
in comparison with other methods. Though many different density gradient systems 
were tried in the present study, the Percoll density gradient method of Haslett et al. 
(1985) followed by the Ficoll-Hypaque gradient separation method of English and 
Andersen (1974) were the most successful and are, therefore, the only methods 
described in detail here. 
4.3.1.1 Reagents 
Dextran (MW 500 000) and Ficoll-Hypaque (marketed as 
Histopaque 1119 and Histopaque 1077) were from Sigma, BSA (fraction V powder) was 
from Boehringer and Perc oIl was from Pharmacia. Sterile saline [NaCl (9 g) in 1 litre 
dist.H20] was from Baxter Laboratories. 
Platelet-poor plasma (PPP). PPP was prepared as described in 
Section 4.3.1.2, below. 
6% Dextran. Dextran (MW 500 000) (6 g) was dissolved in sterile 
saline and made up to 100 ml. 
100% Percoll. A stock solution of 100% Percoll was freshly 
prepared from the commercially supplied solution by diluting the commercial stock 9 
parts to 1 part sterile saline. 
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42% Percoll. Stock Percoll (4.2 ml) was freshly diluted with 
platelet-poor plasma (5.8 ml). 
51 % Percoll. Stock Percoll (5.1 ml) was freshly diluted with 
platelet-poor plasma (4.9 ml). 
PBS, pH 7.2. PBS was made up as described in Section 2.3.1.1 
2% Bovine serum albumin in PBS, pH 7.2 (PBS-BSA). BSA (2 g) 
was dissolved in PBS, pH 7.2, and made up to 100 ml. 
1 % BSA in sterile saline. BSA (1 g) was dissolved in sterile saline 
and made up to 100 ml. 
4.3.1.2 Procedure 
PMNs were separated from 10 ml of blood drawn from healthy 
volunteers into lithium-heparin glass Vacutainers®, and rapidly transferred to sterile 
polystyrene tubes (Greiner, Frickenhausen, Germany). Cells were separated using the 
Percoll gradient method of Haslett et al. (1985) or the Ficoll-Hypaque method of 
English and Andersen (1974). 
Following the method of Haslett et aI. (1985), blood was 
centrifuged (300 x g, 20 min, 20°C), the platelet-rich plasma supernatant harvested and 
centrifuged (2500 x g, 15 min, 20°C) to produce platelet-poor plasma (PPP). 6% Dextran 
(1 ml) was added to the cell pellet, the volume was made up to 15 ml with sterile 
saline, mixed, and left for 30 min for erythrocyte sedimentation to occur. The 
leucocyte-rich supernatant was aspirated and centrifuged (275 x g, 15 min, 20°C). The 
pellet was resuspended in 2 to 3 ml of PPP and transferred to a 15 ml polystyrene tube, 
where it was underlayered with 2 ml of freshly prepared 42% Percoll, which, in tum, 
was underlayered with 51 % Percoll and centrifuged (275 x g, 10 min, 20°C). 
Lymphocytes, some monocytes and platelets were harvested 
from the top layer of the gradient (between the plasma layer and the 42% fraction) 
while PMNs and some monocytes were harvested from the lower wide band between 
the 42% and 51 % Percoll layers. Harvested cells were mostly contaminated with 
erythrocytes. Attempts to denature these, by osmotic shock, were made by adding 
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dist.H20 into the fraction (2 min), after which cells were washed once (400 x g, 10 min, 
20°C) with PBS-BSA, before activation and/ or fixation. 
In the English and Andersen (1974) method, blood was 
centrifuged (275 x g, 5 min, 20°C), the leucocyte-rich fraction harvested and diluted 
50% with sterile saline containing 1 % BSA. A discontinuous gradient was created by 
loading Histopaque 1119 (3 ml) on top of Histopaque 1077 (3 ml), in a 15 ml conical 
polystyrene centrifuge tube, and the leucocyte-rich fraction (2 ml) was carefully layered 
on top of the discontinuous gradient. Harvested cells were washed once (400 x g, 
10 min, 20°C) with PBS-BSA, before activation and/ or fixation. 
4.3.1.3 Results 
PMNs, especially, showed many more osmotic effects and 
spontaneous shape changes, when separated on a Ficoll-Hypaque density gradient 
(Plate I, Fig. I), compared to Percoll (Plate I, Fig. 2). They were also more fragile to 
subsequent processing procedures; some showed evidence of activation, and fractions 
were generally more contaminated with lymphocytes and platelets (Plate I, Fig. 1) 
than fractions separated on Perc oIl gradients. Ficoll-Hypaque density gradient 
separated fractions also appeared to contain a greater number of activated monocytes 
(macrophages) and dendritic-like cells (Plate I, Fig. 1). 
Perc oIl fractions appeared to show the greatest enrichment of 
PMNs, relative to other leucocyte fractions. The actual concentration of leucocytes 
finally isolated, however, was always relatively low, as PMN /monocyte fractions were 
always diluted by the large number of erythrocytes that survived the osmotic shock 
treatment. At best, a large number of erythrocyte "ghosts" or membrane fragments 
are evident in Percoll cell fractions (Plate I, Fig. 2). Platelets contaminated all cell 
fractions (Plate I, Figs 1 and 2). 
4.3.2 Leucocyte activation 
Formylated peptides, characteristic of prokaryote proteins, are extremely 
potent chemotactic agents for PMNs (Schiffman et al., 1975) and monocytes (Estreicher 
et al., 1990). In both cell types, chemotactic activity is stimulated by a cascade of 
messenger molecules, triggered by binding of the formylated peptide to the specific 
receptor on the surface of the cell. Receptor occupancy triggers the rapid exchange of 
GDP by GTP on a pertussis toxin - sensitive G (Gin) protein, resulting in activation of 
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the G protein. The G protein activates phospholipase - C, leading to the formation of 
inositol-1,4,5 triphosphate and diacyl glycerol (DAG), which triggers the release of 
calcium (Verghese and Snyderman, 1989). Further cell signalling events result in 
increased actin polymerisation, changes in cellular morphology and chemotactic 
movement, though the mechanism for these effects is still not known (Niggli and 
Keller, 1993). Phorbol esters, such as PMA, however, activate protein kinase-C and 
mimic the effect of endogenously generated DAG (Verghese and Snyderman, 1989). 
4.3.2.1 Reagents 
PMA, fMLP and trypan blue were from Sigma. 
2% BSA in phosphate-buffered saline (PBS-BSA). PBS-BSA was 
made up as described in Section 4.3.1.1. 
PMA stock (0.5 mg/ml or 1.23 mM). PMA (1 mg) was dissolved 
in DMSO (100 J..lI) and made up to 2.0 ml with dist.H20. The solution was stored at 
-20°C. 
fMLP stock (0.625 mg/ml or 1.43 mM). fMLP (1 mg) was 
dissolved in DMSO (100 J..lI) and 1.5 ml of dist.H20 added. The solution was stored at 
-20°C. 
Dilute fMLP (5 Ltg/ml). Stock fMLP solution (10 J..ll) was made up 
with 1.5 ml with PBS-BSA. 
4.3.2.2 Procedure 
Cells (2,4 x 106/ml) were activated by the introduction of fMLP 
(30 J..lM) or PMA (25 or 40 J..lM) into the medium (30-45 min, 37°C), before being 
washed twice (400 x g, 5 min) in PBS-BSA. Trypan blue exclusion tests indicated a cell 
viability of 90-95%. 
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4.4 Fixation for studies on PMNs 
Extraction and translocation of azurophil granule contents is reported to be a 
common problem in immunolabelling of PMNs (Hibbs and Bainton, 1989; Damiano 
et al., 1986; Cramer et al., 1985; Ganz et al., 1985). It is important, however, for the 
correct classification of granules, on the basis of their complement of antigens, that all 
of the antigens remain in place, during immunolabelling. This is also necessary for 
studies on activated PMNs, aimed at identification of surface-bound proteases, and at 
defining their origin. 
Some antigens occur at very low levels, in some granule populations, so it is 
also important that fixation procedures preserve antigenicity at the highest level 
possible. For this reason, PF A, the least denaturing fixative to a wide variety of 
antigens (Larsson, 1988b; Seligman et al., 1950), was chosen for the present study and 
strategies to improve PFA fixation were employed. 
The pH (Berod et al., 1981; Eldred et al., 1983; Bourgnon and Charlton, 1987; 
Larsson, 1988b), and the concentration of the PFA fixative (Larsson, 1988b), has been 
shown to affect the fixation of various tissue antigens differently. In this study, the 
main problem was to fix the contents of PMN azurophil granules and, to do this, it is 
necessary for the fixative to be able to penetrate the walls of these large granules. At a 
low concentration, PFA exists in a less polymerised form which will be more 
penetrating. Having penetrated, however, a subsequent increase in concentration 
would cause PFA to polymerise to a form more effective in crosslinking (Walker, 
1964). Moreover, PFA mainly reacts with uncharged amino groups (Kallen and 
Jencks, 1966) and these become more numerous as the pH rises. These considerations 
were the basis of the "low-high" step approaches used in this study, as variations in 
pH and concentration were employed in PFA fixation regimes. 
If the initial fixation is too effective, however, it might over-fix the granule 
walls, preventing further penetration of PFA into the granule interior - a "nutshell" 
effect. A possible way of overcoming this, which was developed in the course of this 
study, was to float the newly-cut section onto fixative, prior to labelling, so that the 
fixative could gain access to the granule contents, laterally, through the cut surface, 
without having to cross the granule wall. 
Alternatively, an azurophil granule-stabilising technique, previously described 
by Hibbs and Bainton (1989) was employed, in some cases. The present study was 
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conducted mainly on non-activated PMNs. Results of such fixation studies will be 
described in this section and the results of activation studies will be described mainly 
in Section 4.5. 
4.4.1 Reagents 
Rabbit anti-human cathepsin D was prepared in this laboratory by Philip 
Fortgens and anti-human leucocyte elastase (HLE) IgG was from Athens Research and 
Technology, Athens, Ga. USA (see Section 3.8). Rabbit anti-human lactoferrin IgG, 
globulin-free bovine serum albumin and diaminobenzidine were from Sigma 
Chemical Co., St. Louis, Mo. USA. Rabbit anti-human myeloperoxidase IgG was from 
Dakopatts, Glostrup, Denmark. Foetal calf serum was from Gibco, Paisley, Scotland. 
Protein A gold labels were produced according to the tannic acid method of Slot and 
Geuze (1985), as described in Section 2.3.6, unless otherwise stated. Antibodies were 
diluted in 1% BSA and gold labels were diluted in 0.1% globulin-free bovine serum 
albumin (Section 2.3.7.1) or 5% foetal calf serum in PBS (Section 2.3.3.1), and other 
tissue "blocking" reagents were made as described in Section 2.3.3.1. 
O.lM Tris buffered saline (TBS), pH 7.6. Tris base (12.1g) and sodium 
chloride (9 g) were dissolved in approx. 900 ml dist.H20, titrated to pH 8.0 with HCl 
and made up to 1 litre. 
Diaminobenzidine (DAB) solution. DAB (0.025 mg) was dissolved in 
O.lM Tris buffer, pH 7.6, and 30% H202 (1 Ill) was added, immediately before use. 
4.4.2 Procedure 
PMNs were separated from blood drawn from healthy volunteers and 
fractionated by density gradient centrifugation, as described in Section 4.3.1.2. Cell 
fractions were activated (30 min, 37°C) as described in Section 4.3.2.2 and fixed with 
either a "single" or "double" procedure. In the "single" fixation protocol, cell pellets 
were fixed for 15 min, at room temperature, in either 4% or 8% PFA in 200 mM 
HEPES buffer, pH 7.2 or pH 8.0 (Section 2.3.2.1). In the "double" fixation protocol, cells 
were fixed for 5 min in 4% PFA and 10 min in 8% PFA in 200 mM HEPES buffer, at 
pH 7.2 or pH 8.0. 
In some preparations, after fixation with 4% PFA followed by 8% PFA 
(both in sodium cacodylate buffer, pH 7.2), the generation of a myeloperoxidase 
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reaction product precipitate (oxidised diaminobenzidine) in azurophil granules, was 
used to stabilise granule contents. In this case, the cells were incubated in DAB 
solution, for 20 min at room temperature (Graham and Karnovsky, 1966), washed 
twice in PBS, cryoprotected, and sectioned as below. 
Alternatively, after initial fixation, the pelleted cells were simply 
cryoprotected, frozen and sectioned as described in Section 2.4.3.2. Sections were 
retrieved on a drop of 2.3 M sucrose, placed on a 100 mesh hexagonal, formvar- and 
carbon-coated grid and floated out onto chilled PBS, or fixative, for 30 min. 
Sections were first blocked by incubation in 0.02 M glycine (10 min), 
followed by 1 % BSA or 5% foetal calf serum in PBS (15-30 min). Incubation (1 h) in 
either rabbit anti-HLE (0.88 Ilg in 10 Ill), rabbit anti-human lactoferrin (0.36 Ilg in 
10 Ill), rabbit anti-human myeloperoxidase (0.5 Ilg in 10 Ill) or rabbit anti-cathepsin D 
antiserum (1/40) was followed by washing in several changes of PBS (20 min in total). 
After incubation on 5 or 10 nm protein A-gold probe (10 Ill, AS20 0.1 - 0.5), grids were 
again washed in several changes of PBS (20 min in total). All labellings were 
performed either without or with post-labelling fixation, with 1% glutaraldehyde in 
PBS (5 min) (Tokuyasu, 1986). Double labelling was performed, using the method of 
Slot et al. (1991), in which the sections are treated with 1% glutaraldehyde in PBS 
(5 min) and blocked with 0.02 M glycine (15 min) and 1% BSA (5 min), between the 
two labelling steps. Consistency of labelling with both sizes of gold probe was tested by 
performing labelling for the different antigens in different orders, using both sizes of 
gold probe (always using the smaller gold probe first). Finally, all grids were washed 
in distilled water, contrasted in acidic uranyl acetate/methylcellulose as described in 
Section 2.4.3 and viewed in a Jeol 100CX transmission electron microscope at 80 kV. 
Controls included substituting pre-immune IgG or serum for antibodies 
used in the labelling scheme, omitting the primary antibody, and, where relevant, 
omitting the anti-primary antibody. 
4.4.3 Results 
In assessing different fixation regimes, their success in meeting the 
following criteria must be considered: i) the preservation of antigenicity, ii) the 
preservation of ultrastructure, and, iii) the immobilisation of the antigen. 
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Effect of paraformaldehyde concentration on antigenicity and 
ultrastructure. PFA was used at two concentrations, 4% and 8%, and at two pH values, 
pH 7.2 and 8.0, in various combinations. For clarity, the two values will be referred to 
as "low" and "high", respectively, in each case. For example, "low PFA" means 4% 
PFA. 
Most of the PFA fixation protocols used yielded high density 
immunolabelling, for all antigens tested. Exceptions occurred where extensive 
antigen extraction occurred (Plate 2, Fig. I), or in double-labelling where 
glutaraldehyde was used between labelling steps, lowering the labelling density of the 
second antigen (compare labelling of lactoferrin, Plate 3, Fig. C insert, with that of 
Fig. B, same plate). No obvious differences in labelling densities were evident after 
flotation of sections on fixative, prior to labelling (compare Plate 2, Fig. 5, and Plate 3 
Fig. C). 
Double fixation, at low pH, with low PFA, followed by high PFA, 
(Plate 2, Figs 2, 3a and 3 b), gave slightly better antigen immobilization and improved 
ultrastructure, compared to that given by the individual fixatives (e.g. Plate 2, Fig. I), 
particularly when sections were floated on high PFA, at low pH, after sectioning, and 
also fixed after labelling (Plate 2, Fig. 3 a and b). Elastase was not totally immobilised 
by fixation at pH 7.2, however, even when this was assisted by both pre- and post-
labelling fixation, and some elastase was still translocated across the cell and 
surrounding support film (Plate 2, Fig. 3 b) . . 
Effect of granule and membrane stabilisation techniques. Granule 
stabilisation, with peroxidase reaction products (Hibbs and Bainton, 1989), did not 
result in the complete immobilisation of the elastase antigen, even if fixation was 
extended for as long as long as 1 h (Plate 2, Fig. 4), though the azurophil granule 
appears to be largely stabilised. 
Flotation of sections on fixative prior to immunolabelling. Improved 
results were obtained with sections floated on high PF A, prior to immunolabelling. 
Cells (fixed, at low pH, with low PFA, followed by high PFA) collected on high PFA (at 
low pH), and fixed post immunolabelling (Plate 2, Fig. 3a and b), had better 
ultrastructure, granule preservation and antigen immobilisation than those only post-
fixed after immunolabelling (Plate 2, Fig. 2). However, the complete immobilisation 
of elastase was not achieved by any PFA fixation regime at pH 7.2 only. Cells [fixed 
with low PFA, at high pH, followed by high PFA, at low pH] collected on high PFA, at 
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high pH, showed better immobilisation of elastase, but possibly some distortion of the 
azurophil granules (Plate 3, Fig. C, arrowheads). 
The effect of paraformaldehyde concentration and pH. Brief fixation 
with low PFA, at high pH, followed by high PFA, at low pH (Plate 3, Figs A, B and C), 
gave the best combination of azurophil granule preservation and antigen 
immobilisation. With collection of sections on high PF A, at high pH, prior to 
labelling, the elastase appeared largely contained within granules (Plate 3, Fig. C), 
though some of the larger azurophil granules appear to be distorted and swollen. It 
was initially thought that vacuolation of the cytoplasm, especially of more mature 
PMNs, may have been exaggerated by this flotation regime (e.g. Plate 3, Fig. C). 
Immobilisation of elastase was better than with low PFA followed by high PFA, at low 
pH (Plate 2, Fig. 3 b), and azurophil granule structure preservation appeared better 
than with high PFA, alone, at high pH (Plate 2, Fig. 5). 
At first it seemed that fixation with high PFA at high pH only, appeared 
to rupture and extract azurophil granules to some extent, especially in older cells, 
resulting in "organelles" which label for azurophil antigens, but which are not 
electron dense (Plate 2, Fig. 5). (Though Plate 2, Fig. 5, illustrates a PMA-activated 
PMN, similar results were obtained in some "unactivated cells"). Subsequently, it 
seemed these "organelles" may rather be due to inadvertent activation of the PMNs, 
as these electron-translucent bodies seem to be characteristic of activated PMNs (see 
Section 4.5). 
Less translation of the elastase antigen was seen in cells fixed with low 
PFA, high pH, followed by high PFA at low pH and floated on high pH PFA, high 
concentration fixative prior to labelling, than with fixation with high PFA at high pH 
only (compare Plate 3, Fig. C and Plate 2, Fig. 5). 
4.4.4 Discussion 
Elastase proved to be the most problematic antigen in PMNs, because it 
occurs in high concentration and is difficult to contain within granules. Since it was 
the most difficult antigen in this regard, elastase immobilisation became the primary 
yardstick whereby different fixation methods were assessed. 
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The effect of PF A concentration on fixation. The fixation achieved on 
PMNs, indicates that the concentration of the fixative does influence the quality of 
fixation. Better stability of fixation was evident when high PFA was used. This effect 
can best be ascribed to the different species of fixative present at different 
concentrations. Solid PFA consists largely of polymeric species, partially soluble in 
alkaline solution, which dissolve by slowly depolymerising to smaller, more soluble 
polymers in alkaline solutions (G. Griffiths, pers. comm.; Walker, 1964; Larsson, 
1988b). Stored unfrozen, depolymerisation of the solute soon reaches equilibrium 
(Walker, 1964; Larsson, 1988b). Above 1-72% (w Iv) PFA, the degree of polymerisation 
and concentration of polymers at equilibrium increases progressively with increasing 
PFA concentration (Walker, 1964). 
At low concentrations (1-2%), PFA reacts mainly, and most rapidly, with 
deprotonated primary or secondary amines to form hydroxy-methylene bridges 
(Kallen and Jencks, 1966). At higher concentrations, it reacts with both protonated and 
unprotonated amines (Kallen and Jencks, 1966), producing a more extensive cross-
linking, at physiological pH. 
In the present study, more extensive crosslinking may have been 
facilitated by the increased length of PFA polymers, at high PFA, resulting in 
crosslinking of reactive residues some distance apart. Coupled with greater reactivity 
of PFA at high concentration (with both protonated and deprotonated amino groups), 
this should lead to better preservation of cellular ultrastructure. Fixation with high 
concentrations of PFA alone, especially at physiological pH, however, appears not to 
be adequate to prevent the translocation of azurophil antigens, such as elastase. 
High PFA may cross-link efficiently, but may not penetrate as well as 
lower PFA. In the present study, it was found that fixation with low PFA, to ensure 
rapid penetration of fixative, followed by high PFA, to ensure adequate tissue cross-
linkage, gave better containment of elastase and better ultrastructural preservation 
than any single concentration of fixative. Fixation with any PFA regime, at pH 7.2, 
however, failed to completely immobilise elastase, or to stabilise azurophil granules, 
possibly indicating that fixation is too slow and perhaps reversible at this pH. 
Effect of pH on fixation. PFA reacts primarily with lysine amino groups 
and, according to Kallen and Jencks (1966), its affinity for protonated amines is two to 
three orders of magnitude less than for the non-protonated amine. At pH 7.2, only a 
small proportion of amino groups would be in the reactive, deprotonated form, so 
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fixation would be less effective at this pH. Both proteins, and lipids with primary 
amino groups, should, therefore, be more rapidly and adequately fixed at higher pH. 
In the present study, the rate and extent of fixation was found to be markedly affected 
by pH; high pH giving the best antigen immobilisation and, in some cases, the best 
lipid fixation (see macrophage Plate 13). 
The pH not only affects the rate of reaction of PFA with primary 
amines, but the size of the PFA polymer is also pH dependent. An increase in pH, 
above pH 4.3, results in a progressive depolymerisation of PFA (Kallen and Jencks, 
1966), favouring the formation of smaller, more penetrating, species of PFA. 
Variations in pH may thus also produce polymers of different sizes which may be 
more or less suited to bridge tissue reactive groups distributed at a fixed distance apart. 
Differences in the composition and spatial distribution of such reactive groups may 
explain the different pH optima, for fixation, reported for different tissues (Berod et al., 
1981; Bourgnon and Charlton, 1987; Larsson, 1988b). 
Inadequate penetration of fixative to internal structures in a cell, has 
been reported to be a problem when an attempt is made to improve fixation by 
increasing the pH (Berod et al., 1981; Eldred et al. 1983); the rapid, efficient fixation of 
outer membranes may impede subsequent fixative penetration. In such cases, the "pH 
shift" method of Berod et al. (1981) and Eldred et al. (1983) may be advantageous. In 
this method, fixation is effected with 4% PFA, to allow rapid penetration, at a 
relatively low pH (pH 6.5 or pH 7.2), followed by fixation with 4% PFA at pH 11.0 or 
pH 10.4, the high pH facilitating rapid crosslinkage and immobilisation of the antigen. 
In the present study, a "reverse pH-shift" strategy, combined with an increase in PFA 
concentration, was most successful in immobilising azurophil granule antigens. 
Possibly the low penetration, caused by the increased efficiency of fixation of the 
azurophil granule membranes, at the higher pH, and hence their impermeability to 
the fixative, was partially offset by the low concentration of PFA, and the decreased 
size of the polymers present at the higher pH used for initial fixation. 
Pre- and post-labelling fixation. The present study has suggested that 
floating the newly-cut section onto fixative is an effective way of fixing PMN granule 
contents. Also, post-labelling fixation with glutaraldehyde (Tokuyasu, 1986) has 
proved generally beneficial in stabiliSing sections through subsequent steps. 
Glutaraldehyde fixation not only strengthens the section, by crosslinking tissue 
components, but may also fix the antibodies and gold labels in position, preventing 
them from subsequently dissociating and translocating. 
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In summary, for the immobilisation of the azurophil granule antigen, 
elastase (and possibly other azurophil granule antigens), in PFA-fixed, unembedded 
PMNs, the following points have emerged from this study:-
a) ca. 4% PFA, which would contain a low proportion of polymeric forms of PFA, 
is advantageous for initial infiltration of the cell pellet. 
b) For initial infiltration, short fixation at pH 8.0 is perhaps optimal as the rate of 
fixation is increased at this pH, while the smaller polymers prevalent at this pH 
favour rapid tissue penetration. The short fixation time may limit over-
fixation of azurophil ganule membranes which, otherwise, may prevent 
further penetration of the fixative. 
c) For secondary infiltration, ca. 8% PFA, at pH 7.2, may be used to advantage. 
The higher concentration and lower pH promotes the formation of larger 
polymers, and consequently may also promote more effective bridging of 
distant groups, while the lower pH attenuates the rate of fixation, thereby 
ensuring that penetration of the fixative into the granules is not blocked. 
d) After sectioning, and before labelling, the section may, with advantage, be 
collected onto ca. 8% PFA at pH 8.0. After sectioning, the fixative has easy 
lateral access to all parts of the section and so the most effective fixative, which 
does not destroy antigenicity, may be used without consideration of 
penetration limitations. 
e) After immunolabelling it is no longer necessary to preserve antigenicity and so 
1 % glutaraldehyde, at pH 7.2, may be used to stabilise antibody / 
antigen/immunolabel complexes against the acid uranyl acetate/methyl 
cellulose contrasting-and-sealing process, and fortify the tissue against the 
osmotic shock of distilled water washes. 
In this study, the approach of immunolabelling a section, lightly fixed 
with PFA, and subsequently re-fixing the section with strongly-crosslinking 
glutaraldehyde, facilitated the simultaneous labelling of two PMN azurophil granule 
marker antigens, myeloperoxidase and elastase, as well as cathepsin D and lactoferrin-
in unembedded tissues. Cathepsin D has not been previously immunolocated in 
PMNs, at the electron microscopy level, though it has been demonstrated 
biochemically in PMN fractions of density gradient-separated human leucocytes 
(Ishikawa and Cimasoni, 1977). 
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4.5 Immunolabelling of activated PMNs and spleen cells 
The fixation procedures used were subject to continuous development 
throughout the investigations on PMNs and splenic tissues. The fixation used for 
most of the studies on activated PMNs, for which the results are reported here, i.e. 8% 
PFA in HEPES buffer, pH 8.0, was considered to be optimal, at the time when these 
studies were done. In the light of subsequent studies on fixation, reported in Section 
4.4, it emerges that this may not, in fact, have been an optimal protocol. Nevertheless, 
the studies reported in this section complement those on fixation, as insight was 
obtained into the effect of different activating agents on granule morphology. 
For example, in the fixation study reported in Section 4.4, it was considered that 
perhaps the use of a high PF A, high pH, fixation regime, was responsible for the 
unusual morphology of some azurophil granules. This may equally have been the 
result of inadvertent partial activation of the PMNs used in the fixation study. In 
these "unactivated" cells, besides the known primary and secondary ("specific") 
granules, a third type of elastase-containing compartment was evident. This is a 
swollen, electron-translucent compartment, which, as will become evident, is 
especially prevalent in PMA and fMLP-activated cells, and may have a secretory 
function. 
The view that this compartment may be a consequence of activation, rather 
than an artefact of fixation, is supported by the observed morphology of unactivated 
splenic PMNs in tissues fixed at an even more alkaline pH (8% PFA, pH 9.0), where 
there was no evidence of such compartments (Section 4.5.2). Also, the similarity of 
the compartment in "unactivated" PMNs and in PMNs activated with two different 
agents, seems to support such reasoning. 
An alkaline phosphatase-positive compartment, distinct from the azurophil 
and specific granules, which forms large irregular tubular structures, which increase 
in size upon cell activation, has been described previously (Kobayashi and Robinson, 
1991). From the results of the studies reported here, it seems that similar structures, 
manifest as electron-translucent compartments, may be formed by elastase-containing 
azurophil granules, upon activation of PMNs. 
In the second part of this section, the results of studies of spleen tissue/ 
phagocyte interactions are presented. PMN azurophil granules contain large amounts 
of elastase (1.59 x 10-15 g/granule) (Damiano et al., 1986), which, if it should be released 
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upon activation of the cells, would be potentially damaging to host tissues. 
Immunolabelling results on splenic tissues provided insights into a mechanism by 
which endothelial cell damage, by elastase released from activated PMNs, may be 
minimised. On the basis of these results, it is proposed that a possible secondary 
function of splenic endothelial stave cells is the removal of tissue-damaging 
proteinases from the splenic chord spaces. 
4.5.1 Elastase and cathepsin G in activated peripheral blood PMNs 
Although alkaline phosphatase has been found to associate with the 
surface of fMLP- and PMA-activated PMNs (Kobayashi and Robinson, 1991), elastase 
and cathepsin G have not previously been demonstrated on the surface of activated 
PMNs. The association of these potent proteinases with the "leading edge" of the cell, 
could, however, be relevant in assisting invasive cell movement. Differences in cell 
shape and in the surface distribution of elastase and cathepsin G were, therefore, 
examined using both fluorescent labelling, and immunogold labelling of 
cryoultramicrotomy sections, of PMNs activated in vitro with PMA and fMLP. 
4.5.1.1 Reagents 
Sheep-anti-cathepsin G was from Serotec and rabbit-anti-elastase 
was from Athens Research and Technology, Athens, Ga. USA (see Section 3.8). Goat 
anti-rabbit-FITC conjugate, the rabbit anti-sheep-FITC conjugate, and poly-L-Iysine 
were from Sigma Chemicals, St Louis, Mo. USA. Polyclonal rabbit anti-sheep IgG was 
prepared in this laboratory by Dr Theresa Coetzer. A 3 nm protein A-gold probe was 
prepared as described in Section 2.3.6. 5% Foetal calf serum (FeS), 1% bovine serum 
albumin and 0.02M glycine in PBS were made up as described in Section 2.3.3.1. 
0.05% Poly-L-Iysine. Poly-L-Iysine (0.025 g) was dissolved in PBS 
(50 ml), stored frozen and thawed for use. 
Glycerol-phosphate buffered saline mounting medium. 
Glycerol-PBS mounting medium was freshly prepared by diluting 9 parts of glycerol 
(AR) with 1 part of PBS, pH 7.2. 
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4.5.1.2 Procedure 
Human PMNs were isolated from heparinised peripheral blood, 
using Percoll or Ficoll-Hypaque density gradients, and prepared as described in Section 
4.3.1.2. 
Part of the cell fraction was spread on slides coated with 0.05% 
polylysine, fixed with 8% PFA, pH 8.0, (5 min) followed by 8% PFA, pH 7.3, (15 min) in 
HEPES buffer, and labelled with fluorescent conjugate (as described below). The other 
part of the fraction was similarly fixed and processed for cryoultramicrotomy (Section 
2.4.3) and immunolabelled (as described in Section 4.4.2) for elastase (0.88 Ilg in 10 Ill), 
and cathepsin G (antiserum diluted 1 in 80). 
For immunofluorescence studies on proteases associated with 
the external surface of cells, non-permeabilised cells were used. Residual aldehyde 
reactive groups on slide preparations were quenched with 0.02 M glycine (15 min) and 
5% FeS (15 min), and each slide was incubated in rabbit anti-elastase (22 Ilg in 250 Ill, 
1 h) or sheep anti-cathepsin G serum (diluted 1 in 40, 250IlI), washed in PBS (20 min) 
and the goat anti-rabbit-FITC conjugate (diluted 1 to IS), or rabbit anti-sheep-FITC 
conjugate (diluted 1 to 20) was applied (250 Ill, 1 h). Slides were washed in PBS 
(20 min) and the labelled preparation was covered with a coverslip, mounted with 
glycerol mounting medium and viewed using an Olympus-BHT microscope fitted 
with an epifluorescence attachment and a 490 nm exciter and a 520 nm barrier filter. 
For controllabellings the primary antibody was omitted or a pre-
immune IgG preparation substituted. 
4.5.1.3 Results 
Since immunolabelling for elastase and cathepsin G gave similar 
results, for purposes of illustration, only the results of one or the other will be shown. 
Unstimulated cells are rounded, and showed little or no elastase 
or cathepsin G association with the cell surface (results not shown, but see Plate 3, 
Fig. C). In fMLP- and PMA-activated PMNs, however, a surface distribution of elastase 
and cathepsin G is evident in both immunofluorescence and LE.M. labelling; a 
polarised distribution occurring in fMLP-activated PMNs (Plate 4, Figs 1 and 2 and 
Plate 5). 
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Electron microscopy immunolabelling, of fMLP-activated PMNs, 
for elastase and cathepsin G, reveals a polarisation of elastase- and cathepsin G-
containing azurophil granules towards the "leading edge", and concomitant 
association of elastase and cathepsin G with the diffuse cell surface (Plate 5, Fig. I, 
large arrows indicate leading edge and elastase association with cell surface). Some 
elastase and cathepsin G is also associated with the equally diffuse, ruffled surface 
(Plate 5, Figs 1 and 2, arrowheads), but not with the "trailing edge" of the cell (Plate 5, 
Fig. 2, arrows). Some degranulation is evident (Plate 5, Fig. I, small arrows), but no 
pinocytosis or phagocytosis. A few electron-translucent, elastase and cathepsin G-
containing vesicles are evident. 
PMA stimulation has been reported to result in surface ruffling, 
increased pinocytosis and decreased locomotion (Zimmermann et al., 1988). The 
present study, however, suggests that these effects are dependent on the degree of 
activation. Low dose stimulation (25 J.lM) results in the formation of a trailing edge 
"tail" on one side of the cell (Plate 6, large fat arrows), and some polarisation of 
granule distribution towards the "leading edge" (Plate 6, thin arrows), giving rise to a 
cell shape which resembles that of fMLP-activated cells. Marked pinocytosis is, 
however, evident (Plate 6, P = pinocytotic vesicles). A small amount of elastase and 
cathepsin G is associated with the "leading edge", which is smoother than that of 
fMLP-stimulated cells (Plate 6 and Plate 5, respectively). Fewer elastase and cathepsin 
G-containing electron-translucent granules appear near the "leading edge" surface of 
the PMN activated with the low level of PMA, than are present in fMLP-activated 
cells. More, and larger, electron-translucent, elastase and cathepsin G-containing 
compartments appear within the body of PMA-activated PMNs, than occur in fMLP-
activated cells. 
Immunofluorescent labelling indicates that activation with 
40 J.lM PMA gives rise to a uniform distribution of both elastase and cathepsin Gover 
the external surface of non-permeabilised neutrophils (Plate 4, Fig. 2). Electron 
microscopy examination reveals that these cells are rounded, with few or no surface 
projections (Plate 7, Fig. 2). Degranulation appears to occur by two mechanisms, one 
by which the entire granule is lost, or its contents are expelled (Plate 7, Fig. I, large 
arrow), and one by an exocytosis mechanism, in which the granule membrane appears 
to integrate into the external surface of the cell, giving a "cup-shaped" structure to 
which elastase and cathepsin G adhere (Plate 7, Fig. 4, short arrows). This exocytosis 
occurs on one side of the cell (Plate 7, Fig. 2, arrows). On the opposite surface the 
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membrane becomes diffuse and both enzymes are associated with the diffuse surface 
(Plate 7, Fig. 3, arrows). 
4.5.1.4 Discussion 
Chemotactic peptides activate PMNs via a receptor-mediated, 
protein kinase C-independent mechanism, while phorbol esters (PMA) or 
diacylglycerols (DAGs) activate protein kinase C. In either case, however, both elastase 
and cathepsin G appear to become associated with the surface of activated cells to a 
greater or lesser extent. 
The fMLP-induced changes in cell morphology and apparent 
function, observed in this study, are similar to those reported for other chemotactic 
pep tides (Zimmermann et al., 1988). Differences in the responses to various levels of 
PMA were, however, observed here. These responses appear to resemble those 
described for activation with DAGs (Zimmermann et al., 1988). Locomotion appears 
to be induced by activation with low levels of PMA, though this is a low level 
response compared to that seen with chemotactic peptide activation. Compared to 
activation with fMLP, motility, as evidenced by the shape of the ceil, seems to be 
replaced by endocytotic activity. Similarly, association of proteinases with the cell 
surface occurs to a lesser extent. 
Judging by the shape of the cell, low level (25 JlM) PMA 
activation, seems to induce phagocytosis and the formation of large, electron-
translucent, compartments in the body of the cell. These organelles may pOSSibly 
represent tubular structures, like the recently-described alkaline phosphatase-
containing organelles (Kobayashi and Robinson, 1991). They could only be discerned 
in thick sections of PMNs, however, so sections viewed here may be too thin to reveal 
the precise 3-D nature of these organelles. Upon PMN activation (with 50 JlM PMA), 
the alkaline phosphatase-containing compartment is reported to become distended, 
forming tubules of increasing length, and to empty its enzyme content out onto the 
surface of the cell. At a lower concentration of PMA (25 JlM) perhaps only swollen 
organelles similar to those seen in the present study would be seen. These swollen 
organelles may form as a result of granule fusion. Double labelling studies, 
additionally labelling for other marker enzymes for other granule compartments (for 
which the labelling has been optimised, as described in Section 4.4 above), will be 
useful for future definition of the origin of these organelles. 
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Activation with high levels of PMA (40 Jl.M) resulted in the 
association of large amounts of both cathepsin G and elastase with the cell surface, the 
induction of the swollen organelles and increased exocytosis, as compared to other 
activation protocols. A similar response was reported during activation of PMNs with 
50 Jl.M PMA, in investigations into alkaline . phosphatase-containing organelles 
(Kobayashi and Robinson, 1991). The surface-bound proteinase response and 
exocytosis of proteinases is the response seen during overwhelming (suicidal) 
activation of PMNs in close proximity to an infection site. 
Low level fMLP activation, however, appears to give rise to cell 
movement, which is possibly accompanied by "leading-edge" exocytosis and the 
association of both enzymes with the "leading-edge" of the chemotactically stimulated 
cells. This apparent phenotype could be most relevant in PMN s activated by a 
bacterial peptide, in moving them towards the site of infection. The results suggest 
that both elastase and cathepsin G could be relevant in assisting this "invasive" type 
movement of activated PMNs. Results, more like a true chemotactic response, may be 
obtained if activation was induced by a gradient of chemotractant and not by the 
introduction of the chemotractant directly into the medium. Such experiments 
remain an option for the future. 
Perhaps the most significant results emanating from the present 
study of activation, may be the description of the apparently novel, electron-
translucent, intracellular compartment with elastase and cathepsin G secretory 
properties, that appears to be formed in activated PMNs, and the apparent association 
of elastase and cathepsin G with the surface of activated PMNs. 
4.5.2 Elastase and cathepsin D in splenic PMNs and stave cells 
Human leucocyte elastase (HLE) has been implicated in a number of 
inflammatory pathologies, of which pulmonary emphysema has been recognised as 
pOSSibly the most important (Reilly and Travis, 1980; Barrett, 1981). HLE has a wide 
variety of substrates with elastin, the integral component of the connective tissue 
framework of the lung, being one of the most actively degraded (Barrett, 1981). HLE 
degrades elastin at a rate 78% faster than does cathepsin G, a second elastinolytic 
enzyme found in the same azurophil granules (Reilly and Travis, 1980). 
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The source of HLE is the activated PMN, which has been identified as 
the main source of all the elastinolytic enzymes contributing to pathological lung 
damage (Reilly and Travis, 1980). The lung pathologies of adult respiratory distress 
syndrome, cystic fibrosis and emphysema are all related to the accumulation of PMNs 
in the lung tissues and the release of HLE from these PMNs (Reilly and Travis, 1980; 
Jonas et al., 1991). 
Barrett (1981) reports that HLE is not found in any other type of human 
cell besides the PMN, but the amounts of this enzyme found in the spleen are 
surprisingly high, in view of the relative scarcity of PMNs in splenic tissues. The fact 
that the amount of HLE was high was considered an advantage, in the initial studies 
of PMN fixation and optimisation of PMN immunolabelling protocols, in which 
splenic tissue was used to obviate the effect of the density gradient separation 
protocols on PMN physiology. In turn, these early studies led to a study of possible 
interactions between activated PMNs and splenic endothelial cells and of the 
distribution of HLE in other splenic tissues and cells. The results, reported below, 
embody several novel aspects, including observations on the structure and possible 
function of endothelial cells, on the interaction of activated PMNs and endothelial 
cells, and on the colocalisation of HLE and cathepsin D in activated PMN azurophil 
granules. Moreover, in demonstrating the in vivo association of HLE with the surface 
of activated PMNs, the study substantiates the results of the in vitro activation study 
reported in Section 4.5.1.3. 
4.5.2.1 Reagents 
Most of the reagents used were as previously described in 
Sections 2.4.3 and 4.4.1. A membrane-stabilising staining procedure, using neutral 
uranyl acetate, was additionally incorporated into the procedure (Tokuyasu, 1986). 
The staining reagents are described below. 
Stock 4% uranyl acetate (UA). Uranyl acetate (4 g) was dissolved 
in dist.H20, made up to 100 ml and stored in the dark at lOoe, for up to 2 months. 
0.3 M potassium oxalate. Potassium oxalate (5.53 g) was 
dissolved in 75 ml of dist. H20, adjusted to between pH 7 and pH 7.4, with 10% 
NH40H, and made up to 100 ml. 
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2% Neutral uranyl acetate. A 2% solution of neutral uranyl 
acetate was freshly prepared by mixing equal volumes of 4% uranyl acetate and 0.3 M 
potassium oxalate, immediately before use. 
4.5.2.2 Procedure 
Samples of human spleen tissue (2 x 2 nun), from a 10 year old 
female, subjected to a therapeutic splenectomy for portal hypertension, were fixed in 
8% PFA in 200 mM borate buffer, pH 9.0, (20 min, RT), cryoprotected with 2.1 M 
sucrose, mounted on a copper stub and frozen in liquid nitrogen as previously 
described (Section 2.4.3). Sections were cut, using a cryoultramicrotome, and double 
immunolabelled for elastase and cathepsin D, using 3 nm and 10 nm protein A gold 
probes as described in Section 4.4.2. After labelling, sections were contrasted by the 
"positive-negative" contrasting procedure in which sections are rinsed briefly in 
dist.H20, stained in neutral uranyl acetate (10 min), and further contrast stained as 
described in Section 2.4.3. 
4.5.2.3 Results 
The fixation regime chosen for the fixation of splenic tissues 
seemed adequate, for the preservation of both tissue ultrastructure and tissue 
antigenicity. Labelling for elastase and cathepsin D was facilitated by this fixation 
protocol. 
Sections, cut across the axis of a splenic sinus of red pulp (Plate 8, 
Figs 1 and 2), show the primary function of the splenic endothelial stave cells in 
separating the splenic sinus (S) from the cordal spaces (C) of the spleen (see especially 
Plate 8, Fig. 2) (Chen and Weiss, 1972). The red pulp cords are supported by a delicate 
reticulin skeleton (Plate 8, Fig. 1, arrows lower left-hand-side of plate) which supports 
a population of highly phagocytic macrophages (M), some PMNs (P), and fibroblasts 
responSible for reticulin formation. The phagocytic cells of the cords are speculated to 
effect the final destruction of aged or damaged blood cells (Chen and Weiss, 1972). 
The venous sinuses (S) are lined by unusual, highly elongated 
endothelial cells which lie parallel to the axis of the sinus (Plate 8, Fig. 1, E = 
endothelial stave cell). These sinuses have been likened to tall wooden barrels, the 
endothelial cells representing the wooden staves, hence their name. A cross-section 
of a sinus (Plate 8, Fig. 2), shows how the endothelial stave cells line a sinus, with 
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their nuclei bulging into the sinus lumen at intervals. The "staves" of the "barrel" are 
seen to be held together with a band of basement membrane on their basal surface 
(Plate 8, Fig. 1 arrows right-hand-side and middle of plate, and Fig. 2, arrows). The 
basement membrane is usually discontinuous over the basal surface of the stave cells, 
allowing blood cells, particularly erythrocytes, to squeeze through, to and from the 
pulp cords and venous sinuses, hence imposing a sieving barrier to the passage of 
cells. Effete or less resilient cells are retained or destroyed by the stress of passage. 
Endothelial stave cells also appear to have some phagocytic and 
pinocytotic capabilities. A phagocytosed platelet is seen in the central endothelial 
stave cell (Plate 8, Fig. 1 PI = platelet) and the luminal surface of the endothelial stave 
cells may be seen to contain numerous pinocytotic vesicles (Plates 8, Fig. 1, small 
vesicles on the surface opposite to the basement membrane indicated with arrows, 
center and right-hand-side of plate, and Plate 9, small arrows). Evidence of pinocytotic 
removal of the HLE (3 nm gold particle) and cathepsin D (10 nm gold particle) from 
the splenic sinus occupied by the activated PMN, is given by Plate 9 (small arrows). 
Only in the vicinity of activated PMNs could the endothelial stave cells be seen to 
contain HLE, such as seen in Plate 9. 
Large vesicles in the endothelial stave cell, labelled with 
cathepsin D only (Plate 9, large arrow), are possibly lysosomes. Notice that labelling 
for cathepsin D largely appears membrane associated (e.g. Plate 9, possible lysosomal 
organelle indicated with large arrow). 
In some PMN granules labelling for cathepsin D and elastase (an 
azurophil granule marker enzyme) is colocalised in the same granule, whereas some 
granules were labelled only for cathepsin D. This supports the hypothesis that 
subpopulations of azurophil granules exist (Damiano et al., 1988). The association of 
both cathepsin D and elastase with the surface of activated PMNs also appears to occur 
in vivo (Plate 9, middle-sized arrows and arrowheads, respectively), verifying in vitro 
studies which indicated the association of other azurophil granule antigens with the 
surface of activated PMNs. 
In other sections of blocks fixed with PFA at pH 9.0, in this study, 
numerous artefactual vesicles were seen to form on the surface of cells. Vesiculation 
is reportedly caused by staining with acidic uranyl acetate, and stabilisation of 
membranes by pretreatment with neutral uranyl acetate, has been recommended in 
such cases (Tokuyasu, 1986). Staining with neutral uranyl acetate, prior to the usual 
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acid uranyl acetate staining, and post-labelling fixation, does not seem to have been 
successful in preventing the formation of artificial vesicles on the surface of the 
endothelial stave cell (Plate 9, two large vesicles mid-centre to right of plate). 
4.5.2.4 Discussion 
Splenic tissue samples fixed for a study similar to that described 
for PMNs (Section 4.4), were to be used in this study. The pH of fixation of one block 
of tissue, however, had been increased in an exploratory manner, in order to facilitate 
the denaturation of cathepsin B and favour its labelling. The fixation achieved with 
this high pH fixation regime and 8% PF A was considered more acceptible than other 
blocks fixed in the pH ranges described for the fixation study on PMNs (Section 4.4). 
Fixation at high pH was subsequently found to be one of the regimes that favoured 
cathepsin B inununolabelling (Section 4.6). 
The precise mechanisms by which the spleen performs its 
functions of removing effete cells and particulate matter from the blood circulation, 
are still largely unknown. The reticular meshwork of the cord cells, and the 
phagocytic macrophages in the sinuses of the splenic red pulp, are thought to be 
responsible for the removal of aged erythrocytes (RBCs) from the blood (Chen and 
Weiss, 1972). As an erythrocyte ages, it becomes progressively more fragile and less 
able to survive this chordal pathway. Low oxygen tension, cholesterol content and 
glucose concentrations in the chordal spaces, has also been suggested make RBC 
membranes more rigid by their effects on haemoglobin, the plasma membrane and 
energy-producing capacity. Such induced rigidity may prolong retention of the RBCs 
in the spleen, and physiological stresses may predispose marginally viable RBCs to 
phagocytosis. 
Phagocytosis, and removal of aging RBCs may also be favoured 
by prolonged exposure to the high concentrations of hydrolytic enzymes in 
extracellular fluids in the sinuses, secreted by macrophages (Weiss and Creep, 1977), 
and pOSSibly also by activated PMNs. The presence of such hydrolytic enzyme may 
lead to the observed loss of sialic acid residues, and exposure of galactose sugars on the 
outer membrane of aging cells may facilitate recognition and removal of damaged 
RBCs by phagocytic cells (Weiss and Creep, 1977). In the present study, inununo-
labelling of splenic tissue for elastase and cathepsin D has revealed that the regulation 
of the levels of extracellular hydrolytic enzymes, in the splenic sinuses, may be 
achieved by pinocytotic uptake of these enzymes by endothelial stave cells. 
131 
Endothelial stave cells are also known to stimulate the release of 
significant amounts of elastase and other enzymes by PMNs Gonas et al., 1989). A dual 
mechanism for the control of proteinase levels, by stave cells, can, therefore, be 
envisaged; stimulation of the release of proteinases from phagocytic cells, on the one 
hand, and the uptake of proteinases, by pinocytosis, on the other. Further it seems 
that stave cells may participate in the phagocytic activities of the spleen, in the 
removal of effete cells, as evidenced by phagocytosis of a platelet (Plate 8, Fig. 1). 
Pinocytic activity, but not phagocytic activity, has previously been reported in 
endothelial stave cells (Weiss and Greep, 1977). 
Examination of many neutrophils in splenic tissues" using 
immunolabelling for elastase as a measure of PMN exocytic activity, reveal that not all 
PMNs are stimulated to release enzymes in the presence of endothelial stave cells. 
Such stimulation of phagocytic cells may be the result of specific, controlled activation, 
resulting from the release of specific PMN- or macrophage-stimulating signal 
substances. 
This study also shows, for the first time, colocalisation of 
cathepsin D and elastase enzymes in some granules, whereas other granules seem to 
contain only cathepsin D. Quantitation of the labelling, by direct enumeration of the 
number of gold particles present, indicates that the amount of cathepsin D in PMNs 
appears to be ten-fold lower than the level of elastase. This estimate concurs with 
biochemical analyses, which indicate that the amount of elastase in PMNs is ten fold 
higher than cathepsin D. This makes the content of cathepsin D in neutrophils of the 
order of 0.16 pgs per PMN [calculated from the amount of elastase per cell given by 
Damiano et al. (1988)], assuming that the labelling efficiency is the same for both 
enzymes. The content of cathepsin D in macrophages is reported to be much higher, 
of the order of 1.17 pg per macrophage (Bever et al., 1989). This result was verified by 
fluorescent microscopy labelling (Section 4.7). 
Studies reported in Section 4.5.1 show that elastase and 
cathepsin G become associated with the surface of PMNs, activated in vitro. As shown 
here, cathepsin D and elastase also appear to become associated with the surface of 
PMNs activated in vivo. All three enzymes may, therefore, be involved in the 
invasive activities of PMNs. 
4.6 Immunolabelling of peripheral blood monocytes and macrophages, and 
splenic plasma cells 
132 
A considerable number of studies have been performed to identify and describe 
the distribution of PMN proteinases, and the mechanism of their differential release 
during degranulation (Schiffman, et al., 1975; Bainton, 1977; Brederoo, et al., 1983; 
Perez et al., 1987; Damiano et al., 1988; Sommerhoff et al., 1990). The two major PMN 
serine proteinases, elastase (HLE) and cathepsin G, are now known to be proteinases of 
the azurophil granules and their activities have been well-characterised (Kargi et al., 
1990). Much less, however, is known about the serine proteinases of human 
mononuclear phagocytes. 
Originally it was thought that only PMNs contained HLE and cathepsin G 
(Barrett, 1981), but recent studies have proved that this is not true (Campbell et al., 
1989; Kargi et al., 1990). Several research groups have described serine proteinase or 
elastase-like or elastinolytic activity in human peripheral blood monocytes (Werb and 
Gordon, 1975; Lavie et al., 1980; Campbell et al., 1989) and in macrophages (White 
et al., 1977; Chapman and Stone, 1984). Definitive work on the precise nature of the 
enzyme activity, its subcellular distribution and its relationship to the degree of 
differentiation of the mononuclear phagocyte, has not, however, been reported in all 
cases (Kargi et al., 1990). Investigations on peripheral blood monocytes are hampered 
by the fact that it is more difficult to obtain pure fractions of these cells, in high yield, 
than is the case with PMNs, as less than 10% of leucocyte populations are of the 
monocyte/macrophage type (Kargi et al., 1990). 
In the present study, elastase labelling in human peripheral blood monocytes 
and macrophages is demonstrated, and, for the first time, elastase-like 
immunolabelling of splenic plasma cells is shown. Immunolabelling of precursor 
and mature cathepsin B in unactivated and activated monocytes, is also demonstrated 
for the first time. Granule populations of fMLP-stimulated monocytes (macrophages) 
show high concentrations of precursor cathepsin B, but activated cells (macrophages) 
show no evidence of any surface-association of precursor, or mature, cathepsin B, Of of 
elastase. A secondary objective of this study was to optimise fixation procedures for 
future application to tumour cells, so comment is also made on the fixation and other 
technical procedures found to be optimal for antigen- and tissue ultrastructural 
preservation. 
4.6.1 Elastase in peripheral blood monocytes and macrophages and 
elastase and cathepsin D in splenic plasma cells 
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A membrane-bound elastase-like proteinase has been demonstrated on 
the surface of mononuclear leucocytes, including monocytes (Lavie et al., 1980; 
Zucker-Franklin et al., 1981; Estreicher et al., 1990). This was shown to either be HLE, 
or to be very similar to it, as it is inhibitable with both diisofluorophosphate (DIFP) 
and the elastase inhibitor, Ac-Ala-Ala-Pro-Val-CH2 (Zucker-Franklin et al., 1981). 
Surface elastase may be relevant for the "invasive movement" of mononuclear 
leucocytes through barrier membranes, to sites of inflammation or tumour activity 
(Gauci and Alexander, 1975), as in the case of PMNs. Consequently, in the first part of 
this study peripheral blood monocytes and macrophages, were examined for surface 
elastase, using the cryoultramicrotomy labelling technique. 
In studies on human spleen, the discovery of enzymes 
immunologically resembling elastase and cathepsin D, in plasma cells, was a novel 
and unexpected finding. No immunolabelling on the surface of these cells was seen. 
4.6.1.1 Procedure 
Peripheral blood monocytes/macrophages were isolated using 
the Ficoll-Hypaque method as previously described (Section 4.3.1). Cells were fixed 
immediately, or first activated with fMLP as described in Section 4.3.2. Fixation was 
effected using 4% PFA (5 min) followed by 8% PFA (10 min) both in HEPES buffer, 
pH 7.2, and sections were floated on 8% PFA, pH 7.2 (Section 4.4), until used for 
labelling. Sections were labelled for elastase and post-fixed with 1% glutaraldehyde, as 
described in Section 4.4. 
Human splenic tissue, fixed and processed as described in Section 
4.5.2.2, was simultaneously labelled for elastase and cathepsin D as described in 
Section 4.4. 
4.6.1.2 Results 
Immunolabelling for elastase was observed in monocytes 
(Plate 10, Figs 1 and 2) as well as macrophages (Plate 10, Figs 3 and 4) isolated from 
human peripheral blood. Immunolabelling was observed in both small electron-
dense granules (presumed to be primary lysosomes) and in more electron translucent 
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vacuoles (Plate 10, Figs 1 and 2, arrowheads). Endocytic compartments appear to 
empty their contents into a few larger electron-translucent compartments, and 
lysosome-like granules, containing elastase, seem to have fused with or become 
expelled into the larger electron-translucent compartment, forming a secondary 
lysosome-like compartment (Plate 10, Figs 1 and 2, arrowheads). The elastase present, 
therefore, could easily have arisen from endocytosis. Immunolabelling for cell 
surface-associated elastase is, however, not evident in monocytes (Plate 10, Figs 1 
and 2). 
The activated equivalent of the monocyte, the macrophage, is 
seen to have a larger cytoplasm to nucleus ratio and shows phagocytic activity, rather 
than the less noticeable endocytic activity of the monocyte (Plate 10, Figs 3 and 4, and 
Figs 1 and 2). Generally fewer electron-dense granules labelled for HLE are present, 
possibly because many of the granules could have been discharged into the 
phagosome (Plate 10, Figs 3 and 4, arrowheads). Large aggregates of phagocytosed 
material are visible in some phagosomes but, once again, there appears to be no 
significant association of HLE with the surface of the macrophage (Plate 10, Figs 3 
and 4). 
Splenic macrophages showed similar low labelling densities for 
elastase as the human peripheral blood macrophage (results not shown). Some of the 
few plasma cells (B-cells) seen in the splenic red pulp samples, however, manifest a 
high labelling density for HLE on their endoplasmic reticulum (ER) (Plate 11, Fig. 2). 
No association of elastase with their outer surface was, however, seen. These cells 
also exhibited sparse labelling for cathepsin D (Plate 11, Fig. I, arrowheads). 
4.6.1.3 Discussion 
There is an on-going debate concerning the protein complement 
of typical monocyte/macrophages, and the identity of elastase-like proteinases 
reportedly attached to the surface of monocytes and present in lymphocytes (Zucker-
Franklin et al., 1981; Pierce and Senior, 1981; Campbell et al., 1989; Kargi et al., 1990). 
This debate is fuelled by the heterogeneity among different subtypes of monocytes 
(Campbell et aI, 1989; Kargi et al., 1990) and by an apparent difference in the type of 
elastase expressed by monocytes and macrophages from different animal species 
(Campbell et ai, 1989). 
Studies on human peripheral blood monocytes and murine 
macrophages indicate that human monocytes contain elastase that is 
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immunologically and catalytically indistinguishable from HLE, whereas the murine 
cell lines contain and secrete a metalloproteinase (Senior et al., 1982). A widely-held 
opinion, however, is that the elastase of monocytes may be, in fact, a 
metalloproteinase G. Travis, pers. comm.). Studies on monocytes separated from 
peripheral blood using Ficoll-hypaque density gradient separation, followed by 
elutriation centrifugation and a sensitive competitive-binding ELISA assay, however, 
have shown that monocytes contain approximately 6.3% and 5.2% of the mean 
content of HLE and cathepsin G, respectively, of PMNs (Campbell et al., 1989). The 
determination of endogenous proteinase content is, however, complicated by the fact 
that mononuclear phagocytes are able to take up elastase, and other enzymes, secreted 
from PMNs during density gradient separation (Campbell and Wald, 1983). 
The origin of the elastase in monocytes cannot be determined by 
looking for its mRNA, as no elastase mRNA can be demonstrated in mature 
monocytes. It appears that in both monocytes and PMNs, elastase is formed in the 
bone marrow precursor and the capacity to synthesise this enzyme is lost by the time 
the mature cells reach the bloodstream (Campbell et al., 1989). Alveolar macrophages 
(Campbell and Wald, 1983) and monocytes (Kargi et aI, , 1990) have receptors for HLE, 
however, and are capable of uptake and storage of elastase for as long as 5 days or more 
(Campbell and Wald, 1983). Cells that are this active in endocytOSiS and phagocytOSis, 
may thus become HLE positive by uptake of HLE, perhaps from activated, 
degranulating, PMNs, to which they might be exposed during the isolation 
procedures. This complicates determination of the origin of elastase in monocytesl 
macrophages. 
Studies on the proteinase content of the human promonocytic 
cell line, U937, have been useful in resolving this question, especially when the 
mRNA for the different enzymes is also analysed (Senior et al., 1982; Ward et al., 1990; 
Lindmark et al., 1990). HLE and cathepsin G, the major proteinases found in PMNs, 
have been found in U937 cells which have not been exposed to exogenous sources of 
PMN enzymes. Under the influence of differentiation agents such as PMA, however, 
the monocyte phenotype of the U937 cell line is expressed and there is an associated 
increase in the monocyte proteinase, cathepsin B, and its mRNA, but a decrease in 
levels of PMN elastase and elastase mRNA (Ward et al., 1990). Such studies 
confirmed previous findings on density gradient separated cells and have established 
cathepsin B as a marker for monocyte differentiation and elastase as a quantitative 
marker for the PMN phenotype. 
136 
The bulk of the protein-degrading activity of intact human 
lymphocytes and monocytes, is reported to be due to a surface-bound elastase (Lavie 
et al., 1980). No plasma membrane-bound HLE was seen in labelling experiments, in 
the present study, however. This may be because surface expression of HLE may only 
be a feature of chemotactically activated cells. Repetition of these studies, with fMLP-
activated monocyte/macrophages, proved difficult, however, due to the low yield of 
monocytes and the heterogeneity of monocyte populations. According to Campbell 
et al. (1989), only about 20% of monocytes are replete with HLE and other serine 
proteinases. Finding such cells is, therefore, difficult. 
Stimulated monocytes are known to release enzymes, such as 
elastase taken up from activated PMNs, to a much greater extent than the PMNs 
themselves, in proportion to their total cellular content (Campbell et al., 1989). 
Monocytes are hence thought to playa major role in pulmonary emphysema, despite 
their smaller proportion of enzymes such as elastase (Campbell and Wald, 1983). If 
elastase is, therefore, involved in the invasive activity of monocytes/macrophages, 
the mechanism might be by release of elastase rather than by an association of elastase 
with the external membrane. 
Enzymes which occur to a much greater extent, in monocytes 
(and macrophages), are cathepsin B and cathepsin D (Moreland and Pedersen, 1979; 
Lesser et al., 1989). Cathepsin D is present in larger amounts than cathepsin B, but, 
surprisingly, little importance seems to have been attached to the possible role of 
cathepsin D, in lung patholOgies, cathepsin B being the major focus of attention to 
date (Moreland and Pedersen, 1979; Lesser et al., 1989). 
In tumour tissues too, cathepsin B has been the focus of many 
studies (Sloane et al., 1990). Isolation procedures on tumour homogenates have often 
indicated the presence of high levels of cathepsin B relative to normal tissue, a 
phenomenon which has been attributed to the tumour itself (Sloane et al., 1990). 
Stimulated macrophages, however, greatly increase in cathepsin B content (Lesser 
et al., 1989), and the prognosis of post-surgical remission in cancer patients, has been 
linked, inversely, to the macrophage content of tumours (Gauci and Alexander, 1975). 
It is clearly important, therefore, in investigating the proteinases purportedly 
involved in tumour invasion, not to overlook the contribution which may be made 
by enzymes from cells of the immune system, such as macrophages. 
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An interesting result in the present study was the extensive 
labelling for HLE seen in splenic B cells (plasma cells). Immunolabelling for HLE in 
such cells has not previously been reported, and it is difficult to imagine what the 
potential role of elastase might be in an antibody-producing cell. Though this is a 
curious and unexpected result, it is not completely without precedent. Use of a 
radiolabelled inhibitor, 3HAc-Ala-Ala-Pro-Val-CH2Cl, specific for HLE, has 
demonstrated the presence of an elastase-like enzyme on the surface of intact 
lymphocytes (Lavie et al., 1980), though the type of lymphocyte was not identified. 
Similarly, using a radiolabelled serine proteinase inhibitor, DIFP, 5-8% of lymphocytes 
are reported to show surface labelling for a serine proteinase, which may be elastase 
(Zucker-Franklin et al., 1981). Such labelling, may, however, relate to T cells only; 
HLE being found in both a membrane-bound and soluble form in CD4 + and CD8T+ 
T cells (Bristow et al., 1991). 
The B cell-like lymphocyte shown in this study to label with 
anti-elastase antibodies, fits the description of an OKT3 negative, B lymphocyte 
[classed as a "lymphoplasmacytoid cell" by Matutes and Catovsky (1982)], rather than a 
T cell. Immunoreactivity with the anti-HLE antiserum was also shown in eosinophils 
(EM results not shown, but see immunofluorescent pictures, Plate 4, Figs 1 and 2). 
There is a danger in relying on immunoreactivity alone to 
indicate the presence of a specific proteinase, in immunolabelling studies on 
leucocytes, however, in that many proteinases have quite extensive sequence 
homologies and there is a fair chance that different proteases may cross-react, 
immunologically. Sequence homologies of 47% and 56% have been described 
between rat mast cell proteinase II, and a product of activated mouse cytotoxic T cells, 
and cathepsin G (Salvesen et al., 1987). Similarly, an antibacterial protein, with no 
proteolytic actiVity, has been described as having a 33% homology with cathepsin G, a 
44% homology with HLE, a 45% homology with PR 3 (an azurophil granule 
proteinase), and 33% homology with human lymphocyte protease (the human 
homologue of the murine cytolytic T cell proteinase) (Almeida et al., 1991). The 
immunological reactivity with anti-HLE antibodies, observed in eosinophils and 
B cells, therefore, requires biochemical confirmation, before it can be irrefutably 
concluded that these cells contain elastase. 
4.6.2 Cathepsin B in splenic endothelial stave cells, and splenic and 
peripheral blood macrophages 
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This part of the present study was aimed at optimising 
immunolabelling conditions for the labelling of cathepsin Band procathepsin B, and, 
for this purpose, the distribution of cathepsin B in splenic endothelial stave cells, and 
in the macrophages of the spleen and blood was studied. The ultimate aim, once 
immunolabelling conditions had been optimised, was to compare the distribution, 
and trafficking, of precursor and mature forms of cathepsin B, and other lysosomal 
enzymes, in tumour and normal tissues. 
Most tissue, unfortunately, contains relatively low levels of cathepsin B 
and even lower levels of procathepsin B. Optimisation of immunolabelling for these 
two antigens, therefore, proved quite difficult. As previously mentioned, 
immunolabelling for cathepsin B is in any event difficult because cathepsin B 
spontaneously denatures at neutral pH and above. For this reason, antisera raised in 
experimental animals generally recognise only the denatured form of cathepsin B. 
Immunoreactivity, therefore, requires prior denaturation of the enzyme (Rowan et aI., 
1992). The rapid fixation with PFA, at physiological pH, and the processing of cells and 
tissues for cryoultramicrotomy, as used in all other studies, proved to be too mild to 
promote the denaturation, and consequent immunoreactivity, of cathepsin B. 
Efforts to promote the denaturation of cathepsin B, and to improve the 
fixation of elastase, by exposing the tissue to a high pH, fortuitously led to the solution 
of both problems. Exposure to the high pH, during short fixation periods, denatured 
cathepsin B sufficiently to promote immunolabelling and accommodated 
immunolabelling for procathepsin B also. The only other way in which 
immunolabelling of cathepsin B could be effected was subsequent to a denaturing, 
dehydration step, which is a normal part of resin-embedding protocols. For 
embedding in LR White resin, short fixation periods using PF A proved to be 
inadequate for adequate ultrastructural preservation of the tissue, however, and it was 
necessary to use glutaraldehyde, for stronger fixation. 
Due to their very low levels in most other tissues, immunolabelling for 
cathepsin B precursors was initially optimised on monocytes and macrophages, 
present as contaminants of PMN fractions separated by denSity gradient 
centrifugation. Immunolabelling of fMLP-activated cell fractions proved most 
rewarding. Activated macrophages are known to increase cathepsin B synthesis to 
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about 8 times the basal level (Padilla et ai., 1988) and, in this study, fMLP-activated 
human peripheral blood monocytes were found to contain unexpectedly large 
amounts of cathepsin B precursor. No surface expression of precursor or mature 
cathepsin B was evident in any of these immunolabelling studies, however. 
Immunolabelling studies of this kind have not been previously reported. 
4.6.2.1 Procedure 
Splenic tissue, fixed with 8% PFA in PBS, pH 7.2 or 8% PFA in 
borate buffer, pH 9.0 and processed for cryoultramicrotomy as described in Section 
4.5.2.2, was simultaneously labelled for cathepsin B and procathepsin B, using sheep 
anti-cathepsin B (0.20 Ilg in 10 Ill) and anti-ppB22-36 (2 Ilg in 10 Ill) as described in 
Section 4.4. 
Similarly, splenic tissue samples were fixed with 4% PFA 
containing 0.2% glutaraldehyde in 0.1 M cacodylate buffer, pH 7.2 (Section 2.3.2.1), 
embedded into LR White resin, and immunolabelled as described in Section 2.5. 
Double labelling for cathepsin B and procathepsin B was perfonned, using sheep anti-
cathepsin B (0.20 Ilg in 10 Ill) and anti-ppB22-36 (2 Ilg in 10 Ill) and 6 nm and 10 nm 
protein A gold probes, respectively, and using a 1% glutaraldehyde fixation step 
between immunolabelling steps, essentially as described in Section 4.4. 
Finally, the PMN fraction of peripheral blood, separated using 
the Percoll gradient centrifugation method (Section 4.3.1.2), was activated using 30 IlM 
fMLP, as described in Section 4.3.2.2, and processed for cryoultramicrotomy, as 
described in Section 4.5.2.2. Sections were labelled for cathepsin B or procathepsin B, 
using sheep anti-cathepsin B (0.20 Ilg in 10 Ill) or anti-ppB22-36 (2 Ilg in 10 Ill), as 
described in Section 4.4.2. Controls additionally included an adsorption controL For 
the adsorption control, the anti-peptide antibody (ppB22-36, diluted to 200 Ilg/ml) was 
preadsorbed with 200 Ilg/ml of the peptide against which the antibody was raised 
(30 min, RT), centrifuged (10000 x g, 15 min, RT), and used in the immunolabelling 
procedure. 
4.6.2.2 Results 
For immunolabelling studies on cathepsin B and its precursor, 
fixation with 8% PFA at pH 8 or 9, for "cryo"-labelling of fMLP-activated monocytes 
and splenic tissues, proved satisfactory. Fixation with 4% PFA containing 0.2% 
140 
glutaraldehyde, at pH7.2, followed by dehydration and LR White embedding, was also 
satisfactory. Fixation with 8% PFA at pH 7.2 was unsatisfactory for "cryo"-
immunolabelling of cathepsin B, as no labelling of this antigen was observed at this 
pH. 
In endothelial stave cells, electron-dense vesicles, possibly pre-
lysosomal or lysosomal compartments (Plate 11, Figure 4, medium arrow, Fig. 3, 
arrows) and Golgi elements (Plate 11, Figure 4, G and small arrows), labelled for both 
the mature (10 nm) and precursor cathepsin B (3 nm), whereas large electron-
translucent vesicles labelled for mature cathepsin B only (Plate 11, Figure 3, 
arrowheads, lower left). Electron-dense organelles are usually classified as lysosomes, 
but the presence of large quantities of procathepsin B in the electron-dense 
compartment, makes this more likely to be a prelysosomal organelle. The presence of 
mature cathepsin B in the electron-translucent compartment suggests that this is a 
lysosome. 
Sections from LR White-embedded splenic tissue showed much 
swelling and distortion (Plate 12, Figs 1 and 2). In macrophages, two populations of 
secretory granules were present; an electron-translucent and a more electron-dense 
granule population. The more electron-translucent secretory granules of 
macrophages, however, showed labelling for mature cathepsin B, the larger vesicles 
giving lower labelling densities (Plate 12 Fig. I, arrows). The occasional, more 
electron-dense, larger vesicles, showed labelling for the precursor enzyme, a feature 
characteristic of immature vesicles in a secretory cell (Plate 12, Fig. 2). 
fMLP-activated macrophages (Plate 13), compared to their 
unstimulated counterparts, showed a greater proportion of cytoplasm and increased 
nuinbers of granules and Golgi compartments. A certain population of electron-
translucent and semi electron-dense granules showed dense labelling for 
procathepsin B (Plate 13, Figs I, 2 and 4). Immunolabelling for procathepsin B was 
also present in Golgi bodies, as would be anticipated (Plate 13, Fig. 4, arrow indicates 
procathepsin B labelling). No surface labelling for procathepsin B was seen (Plate 13, 
Fig. 1). In all activation procedures there are always a few cells that show greater 
activation than others. 
Double immunolabelling of this cell, for the precursor and 
mature forms of the enzyme would have been useful in both verifying the labelling of 
the peptide antibody and for the assessment of the relative distribution of precursor 
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and mature forms of the enzyme in different granule populations. This labelling was 
obtained in a cryoultramicrotomy system, where serial sectioning is not possible, so 
immunolabelling of replicate sections of the same cell, as shown in Plate 13, for 
cathepsin B, could not be performed. 
A less satisfactory approach in assessing the relative distribution 
of precursor and mature forms of cathepsin B, is to compare single labelling results in 
different cells. The anti-mature cathepsin B antibody will recognise all forms of 
cathepsin B, including the precursor form, so to obtain a true picture of the 
distribution of mature enzyme only, it is necessary to assess the difference between 
specific procathepsin B labelling and total cathepsin B labelling. The cell shown in 
Fig. 3 of Plate 14 (labelled with anti-mature cathepsin B) seems to have slightly more 
cathepsin B labelling than the cell depicted in Plate 13 (labelled for procathepsin B). 
This may indicate that the cell depicted in Plate 14 may contain some vesicles that 
label for mature cathepsin B only, though the majority of vesicles would probably 
have precursor and mature cathepsin B colocalised. 
Cathepsin D labelling was only performed on unactivated 
monocyte-containing cell fractions, but these monocytes contained moderate numbers 
of granules that labelled for cathepsin D (Plate 13, Fig. 3). 
All control immunolabellings were satisfactory, giving negligible 
background labelling. The adsorption control performed with the peptide antibody, 
showed an 80% reduction of immunolabelling . 
Though the cells depicted in Plates 13 and 14 were all cut from 
the same block, the difference in organelle integrity in the different cells, is marked. 
The section from the macrophage, depicted in Plate 14, Fig. 3, is the thinner section 
(pOSSibly 80-100 nm), while the sections of cells illustrated in Plates 13 and 14, Figs 1 
and I, respectively, are of approximately the same thickness (pOSSibly 120-150 nm). 
The cell illustrated in Plate 13, and Plate 14 Fig. 2, however, was found near a grid bar, 
whereas the cells illustrated on Plate 14, Figs 1 and 3, were mid-way between grid bar 
meshes. The thickness of the uranyl acetate/methyl cellulose film finally covering 
the section varies, not only in overall thickness, depending upon how much methyl 
cellulose is removed prior to the final drying process, but also with distance of the cell 
from the grid bar mesh. 
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The preservation of organelle structure, therefore, seems to 
depend, not only on the fixation regime used, but also on the thickness of the section 
and the thickness of the final film of methyl cellulose covering the section. Greater 
membrane definition and cellular integrity seems to be preserved in thicker sections, 
covered by slightly thicker films of uranyl acetate/methyl cellulose sealing agent. A 
thicker section may help to prevent granule extraction, but not completely in all cases, 
as illustrated in Plate 14, Fig 2, where a large granule can be seen to have been 
extracted from the macrophage depicted (large arrows indicate the hole and the 
extracted granule). 
4.6.2.3 Discussion 
Immunolabelling for cathepsin B, with the polyclonal anti-
human liver cathepsin B antibody, seems to require that the antigen be denatured by 
exposure to high pH during fixation for cryoultramicrotomy, or by exposure to 
dehydration, during resin embedding after fixation at physiological pH. Labelling 
with the procathepsin B peptide antibody, however, seemed to be favoured by most 
regimes. 
Relatively low levels of mature and precursor cathepsin B were 
anticipated to be present in most cells. A slight increase in cathepsin B precursor 
levels, concomitant with increased synthesis of cathepsin B, however, was anticipated 
in response to cell activation. The observed result, however, indicates a much greater 
increase. 
The increase in cathepsin B activity of stimulated macrophages, 
from different sources, has been shown to differ to a great extent; pulmonary 
macrophages showing a greater increase than peritoneal macrophages (Lesser et al., 
1983). Cathepsin B activity, in alveolar macrophages, also seems to increase, under the 
influence of certain stimulae, where other enzymes, such as cathepsin D, actually 
decrease (Lesser et aZ., 1989). No information of how much precursor enzyme is 
actually present in activated peripheral blood monocytes, however, is available. 
In the pr:sent study, all immunolabelling controls, including the 
adsorption control for the peptide antibody, however, appeared to be satisfactory, 
indicating that immunolabelling results should be reliable. Immunolabelling is 
always, best verified witb biochemical data, however. In this case, PMA-differentiated 
U937 cells would be a suitable subject for such confirmatory biochemical studies and as 
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a preliminary to such studies, and to confirm some of the labelling results obtained for 
cathepsin D and B, the U937 cell line was acquired. 
4.7 Immunofluorescence studies on the U937 cell line 
The U937 cell line is a promonocytic cell line which grows readily in culture 
and which, upon treatment with PMA, differentiates to acquire the phenotypic 
characteristics of normal mature monocytes (Senior et al., 1982; Lindmark et al., 1990; 
Ward et al., 1990). This cell line, therefore, theoretically provides an ideal model in 
which monocyte and macrophage proteinases may be studied. Alternatively, 
differentiation towards the PMN phenotype may be induced by exposure of U937 cells 
to dimethyl sulphoxide (DMSO) (Lyons and Askam, 1989). 
Differentiation to the monocyte phenotype leads to an increase in cathepsin B 
mRNA and cathepsin B synthesis, and a decrease in elastase mRNA and elastase 
(Ward et al., 1990), and cathepsin G (Welgus et al., 1986), levels. Other monocyte 
differentiation and maturation-related antigens recorded include a gelatinase/type IV 
collagenase, a strome lysin and a matrilysin (Watanabe et al., 1993). Studies on the 
effect of differentiation on cathepsin 0 levels, in U937 cells, have not been previously 
reported, though in density gradient-separated peripheral blood PMNs, cathepsin D 
has been reported to be between 5 and 10 times lower than the level of elastase i.e. of 
the order of 0.16-0.8 pgs/PMN (Ishikawa and Cimasoni, 1977; Damiano et al., 1988). 
Studies on peripheral blood cells are complicated by poor yields, and by 
activation, especially of monocytoid cells, by density gradient separation procedures, so 
it was decided to pursue further investigations, into the proteinases contributing to 
the invasive capabilities of monocytes and PMNs, using the U937 cell line. Some 
leukemic cell lines have characteristics different from the corresponding normal cell 
type (Lyons and Askam, 1989) but the protease profile of the U937 cells, is reported to 
be the same as that of the normal cell equivalent (Welgus, et al., 1986; Lindmark et al., 
1990). 
In the studies reported here, the level and distribution of cathepsins D and B, 
and the M-6-P receptor status of the cells, was assessed by fluorescent 
immunolabelling of U937 cells, differentiated to the monocytoid phenotype, using 
PMA, and to the PMN phenotype, using DMSO. This was done mainly to verify the 
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success of U937 differentiation procedures, preliminary to further studies, and to 
verify some of the results obtained using isolated peripheral blood leucocytes. 
4.7.1 Reagents 
The rabbit anti-cathepsin D antibody, was from Dr Hasilik, Physiolisch-
Chemisches Institut, UniversiUit Munster, Munster, rabbit anti-bovine 215 kDa 
mannose-6-phopshate receptor antibody was from Dr Hofflack, European Molecular 
Biology Laboratory, Heidelberg, and the anti-human liver cathepsin B antibody was 
from Dr Lukas Mach, Zentrum fiir Angewandte Genetik, Universitat fiir 
Bodenkultur, Vienna, Austria. 
The U937 cells were a gift from Dr Josef Glossl, Zentriim fur 
Angewandte Genetik, Universiilit fur Bodenkultur, Vienna. The RPM! 1640 medium 
was from Highveld Biologicals, Sandton, and the foetal calf serum from Delta Labs, 
Sandton, the bovine serum albumin (BSA) Fraction V, was from Boehringer 
Mannheim, and Saponin and FITC-labelled mouse anti-rabbit monoclonal antibody 
was from Sigma Chemical Co., St Louis, Mo. Anti-Fade®, immunofluorescence 
coverslip mounting medium, was from Molecular Probes Inc. Eugene, Or. 
Phosphate Buffered Saline (PBS-F). The PBS used in immuno-
fluorescence labelling studies, unlike that used in the EM immunolabelling studies, 
contained calcium and magnesium and will, therefore, be referred to as PBS-F. NaCl 
(7.99 g), KCl (0.199 g), Na2HP04 (1.145 g), KH2HP04 (0.2 g), CaCl2 (0.147 g) and MgCb 
(0.102 g) were dissolved in approx. 700 ml Dist.H20. The solution was adjusted to 
pH 7.2 with 1M NaOH, if necessary, and made up to 1 litre. 
4% Paraformaldehyde. 4% PFA (16 ml) was made by diluting a 16% 
stock solution (Section 2.3.2.1) (4 ml) with PBS-F (12 ml). 
2% Bovine serum albumin (BSA). 2% BSA was made by dissolving 
BSA (0.8 g) in PBS-F and making up to 40 ml. 
5% Foetal calf serum. Foetal calf serum (0.5 ml) was dissolved in PBS-F 
and made up to 100 ml. 
0.1% Saponin in PBS-F (PBS-sapOnin). Saponin (0.1 g) was dissolved in 
PBS-F and made up to 100 ml. 
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4.7.2 Procedure 
U937 cells were cultured in RPMI 1640-supplemented 15% foetal calf 
serum, at 37°C, in a humidified atmosphere, containing 5% C02. A sterile glass 
coverslip (15 mm) was placed in each well of a 12 well Nunc multiwell plate and each 
well was seeded with approx. 5 x 104 cells in 1 ml. Differentiation was induced, in 
duplicate wells, by addition of either PMA (1 J.lI of a 10 J.lM solution in DMSO/well) or 
1 % DMSO (10 J.ll/well) and incubation for 3 days. A 25 ml flask of similar cell 
concentration was concurrently incubated to supply a source of unactivated cells. 
Cell populations, exposed to either differentiation reagent, generally 
become adherent to glass upon differentiation. Cells adherent to coverslips, were 
washed 3 times with PBS-F, and undifferentiated cells in suspension, from the 25 ml 
flask, were pelleted by gentle centrifugation (100 x g, 5 min, RT), and washed 3 times in 
PBS with repeated centrifugation (100 x g, 5 min, RT). 
The final pellet of undifferentiated cells, resuspended in a suitable 
quantitiy of PBS-F, was spread on a sterile coverslip. These cells and the adherent cells 
were fixed onto the coverslips with 4% PFA (200 J.lI, 10 min, RT), rinsed 3 times with 
PBS-F, and non-specific residual fixative binding sites were blocked by incubation in 
0.2% BSA (45 min, RT). 
The coverslip was incubated in the primary antibody (200 J.lI, 1 h, RT): 
the anti-cathepsin B antibody at 40 J.lg/ml, the anti-human cathepsin D serum diluted 
1/40, or the mannose-6-phosphate antibody diluted 1/50 in PBS-saponin. After six 
rapid washes with PBS-sapOnin, 5% foetal calf serum secondary block solution (200 J.ll, 
30 min, RT) was applied. After the required incubation period the secondary, FITC-
labelled, mouse monoclonal antibody, diluted 1/40 in PBS-F-saponin, was applied 
(200 J.lI, 1 h, RT). After six washes with PBS-sapOnin, cells were refixed with 4% PFA 
(200 J.lI, 10 min, RT), washed with PBS-F-saponin, rinsed well in dist.H20 and allowed 
to drain dry. The coverslips were mounted, face-down in a minimum amount of 
Anti-Fade®, and viewed in an Olympus BH2 microscope, fitted with a BH2-RFC 
Reflected Light (epifluorescence) Attachment, fitted with a 460 nm interference filter 
and a 520 nm barrier filter. 
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4.7.3 Results 
U937 cells labelled with the rabbit anti-human liver cathepsin B 
antibody, showed very weak immunolabelling of undifferentiated cells (Plate 15, 
Fig. 1a) and strong, polarised, immunolabelling of PMA-treated cells (Plate 15, Fig. 1b). 
DMSO-treated cells (PMN phenotype) showed no labelling at all (results not shown). 
Immunolabelling for cathepsin D showed that cathepsin D is 
present in the undifferentiated cell line (Plate 15, Fig. 2a) but to a lesser extent than in 
PMA-treated cells (Plate 15, Fig. 2b). DMSO-treated cells showed only very weak, 
almost negative, labelling (result not shown). 
Finally, immunolabelling for the mannose-6-phosphate 
receptor, indicated that this is only present in cells differentiated with PMA (Plate 15, 
Fig. 3a and 3b), indicating that only the monocyte expresses the mannose-6-phosphate 
receptor. 
4.7.4 Discussion. 
The combined labelling results indicate the success of 
differentiation procedures, as cathepsin B (Ward et al., 1990) and D (Bever et al., 1989) 
are known to be present in monocytes. Mean levels of cathepsin B in undifferentiated 
U937 cells have been reported as being of the order of 15 ng/106 cells, whereas, upon 
exposure to PMA, these levels rise to approximately 297 ng/l06 cells (Ward et al., 
1990). Levels of cathepsin B, in peripheral blood PMNs, have been determined to be of 
the order of 0.45 ng/106 cells (Assfalg-Machleidt et al., 1991). These results seem to 
concur with the trends seen in the present immunolabelling study, on the U937 cells. 
Labelling for cathepsin B in PMNs appears negative, as anticipated, as such levels of 
cathepsin B are below the detection limit of this immunofluorescence system. 
Levels of cathepsin D in U937 cells do not seem to have been 
previously determined. Cathepsin D levels in human peripheral PMNs, however, 
have been estimated as being of the order of 0.16 - 0.8 pgs/cell (Ishikawa and Cimasoni, 
1977; Damiano et al., 1988). If these estimates are correct, it is not surprising that the 
immunolabelling for cathepsin D, on DMSO-treated U937 cells, was negative. On the 
basis of immunolabelling results (Section 4.4.2), it was anticipated that the PMN-like 
phenotype, induced by DMSO-treatment, would have shown some immunolabelling 
for cathepsin D. There are two possible explanations for this apparent discrepancy: 
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i) the PI\.1N labelled for cathepsin 0 may have been an early form of PMN, and contain 
more cathepsin D than most mature PMNs, ii) the level of cathepsin D present in 
PMNs may be below the sensitivity of the present immunofluorescence labelling 
system. 
Immunolabelling for the M-6-P receptor also seems to be a good 
alternative marker for the monocyte phenotype. Monocytes are known to have two 
receptor populations that are responsible for lysosomal enzyme clearance and 
trafficking, the mannose receptor and the M-6-P receptor (Shepherd and Stahl, 1984). 
Though little seems to be known about the trafficking and processing of enzymes in 
monocytes and PMNs, it is known that PMNs are devoid of these receptors (Shepherd 
and Stahl, 1984; Lindmark et al., 1990), a result confirmed in the present study. 
The present studies have served to confirm the utility of the 
U937 cell line in providing a simpler system on which preliminary studies may be 
conducted before subsequent confirmation on more refractory peripheral blood and 
bone marrow cells. 
4.8 Discussion 
4.8.1 Significance of the immunolabelling results 
The association of elastase, cathepsin D and cathepsin G with the surface 
of activated PMNs, demonstrated in the present study, provides the first indication 
that these enzymes may be involved in the invasive movement of PMNs through 
basement membranes. Only one other study has previously indicated that elastase 
may become associated with the surface of activated PMNs. This was a biochemical 
demonstration that proposed the presence of an elastase receptor on the surface of 
activated PMNs (Dwenger et al., 1986). Perhaps the main reason why elastase has not 
previously been demonstrated on the surface of PMNs, is that PMNs are difficult to 
isolate, they are fragile and easily stimulated to degranulate. PMNs contain a large 
amount of elastase, which mostly occurs within the granules and, if this is not 
contained during isolation and immunolabelling, it becomes impossible to determine 
where else the elastase might naturally occur. Therefore, the development of 
adequate methods for the fixation of PMNs, although a tiresome necessity, in fact 
"opened up" PMNs for the studies reported here and has made them accessible for 
further immunocytochemical studies, in the future. 
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Cathepsin B and procathepsin B, in activated monocytes, were easier to study, 
in some respects. These enzymes, however, do not seem to be membrane associated 
and, therefore, would appear to not play a role in the movement of macrophages 
through barrier basement membranes The high content of procathepsin B in fMLP-
activated monocytes is interesting. If precursor enzyme was secreted into an acid 
pocket, such as formed by an osteoclast in intimate contact with its target tissue 
(Eeckhout, 1990), the precursor enzyme would constitute a readily-available source of 
mature cathepsin B. In an acid environment, the precursor enzyme is rapidly 
autocatalytic ally cleaved to the active enzyme (Mach et ai., 1993), and hence could play 
a role in basement membrane hydrolysis and the "invasive" movement of activated 
monocytes through barrier tissues. 
The interaction of PMNs and monocytes with endothelial cells is also of 
interest, as, preliminary to leucocyte, or tumour invasion, interactions between the 
leucocyte or tumour cell and the endothelial cells of the vasculature, take place (Dean 
et ai., 1991; EI-Sabban and Pauli, 1991). Macrophages in contact with endothelial cells 
and fibroblasts, are reported to induce the formation of "caviculae", or small vesicles, 
very similar to those seen in the endothelial stave cells in this study. These vesicles, 
in the macrophage/fibroblast cell environment, are seen to take up products from the 
macrophage. In the study reported by Dean et ai. (1991), these were BSA-gold adducts, 
previously endocytosed by the macrophage, and not ordinarily taken up by fibroblasts, 
were seen to be transfered from the monocyte to the fibroblast cell, indicating the 
establishment of possible "communication" channels between cells. 
Similarly, the metastatic potential of B16-FIO murine melanoma cells, 
has been demonstrated to be correlated with the transfer of cytoplasmic dye, from the 
tumour cell to the vascular endothelium (EI-Sabban and Pauli, 1991). In this case 
tumour-endothelial cell communication is mediated by gap junction channels formed 
after adhesion to the vascular endothelium. This interaction is cited as playing a 
possibly crucial role in tumour cell extravasation at a secondary site (EI-Sabban and 
Pauli, 1991) and similar interactions between PMNs and monocytes and the 
endothelia, may be relevant in leucocyte "invasive "activities. Low molecular weight 
components, such as the arachidonic acid derivative HETE (Dean et ai., 1991), 
synthesed by the tumour cell or the leucocyte, could be transfered to the endothelium, 
to stimulate endothelial cell retraction, exposing the basement membrane to 
proteolysis and thereby assisting tumour cell- or leucocyte invasion. Proteolysis may 
be effected by proteinases from the invading cell, or else messenger products may 
stimulate the endothelial cells themselves to secrete proteinases. 
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4.8.2 The cryoultramicrotomy approach 
On the technical side, a novel aspect of this study is the fact that none of 
the studies reported here have previously been attempted using the 
cryoultramicrotomy technique. Elastase has been immunolabelled in peripheral 
blood monocytes (Kargi et ai., 1990), but not using cryoultramicrotomy. The 
cryoultramicrotomy approach allows the use of weak fixation regimes, as tissues do 
not have to withstand the harsh processes of resin embedding. Because of this, it was 
possible to develop an optimal fixation protocol, thereby "opening up" PMNs for 
immunocytochemical study. 
At the commencement of this study, the speed with which results may 
be obtained using cryoultramicrotomy, and the fact that tissue fixation is the only 
antigen-denaturing step, made the "cryo" approach very attractive for optimisation of 
fixation, and for antibody optimisation procedures. Processing of a tissue to the final 
cutting and labelling stages, may be done in one day, under ideal conditions, whereas 
resin embedding procedures may take up to a week (Griffiths, 1993). With experience, 
however, some of the draw-backs of the "eryo" technique came to be appreciated 
In the "cryo" system, there is no resin matrix holding the elements of 
the section together, as there is in a resin section. Despite the carbon and formvar 
support film beneath the specimen, the fully-hydrated specimen is easily damaged by 
rapid changes in osmotic pressure and by dessication. Osmotic stresses, such as occur 
when the section is picked up off the microtome knife, with 2.3 M sucrose, placed on 
the grid and floated off onto buffer, may produce tissue vesiculation. Strategies to 
overcome this effect have been suggested (Tokuyasu, 1986), e.g. floating sections off 
onto a protein solution, such as 2% BSA containing 1 M sucrose. In the present study, 
these were found to offer no significant benefit. 
Another effect of capturing the section on sucrose is that it is easy for 
weakly-held cell components, such as azurophil granules, to be pulled out of the 
section as the dense sucrose droplet falls away from the grid section, when this is 
floated on buffer. Floating the sections off onto fixative, thereby effecting lateral 
fixation, was the only process found to be beneficial, both for osmotic effects and for 
the retention of the azurophil granules. 
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The fact that the cryoultramicrotomy section is unsupported, makes 
crosslinking of the contents of large granules, to hold the granules in place, much 
more critical. Lateral fixation, by flotation of the section on fixative, subsequent to 
cutting and before immunolabelling, assisted in retaining the azurophil granules. It 
was only appreciated later, however, that with increasing thickness of the section, 
there was an incresing probability that the granules would be retained and the elastase 
antigen would be prevented from being extracted and translated over the section. 
Another feature of the fully-hydrated cryoultramicrotomy section, is 
that it is easily damaged by dessication. If the final sealing film of methyl cellulose is 
too thin, drying artefacts can result from the "explosion" of some cell components, 
with damage to the surrounding ultrastructure. Such drying effects may be confused 
with other influences, such as poor fixation, or a poor knife edge used in sectioning, or 
an inappropriate density gradient method used in cell preparation, which may all lead 
to poor ultrastructure. The fragility of PMNs is also an age-related phenomenon; the 
older the PMN, the more fragile it is. This influences the reproducibility of the results 
and, taken together with all the above-mentioned factors, means that it is necessary to 
evaluate a large number of sections, before any conclusions can be drawn. 
The final aspect which was not full appreciated at the outset, was that, 
for the assessment of the association of proteinases with the surface of PMNs, where a 
polarised distribution of proteinases occurs only in the direction of movement, the 
orientation of sectioning is not easily changed for a cryoultramicrotomy block. The 
orientation of sectioning is critical, however, and should be parallel to the direction of 
cell movement, in order for any "invasion front" proteinases to be demonstrated. No 
serial sectioning or changing of the orientation of the frozen block of tissue on the 
microtome stub is possible in cryoultrasectioning, however, unlike resin sectiOning. 
For this reason, a great many sections were evaluated before the results presented here 
were recorded. 
For a number of reasons, therefore, coupled with the technical difficulty 
of the technique per se, the cryoultramicrotomy approach was possibly the most 
difficult approach that could have been used for the studies reported above. On the 
other hand, it has led to insights which could not have been achieved with any other 
technique. 
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4.8.3 Immunofluorescent labelling 
For the assessment of the general distribution of an antigen, 
immunofluorescent microscopy is a valuable method, giving a greater appreciation of 
the overall features of cells, due to the low magnification at which the labelling is 
visible, while giving greater sensitivity of detection than is possible with other light 
microscopy imrnunolabelling approaches. A microscope, equipped with an 
epifluorescence attachment, only became available in the closing phases of the studies 
reported here, however. 
Similarly, adequate facilities for culture of human cell lines were also 
acquired only in the closing phases. Cell culture has many advantages, allowing the 
age and population type and state of differentiation of the cells to be controlled, and 
eliminating the effects of cell isolation procedures. The availability of facilities for 
fluorescent microscopy and for cell culture was exploited in the studies on U937 cells, 
reported in this chapter, and in the studies on human breast epithelial cells, reported 
in Chapter 5. 
4.8.4 Conclusion 
The studies reported in this chapter were undertaken largely to develop 
methods, and leucocytes were initially chosen simply as a model of invasive cells. 
Nevertheless, in addition to the methods-development, exemplified by the section on 
fixation, a number of novel findings of biological significance have emanated from 
the present study. These findings were dependent on prior methods development, 
since they were only made possible by the development of an adequate fixation 
protocol, and include:-
i) the demonstration of elastase, cathepsin G and cathepsin D on the surface of in 
vivo f-MLP activated- and/or in vitro activated PMNs. 
ii) the demonstration of the effect of exposure of PMNs to different levels of the 
activating agent PMA, 
iii) the demonstration of a novel secretory body in activated PMNs, 
iv) the ultrastructural demonstration of cathepsin B and procathepsin B in fMLP-
activated peripheral blood monocytes, 
v) the demonstration of elastase and cathepsin D in plasma cells, 
vi) observations on the interaction of activated PMNs and splenic endothelial 
cells, specifically the uptake of elastase from the splenic spaces by the 
endothelial stave cell. 
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In addition, immunofluorescence labelling of variously differentiated and 
undifferentiated U937 cells has shown that these have a particular usefulness in 
immunocytochemical studies of leucocytes. 
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CHAPTERS 
PROTEINASE DISTRIBUTION IN "NORMAL" AND ras-TRANSFECTED BREAST 
EPITHELIAL CELL LINES 
5.1 Introduction 
The study reported in this chapter represents a brief contribution to the overall 
aim of the studies reported in this thesis, which was to discern which proteinases may 
be involved in the invasive movement of tumour cells and peripheral blood cells. 
During the course of the study on peripheral blood leucocytes, the advantages of 
working with a cell line became apparent. It was realised that it is far easier to 
examine individual, well-defined cell populations, in culture, rather than to isolate 
cells or search for appropriate cells in tissue samples. 
This is especially true of tumour tissues, where the presence of a 
heterogeneous population of uncharacterised tumour cells, and many other cells, may 
confuse the results. Moreover, tumour tissues are not easily accessible. For this 
reason, it was always intended that preliminary studies on human tumours would be 
performed on tumour cell lines. For the culture and handling of human tumour cell 
line, however, at least a Class II laminar flow bench and a functional, humidified, C02 
incubator are required. The brevity of this part of the study was due to the fact that 
both the equipment necessary for the culture of human tumour cell lines and the 
MCF-lO cell lines were acquired very late in this study. 
5.1.1 The MCF-I0A and MCF-I0A-Neo-T breast epithelial cell lines 
The MCF-I0A and MCF-I0A-Neo-T-c-Ha-ras human cell lines are a 
unique, newly characterised, pair of cell lines, comprised of an adherent, immortal, 
"normal" breast epithelial cell line (designated MCF-I0A) and a tumour cell line 
equivalent (deSignated MCF-I0 A-Neo-T, or simply Neo-T), derived from the 
MCF-I0A cell line, by transfection with the ras oncogene. These cell lines were 
developed at the Michigan Cancer Foundation (hence, "MCF"), and were provided to 
this laboratory by Dr Bonnie Sloane, of Wayne State University, Detroit. 
The MCF-I0 cell line is an oestrogen receptor-negative, spontaneously 
immortalised breast epithelial cell line, derived from mastectomy tissue from a 36-
year-old parous, premenopausal woman with fibrocystic disease (Tait et aI., 1990; 
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Soule et al., 1990). This cell line is unique as it is the first spontaneously immortalised 
line of breast epithelium, for which there is direct evidence that the normal diploid 
chromosome pattern, of the original explanted tissue, was retained for over a year in 
culture. Transformation to the aneuploid or near diploid karyotype, characteristic of 
an immortal cell line, moreover, took place spontaneously, with minimal 
chromosome rearrangement, whereas in other currently available breast epithelial 
cell lines, immortality was induced by treatment with carcinogenic drugs, or the cell 
lines were transformed using the SV 40 virus and still harbour some transforming 
SV40 genetic information (Soule et ai., 1990). 
The parent MCF-10A cell line, therefore, represents the nearest to "normal" 
breast epithelial cell line available, allowing the effect of a single oncogene 
transfection to be more easily discerned. Transformation with the ras oncogene is, 
however, especially interesting. ras-Transformation of human and murine fibroblasts 
has been shown to cause alkalinisation of the lysosomes (Jiang et al., 1990). 
Alkalinisation of acidic compartments, such as endosomes and lysosomes, in turn, 
causes disturbances in proteinase processing and secretion (Nishimura et ai., 1988). As 
mentioned in Chapter I, default secretion may be due to a lack of acidification of the 
late endosome, preventing dissociation of receptors and ligands. This would result in 
immobilisation of mannose-6-phosphate receptors in swollen, late endosomal bodies, 
effectively preventing them from recycling and participating in proteinase trafficking 
(Brown at al., 1986). This could cause proteinases to enter the constitutive, default, 
secretory pathway. 
The acquisition of the MCF-10A and MCF-10A-Neo T cell lines, provided a 
unique opportunity to study the effect of the transforming c-Ha-ras protooncogene on 
the distribution of proteinases in a defined breast tumour cell line, in comparison to 
its "normal" counterpart. This study is especially relevant, as overexpression of the 
c-Ha-ras-specific protooncogene mRNA and its protein product, p21, is reported to 
occur in 60-70% of human primary breast tumours (Ciardiello et ai., 1990). 
Consequently, it was felt that some immunocytochemical studies on these cells 
should be reported here, even though these are at a very preliminary stage. 
5.1.2 Confocal microscopy and electron microscopy on Lowicryl resin 
embedded sections 
As indicated in the previous study on leucocyte proteinases, fluorescent 
microscopy is often of unique value when an "overall" impression of the distribution 
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of a specific antigen is required. Immunofluorescence combines a high sensitivity of 
antigen detection with the low magnification of light microscopy. 
The epifluorescence microscope, mainly used in this study, was 
acquired late in the time frame of the studies reported here. However, during the 
course of this study, a unique opportunity arose to use a "state of the art" confocal 
microscope. Access to a Zeiss Laser Scanning confocal microscope, equipped with 
three independent lasers, a Silicon Graphics Workstation and Voxelview software, 
was afforded by an invitation, from Dr B. Sloane, to visit her laboratory in the 
Department of Pharmacology, Wayne State University, Detroit, Michigan. 
The confocal microscope allows low light video detection and digital 
image analysis. It can be used to quantitate the spacial distribution of fluorescent 
probes with a resolution of approximately 0.2 I-lm in the x and y axes and 0.8 I-lm in the 
z axis. By comparison, conventional light microscopes capture images with a depth of 
field, at high magnification, of between 2 to 3 I-lm (Dr Sonia Wolfe-Coote, pers. 
comm.). By focusing the laser beam to a point, which is scanned back and forth, 
"optical sectioning" (confocal microscopy) through a cell is possible. The plane of 
optical sectioning can be altered in stepwise fashion and the resulting series of images 
can be collected and stored in a digitised form, allowing subsequent 3-D image 
reconstruction. 
In the present study, the 3-D reconstruction facility was not used, but the 
"optical sectioning" capability was used, in some cases, to discern whether labelled 
compartments were distributed on the apical or baso-Iateral surface of the cell, i.e. to 
reveal any differences in proteinase distribution in the "z" -dimension within the 
MCF-lOA and Neo-T cells. 
Reporting results in this study required the selection of the most 
representative images to illustrate the findings. Conclusions were drawn after long 
and careful examination of many fields of fluorescently labelled cells, though, often, 
no one cell is truely representative of the overall impression gained. Although one 
may strive to be as objective as pOSSible, there appears to be no way of aVOiding some 
subjectivity in the interpretation of immunofluorescent labelling micrographs, a 
question discussed by Griffiths (1993). 
Some preliminary immWlolabelling studies, using Lowicryl embedding 
and progressive low temperature embedding, are also included. The facility to do this 
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was established in our laboratory by the time this investigation was undertaken and 
afforded the opportunity to immunolabel MCF-IO cells for examination by electron 
microscopy, and to explore resin embedding as an alternative to the "cryo" approach 
for certain studies. 
5.2 Distribution of cathepsins B. Hr L and Dr in MCF-10A and MCF-10A-Neo-T cells 
using confocal and conventional immunofluorescence microscopy 
In the immunolabelling studies reported here, the antibodies previously used 
in the cryoultramicrotomy studies, reported in Chapter 4, were again used. Double 
and triple immunofluorescence labelling, however, requires the use of antibodies of 
different species. This study was facilitated by the fact that a unique portfolio of anti-
cathepsin polyclonal and peptide antibodies (described in Section 3.3), raised in 
different species of experimental animals, had already been assembled in this 
laboratory. 
The anti-cathepsin B polyclonal antibody previously used in the studies 
reported in Chapter 4, and the peptide antibody raised against residues 192-201 of the 
mature human liver cathepsin B sequence (Section 3.8) did not prove satisfactory in 
immunofluorescence labelling. This study, however, shows susccessful immuno-
labelling for cathepsins H and L and procathepsin B, using peptide antibodies. 
This study concentrates on cathepsins H, Land D, though some results on 
cathepsin B are reported. Some of this work was done in Detroit, using the confocal 
microscope, and some was done in this laboratory, using conventional 
epifluorescence microscopy. Consequently, the results reported here, are comprised of 
a mixture of conventional and confocal fluorescent micrographs. 
5.2.1 Reagents 
Immunofluorescence labelling reagents, were as reported in Section 
4.7.1. Primary antibodies used, however, were i) the polyclonal IgY anti-porcine 
cathepsin D (306 Ilg/ml), ii) sheep anti-human liver cathepsin B (300 Ilg/ml), iii) anti-
ppB22-36 anti-procathepsin B (730 Ilg/ml) and anti-ovalbumin-conjugated B192-201 
(anti-mature human liver cathepsin B) peptide antibodies (739 Ilg/ml) (characterised 
as described in Section 3.8), iv) the rabbit anti-sheep cathepsin L (386 Ilg/ml), and, v) 
rabbit anti-human cathepsins L- and H-ovalbumin-conjugated peptides (equivalents 
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of peptide Bl92-201 of human liver cathepsin B - see Fig. 11 and Section 3.3) 
(394 )lg/ml and 412 )lg/ml, respectively) [characterised by Coetzer et al. (1991) and 
Coetzer (1993), respectively]. 
Other rabbit antibodies used were: the anti-bovine 215 kDa mannose-6-
phopshate receptor antiserum (used at 1/20) (from Dr B. Hofflack, EMBL, Heidelberg), 
and the secondary antibodies, rabbit anti-IgY serum (used at 1/200) and rabbit anti-
sheep IgG serum (used at 1/150), prepared in this laboratory by Dr Theresa Coetzer. 
The fluorescent conjugates used were a green fluorescent, DTAF-labelled, affinity 
purified, donkey anti-rabbit conjugate, pre-adsorbed against bovine, goat, horse, 
human, mouse, rat and sheep IgG, to eliminate cross-reactivity (used at 1 140), a red 
fluorescent, CY3™-labelled, affinity purified, rabbit anti-chicken, not adsorbed against 
IgGs of other species (used at 1 160) and a Texas Red-labelled donkey anti-rabbit 
antibody (pre-adsorbed as described for the DTAF-Iabelled antibody and used at 1 140). 
These antibodies, and a normal donkey serum, used for blocking, were obtained from 
Jackson ImmunoResearch Laboratories, Inc., West Grove, P A. Mouse anti-~ tubulin 
(used at 1 140) was from Boehringer Mannheim, Germany. 
Cell culture components, including insulin, hydrocortisone, 
Penicillin G/Streptomycin (10 000 units and 10 mg/ml, resp.), Dulbecco's Minimal 
Essential Medium (DMEM): Hams F-12 Medium, trypsin-EDTA solution (Xl) and 
Hanks balanced saline solution (HBSS) were from Sigma Chemical Co., St Louis, Mo.; 
Fungizone (250 )lg/ml) and horse serum were from Gibco, Paisley, UK, and epidermal 
growth factor (EGF) was from Upstate Biotechnology Incorporated, Lake Placid, NY. 
MCF growth medium . The DMEM:Hams F-12 medium (1 D was 
supplemented with horse serum [5 % (v Iv), 52.6 ml], EGF (20 )lg, 0.43 ml), insulin 
(10 mg, 4.2 ml), antibiotics (100 mg Streptomycin and 100 000 units Penicillin G, 10 mD, 
Fungizone (0.25 mg, 1.1 mI) and hydrocortisone (0.5 mg, 2.14 mI). 
MCF serum-free growth medium. Serum free growth medium was 
prepared as described above, but the serum was omitted. 
5.2.2 Procedure 
MCF-l0A and Neo-T cells were grown to near confluence in MCF 
growth medium, in a humidified atmosphere, containing 5% C02, at 37°C. Cells were 
washed with HBSS, trypsinised with lX trypsin-EDTA solution, and seeded (at approx. 
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1 x 10 4 cells/ well) into duplicate 12-well Nunc Multiwell plates, one plate containing 
a 15 mm sterile glass coverslip, in each well. When cells were near confluence, they 
were washed with HBSS and incubated overnight in MCF serum-free medium before 
being immunolabelled. 
Immunofluorescent labelling was performed as described in Section 
4.7.2. Sections were blocked with 5% normal donkey serum, made up as described for 
the foetal calf serum described in Section 4.7.2. Fluorescent conjugates, diluted to the 
required dilution (given above) were pre-adsorbed against unfixed, unpermeabilised, 
monolayers of the MCF-I0A and Neo-T cell lines, in duplicately seeded Nunc 
multiwell plates (30 min, RT), immediately prior to use of the conjugate, to adsorb out 
any non-specific antibodies. 
The confocal mode of the Zeiss Laser Scanning microscope was used to 
examine some sections. The HENE (543 nm) laser was used for examination of Texas 
Red and CY3 labelled sections, and phase contrast images, and the Argon (488 nm) 
laser for DTAF-Iabelled sections. Otherwise, sections were viewed in an Olympus BH2 
microscope, fitted with a BH2-RFC Reflected Light (epifluorescence) Attachment 
(Section 4.7.2). 
5.2.3 Results 
The distribution of proteinase labelling was judged, on the basis of the 
distance of labelled organelles from the outer membrane of the cell, as perinuclear 
(normal) or peripheral (abnormal). Generally, a more peripheral distribution of 
proteinases was observed in the Neo-T cells, compared to the MCF-I0A cells. 
Immunofluorescent labelling for procathepsin B and cathepsin B 
generally indicates the presence of a greater quantity and a less perinuclear 
distribution of procathepsin B in the Neo-T cells than in the MCF-I0A cells [Compare 
Plate 16, Figs 1 and 4, (Neo-T cells) with Figs 2 and 3b (MCF-I0A cells) labelled for 
procathepsin B, and compare Figs 7 and 8 (Neo-T cells) with Figs 6 and 5 (MCF-IOA 
cells) labelled for cathepsin B with peptide (Figs 6 and 7) and sheep antibody, (Figs 5 
and 8)]. Labelling for cathepsin B with the anti-BI92-201 peptide antibody (Plate 16, 
Figs 6 and 7) and the sheep anti-human (Plate 16, Figs 5 and 8) antibody, was poor, 
showing a non-punctate, generalised distribution around the nucleus of the cell, with 
the peptide antibody giving the least labelling specificity, in that nuclear staining is 
evident. 
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Immunolabelling for cathepsin D and L generally indicates that 
labelling is, once again, perhaps, less perinuclear in the Neo-T cells than in the MCF-
lOA equivalent [Plate 17, for cathepsin D, compare Fig. I, (MCF-10A cells) with Fig. 2 
(Neo-T cells) and Fig. 3a (MCF-10A) with Fig. 4a (Neo-T): for cathepsin L, compare 
Fig. 3b (MCF-10A) with Fig. 4b (Neo-T)]. Double labelling for cathepsins D and L 
indicates that organelles labelling for cathepsin D are more numerous, and only in 
some cases are colocalised with immunolabelling for cathepsin L [Plate 17, Figs 3a and 
3b (MCF-10A), and Figs 4a and 4b, (Neo-T cells) labelled for cathepsin D (Figs 3a and 4a) 
and L (Figs 3b and 4b)]. 
Plate 18 illustrates how in both the Neo-T and MCF-10A cells, 
organelles labelled for proteinases (cathepsin L in this case) have a distribution that is 
orientated along microtubule tracks [Plate 18, Figs 1a and 1b (Neo-T), and 2a and 2b 
(MCF-10A), show labelling for p tubulin (Figs 1a and 2a) and cathepsin L (lb and 2b)] . 
The Neo-T cells generally show a more extended microtubule backbone than the 
MCF-10A cells (Plate 18, Figs 1a and 2a, respectively). The labellings for cathepsin L, in 
Plate 18, Figs 1b and 2b, and Figs 3 and 4, illustrate immunolabellings performed with 
the peptide antibody (Figs 1b and 2b) and with polyclonal anti-sheep cathepsin L 
antibodies (Figs 3 and 4). The polyclonal antibody gave more consistent, and more 
intense, labelling. However, the peptide and polyclonal antibodies gave similar 
labelling patterns, thereby validating the peptide antibody labelling. 
Immunolabelling for cathepsin H in MCF-10A (Plate 19, Figs A, C and E) 
and Neo-T cells (Plate 19, Figs B, D and F) shows that the cathepsin H distribution in 
these two cell lines appears similar, especially when viewed by conventional 
fluorescence microscopy. Immunolabelling examined using the confocal facility of 
the Laser Scanning Microscope, to optically section different planes of the MCF-10A 
and Neo-T cells and identify areas of maximal labelling, indicates that MCF-10A cells 
(Plate 19, Figs C and E) have a greater distribution of cathepsin H on the baso-Iateral 
surface of the cell, whereas the Neo-T cells appear to have a greater labelling density 
on the apical surface of the cell (Plate 19, Figs D and F) (The plane of optical sectioning 
is identified by the "z" co-ordinate). The Neo-T cells also have a more "spread" 
distribution of proteinases than the MCF-10A cells (Compare Plate 19 Fig. E with 
Fig. F). 
Plate 20 illustrates the proportionally higher amount of immuno-
labelling for the 215 kDa mannose-6-phosphate receptor seen in MCF-lOA cells 
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(Plate 20, Figs la, 1b and 1c) compared to that seen in Neo-T cells (Plate 20, Figs 2 and 
3). Not all cells in anyone preparation of MCF-10A and Neo-T cells show 
immunolabelling for the mannose-6-phosphate receptor. If, in a random selection of 
10 fields, cells showing labelling are selected and their receptors counted, the Neo-T 
cells show an average of 3 punctate receptor labellings per cell, whereas MCF-IO cells 
give an average of approximately 5-8. 
5.3 Immunolabelling of Lowicryl-embedded sections 
The natural structure and organelle distribution of an adherent cell is best 
observed on cells which have not been subjected to proteinase digestion .and removal 
from their substratum (Bou-Gharios et al., 1988). One of the resins which has proved 
most successful for embedding adherent cells is Lowicryl K4M (Bou-Gharios et al., 
1988; Griffiths, 1993). A monolayer of cells is grown in a flaskette and embedded using 
a simple technique (Bou-Gharios et al., 1988). 
An excellent review on the Lowicryl resins and their use is given by Griffiths 
(1993) and a few points from that review will be repeated here. Lowicryl resins are 
comprised of mixtures of aliphatic acrylate and ethacrylate esters, the side chains of 
which may be altered to vary the hydrophilicity of the resin, giving the more 
hydrophilic K4M variety or the more hydrophobic HM20 resins. K4M, the more 
hydrophilic resin, was chosen for this study. 
K4M resin was designed to have a low freezing pOint, low viscosity at low 
temperatures and very good sectioning and beam stability properties. It polymerises 
in the presence of up to 5% water, at a temperature of down to -40° C, under long 
wave (360 run) ultraviolet irradiation (under nitrogen gas, as oxygen inhibits resin 
polymerisation). These properties enable dehydration and heat polymerisation steps 
(potentially antigen damaging) to be avoided, while giving excellent preservation of 
tissue ultrastructure and antigenicity. A refinement of room temperature embedding 
procedures, giving the best preservation of ultrastructure, is the "progressive lowering 
of temperature" (PLT) technique, in which dehydration takes place in an ascending 
series of ethanol concentrations, with descending temperatures (from O°C to -35°C), in 
a specially designed refrigerator, equipped with a "heat sink" and nitrogen gas supply, 
as described by Griffiths (1993). The Lowicryl PLT system was recently established in 
this laboratory by Philip Fortgens, who did the embedding for the studies reported 
here. 
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A procedure modified from that used by Bou-Gharios et aI, (1988), using a 
Nunc Lab-Tek Tissue Culture (Multi-) Chamber Slide Vessel, with a glass slide on the 
under side, was used, as one of the difficulties encountered in embedding a monolayer 
in Lowicryl is that Lowicryl adversely affects the polystyrene tissue culture flasks in 
which the cell line is usually grown. Use of the Multiwell Slide Chamber overcomes 
this difficulty and allows many small blocks to be embedded. 
5.3.1 Procedure 
MCF-I0A and Neo-T cells were grown and seeded in a Nunc Lab-Tek 
Tissue Culture (Multi-) Chamber Slide Vessel, as described in Section 5.2.2 (without 
coverslips in the wells). Cells, grown to confluence as described previously (Section 
5.2.2), were fixed in 2% PFA, containing 0.2% glutaraldehyde, in HEPES buffer (Section 
2.3.2) (15 min, RT) and PLT embedding was performed as described by Griffiths (1993). 
Sections were cut at right angles to the slide surface, and collected on formvar-coated 
nickel grids (Hayat, 1986), as described in Section 2.5.2.2. 
Immunolabelling, using the sheep anti-human cathepsin B and chicken 
anti-porcine cathepsin D antibodies (characterised as described in Section 3.8) was 
performed, essentially as described in Section 4.4.2, except that incubations in gold 
probes were prolonged to 1 h. Sections were counterstained in uranyl acetate and lead 
citrate and viewed as described previously (Section 2.5.2.2). 
5.3.2 Results 
Plate 21, Figs 1 and 2, show sections of Neo-T and MCF-I0A cells, 
respectively, sectioned perpendicular to the slide plane, the basal surface of the cell 
being indicated with arrowheads. The MCF-I0A cells show a greater number of 
• tonofilaments (electron-dense filaments seen in Plate 21, Fig. 2 lower and upper cell, 
large arrows) than the Neo-T cells. Non-adherent and semi-adherent cells show a 
greater number of electron-translucent vesicles and "autophagic vacuoles" than 
adherent cells (Plates 21and 22) and the Neo-T cells contain more electron-translucent 
vesicles (Plate 21, Fig. 1) than the MCF-I0A cells (Plate 21, Fig. 2). 
"Autophagic type" vacuoles, in both the MCF-I0A and Neo-T cells are 
seen to be a complicated conglomerate of membrane-bound, electron-translucent 
swollen vesicles, which label for cathepsins Band D (Plates 23 and 24). 
Immunolabelling for these enzymes show that they occur in more electron-dense 
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aggregates, within the electron-translucent vesicles (Plate 24, Figs. 1 and 2). Double 
labelling indicates that some electron-translucent vesicles label for both cathepsins B 
and D, some for only one of these enzymes, while some label for neither (Plate 24, Figs 
1 and 2). In a few instances, Neo-T cells are seen to produce protuberances which 
contain electron-translucent granules containing cathepsin B, and microvilli with 
cathepsin B associated with their external surface (Plate 25). 
5.4 Discussion 
5.4.1 MCF-10A and MCF-10A-Neo-T cells 
In contrast to some breast tumours and breast tumour cell lines, mortal 
and immortal MCF-10 cell lines lack amplification, rearrangement or mutational 
activation of cellular protooncogenes on chromosome 17 (c-erb/HER-2/neu and 
c-erbA-l), or chromosome 11 (int.-2 and c-Ha-ras-). Such mutations or alterations 
may, conceivably, have occurred in the MCF-I0A immortalisation process, but did not 
in this case. 
Also, using restriction fragment length polymorphism analysis and 
DNA sequencing, no activating missense mutations in the common activation sites of 
Ha-ras oncogenes have been found, and at least 99% of the Ha-ras alleles in the 
MCF-10A cells were found to be normal in codon 12/13 and 59/61/63 regions (Soule 
et al., 1990). Analysis for the presence of other H-ras mutations, prior to the 
transfection of the ras protooncogene, was also performed on the original MCF-I0A 
cells. This was important as the ras protooncogenes have been shown to block 
calcium-induced senescence in keratinocytes and to initiate epidermal cell neoplasia. 
The v-Ha-ras oncogene has been shown to be both a potent initiator of mammary 
neoplasia in transgenic mice and to be activated in nearly all rat mammary tumours 
induced by nitrosomethylurea (Soule et al., 1990). 
However, no alterations of any of the above protooncogenes were 
found to be involved in either the immortalisation or loss of calcium-induced 
senescence, in the MCF-10 cells. In all obvious respects, therefore, the MCF-lOA cell 
line is the ideal "normal control" and the lack of ras-related mutations offers a unique 
opportunity to study the phenotypic effect of the transformation induced by ras-
oncogene transfection. 
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c-Ha-ras- transformation of MCF-10A cells, giving rise to the Neo-T 
phenotype, was found to result in:-
i) increased expression of transforming growth factor-a (TGF-a) mRNA and 
secretion of TGF-a, 
ii) the ability to grow in soft agar and enhanced growth in serum-free 
medium and, 
iii) reduced mitogenic response to exogenously added EGF and TGF-a 
(Ciardiello et al., 1990). 
All of these are indicative of the acquisition of the transformed phenotype. As 
reported in human and murine fibroblasts (Jiang et al., 1990), preliminary studies by 
Sameni et al., (1993) indicate that, upon ras-transformation of MCF-10A cells, a slight 
alkalinisation of the cytoplasm pH was also induced. 
These epifluorescence studies indicate that alkalinisation is 
accompanied by a more peripheral distribution of lysosomes, indicated by labelling for 
the LAMPS-1 antigen, and cathepsins B and D. Cathepsins B and D are perinuclear 
and colocalised in the MCF-10A cells, but are only colocalised in the perinuclear area 
of the NeoT cells (Sameni et al., 1993). This lack of colocalisation possibly reflects a 
difference in trafficking of cathepsins Band D, which may correlate with the 
acquisition of the invasive phenotype. 
The results of immunolabelling, in the present study, are the first 
immunolabelling results for cathepsins Hand L reported on these cells. The 
distribution of cathepsin B was difficult to assess, due to the poor quality of the 
available antisera, but procathepsin B, and cathepsins D, Hand L, do seem to show a 
more peripheral distribution. No membrane-bound cathepsins were evident, in this 
study. 
The results reported here suggest, however, that it might be profitable to 
investigate, using the confocal Laser Scanning Microscope, whether a more apical 
distribution of proteinases is a consistent feature of Neo-T cells as compared to a more 
baso-lateral distribution in MCF-10A cells. A more apical distribution of proteinases, 
in the Neo-T cells, is consistent with a pattern induced by alkalisation of endosome/ 
lysosome compartments, in normal epithelial cells exposed to an alkaline pH (Parton 
et al., 1991) Also, down-regulation of M-6-P receptors seems to parallel 
transformation. 
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5.4.2 Antibodies used in immunofluorescence labelling 
Immunofluorescence labelling, using the anti-B192-201 peptide 
antibody and the sheep anti-human liver cathepsin B antibody, proved to be 
unsatisfactory due to its generalised, non-discrete nature. Similar non-discrete 
immunolabelling has previously been observed, with other antibodies, where the 
antibody was used at a dilution greater than optimal. This suggests that a higher 
concentration of the cathepsin B anti.h0dies in question may give a more specific, 
punctate labelling pattern. 
Inununolabelling of permeabilised cells, in general, seems to require 
higher concentrations of antibodies than any other sort of labellings. Control 
immunolabellings, in which non-immune IgG of the same species and at the same 
concentration as the test, is substituted, however, indicate that the maximum 
concentration level for which specificity is still possible has almost been exceeded at 
the test levels. Anti-cathepsin B antibodies proved, once again, to be the most 
refractory, both to raise and use. A less perinuclear distribution of cathepsin B 
labelling in Neo-T cells, compared to MCF-10A cells, reported by Sloane et al. (1990), 
however, is indirectly verified by immunolabellings, in the present study, with the 
procathepsin B peptide antibody. 
Though peptide antibodies generally gave weaker reactions, requiring 
the use of high concentrations of IgG (approx. 700 Jlg/ml), better quality peptide 
antibodies, such as the anti-cathepsin Land H antibodies, could be used at lower 
concentrations (approx. 400 Jlg/ml). These antibodies gave labelling comparable to 
that of polyclonal antibodies and proved to be very good reagents. 
5.4.3 Electron microscopy of Lowicryl-embedded cells 
Griffiths (1993) has cautioned against over-interpretation of fluorescent 
labelling results. For this reason, confirmatory electron microscopy immunolabelling 
studies were undertaken. 
The reliability of results obtained on the MCF-10A and Neo-T cell lines, 
depends upon proper characterisation of the ultrastructural features that identify the 
cells as epithelial and breast in nature (Tait et al., 1990), in the first place, and on the 
continued monitoring of these features during the course of the study, to ensure that 
no phenotypic drift has occurred. Upon establishment in our laboratory, this was a 
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cause for concern, as both the MCF-10A and the Neo-T cell lines, showed some 
evidence of aberrant morphology. 
The source of the aberrant intracellular vesicles seen in both the MCF-
lOA and Neo-T cells is not clear at this stage. The cells may be showing signs of stress, 
due to a fault in the C02 supply, in the incubator used for the cell culture, at the time. 
The abnormal vesicles may be a result of alkalinisation of the culture media, due to 
the low C02 levels prevailing at the time of culture. The effects of low C02 levels 
appear to be similar to those of lysosomotrophic agents (reagents that increase the pH 
of acidic cellular organelles) (Brown et al., 1986). Organelles seen here are distended, 
as previously recorded in other cell lines exposed to lysosomotrophic agents (Brown 
et al., 1986). As mentioned previously, the pH of the external medium is known to 
affect the pH of internal organelles such as lysosomes and endosomes (Tannock and 
Rotin, 1989; Jahde et al., 1989). 
Another possibility, however, is that these cells may be expressing more 
of the MCF-10F, floating cell line phenotype, as it is notewothy that only the non-
adherent cells contain these vesicles. Of the two cell lines that arose from the mortal 
MCF-10M cell line, the MCF-10A line grows as attached cells in normal concentrations 
of calcium whereas the MCF-10F grows as free-floating cells in media containing high 
levels of calcium (Soule et al., 1990). MCF-IOF cells have been described as exhibiting 
the "formation of intracellular lumens .. .. . or channels similar to those reported in 
numerous normal as well as neoplastic cell types" (Tait et al., 1990), that may be 
comparable to those seen in this study. Secretion of electron-dense material into these 
lumens (as seems to have occurred here also - Plate 22, Fig. 2 and Plate 23, Fig. 2) is 
reported to indicate that the MCF-10F cells, "have preserved their secretory function, 
although with changed polarity". Immunolabelling studies were temporarily 
suspended until the origin of the abnormal vesiculation was determined and the true 
phenotype of these cells was established. 
In agreement with the findings from the immunofluorescence labelling 
studies, however, cathepsins B and D do not appear to be commonly associated with 
the membrane of these cells, under the conditions under which they were grown. 
Cathepsin B was found to be associated with the surface of only a very few Neo-T cells 
in I.E.M. studies (Plate 25). 
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The preservation of ultrastructural detail and tissue antigenicity, seems 
to be adequate using this fixation, PLT and Lowicryl embedding technique. The use of 
PLT and Lowicryl embedding will be useful for future studies on the distribution of 
multiple antigens. This technique not only allows 3-D reconstruction of cells, by serial 
sectioning, but also allows alteration of the block orientation. The in situ embedding 
procedure, modified from that of Bou-Gharios et al. (1988), as outlined above, also 
overcomes the otherwise undesirable necessity to trypsinize cells, which may generate 
artefacts. This technique will, therefore, complement future electron microscopy 
studies using the "cryo" approach. 
The combination of the MCF-10 cell lines and Lowicryl embedding 
appears very promising for future studies. The MCF-10 cell lines afford the best 
opportunity yet for unravelling the processes of oncogenic transformation that lead to 
the development of the malignant phenotype. They are unique in not having been 
affected by viral or chemical agents (Ciardiello et al., 1990; Soule et al., 1990; Tait et al., 
1990), and the MCF-10A line provides the ideal "control" for all future work. 
5.4.4 Conclusion 
Membrane association of proteinases does not seem to occur upon 
ras-transformation of MCF-10A cells. The more peripheral distribution of proteinases 
and decreased levels of M-6-P receptors in the Neo-T cells may, however, relate to 
increased secretion or "directed" secretion, such as seen in osteoclasts (Eeckhout, 1990), 
and may, therefore, be relevant to invasion. 
This question could be addressed by observing cells in the process of 
invasion and, to this end, in vitro assays of invasion are presently being set-up. In 
these assays, cells are chemotactically activated to invade through a barrier matrix, in 
an invasion chamber. Immunolabelling of the "invasion front" of cells, in the 
process of invading, should provide the most direct evidence of the mechanism of 
invasion and for the involvement of specific proteinases. The matrix could be fixed 
and processed for "cryo"-immunolabelling (Parton et al., 1991), or, if sections of cells in 





The invasive movement of cells, involving a combination of chemotactic 
activation and diapedesis, and requiring the use of adhesion molecules, hydrolytic 
enzymes and directed cell movement, is a fascinating subject for study. That it is a 
phenomenon common to both malignant tumour cells and normal macrophages and 
PMNs (Terranova et al., 1986; Condeelis et al., 1992), is also a somewhat sinister 
concept. 
Elucidation of the processes of invasive movement has emerged from a blend 
of techniques drawn from the disciplines of cell biology, biochemistry and molecular 
biology. Studies of this kind have been spearheaded by microscopy studies, including 
immunofluorescence studies at the light microscope level and immunocytochemistry 
at the electron microscope level, and have been considerably assisted by the use of 
well-characterised, genetically manipulated, cell lines (Ciardiello et al., 1990). 
The studies reported in this thesis were aimed, ultimately, at elucidating which 
proteinases might be involved in invasion, and they have two aspects, which, for ease 
of discussion, might be designated "technical" and "biological", respectively, though, 
in places, these tended to overlap. Since development of techniques and equipment, 
of necessity, preceded the acquisition of biologically significant results, technical 
aspects of the study will be discussed first. 
The central technique used in the present investigation was the "Tokuyasu" 
technique, of immunolabelling and EM-viewing of fully-hydrated sections, cut using a 
cryoultramicrotome. For brevity this is called the "cryo" technique. The strength of 
the "eryo" technique is that results may be generated very rapidly. A tissue may be 
fixed and processed for cryoultramicrotomy, in the morning; cut, labelled and viewed 
and the micrograph obtained by the evening of the same day. This is not possible in 
under 3 days, with alternative systems. This makes the "cryo" technique very suitable 
for trafficking studies, especially on cell culture systems, where cultures may be easily 
manipulated to explore different effects. The "cryo" technique is also very suited to 
the optimisation of fixation and immunolabelling parameters, as it involves only 
mild tissue processing, which allows the use of weak fixatives, and short fixation 
regimes. Additionally, it is the only system in which fixation is the only potentially 
antigen-damaging tissue processing step (Griffiths, 1993). 
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Having said that, two shortcomings of the technique became obvious in this 
study: the near-impossibility of replicate sectioning, for comparative purposes, and the 
fact that the orientation of a block may not be radically changed to allow sectioning in 
a different plane. This shortcoming became obvious during immunolabelling studies 
on activated cells, where, in order to demonstrate immunolabelling on the "leading 
edge", the plane of sectioning must be orientated along the axis of movement. 
As is apparent from the structure of this thesis, much method and reagent 
development was necessary, prior to the application of the "cryo" technique. At the 
outset, a well-equipped Electron Microscope Unit was accessible and a cryo-
ultramicrotome was soon acquired. Modification of some existing equipment, was 
also necessary, as cryoultramicrotomy and immunocytochemistry were not previously 
established here. Further items of equipment were obtained in the course of these 
studies. The order in which some investigations were undertaken, therefore, was 
dictated largely by the availability of different items of equipment, at different times in 
the investigation. 
The cutting of acceptable frozen sections, in a cryoultramicrotome, is only 
possible with an exceptionally sharp glass knife. A knife, sharper than is required for 
cutting sections from plastic-embedded tissues, is essential for cutting frozen blocks. 
The making of glass knives for cryoultramicrotomy requires skills that are becoming 
uncommon, as the trend, for sectioning of plastic-embedded material, is towards the 
use of diamond knives. In this study it was soon learned that, in addition to skill, a 
precision-built knife maker is required; one with closer tolerances than are found in all 
commercially-available glass knife makers, even the latest. Consequently it became 
necessary to rebuild a knife maker, essentially to eliminate all sources of "play" in the 
mechanism. The modifications, reported in Chapter 2 and by Morewood et al. (1992), 
increased the successs rate, in making acceptable knives, by at least 100%, 9 to 12 
knives being selected from a single piece of glass (16 squares). 
In practice, it was found that the breaking pins regularly need repolishing, as 
they develop "flat spots" which disturb the evenness of the breaking stresses. The fact 
that metal parts expand and contract with the ambient temperature also necessitates 
adjustment of the machine almost every time a new batch of knives is cut. It was 
consequently found best to produce a large number of knives at anyone time. The 
quality of the final knife-edge, and its durability in storage, is improved by metal-
coating the newly-made knife, in vacuo, with a thin layer of tungsten. 
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Metal-coating, in vacuo, is not to be confused with "glow-discharging", 
in vacuo. In the present study, it took some time to find out that "glow-discharging" 
means ionising the surface of the carbon-coated grid so that the hydrated tissue section 
will be more likely to adhere. Glow-discharging is achieved by placing the grids in a 
"Crooke's dark space" (Benade and Pokorny, 1990) which develops in a discharge 
between two electrodes, closely spaced in a vacuum. 
Besides the necessary equipment, a key essential for immunocytochemistry is 
the availability of adequate antibodies. The production of such antibodies may be 
considered, at once, both "technical" and "biological". For the production of 
polyclonal antibodies targeting human antigens, there are three possible approaches, i) 
to isolate the immunogen from human tissue, ii) to isolate the immunogen from 
animal tissue, thereby relying on between-species immuno cross-reactivity, or, iii) to 
use peptide antibodies. All three approaches have been successfully applied, in this 
laboratory. In the case of cathepsin B, however, the peptide antibody approach was 
largely used here, with polyclonal anti-human cathepsin B being obtained by 
collaboration with other workers. 
Peptide antibodies (Coetzer et ai., 1991) [and the production and 
characterisation of gold probes (Elliott and Dennison, 1990)], were the subject(s) of the 
early part of this study. In the course of these studies, much was learned about peptide 
antibodies. The first, and conceptually most tantaliSing aspect, concerned the selection 
and production of peptide antibodies, and the faith that can be placed in peptide 
selection programmes. Eight peptide antibodies have now been raised in this 
laboratory, the raising and characterisation of four of these being reported in this 
thesis. It now appears that this is a costly approach, with useful peptide antibodies 
being elicited in about 50% of the cases, if only the criteria of hydrophilicity (Hopp and 
Woods, 1981; 1983) and flexibility (Westhof et ai., 1984), are used for the selection of 
peptides. With the knowledge gained from this study, however, it is considered that 
this success rate could be significantly improved. 
Successful peptide antibodies are worth the outlay expended in their 
production. Peptide antibody technology obviates the time-consuming difficulties of 
protein isolation, required for the production of conventional polyclonal antibodies. 
Peptide sequences selected from the sequences of human antigens may be used to 
produce "whole protein-reactive" anti-human antigen antibodies, where human 
tissues are not available for protein isolation and immunogen preparation. Peptide 
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antibodies can also be made to target regions on the antigen that would not naturally 
be targeted. 
The peptide sequence chosen must fit well into the paratope of an existing 
clone of an antibody-producing cell to elicit high avidity antibodies (Larsson, 1988a). 
Since the immune competence varies from animal to animal and species to species 
(Larsson, 1988a), there is no way of predicting this. This is why it is best to inoculate 
more than one test animal with each immunogen and why the production of useful 
antibodies, using any criterion for peptide selection, is not assured. 
Peptides are highly mobile in solution, only about 1 in 104 - 105 peptides 
adopting the same conformation as in the native protein (Todd et aI., 1982). This very 
mobility makes the different conformations more likely to find "fitting" para topes, 
eliciting a "cocktail" of weakly-reacting, conformation-specific, antibodies that mayor 
may not recognise the conformation in the native protein. For this reason, also, an 
antibody that recognises a protein antigen in a western blot of an SDS-P AGE gel may 
not recognise the same antigen in fixed tissues and vice versa. 
The inoculation of "free" peptides appears to produce the poorest antibodies, 
possibly because the peptide must be more mobile than in a conjugate. Peptides 
appear partially restrained by conjugation to a carrier protein, as, in general, 
conjugated peptides elicited the production of higher titre, more avidly-binding 
antibodies than free pep tides, implying the production of the major portion of the 
constituent antibodies in the polyclonal antibody, against one main, restrained 
epitope. Choice of the protein conjugate is critical, however. Conjugation with 
keyhole limpet haemocyanin (KLH) should be avoided, as anti-KLH antibodies are 
difficult to remove and cause cross-reactivity with many epitopes in tissues. 
Conjugation to ovalbumin proved a good choice, here. 
In this study, it was realised that selection of sequences that will elicit "protein-
reactive" antibodies are best made by considering the protein's 3-D structure and by 
choosing sequences that will be accessible for antibody binding. It is almost impossible 
to predict "protein-reactive" sequences on the basis of primary sequence only. This is 
because most "protein-reactive" antibodies recognize conformational epitopes which 
are themselves difficult to predict from the primary sequence. In a retrospective 
analysis of the results of this study, the programmes that appear most successful in 
predicting appropriate sequences were the Chothia accessibility plot (Chothia, 1976), 
the Welling antigenicity prediction plot (Welling et al., 1985), which predicts protein-
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reactivity on the basis of the relative occurrence of amino acids in known antigenic 
sites, and the T-cell epitope predictive programme (Margalit et aI., 1987), which 
predicts "amphipathic" sequences. 
As the T-cell epitope programme predicts, and the flexibility plots of Karplus 
and Schultz (1985), indicate, some non-mobility in the chosen peptide sequence is 
advantageous. This is confirmed by the Hopp and Woods (1981) plot, which indicates 
that immobilisation is best effected by the presence of some hydrophobic region in the 
peptide sequence. 
Perhaps inclusion of the results of the cathepsin B peptides, biases the statistics 
for the success rate of peptide antibody production, as it has always been difficult to 
produce anti-cathepsin B antibodies. The best anti-(mature)-cathepsin B peptide 
antibody has been successfully used on western blots but was not successful in electron 
microscopy studies and only successful to a limited extent in immunofluorescence 
studies. This is not surprising, when even the best polyc1onal anti-(whole protein) 
human liver cathepsin B antibody, available at the time, was unsuccessful and proved 
difficult to use in electron microscopy studies. The procathepsin B peptide antibody, 
anti-ppB22-36, was, however, very successful and useful. 
Peptide antibodies may contain cross-reactive antibody species, since they are 
comprised of a polyc1onal mixture of antibodies, against the different conformations 
which the peptide can adopt. Cross reactive epitopes may be changed in western 
blotted proteins compared to tissue samples and cross-reactivity may disappear, and 
hence go undetected. Adsorption controls, similarly, have the peptide in solution and 
conformations causing cross-reactivity would simultaneously be adsorbed out along 
with the specific antibody (Larsson, 1988a). 
From the experience gained in this study, two controls, are now considered the 
minimum acceptable, and a third is considered highly desirable for absolute proof of 
the validity of immunolabelling observed. The first is a check on the specificity of the 
antibody using a western blot of an SDS-P AGE gel which has been overloaded with 10-
to lOO-fold more than optimal crude and purified protein antigen (Larsson, 1988a) and 
probed with the antibody preparation and a non-immune control IgG preparation, 
with the IgG at the level which is to be used in the immunolabelling. This control 
indicates non-specific IgG binding due either to the loading of too much protein or use 
of too high a level of antibody, both of which will be indicated by similar labelling of 
the control and test. Use of high levels of antibody, to probe the western-blotted 
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protein, also favours the interaction of low affinity cross-reacting antibodies and will 
indicate their presence. Antibody levels as high as possible should, therefore, be 
employed, when testing antibody specificity. 
The second vital control, for EM-level immunolabelling, involves the 
substitution of a non-immune IgG control. The IgG preparation must be used at the 
same concentration as the immune IgG preparation, to check for non-specific IgG-
binding proteins and protein-protein binding interactions. IgG preparations of 
antibodies are preferred, therefore, as it is easier to use an IgG control preparation with 
the equivalent amount of IgG present, than with a pre-immune serum. The last 
control involves the comparison of immunolabelling results with results achieved in 
another system, preferably a biochemical analytical system. 
"Good" antibodies, either peptide or polyclonal, generally give positive 
labelling results after labelling is attempted using a reasonable range of antibody 
concentrations (10-250 J..lg/ml, for "cryo" /immunogold and 200-750 J..lg/ml for 
immunofluorecent labelling) (the first figure being for polyclonal antibodies and the 
second for peptide antibodies). Provided a relatively short, weak fixation regime is 
used, a short incubation period (generally between 30-60 min, RT), is generally 
adequate for immunoreactivity. Poor, low affinity and low avidity, antibodies are 
easily recognised as they do not produce immunolabelling results easily. Usually they 
require adjustments to the labelling regime, such as length of time for which the 
tissue is exposed to the primary antibody, and adjustments of fixation regimes. 
Generally, in the experience gained from this study, such antibodies are not worth the 
expenditure of any further effort. A key lesson learned has been that it is important to 
establish quickly whether the antibody is "good" or not, and only to expend effort on 
good, high affinity, high avidity, antibodies. 
The peptide antibodies used in this study were raised with a view to producing 
antibodies that would be not only protein-reactive and useful in immunolabelling 
studies, but also as reagents that would potentially be immunoinhibitory; possibly 
finding use in the treatment of tumour invasion. Mouse sequences were compared 
with human sequences (Chapter 3), due to the availability of a mouse model system in 
which the efficacy of immunotherapy treatments may be tested. The BL6-BI6 
melanoma cell line, inoculated into the foot-pad of a nude mouse, provides a useful 
model for studying metastasis, as the melanoma cells metastasise to the lung. 
Colonies are easily enumerated after the lungs are removed and cleared in glycerol, as 
colonies form black foci that are easily seen. 
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Immunolabelling studies (not reported in this thesis) indicate that the BL6-B16 
mouse melanoma cell line secretes cathepsin B and has membrane associated 
cathepsin B, both phenomena that may be relevant in the invasive activity of this 
tumour. Peptide antibodies produced against the peptide sequences in or near the 
active site of cathepsin B, proved to be non-immunoinhibitory, however, and 
immunolabelling with the peptide antibody at the electron microscope level, was 
unsuccessful. For this reason, the immuno-therapy aspect of this study was 
suspended, pending the finding of a suitable immunoinhibitory antibody. 
Access to equivalent antibodies, raised here in a number of different species, 
was useful for immunofluorescence studies, due to the availability of species-specific 
detection systems. Rabbit and chicken antibodies are the most easily produced, but 
antibodies raised in rabbits are the most commonly produced. For EM-studies, the 
protein A gold system has advantages, in its stability compared to immunogold 
probes, and the fact that double and triple labelling is easily performed using only 
rabbit antibodies. Multiple labelling, using protein A, with intermediate fixation, has 
the advantage that one detection system type can be used for different antigens, using 
different sizes of gold probe. Protein A does not react with chicken, IgY, antibodies, 
but a linking rabbit anti-chicken antibody enables protein A to be used and, 
simultaneously, gives amplification of labelling. 
In the confocal and epifluorescence study reported in the last chapter, it was 
found that labelling of permeabilised cells seems to require the use of very high levels 
of antibody compared to other techniques using non-permeabilised cells. This seems 
to be the most stringent test to which antibodies could be subjected. In such labelling 
protocols, antibodies raised against free peptides had to be used at a much higher 
concentration than antibodies raised against their conjugated peptide equivalents, 
verifying their generally poorer quality. Immunofluorescence, therefore, constitutes a 
good screening method, for selecting antibodies on which to invest further effort. 
Immunofluorescence also gives a better "overall impression" and is, therefore, 
also best for preliminary assessment of the distribution of antigens in tissue sections 
or cell culture preparations. Immunofluorescence studies should, therefore, ideally, 
precede electron-microscope level immunocytochemical studies. 
With the hardware and suitable antibodies to hand, the next technical question 
concerns tissue fixation methods. From the experience gained in this study, it is 
possible to recommend a simple approach to fixation, which should be widely 
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applicable. When beginning a labelling study of a new antigen, for which a suitable 
tissue fixation regime is unknown, fixation of tissue with either 4% or 8% 
paraformaldehyde (PFA) or 2% PFA plus 0.2% glutaraldehyde (10 min), should be 
adequate to allow the survival of the antigenicity of almost any antigen (this was true 
of at least 8 antigens examined in this study). Such a fixation regime should allow the 
optimisation of the level of antibody to be used in subsequent immunolabelling. If 
this approach fails, it is now believed, the suitability and quality of the antibody 
should be questioned. Once successful labelling has been achieved, the fixation 
protocol may be modified to achieve optimal preservation of tissue ultrastructure. 
One of the biggest fixation challenges with "cryo" sections of tissues, such as 
PMNs, filled with large, highly extractable material, is that, as the sucrose used to 
retrieve the section from the knife falls away from the grid-adherent section, when it 
is floated out onto buffer, the granule contents and other extractable components may 
fall away with it. Observations made during double immunolabelling procedures, 
where primary antibody and residual protein A gold reactivity were blocked by an 
intermediate fixation step (Slot et al., 1991), suggested a solution. When such an 
intermediate fixation of the section was used, greater immobilisation of granule 
contents was observed. This suggested that direct flotation of newly-cut sections onto 
fixative might improve granule retention. This was found to be true and lateral 
fixation of the sections, prior to immunolabelling, greatly improved granule 
retention. 
Further improvements were made using primary fixation strategies. In these 
studies on fixation, it seemed that the contents of the granules were not being 
adequately fixed, perhaps, due to the "nut-shell" effect of fixation strategies that were 
being used at the time; diffusion of fixative from the cell periphery inwards pOSSibly 
resulting in premature fixation of the outer membrane of the granule, preventing 
proper fixation of the contents of the granule. This problem was largely overcome by 
a combination of the pH and concentration shift strategy protocols reported here and 
by the use of lateral fixation. Up to now, azurophil granule fixation seems to have 
been a problem to many researchers, seemingly irrespective of the fixation regime 
used (Hibbs and Bainton,1989; Damiano et al., 1986; Cramer et al., 1985; Ganz et al., 
1985). 
The study on the fixation of elastase in PMNs, has also opened up prospects for 
further studies on PMNs. The novel approaches to fixation of these cells, reported 
here, will allow multiple immunolabelling studies that were previously frustrated by 
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translation of elastase over all the different granule populations. Double labelling of 
azurophil granules for cathepsin D and elastase, already performed in this study, 
seems to endorse the existence of previously speculated subpopulations of azurophil 
granules (Damiano et al., 1988). Double labelling will also assist in the identification 
of the origin of the novel "secretory body" identified in PMNs. Perhaps this may also 
be a "thread-like" lysosomal body whose ultrastructure may be improved by a 
modification of the protocol used here. 
A question of central importance to studies on proteinases, using 
immunocytochemistry, concerns the possible induction of artefactual organelles by 
fixation protocols, i.e. whether the structures subsequently observed are real or 
fixation artefacts. For example, fixation appears to have a marked effect on the 
observed morphology of some organelles, especially lysosomal bodies. These have 
been shown, in unfixed or extremely rapidly fixed tissues (Swanson et al., 1987; 
Robinson et al., 1986; Robinson and Karnovsky, 1991), to be naturally tubular in 
nature. The stability of these organelles, in their natural, tubular form, in turn, seems 
to depend on the stability of micro tubules (and possibly actin filaments) (Swanson 
et al., 1987; Sakai et al., 1989). 
Most studies of these organelles have been in macrophages, in which a highly 
dynamiC network of thread-like lysosomal organelles, which participate in autophagy, 
heterophagy, and pinocytosis, has been revealed. Sakai et al. (1989) observed that a 
characteristic change in macrophage lysosomes was induced by pinocytosis. Long 
"thread-like", lysosomes (nematolysosomes), capable of dynamic shape changes and 
movement, were induced in the cytoplasm of such cells. Movement of all types of 
lysosomes was found to be actin-, microtubule-, and energy dependent. Similar 
observations have been made in other cell types (Robinson et al., 1986; Robinson 'and 
Karnovsky, 1991). 
Disagreement seems to exist on how these nematolysosome structures are best 
preserved. Aldehyde fixation and 5% sucrose was used in the studies of Sakai et al. 
(1989), whereas in the studies of Robinson and Kamovsky (1991) ultrarapid freezing is 
advocated, followed by freeze-substitution. It seems, however, that calcium and 
magnesium-containing buffers may be required for the maintenance of these 
structures (and possibly also the presence of 5% sucrose), as Buckley (1973) reported 
that similar structures observed in chick embryo cells were preserved by fixation using 
glutaraldehyde and a calcium-rich, hypertOnic, buffer containing 0.3 M sucrose. 
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In the present study the requirement for calcium-containing buffers may be 
substantiated by an example of an image captured during confocal observation of 
immunofluorescent labelling of the MCF-10 cell lines for M-6-P receptor (Plate 20, Figs 
1 a and 1b), in which calcium and magnesium-containing buffers were used. In the 
lower right-hand comer of these figures, an extensive tubular network, possibly a 
lysosomal body, is visible in an MCF-10A celL (M-6-P receptor does not occur in 
lysosomes). These organelles were seen in both cell lines. 
Optimisation of fixation for the preservation of these tubular organelles is, 
perhaps, critical to studies on the distribution of proteinases in normal and cancer 
cells. Tubular lysosomal bodies were not observed in fMLP-activated cells, in this 
study, but have been observed in PMA-stimulated peritoneal monocyte/macrophages 
(Swanson et al., 1987). This suggests that a PMA-activated U937 cell line might be an 
ideal model for a systematic study of fixation conditions aimed at preserving these 
tubular bodies. 
The pH prevailing during incubation of cells may also have a marked 
influence on the apparent distribution of lysosomes and on their shape. In cell 
culture of macrophages, Heuser (1989), reports that alkalinisation of the medium 
causes the redistribution of lysosomes to the perinuclear area. In epithelial cells, 
alkalinisation causes the redistribution of late endosomes to the apical surface of the 
cell (as may be the case in alkalinisation caused by ras-transfection in the Neo-T cells), 
whereas, acidification has the opposite effect (Parton et al., 1991) and causes secretion 
of mature enzymes (Krepela et al., 1989). Different cells may thus behave differently 
and unpredictably at different pH values. During fixation, also, pH changes and the 
absence of microtubule and actin-filament-stabilising ions, such as calcium and 
magnesium, might change the distribution and shape of the observed organelles. The 
effect of pH changes, and cytoskeleton-stabilising ion concentrations in fixation 
protocols should, therefore, be investigated. 
Fixation conditions optimised in this study, however, have proved adequate 
for immunolabelling purposes, and these studies have led to several novel findings, 
including the observed labelling for cathepsin D and HLE in plasma cells and HLE in 
eosinophils. The finding of elastase in cells other than PMNs is unexpected, but 
would serve to explain why more elastase may be isolated from splenic tissue than is 
commensurate with the number of PMNs present. 
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The in vitro activation study on PMNs and the in vivo study of the spleen, are 
the first cryoultramicrotomy studies of their kind. They are also the first studies that 
have demonstrated cathepsins G and D and elastase on the surface of activated PMNs, 
and the first to note the different effects of PMN activation with PMA at different 
levels. The reported study on endothelial stave cells was the first such study on the 
lysosomal enzyme content of endothelial stave cells and the first report of their 
possible secondary function in regulating proteinases. There would appear to be 
much promise in extending these studies. 
For the future, similar studies are planned on U937 cells, differentiated to 
become PMNs or monocytes/macrophages, and on the MCF-I0 cell lines, using a 
gelatin-agarose slide well diffusion chamber method (Wilkinson, 1986). In fact, the 
stage is set for many future studies, using cell culture. For example, using 
Wilkinson's system, it would be interesting to see what happens to the distribution of 
cathepsin D in fMLP-stimulated monocytes. Monocyte/macrophages are enigmatic 
cells in which the effects of fMLP-activation do not seem to have been studied. The 
differentiation-related differences in cathepsin D distribution have not been 
previously demonstrated in U937 cell lines. Electron microscopy studies on this and 
on the differentiation-related distribution of cathepsin B would be unique and highly 
instructive. 
In the present study, both cathepsin Band procathepsin B were demonstrated, 
in monocytes, for the first time, at the electron microscopy level. These studies were 
made difficult, however, by the relative scarcity of monocytes in peripheral blood cell 
preparations. The availability of U937 cells, which can be differentiated to the 
monocyte phenotype, will facilitate such studies and studies on peripheral blood 
monocytes could be used for result confirmation only. 
Studies on the trafficking of cathepsin B were delayed when the anti-ppB64-77 
antibody proved unsuitable for immunolabelling. This proved a set-back to planned 
studies to demonstrate the presence, or absence, of the truncated form of the precursor 
enzyme in tumour and normal cells. The prospects for useful studies on the 
differently processed forms of cathepsin B have, however, now been significantly 
improved as Dr Mach has not only supplied a better anti-mature human liver 
cathepsin B antibody than that used in this study, but has also supplied two more anti-
human cathepsin B peptide antibodies, one against a 9-residue C-terminal extension 
and the other against a 12-residue N-terminal extension of mature human liver 
cathepsin B (Mach et al., 1993). 
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These antibodies will detect an intermediate processing form, between the 
precursor and mature sequence, that is believed to be found in secretory vesicles and 
late endosomes only (Dr L. Mach, pers. comm.). Labelling with these peptide 
antibodies may help define the relative proportion of enzymes entering the secretory 
pathway, as opposed to the normal lysosome route, in normal and cancer cells. Good 
model systems for these studies will be the MCF-10, and U937 cell lines, and normal 
peripheral blood monocytes. These antibodies only became available, however, 
during the write-up stage of this thesis, when Dr Mach visited this laboratory, for a 
three-month period. 
In the question of which proteinases are involved in the invasive movement 
of invading cells, some of the most Significant results obtained here have been those 
from in vitro activation studies on isolated and activated PMN fractions. 
Chemotactically activated PMNs were shown, in this study, to exhibit movement-
related association of elastase, cathepsin G and cathepsin D with the "invasion front" 
of activated cells. All of these enzymes have now been shown to be azurophil 
granule-associated proteinases and are known to be some of the most proteolytically 
active proteinases present in PMNs. Their association with the invasion front upon 
activation seems to suggest strongly their relevance in the invasive activity of PMNs. 
MCF-7 cells have been shown to be capable of chemotactic movement and, although, 
in the present study, no strong evidence of the association of cathepsin B with the 
surface of unactivated, ras-transformed Neo-T cells has been found, similar 
movement-directed association of proteinases may occur in chemotactically activated 
Neo-T cells. Labelling may now be performed with the anti-cathepsins B, H, L and D 
antibodies and the procathepsin B antibodies optimised in the immunofluorescence 
studies on the MCF-10 cell lines. 
In future studies, it is planned to examine these cells for the association of 
proteinases with the "invasion front", in the gelatin-agarose chemotractant chamber 
of Wilkinson (1986). The migrating cells will be fixed in situ in the gelatin-agarose 
and orientated for cryoultramicrotomy and labelling, in blocks cut from the matrix. 
Activation studies on PMNs have also shown the presence of swollen 
organelles which may be related to the activation-related tubular lysosomal bodies 
that have been observed in macrophages. PMN azurophil granules are known to be 
the equivalent of lysosomes in other cells, and the presence of elastase in these 
swollen tubular structures suggests that these may be lysosome-like structures. As 
studies reported here suggest, these may be secretory bodies which may form transient 
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connections with the cell surface, integrating their membrane with the external 
surface, while emptying their contents of enzymes onto the surface of the cell in a 
non-specific fashion or in a directed fashion. This may be the mechanism by which 
surface association of proteinases occurs. Discharge of proteinases into an invasion 
"pocket" may also occur, under certain conditions of activation. 
Lysosome associated membrane proteins (LAMPS) have similarly been seen to 
be associated with the surface of more highly malignant metastatic cancer cells 
(Hefferman et al., 1989). Together these observations suggest that similar phenomena, 
as seen in PMNs, may occur in metastatic tumour cells: the non-specific fusion of 
lysosomal tubular structures with the surface of "activated" tumour cells, or the 
directed discharge of proteinases into an invasion "pocket" or association of 
proteinases with the cell surface. 
It is difficult to say whether membrane association of proteinases may be a 
generalised phenomenon in invasive cells. It does seem possible that most 
chemotactically activatable cells may follow this model. fMLP-activated macrophages 
have been shown in this study to have no membrane associated pro- or mature 
cathepsin B associated with the cell surface, but only immunolabelling for cathepsin B 
was performed. Though membrane expression of proteinases does not seem to be a 
generalised consequence of malignant transformation, tumour cells may, additionally, 
require chemotactic activation, for this to occur. 
The distribution of enzyme:-Iabelled organelles indicated by immuno-
fluorescent labelling, needs to be confirmed at the electron microscopy level, 
preferably using a new fixation protocol which will preserve the integrity of any 
tubular lysosomes present, and a labelling system which will allow a low 
magnification overview of the immunolabelling. For this purpose, it is planned to 
use Lowicryl-embedded or "cryo" sections of cells grown on membrane filters and a 
peroxidase-diaminobenzidine electron-dense detection system (Parton et al., 1991) to 
give low magnification resolution of labelled organelles. 
With regard to the original aims of this study, using the criterion of a surface 
disposition of the enzymes, it would appear that cathepsins G and D and elastase could 
playa role in the invasive action of PMNs. In activated monocyte/macrophages, and 
in ras-transformed Neo-T cells, however, none of these proteinases (including 
cathepsin B which is absent in PMNs), could be detected on the surface. This raises a 
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question as to whether, in fact, a surface disposition of proteinases is required for 
invasion, since macrophages, at least, are known to have invasive properties. 
Another model that warrants investigation, is the "extracellular lysosome" 
model, in which it is envisaged that lysosomal enzymes are secreted into an acidified 
"pocket", formed between the invading cell and the surface being invaded. 
Immunofluorescence studies on cathepsins B, H, Land D in MCF-I0 cells suggest that, 
in ras-transfected cells, organelles containing these enzymes become more 
peripherally distributed subsequent to ras transfection. This phenomenon may be an 
expression of the malignant phenotype, favouring the secretion of proteinases. The 
more peripheral distribution of lysosomal enzymes, in transformed Neo-T cells, 
compared to their normal counterparts, therefore, could be indicative of cells more 
"prepared" for exocytosis of lysosomal enzymes, and, thus potentially more invasive. 
The relative decrease in M-6-P receptors observed in Neo-T cells, suggests a 
third possibility; that proteinases may enter the default secretion pathway, due to a 
deficiency in M-6-P receptors. 
The question of which model actually applies could, perhaps, best be addressed 
by observing cells in the process of invasion and, to this end, assays of invasion 
through a basement-membrane-like substitute, called matrigel, are presently being set-
up. Fixation, embedding and labelling of this matrix, as the cells invade, should show 
- by the most direct means possible, the observation and labelling of the "invasion 
front" - how invasion is achieved and which, if any, of the proteinases are relevant in 
cancer cell invasion. It is anticipated that the defined, normal, MCF-lOA cell line and 
its Neo-T, ras-transformed, equivalent will be especially useful in these studies. 
Future studies on the trafficking of proteinases in the MCF cell lines should 
also be highly instructive. Dynamic tubular lysosomes may be relevant to the 
trafficking of proteinases and invasion process in PMNs, other leucocytes and tumour 
cells. Research into the possible presence, preservation, and function of these tubular 
structures is, therefore, considered a priority. Fixation studies aimed at ensuring the 
survival of these organelles are, therefore, planned. These would, perhaps, best be 
undertaken in PMA-activated U937 cells (monocyte phenotype), in which these 
lysosomal bodies should be present, as they have been reported to occur in PMA-
treated monocytes. 
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In retrospect, the studies reported in this thesis can be seen to have been a long 
and, at times, frustrating, climb up a fairly steep le~rning curve. Nevertheless, the 
study has been rewarding since, along the way, much has been learned of a technical 
nature and some biologically relevant findings have been made. Again, in retrospect, 
these studies can be seen to have constituted a necessary preface to future studies. 
Only now that the technical problems have been mastered, and the biological 
questions have become more focussed, can envisaged future experiments be planned 
and executed with confidence. From this vantage point, therefore, it appears that the 
most exciting phase lies yet ahead. 
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Short Technical Note 
Further modification of the LKB 7800 series KnifeMaker for 
improved reproducibility in breaking 'cryo' knives 
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SUMMARY 
This note describes further modifications to the LKB 7800 series KnifeMaker to 
improve the precision of scoring of glass strips and the consequent reproducibility of 
breaking of'cryo' knives, by largely eliminating play in the mechanism, and by accurate 
adjustment of the cutting wheel position. 
INTRODUCTION 
The principles of knifemaking for cryoultramicrotomy have been discussed by 
Griffiths et al. (1983). Without modification, our LKB 7801 B KnifeMaker was found to 
be incapable of reproducibly making knives acceptable for cryoultramicrotomy. When 
modified as suggested by Stang (1988), the performance of the KnifeMaker improved, 
but it was still unable reproducibly to cut to within 0·1 mm of the corner of a 25-mm 
square, resulting in rejection of a large proportion of the knives. 
The principal cause of the irreproducibility was the cumulative effect of a number of 
manufacturing tolerances, and/or wear, in the clamping head and cutter wheel holder 
assembly which, together, allowed the cutter to move sideways over a distance of 0·34 
mm. Clearly with this amount of play in the mechanism, cutting to within 0·1 mm of the 
corner was largely a matter of chance. This note describes modifications made to 
improve the accuracy of the mechanism, as well as other modifications, which have led 
to a marked improvement in the reproducibility of knifemaking, and a corresponding 
increase in the proportion of acceptable knives produced. 
MODIFICATIONS 
The KnifeMaker was first modified according to Stang (1988). This involved 
manufacture of the aluminium T -shaped holder, and machining of the '38' cam lobes of 
the scoring selector, to reduce the score length to 12 mm. This 12-mm score was used 
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Fig. 1. (a) Illustration of the beryllium-copper spring inserted to eliminate play between the cutter wheel 
holder bracket (LKB part No. 24-10 688) and the scoring shaft. The arrows indicate the two lines of contact 
between the spring and the scoring shaft. Note the clearance between the end of the spring and the end of the 
machined recess. (b) The holes drilled and tapped into the clamping head to accommodate grubscrews. The 
arrows indicate the position of the two holes. 
for all glass pieces, including long pieces. In addition, the following modifications were 
made. 
(a) The play between the cutter wheel and the cutter wheel holder bracket was 
eliminated by removing the cutter wheel and bending the side plates of the cutter wheel 
holder bracket inwards, by about 0 ·01 mm at a time, until only a very slight interference 
fit was perceptible between the cutter wheel and the holder bracket, which nevertheless 
still allowed free rotation of the cutter wheel. 
(b) Similarly, the play between the cutter wheel holder and the cutter wheel holder 
bracket (LKB part No. 24-10 688; originally 0·06 mm) was eliminated by bending the 
side plates towards each other, by about 0·01 mm at a time, until only a very slight 
interference fit was perceptible. 
(c) The play (originally 0·11 mm) between the cutter wheel holder bracket and the 
scoring shaft was eliminated by machining a recess 1·3 mm (deep) x 6·5 mm x 15 mm 
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into the cutter wheel holder bracket and inserting a beryllium copper spring, 0·5 mm 
thick, bent to form two lines of contact with the scoring shaft, for extra stability (Fig. 
1a). This spring must not press too firmly against the scoring shaft, or the cutter wheel 
holder bracket will not retract after leaving the cam. 
(d) The play (originally 0·06 mm) between the scoring shaft and the clamping head 
was eliminated by drilling two 2·S-mm holes, into the clamping head (Fig. 1 b), and 
tapping these with a 3-mm I.S.O. thread. Small Teflon _plugr'" were inserted into 
the holes, followed by grubscrews that were tightened to an extent which just allowed 
free travel of the scoring shaft. 
(e) The breaking pins, which apply the breaking force to the glass, were removed, 
smoothed in a lathe with fine water paper and buffed to a polished finish. 
(f) The play between the scoring shaft guide and the scoring shaft itself was 
eliminated by bending the outer 'forks' of the scoring shaft guide outwards, a small 
amount, until a slight interference fit was achieved in the scoring shaft groove. 
The angle at which the glass breaks, which should be 900 to the glass surface, is 
determined by the exact positioning of the cutter wheel scoring edge over the domed 
breaking pins. Consequently, it is necessary that the cutter wheel is accurately 
centralized and locked between the support studs to ensure that the score is directly 
over a line joining the axes of the breaking pins. The holes in the scoring shaft guide are 
larger than the screw diameters and so the position of the scoring shaft guide can be 
altered. Movement of the scoring shaft guide causes rotation of the scoring shaft and 
thus lateral displacement of the cutter wheel. The necessary adjustment can be made, 
without waste, by test breaks while cutting the glass strips into 50 x 2S-mm rectangles. 
If the cutter wheel is off-centre, the glass will not fracture at 900 to the plane of the glass. 
If this is so, the shaft guide screws may be loosened slightly, the shaft guide plate moved 
in the appropriate direction to compensate, and the screws retightened. Further test 
cuts may be made and small corrections made by loosening the shaft guide screws, 
tapping the plate left or right and retightening the screws. This procedure is repeated 
until the break in the test piece is true and vertical. When the cutter wheel is properly 
centred, the KnifeMaker will break optimal knives, with cutting edges at 900 to the 
plane of the glass. Conversely, if the cutter wheel is off-centre, the resulting knives will 
have suboptimal, out-of-square cutting edges. Proper adjustment in this respect greatly 
improves the accuracy of knife breaking. 
Accurate and reproducible positioning of the glass pieces is also important. The rear 
and front glass holders have tongues which slide in slots in the base of the KnifeMaker. 
On our KnifeMaker the clearance, between the tongues and the slots, was about 0·11 
mm, which enabled each glass holder to move left or right by about 0·08 mm, and 
this affected the reproducible positioning of the glass . The play was consequently 
eliminated, by peening the end of each slide tongue on the inner side and filing the raised 
section to a slight interference fit, using a no. 4 needle file. While this approach proved 
adequate, the same effect might be better achieved using appropriately inserted captive 
balls and springs. 
In addition to the modifications and adjustments to the KnifeMaker itself, it was 
necessary to orientate the glass strips and glass pieces in the KnifeMaker in a specific 
manner. The glass strip should be orientated on the KnifeMaker with the scored long 
edge break downwards and the clean edge break upwards. When using 2S-mm strips, 
the strip is first cut into 25 x SO-mm rectangles, marked as shown in Fig. 2(a) with a felt-
tipped pen and cut into two 2S-mm squares. The resulting squares are orientated in the 
KnifeMaker, for breaking, as shown in Fig. 2(b). It is important to check that the glass 
strips used have consistent dimensions: this was not true of glass strips from all 
manufacturers. 
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__ ~_ break line 
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Fig. 2. Orientation of glass blocks for cutting 45° knives, from a 25-mm strip. (a) Marks are made on the glass 
rectangle as shown, using a felt-tipped pen, before it is cut into 25-mm squares. (b) The 25-mm squares are 
orientated as shown, before being broken into knives. 
CONCL USIONS 
Analysis of the performance of an LKB 7800 series KnifeMaker revealed that its 
random failure was largely due to an accumulation of manufacturing tolerances, and of 
wear in the mechanism. After the play was eliminated it was still necessary to adjust the 
cutter wheel position accurately in order to obtain acceptable knives. With the 
modifications and adjustments outlined above, the number of acceptable knives that 
could be obtained from one strip of glass was improved by at least 100% . 
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FIXATION AND POST-LABELLING PROCEDURES FOR IMPROVEMENT OF TISSUE 
STRUCTURE FOR ENZY'ME IMMUNOLOCALISATION FOR 
CRYOULTRAMICROTOMY 
E. Elliott and C. Dennison 
Department of Biochemistry, University of Natal, Pietermaritzburg 
The choice of fixative, and fixation conditions, for immunocytochemistry, must primarily 
be aimed at preservation of antibody-antigen recognition reactions. Tissue integrity, though 
of secondary importance, must also be adequately preserved. Fixation must allow definition 
of organelles and prevent target antigen extraction or translocation. With labile antigens 
such as the enzymes in human leucocytes and spleen, the fixative which met these criteria 
most successfully, consisted of a high concentration of para formaldehyde (8% v/v), used at pH 
8,0 and for short times (15 min). Paraformaldehyde (8%), in combination with post-labelling 
lipid-stabilizing procedures!, considerably improved tissue structure and antigen retention. 
Human splenic tissue (2 x 2 mm) and Ficoll-Hypaque® gradient fractionated human 
polymorphonuclear leucocytes (PMNs) and macrophages, were fixed in either 0,1%, 0,2%, 
0,5%, or 1% glutaraldehyde (15 min, RT), in 8% paraformaldehyde (pH 7,2), or 4% 
paraformaldehyde (pH 7,2) (5 min, RT) followed by 8% paraformaldehyde (pH 7,2) or 8% 
paraformaldehyde (pH 8,0) (15 min, RT) (all vlv, in either O,lM sodium cacodylate or 0,2M 
HEPES). Specimens were washed, cryoprotected, mounted on a copper stub and frozen in 
liquid nitrogen2• Ultrathin sections were cut using tungsten-coated glass knives, using an 
RMC-MT-600XL ultramicrotome fitted with a CR-200 cryo-attachment. Sections were 
immunolabelled for the enzymes, elastase, myeloperoxidase and cathepsins Band D, and for 
lactoferrin2, using a goat anti-rabbit (30nm) or a protein A gold probe (4nm). Controls 
included omitting the primary antibody, substituting pre-immune serum or IgG at the same 
concentration as the test, and the substitution of pre-adsorbed sera or IgG. After labelling, 
the section was either directly contrasted by a "positive-negative" contrast procedure using 
uranyl acetate and methyl cellulose2, or post-fixed with 1% glutaraldehyde or with neutral 
uranyl acetate, followed by the "positive-negative" contrasting procedure. 
Fixation with any concentration of glutaraldehyde resulted in a marked decrease or 
extinction in immunolabelling for elastase. Fixation with 8% paraformaldehyde (pH 8,0) 
followed by neutral uranyl acetate treatment, before the "positive-negative" contrasting 
procedure, resulted in the best preservation of u ltrastructure and general antigenicity, and 
retention of antigen in situ (figs 4 and 5). Ultrastructural detail was found to be enhanced 
in the latter, slightly thicker sections (approx. 200nm). Less extraction of cytosolic 
constituents was evident in tissues fixed in fixatives in HEPES buffers (figs 2, 3, 4, 5 and 6) 
as compared to those fixed in cacodylate buffers (fig. 1). The occurrence of aldehyde fixation 
artefacts, such as "blebs" and vesiculation (fig. 6) was also found to be reduced by post-
labelling lipid-stabilisation by neutral uranyl acetate, or further glutaraldehyde fixation. 
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Fig 1. A PMN fixed (15 min, RT) in 8% paraformaldehyde (in 0,1m sodium cacodylate, pH 
7,2) and labelled for elastase. Note decreased cytosolic density (arrows). 
Fig 2. PMN fixed (15 min, RT) in 8% paraformaldehyde (in HEPES, pH 7,2) and labelled for 
elastase (without post-fixation). Note poor preservation of ultrastructure. 
Fig 3. PMN fixed (5 and 10 min, respectively) in 4% paraformaldehyde followed by 8% 
paraformaldehyde (in HEPES, pH 7,4) and fixed post-labelling with 1% 
glutaraldehyde. Note translocation of elastase antigen (arrows). 
Fig 4.& 5. 
Activated macrophage fixed (15 min, RT) in 8% paraformaldehyde (in HEPES, pH 8,0) 
post-fixed with neutral uranyl acetate, labelled for pro-cathepsin B. Note improved 
organelle membrane definition. G = Golgi. 
Fig 6. Human spleen fixed (15 min, RT) in 8% paraformaldehyde (in HEPES buffer, pH 8,0) 
without post-fixation. Note marked membrane "blebbing" artefacts (arrows). 
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POSSIBLE SECONDARY FUNCTION OF SPLENIC ENDOTHELIAL STAVE CELLS 
REVEALED BY IMMUNOLABELLING STUDIES 
E. Elliott, P .H. Fortgens and C. Dennison 
Department of Biochemistry, University of Natal, Pietermaritzburg 
The reticular meshwork of the cord cells and the phagocytic macrophages in the sinuses 
of the red pulp of the spleen (fig. 1), are thought to be responsible for the removal of aged 
erythrocytes from the blood. Phagocytosis, and hence removal of ageing, more rigid, 
erythrocytes may be f~voured by prolonged exposure to the high concentrations of hydrolytic 
enzymes in extracellular fluids in the sinuses l . Such exposure may lead to the observed loss 
of sialic acid residues and the exposure of galactose sugars on outer membranes of ageing 
cells, possibly leading to phagocytosis by phagocytic cells l . In the present study, 
immunolabelling of human splenic tissue for elastase and cathepsin D has revealed that 
regulation of the levels of extracellular hydrolytic enzymes may be achieved by pinocytosis 
by splenic endothelial stave cells. 
Human spleen (2 x 2 mm) was fixed in 8% paraformaldehyde in 0,1 M sodium cacodylate 
(pH 8,0, 20 min), cyroprotected by infusion with 2,1 M sucrose (30 min), mounted on a copper 
stub and frozen in liquid nitrogen2• Sections were double immunolabelled for elastase and 
cathepsin Dusing 3 nm and 10 nm protein A gold probes. Control labellings consisted of 
omitting the primary antibody, substituting pre-immune or pre-adsorbed serum or IgG at the 
same concentration as the test, and performing labellings for one antigen at a time (single 
labelling). After labelling, sections were contrasted by a "positive-negative" contrast 
procedure, using uranyl acetate and methyl cellulose2• 
Cathepsin D has not previously been localised in neutrophils by immunocytochemistry. 
The present labelling indicates that cathepsin D is present at a concentration approximately 
ten fold lower than that of the enzyme elastase, and is co-localised with elastase in the 
azurophil granules ofneutrophils (figs 2 and 3). This concurs with biochemical findings. The 
presence of elastase and cathepsin D, in some pinocytotic vesicles of endothelial stave cells, 
adjacent to stimulated neutrophils (fig. 3), suggests the co-secretion of these enzymes by 
neutrophils and simultaneous uptake by endothelial stave cells. The smaller stave cell 
vesicles, are probably pinocytotic vesicles (figs 2 and 3), due to their size, relatively low 
cathepsin D content (non-lysosomal nature), and, in the absence ofneutrophils, their usually 
low content of the enzyme elastase. The relatively high content of cathepsin D (usually a 
lysosomal marker enzyme) in larger stave cell vesicles, present adjacent to the pinocytotic 
vesicles, indicate that the larger organelles are possibly lysosomes. The uptake of enzymes 
and hence regulation of the level of enzyme concentration in extracellular fluids in the 
splenic sinuses, by pinocytosis, may be a mechanism by which endothelial cells may perform 
a secondary function , the control of levels of extracellular enzymes. 
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Fig 1. An area of red pulp from a human spleen showing endothelial stave cells (e), 
macrophages (m), basement membrane (arrows), sinuses (s) and neutrophils (n). 
Fig 2. Enlargement of vesicle populations seen in the section of the endothelial stave cell 
(lower right, fig. 3 below). The smaller, pinocytotic vesicles contain mainly elastase 
(3 nm gold label, small arrow), while larger vesicles (lysosomes) contain only 
cathepsin D (10 nm gold label, large arrow). 
Fig 3. Neutrophil (Nu) and adjacent endothelial stave cell (e) labelled for cathepsin D (10 
nm gold label, large arrow) and elastase (3 nm gold probe, small arrow). Note 
pinocytotic vesicles (open arrow head) and lysosomal compartments (medium arrow) 
and co-localisation of elastase and cathepsin Din azurophil granules ofNu and some 
pinocytotic vesicles (double arrow head). 
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Anti-peptide antibodies to cathepsins B, Land D 
and type IV collagenase 
Specific recognition and inhibition of the enzymes 
Theresa H.T. Coetzer, Edith Elliott, Philip H. Fortgens, Robert N. Pike and Clive Dennison 
Deparrmenr of Biochemisrry, Universiry of Naral, P.O.Box 375, Pierermarirzburg 3200, Republic of Sourh Africa 
(Received 20 July 1990. revised received 19 September 1990. accepted 15 October 1990) 
Anti-peptide antibodies were raised against synthetic peptides selected from the sequences of human 
cathepsins B and L, porcine cathepsin D and human type IV collagenase. Sequences were selected from 
the active site clefts of the cathepsins in the expectation that these would elicit immunoinhibitory 
antibodies. In the case of type IV collagenase a sequence unique to this metalloproteinase subclass and 
suitable for immunoaffinity purification, was chosen. Antibodies against the chosen cathepsin B sequence 
were able to recognize the peptide but were apparently unable to recognise the whole enzyme. Antibodies 
against the chosen cathepsin L sequence were found to recognise and inhibit the native enzyme and were 
also able to discriminate between denatured cathepsins Land B on Western blots. Antibodies against the 
chosen cathepsin D sequence recognised native cathepsin D in a competition ELISA, but did not inhibit 
the enzyme. Native type IV collagenase was purified from human leukocytes by immuno-affinity 
purification with the corresponding anti-peptide antibodies. 
Key words: Anti-peptide antibody; Cathepsins B, L, D; Type IV collagenase; Immunoinhibition 
Introduction 
Cathepsins B, Land D and type IV collagenase 
have been implicated in tumour invasion and 
Correspondence to: C. Dennison, Department of Biochem-
istry, University of Natal, P.O. Box 375, Pieterrnaritzburg 
3200, Republic of South Africa. 
Abbreviations: ABTS, 2,2' -azino-di(3-ethyl)-benzthiozoline 
sulphonic acid; BSA, bovine serum albumin; ELISA, enzyme-
linked immunosorbent assay; HRPO, horseradish peroxidase; 
KLH, keyhole limpet haemocyanin ; MBS, m-maleirnidoben-
zoic acid N-hydroxysuccinimide ester; M" relative molecular 
weight; NHMec, 7-(4-methyl)coumarylamide; PBS, phosphate-
buffered saline; SBT!, soybean trypsin inhibitor; SDS-PAGE, 
sodium dodecyl sulphate polyacrylamide gel electrophoresis; 
TBS, Tris-buffered saline; Z-, benzyloxycarbonyl. 
metastasis (Liotta et aI., 1980; Sloane and Honn, 
1984; Denhardt et aI., 1987; Spyratos et al. , 1989). 
The role of these enzymes in tumour invasion may 
be explored using specific antibodies and in this 
context anti-peptide antibodies (Briand et aI. , 
1985) have many advantages. A sequence of ten or 
more amino acids has a very high probability of 
being unique to a particular protein and the corre-
sponding anti-peptide antibody is, therefore, also 
likely to . allow highly specific detection of the 
protein. Moreover, for immunocytochemistry, for 
example, with polyclonal anti-peptide antibodies 
against a linear peptide sequence, there is an in-
trinsically lower probability of the epitope(s) being 
destroyed during tissue processing, than in the 
case of a monoclonal antibody which may be 
targeted at a single, labile, discontinuous epitope. 
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The utility of anti-peptide antibodies may be 
increased if these are additionally able to inhibit 
enzymic activity. In the case of the cysteine 
cathepsins, B, Hand L, for example, inhibiting 
anti-peptide antibodies might constitute tools with 
a unique ability to discriminate between these 
enzymes, and might thus aid in their identifica-
tion. I t has also been suggested (Dennison, 1989) 
that inhibiting anti-proteinase anti-peptide anti-
bodies might be therapeutically useful. 
To raise anti-peptide antibodies against the 
cathepsins, peptide sequences were selected from 
their primary sequences, mainly by consideration 
of their 3-dimensional structure, but also with 
reference to the mobility and hydrophilicity of the 
chosen peptide sequence. The cathepsins are in-
volved in antigen processing (Takahashi et al., 
1989; Van Noort and Van der Drift, 1989) and 
consequently may be regarded as integral parts of 
the immune system. The question thus arises as to 
whether there is any prejudice against production 
of anti-peptide antibodies to these proteinases, 
especially against their conserved sequences. As a 
basis for comparison, therefore, anti-peptide anti-
bodies were also raised against a sequence in a 
non-lysosomal proteinase, type IV collagenase, 
similar to that previously shown to successfully 
elicit anti-peptide antibodies (Hoyhtya et aI., 
1988). We report here our observations on raising 
antibodies to the selected pep tides and on the 
effectiveness of the resulting antibodies in binding 
to, and inhibiting, the target enzymes. 
Materials and methods 
Reagents 
KLH and MBS were obtained from Sigma. 
Glutaraldehyde .(E.M. grade) and cyanogen 
bromide were from Merck and ABTS was from 
Boehringer Mannheim. Human liver cathepsin B 
was a gift from Dr. D. Buttle, Strangeways 
Laboratory, Cambridge, U.K. Sheeps' liver 
cathepsin L was isolated by a modification of the 
method of Pike and Dennison (1989); chromatog-
raphy on S-Sepharose, at pH 4.5, being sub-
stituted by chromatography on Sephadex G-75. 
Human spleen cathepsin L was similarly isolated, 
though in the form of a complex with cystatin, in 
a study to be reported elsewhere. Human kidney 
cathepsin L was purchased from Novabiochem, 
U.K. Cathepsin D was isolated from human, 
porcine and bovine spleens by the method of 
Jacobs et al. (1989). Type IV collagenase was 
purified from human leukocytes by immunoaffin-
ity chromatography with the anti-peptide anti-
body imrnobilised on CNBr-activated Sepharose 
4B. Z-Phe-Arg-NHMec and Z-Arg-Arg-NHMec 
were obtained from Cambridge Research Bio-
chemicals. 
Selection of pep tides 
The peptide sequences from cathepsins B and L 
(Table I) were selected by considerations of 3-di-
mensional structure, based on a published struc-
ture of the analogous enzyme, papain (W olthers et 
aI., 1970). The 3-dimensional structures of 
cathepsins B, Hand L have been deduced, from 
amino acid sequence information, to be compara-
ble to that of papain (Kamphuis et at, 1985; 
Dufour, 1988). 
The sequence selected for cathepsin B, corre-
sponds to residues 13-22 in the structure of hu-
man liver cathepsin B (Turk et aI., 1986). This 
sequence is in an accessible position, at one end of 
the substrate-binding cleft of the enzyme (Wolthers 
TABLE I 
THE PEPTIDE SEQUENCES SELECTED FOR THE GEN-
ERATION OF ANTI-PEPTIDE ANTIBODIES, FROM THE 
AMINO ACID SEQUENCES OF THE PROTEINASES IN-
DICATED 
Peptide Sequence Corresponding 
proteinase 
B13-22 Q-C-P-T-I-K-E-I-R-D Human 
(+C) a cathepsin B 
Ll53-165 E-P-D-C-S-S-E-D-M- Human 
O-H-G-V cathepsin L 
D1l2-122 T-K-Q-P-G-L-T-F-I- Porcine 
A-A (+C) cathepsin D 
COlA76- 490 M-G-P-L-L-V-A-T-F- Human 
W-P-E-L-P-E collagenase IV 
a The selected pep tides were modified for synthesis by the 
substitution of the cysteine residues in peptides B13-22 and 
Ll53-165 with a-amino butyric acid and by the addition of an 
extra cysteine residue to the C tennini of B13-22 and D1l2-122 
respectively, in addition to the acetylation of the N tenninus of 
B13-22 and amidation of the C terminus of Ll53-165. 
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Fig. 1. Hydrophilicity and segmental mobility profiles of the selected peptides . • , hydrophilicity, calculated according to Hopp and 
Woods (1981,1983); 0, segmental mobility, calculated according to Westhof et aL, (1986). Profiles indicated are for the peptides: (a) 
B13-22; (b) L153-165; (c) D112-122; and (d) COL476-490. 
et aL, 1970). It also corresponds to a peak of both 
hydrophilicity (Hopp and Woods, 1981, 1983) and 
segmental mobility (Westhof et aI. , 1984) (Fig. 
10). 
A sequence different from that for cathepsin B 
was chosen for cathepsin L, to potentially maxi-
mise the information gained from the experiments. 
Also, the region chosen for cathepsin B is not a 
suitable choice for human cathepsin L since the 
human cathepsins Land H have analogous se-
quences in this region, with seven out of 'the 11 
amino acids being similar or identical (Ritonja et 
al., 1988). There is thus an increased probability 
that an anti-peptide antibody to the sequence in 
cathepsin L may cross-react with cathepsin H. 
By contrast, the loop of amino acids containing 
the active site histidine is also accessible (Wolthers 
et al., 1970), and there are marked differences in 
the sequences in this region between the different 
cysteine cathepsins. The presence of the active-site 
histidine in this sequence was also thought to 
increase the probability that antibodies targeting 
this region might be inhibitory. The chosen se-
quence corresponds to residues 153-165 in the 
amino acid sequence of human cathepsin L 
(Ritonja et aI., 1988); in papain the comparable 
residues are 150- 161. The sequence is largely hy-
drophilic but has a cluster of hydrophobic re-
sidues towards its C terminus (Fig. Ib). The 
L153-165 sequence is also relatively conserved 
between species and may be expressed as Glu-Pro-
Asx-Cys-Ser-Ser-A-Asx-B-Asp-His-Gly-V al, where 
Asx is either Asp or Asn, A is Glu or Lys and B is 
Met or Leu (Dufour et al., 1987; Ishidoh et 
al.,1987; Ritonja et aL, 1988). An additional crite-
rion in its selection, therefore, was its potential to 
target cathepsin L across species. 
The sequence chosen for cathepsin D (Table I) 
was based on the 3-dimensional structure of a 
related aspartic proteinase, penicillinopepsin (Hsu 
et al., 1977), since no 3-dimensional structure of 
cathepsin D ' has been published. The sequence 
corresponds to residues 1l2-122 in porcine 
cathepsin D (Faust et al., 1985), and corresponds 
to a loop on the rim of the substrate-binding 
groove of penicillinopepsin. It has low hydro-
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philicity and mobility (Fig. 1c) and differs from 
human cathepsin 0 in a single. conservative, sub-
stitution of leucine for isoleucine at position 117 
(Faust et a!., 1985). 
The sequence chosen for human type IV col-
lagenase (Table I) is based on the sequence of a 
CNBr-generated fragment of this enzyme from 
human melanoma A2058 cells (CB4 peptide), re-
ported by Hoyhtya et a!. (1988) to elicit antibodies 
which bind only to type IV collagenase and not to 
related, secreted, extracellular matrix metallopro-
teinases, such as interstitial collagenase and 
stromelysin. The sequence corresponds to residues 
476-490 in human type IV procollagenase (Collier 
et a!., 1988) and is hydrophilic towards its C 
terminus and mobile in its centre (Fig. 1d). In the 
present study the C terminal Lys was omitted 
from the CB4 peptide to ensure that glutaralde-
hyde conjugation was effected exclusively through 
the N terminus, thereby exposing the hydrophilic 
part of the peptide. 
Synthesis of peptides 
The selected pep tides were modified, before 
synthesis, by the substitution of the cysteine re-
sidues in pep tides B13-22 and Ll53-165 with 
a-amino butyric acid and by the addition of an 
extra cysteine residue to the C-termini of B13-22 
and 0112-122 respectively. The resulting pep tides 
were custom synthesised by Multiple Peptide Sys-
tems, San Diego, CA. 
Conjugation 
All four pep tides were conjugated to KLH, 
using two different conjugation methods. Pep tides 
B13-22 and 0112-122 were conjugated, through 
their C termini to KLH, using MBS (Robertson 
and Liu, 1988). The maleirnide content of KLH-
MBS was determined by the addition of 
mercaptoethanol and subsequent assay for re-
duced thiol content (Kitagawa and Aikawa, 1976). 
Due to their solubility differences, it was neces-
sary to treat B13-22 and 0112-122 differently. 
B13-22 was dissolved in 200 mM sodium phos-
phate buffer, pH 8.0, and 0112-122 was dissolved 
in the same buffer, but containing 8 M urea, 
before reduction and conjugation. The method of 
Sedlak: and Lindsay (1968) was used to determine 
the peptide reduction. Pep tides Ll53-165 and 
COL476-490 were conjugated to KLH, through 
TABLE II 
INOCULATION PROTOCOL 
Week Freund's Site Dose 
adjuvant 
o Complete s.c. a 200 p.g conjugated peptide 
2 Incomplete s.c. 200 p.g conjugated peptide 
3 Bleed 
6 Incomplete s.c. 200 p.g conjugated peptide 
8 Bleed 
10 Incomplete s.c. 200 p.g conjugated peptide or 
i.v. b 1 mg free peptide 
12 Bleed 
Monthly boosters as indicated for 10 weeks 
a s.c. = subcutaneous injection on the back at each of five sites. 
b i.v. = intravenous in marginal ear vein. 
their N termini, using 1 % (v /v) glutaraldehyde, 
according to Briand et al. (1985). A carrier pro-
tein-to-peptide ratio of 1 : 40 was used. 
Inoculation protocol 
For each peptide two rabbits were inoculated 
with peptide conjugate according to the protocols 
summarized in Table II . For comparison the pro-
tocol of Richardson et a!. (1985) was followed, in 
which conjugate was replaced by free peptide from 
week 10. B13-22 was only subjected to the latter 
protocol. 
ELISA for anti-peptide antibodies 
Wells of micro titre plates (Nunc Immunoplate) 
were coated overnight at room temperature with 
peptide solution in PBS, pH 7.2, at 5 J,Lg/ml 
(B13-22 and Ll53-165), 0.5 J,Lg/ ml (0112-122) 
and 1 J,Lg/ ml (COL476-490). Wells were blocked 
with 0.5% BSA in PBS for 1 h at 37°C and washed 
3 X with 0.1% Tween 20 in PBS (PBS-Tween). 
Dilutions of the primary antiserum in 0.5% BSA-
PBS were then added, incubated at 37°C for 2 h, 
and excess antiserum was again washed out 3 X 
with PBS-Tween. A 1/200 dilution of sheep anti-
rabbit IgG-horseradish peroxidase conjugate, in 
0.5% BSA-PBS, was added and incubated for 30 
min at 37°C. The ABTS substrate (0.05% in 150 
mM citrate-phosphate buffer, pH 5.0, containing 
0.0015% H 20 2 ) was added and incubated for 15 
min. The enzyme reaction was stopped by the 
addition of 0.1 % NaN) in citrate-phosphate buffer 
and the absorbance was read at 405 nm m a 
Bio-Tek EL307 ELISA plate reader. 
ELISA for immobili::ed en::rme 
The ability of anti-peptide antibodies to cross-
react with the respective whole enzymes (not nec-
essarily in their native form) was measured by 
coating the wells of microtitre plates with either 
cathepsin B or L (5 fLg/ rnl and 1 fLg/ rnl. respec-
tively, in 50 mM carbonate buffer. pH 6.0, for 3 h 
at 37°C, followed by overnight at 4°C) or cathep-
sin D (2 fLg/ rnl in PBS, pH 7.2. overnight at room 
temperature). The remainder of the procedure was 
as outlined above except that IgG was purified 
from serum, by the method of Polson et aL (1964), 
to remove serum inhibitors of the enzymes (e.g. 
cystatin). Species cross-reactivity of anti-peptide 
antibodies was measured using the same ELISA 
by coating with cathepsins purified from various 
sources. 
Competition ELISA for native enzyme 
The binding of the anti-peptide antibodies to 
the native cathepsins was tested in an ELISA in 
which free enzyme was permitted to compete with 
immobilized peptide for binding to the antibody 
and thus prevent a fraction of the antibody from 
being immobilized. Microtitre plates were coated 
with peptide as described above. Various amounts 
of antibody (between 10 and 450 fLg/ rnl IgG) 
were pre-incubated at 37°C for 30 min with differ-
ent levels of enzyme (molar ratios of peptide-to-
enzyme from 1: 24 to 1 : 0.5), before the incuba-
tion mixture was transferred to the peptide coated 
wells. After a further 1 h incubation at 37°C, the 
ELISA was developed as described above. 
Removal of anti-KLH antibodies 
KLH was coupled to cyanogen bromide 
activated Sepharose-4B according to Kohn and 
Wilchek (1982). Anti-KLH antibodies were re-
moved from immunoglobulin fractions, purified 
from serum according to Polson et aL (1964), by 
passage through KLH-Sepharose. 
Immunoblotting 
. The different enzymes were subjected to reduc-
mg SDS-PAGE (Laemmli, 1970), before transfer 
203 
to nitrocellulose membranes (Schleicher and 
SchulL BA 85.0.45 fLm) essentially as described by 
Towbin et al. (1979). Following electro-blotting 
for 16 h. the nitrocellulose membrane was air 
dried for 1.5 h and non-specific binding sites were 
blocked with low-fat dried milk powder (5 % in 
TBS) for 1 h. After this. and at all subsequent 
steps. the membrane was washed (3 X 5 min) with 
TBS. Anti-peptide antibodies, from which anti-
KLH antibodies had been removed. were diluted 
in 0.5 % BSA-TBS and incubated with the mem-
brane (2 h), followed by sheep anti-rabbit IgG-
HRPO conjugate (1 h). All incubation steps were 
carried out at room temperature. The HRPO reac-
tion was detected with 0.06% 4-chloro-l-naphthol 
in TBS, containing 0.0015 % H 20 2 • The reaction 
was stopped by rinsing in TBS containing 0.1% 
NaN). Targeting of sheep and human cathepsin L 
by anti-L153- 165 antibodies was also visualised 
by protein A-gold labelling with silver amplifica-
tion (Moeremans et aL, 1984). 
Immunoinhibition assays 
Assays for the immunoinhibition of cathepsins 
Band L were carried out using the substrates 
Z-Arg-Arg-NHMec and Z-Phe-Arg-NHMec, re-
spectively, as described by Barrett and Kirschke 
(1981 ). Cathepsin B (250 ng) or cathepsin L (25 
ng) were incubated at 30°C for 15 min with anti-
peptide IgG, or normal rabbit IgG, at the ap-
propriate concentration in 400 mM Na-phosphate 
buffer, pH 6.0, containing 1 mM EDTA and 0.1 % 
Tween 20. Assays against the Z-Phe-Arg-NHMec 
substrate revealed that the IgG fractions had in-
trinsic activity against this substrate, which is 
probably attributable to contaminating plasma 
kallikrein which cleaves this substrate (Barrett and 
Kirschke, 1981). This activity was controlled by 
the addition of 40 fLg/ rnl of SBTI, and by sub-
t~acting the residual activity in the antibody frac-
tIOns from the measured cathepsin L activity. SBTI 
i~bits kallikrein but not cathepsin L Stopped 
hme assays were carried out over the range of IgG 
c0n.cent~ations, and the inhibition by anti-peptide 
antlbodies was calculated in comparison to nor-
mal rabbit IgG. Immunoinhibition of cathepsin D 
was carried out using acid denatured hemoglobin 




Anti-peptide antibody production 
All four peptide conjugates elicited antibodies, 
which reacted with the corresponding immobilized 
pep tides in an ELISA (Fig_ 2)_ In each case_ it 
appears that the antibody titer peaked at about 
8- 12 weeks_ No significant difference could be 
observed in titer obtained with the two inocula-
tion protocols (using conjugate throughout or 
changing to free peptide after 10 weeks) when 
tested against immobilized peptide_ Anti-B13-22 
antibodies showed a decline after 12 weeks, but 
this could not be attributed to changing to inocu-
lation with free peptide since anti-D112-122 anti-
bodies, for instance, showed a similar decline in 
titer after 8 weeks with both inoculation protocols_ 
Recognition of enzymes coated to ELISA plates 
The anti-B13-22 antibodies, although able to 
recognize the peptide B13-22, were unable to 
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plate at pH 6_0. 7.2 or pH 9_6 (results not shown). 
By contrast. anti-L153-165 antibodies were able 
to recognize both human and sheep cathepsin L. 
immobilised on ELISA plates (Fig_ 3a)_ They 
apparently reacted more strongly with the sheep 
than the human enzyme, from which the peptide 
sequence was selected, but this may merely be a 
concentration phenomenon _ Human spleen 
cathepsin L, used in this test, was complexed to 
cystatin and the measured protein concentration 
was therefore not a true reflection of the amount 
of cathepsin L present per se_ Anti-porcine 
cathepsin D, was able to recognize whole human, 
porcine and bovine cathepsin D enzymes, im-
mobilised on an ELISA plate (Fig_ 4)_ The peptide 
antibodies, raised against D112-122 (a sequence 
from porcine cathepsin D), apparently reacted 
better with human than with porcine or bovine 
cathepsins D_ In the region corresponding to the 
chosen peptide, the human cathepsin D sequence 
shows a single substitution of leucine for iso-




















-4 .5 -3 .5 -2 .5 - 1.5 -0 .5 
-log(Antiserum dilution) 
Fig_ 2_ Progress of immunisation with peptide conjugates as determined by ELISA_ .Peptides were c~ated to ~crotitre plates, (a) 
B13-22; (b) Ll53-165; (c) D112-122; and (d) COL467-490 and incubated with ~enal two-fold dilutIOns Of. antIs~ra collected. after 
3 (_ ), 8 (0), 12 (.:.), 30 (.A.) and 32 weeks (x). Normal rabbit serum control (0). This was followed by mc~batIon With .HRPO- hnked 
secondary antibody and ABTS as a chromogenic substrate, as described under materials and methods sectIon. Each pomt IS the mean 
absorbance at 405 nm of duplicate samples. 
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Fig. 3. ELISA of binding of anti-peptide antibodies to whole immobilised cathepsin L. Cross-reaction of anti-L153- 165 antibodies 
with human (+ ) and sheep (.c.) cathepsin L. and peptide L153-165 (.). Normal rabbit JgG (0). Experimental procedure as in Fig. 2 
and in the materials and methods section. (a) anti-L153- 165 antibodies elicited by use of conjugated peptide throughout. (b) 
anti-L153-165 antibodies elicited by use of conjugated peptide followed by free peptide in the inoculation procedure. 
enzyme, and it may be inferred from the results 
that the bovine enzyme must also be very similar 
in this region. Due to the lack of sufficient en-
zyme, the anti-COL476-490 antibodies could not 
be tested against the collagenase IV enzyme, in an 
ELISA. 
Although antibodies raised using the two dif-
ferent immunisation protocols apparently had the 
same titer against immobilised peptide, a clear 
difference was sometimes seen in their ability to 
target the immobilised whole enzyme. In the case 
of anti-Ll53-165 peptide antibodies, for example, 
where conjugate was used throughout, the result-
ing antibodies cross-reacted with the whole pro-
tein to a much higher degree (Fig. 3). This phe-
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Fig. 4. ELISA of binding of anti-peptide antibodies to whole 
immobilised cathepsin D. Cross-reaction of anti-D1l2-122 
antibodies with human (+). porcine (.c.) and bovine (.6.) 
cathepsin D. and peptide DIl2- 122 (0). Normal rabbit JgG 
(0). Experimental procedure as in Fig. 2 and in the materials 
and methods section. 
D (result not shown). Anti Bl3- 22 antibodies, 
tested against whole cathepsin B, did not give a 
positive reaction at any stage, including at 8 weeks, 
before the switch to free peptide. 
Specificity of anti-peptide antibodies: Western blot 
analyses 
In Western blot analyses it was found that a 
more specific reaction was obtained if anti-KLH 
antibodies were removed by passage through a 
column containing immobilised KLH. Anti-Ll53-
165 antibodies targeted human cathepsin L to a 
much higher degree than the sheep enzyme and 
protein A-gold labelling with silver amplification 
was required to show the targeting of sheep 
cathepsin L (Fig 5A). The specificity of this target-
ing was evidenced by the fact that there was no 
cross-reactivity with human cathepsin B. Anti-
Bl3-22 and Dll2- 122 antibodies did not show 
any reaction with the corresponding enzymes on a 
Western blot (result not shown). The anti-
COL476- 490 antibodies detected a Mr 66,000 
band of type IV collagenase purified from human 
leukocytes (Fig. 5B). 
Recognition of native enzymes 
Anti-Bl3-22 antibodies did not interact with 
the native form of cathepsin B when tested in a 
competition ELISA and immunoinhibition assays, 
all at pH 6.0 (results not shown). Cathepsin D 
inhibited the binding of anti-D112- l22 antibodies 
(250 J..tg/ml) to the peptide coated to multi titer 
plates, in a dose-dependent manner, up to 60% at 
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Fig. 5. Targeting of cathepsin L and typo! IV collagenase by 
anti-peptide antibodies on Western blots. A: samples «1) 
sheep cathepsin L; (2) human cathepsin L: (3) human cathep-
sin B) were subjected to 12.5% reducing SDS-PAGE, electro-
blotted onto nitrocellulose and then incubated with anti-
KLH-purified anti-L153-165 IgG. before developing with (a) 
protein A-gold with silver amplification or. (b) sheep anti-rab-
bit-HRPO conjugate as described in the materials and methods 
section. B: human type IV collagenase was electrophoresed on 
a 7.5% SDS-polyacrylamide gel with reduction. transferred to 
nitrocellulose and immunologically stained with anti-KLH-
purified anti-COL476-490 IgG as described in the materials 
and methods section. 
446 fLg/ml (Fig. 6) , suggesting that the antibody 
recognizes the native enzyme. Because of the rela-
tively high concentrations of enzyme required for 
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Fig. 6. Competition ELISA for native cathepsin D. The ability 
of cathepsin D to inhibit the binding of anti-D1l2-122 anti-
bodies to immobilised DIl2-122 was measured by pre-in-
cubating various amounts of IgG with different levels of en-
zyme befofe transfer of the incubation mixture to peptide 
coated plates. The ELISA was de"eloped as in the materials 
and methods section. The percentage inhibition was calculated 
from control incubations containing either normal rabbit IgG 
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Fig. 7. Immunoinhibition of human and sheep cathepsin L by 
anti-L153-165 antibodies. Stopped time assays were carried 
out using human (0) and sheep (.:.) cathepsin L as described in 
the materials and methods section and the percentage inhibi-
tion calculated relative to control assays with normal rabbit 
IgG. 
this assay. cathepsin L and type IV collagenase 
were not included in these tests. Cathepsin D 
activity was, however, not inhibited by anti-
DI12-I22 antibodies m the enzyme Im-
munoinhibition test. 
An indication that anti-COL476-490 antibod-
ies bind to native type IV collagenase is given by 
their effectiveness in irnmunoaffinity purification 
of the enzyme. Type IV collagenase thus purified 
from human leukocytes showed gelatinolytic activ-
ity on a gelatin zymogram (result not shown). 
The LlS3-I65 antibodies almost completely in-
hibited human cathepsin L at high antibody con-
centrations and inhibition decreased with decreas-
ing antibody concentration until a plateau was 
reached at low antibody concentration (Fig. 7). 
Sheep liver cathepsin L was also inhibited, but to 
a lesser extent than the human enzyme. These 
results therefore show that the antibody was able 
to bind to and inhibit native human and sheep 
cathepsin L. Anti-LlS3-16S antibodies did not 
inhibit cathepsin B (results not shown), showing 
the specificity of this immunoinhibition for 
cathepsin L. 
Discussion 
The failure of the anti-B13-22 peptide antibod-
ies to recognize whole human cathepsin B was not 
expected since the peptide corresponds to peaks of 
both hydrophilicity and mobility in the sequence 
of cathepsin B (Fig. 1 a) and. from a consideration 
of the 3-dimensional structure of papain. it would 
also appear to be on the surface of the molecule. It 
has been reported that, in general. segmental mo-
bility is an important criterion for the recognition 
of the native protein by anti-peptide antibodies 
(Van Regenmortel. 1988a). This does not appear 
to hold for the peptide B13- 22. and it may be 
speculated that the presence of a disulfide bridge 
might, perhaps. constrain the peptide in a particu-
lar way in the native protein. There is thus an 
apparent conflict between the high mobility value 
assigned to Cys-14, by Westhof et al. (1984) anti-
genicity prediction profile, and its participation in 
a constrained disulfide bridge. Comparison with 
the results obtained for the cathepsin L peptide, 
L153-165, may be instructive. The peptide L153-
165 was conjugated through its N terminus, which 
is close to the Cys residue involved in a disulfide 
bridge, and in this case antibodies to the peptide 
were able to recognize the native protein. In both 
cases, the Cys residue was substituted by an (l -
amino butyric residue, but since the peptide 
L153 - 165 elicited competent antibodies, this sub-
stitution per se is probably not the reason why the 
peptide B13-22 failed to raise antibodies able to 
recognize the native enzyme. It may be interesting 
to examine the possible recognition of the native 
protein by antibodies raised against B13- 22, but 
conjugated through its Cys residue, or its N 
terminus. 
It must be noted that cathepsin B is generally a 
refractory enzyme with regard to antibody pro-
duction and normal polyclonal antibodies, raised 
against whole cathepsin B, are only able to recog-
nize denatured forms of the enzyme (Barrett, 
1973). Monoclonal antibodies against native 
cathepsin B have been reported (Wardale et aI. , 
1986). Monoclonal antibodies are produced in 
vitro, however, and it may be speculated that there 
is a prejudice against production of anti-cathepsin 
B antibodies in vivo, due to its involvement in 
antigen processing. By contrast, antibodies are 
easily raised against native cathepsin L, and it is 
interesting to note, in this regard, that Takahashi 
et al. (1989) have concluded that cathepsin B, and 
not cathepsin L, might be the major enzyme in-
volved in antigen processing. Therefore, if human 
B13- 22 shares sequence homology with its rabbit 
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counterpart, any rabbit B cell clones producing 
anti-B13- 22 antibodies capable of recognising na-
tive cathepsin B may be suppressed. 
The cathepsin L peptide. Ll53 - 165. is much 
less hydrophilic and mobile at its exposed C 
terminus. than at its N terminus (Fig. 1b), but it 
was decided to conjugate it through its N terminus 
so as to expose the active site histidine. This 
stratagem appears to have been successful in elicit-
ing anti-peptide antibodies able to inhibit native 
human and sheep cathepsin L (Fig. 7). Due to the 
specificity of this inhibition, anti-L153-165 
peptide antibodies may be useful research tools, 
since the inhibitors currently in use are unable to 
discriminate qualitatively between cathepsins B 
and L (Kirschke et aI. , 1988). Anti-Ll53- 165 anti-
bodies also discriminate very specifically between 
cathepsins Band L on Western blots (Fig. 5A), 
which suggests that they may also be useful in 
immunocytochemistry. They may also be useful as 
therapeutic agents in pathologies arising from ex-
cessive cathepsin L activity. 
A criterion in the selection of the peptide 
L153- 165 was the potential of antibodies to this 
peptide to target cathepsin L across species. The 
cross-reactivity between anti-L153- 165 antibodies 
and sheep cathepsin L, immobilised in ELISAs 
and on Western blots, and in the enzyme im-
munoinhibition assays (Figs. 3, 5A and 7), con-
firms this expectation. 
Anti-D1l2- 122 antibodies recognized the 
peptide as well as whole human, porcine and 
bovine cathepsin D enzymes, immobilised on mul-
tititer wells (Fig. 4). Nevertheless, the colour took 
a relatively long time (about 1 h) to develop in the 
ELISA assay against immobilised whole enzymes. 
There is evidence (Van Regenmortel, 1988b) that 
proteins become partially denatured or undergo 
conformational changes when adsorbed to solid 
phases, so the slow colour development may indi-
cate that anti-D112-122 antibodies recognize the 
partially denatured enzymes only weakly or that 
only a small percentage of the enzyme adopts a 
conformation suitable for antibody binding. The 
antibody clearly recognizes the native form of 
human cathepsin D, as evidenced from the compe-
tition ELISA results (Fig. 6), but does not target 
the fully denatured enzyme on a Western blot. It 
may be inferred, from these results, that the epi-
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tope in the native enzyme. recognized by anti-
0112-122 antibodies, may be a continuous but 
conformationally specific epitope which is de-
stroyed by reducing SOS-PAGE. Consideration of 
the 3-D structure of penicillinopepsin reveals a 
prominent spiral turn in the region corresponding 
to the 0112-122 sequence and suggests that this 
may constitute such a conformational epitope. 
Conjugation of the peptide 0112-122. to KLH, 
was effected through its C terminus. since these 
residues appear to be less accessible in the native 
protein; a situation which may therefore be 
mimicked in the conjugate by the presence of the 
carrier protein. The more exposed N terminal 
residues proved to be antigenic and the resulting 
anti-peptide antibodies were able to bind to the 
native protein, but were not able to inhibit the 
enzyme. The paratope-epitope interaction is possi-
bly too distant to occlude the substrate binding 
cleft. 
From a methodological point of view it is of 
interest that although peptide 0112-122 is largely 
hydrophobic, and was initially insoluble in all 
solvents tested except 8 M urea, it remained in 
solution after subsequent removal of the urea and 
could successfully elicit antibodies able to recog-
nize the native enzyme. The significance of this is 
that many enzymes apparently have hydrophobic 
binding sites. From the results obtained using 
peptide 0112- 122, it would appear that genera-
tion of peptide antibodies against such hydro-
phobic sites is not impossible. 
Omission of the CB4 C terminal Lys-residue 
(Hoyhtya et aI., 1988), in COL476-490, used in 
the present study, ensured glutaraldehyde conju-
gation exclusively via the N terminus. This presen-
tation, exposing the more hydrophilic C terminus, 
proved to be sufficiently immunogenic to elicit 
anti-peptide antibodies which are able to interact 
with native type IV collagenase from human 
leukocytes in immunoaffinity purification. This 
result confirms the finding of Hoyhtya et al. (1988) 
that the anti-CB4 antibody specifically im-
munoprecipitated native type IV collagenase from 
a mixture of metalloproteinases secreted by hu-
man melanoma cells and also recognized the dena-
tured proteinase (Mr 68,000) on Western blots 
following SDS-PAGE. Targeting of a 67,000 band 
on a Western blot by anti-CB4 antibodies was also 
used by Spinucci et al. (1988) to positively identify 
the proteinase purified from c-Ha-ras oncogene 
transformed mouse NIH 3T3 fibroblasts. In the 
present study anti COL476-490 antibodies simi-
larly recognized the denatured Mr 66.000 pro-
teinase from human leukocytes (Fig. SB). From 
these results it may be inferred that these anti-
peptide antibodies recognize native and denatured 
type IV collagenase from both normal (leukocyte) 
and malignant (melanoma) human sources as well 
as oncogene transformed mouse NIH 3T3 fibro-
blasts. 
From this study it is clear that there is as yet no 
reliable basis on which to predict which pep tides 
will sucessfully elicit antibodies capable of recog-
nising the native target protein. Consideration of 
the 3-D structure, when this is available, appears 
to be the most promising approach and was suc-
cessful with cathepsin L, though not with cathep-
sin B. It will be interesting, in future, to further 
explore the structures of cathepsins B and D with 
a view to finding inhibitory peptide antibodies to 
these proteinases. 
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Colloidal gold particles of different size (3-20 nm in 
diameter) were prepared by tannic acid-citrate and ci-
trate reduction methods. From these colloids, different 
probes were prepared using sheep anti-rabbit antise-
rum, sheep anti-rabbit IgG, bovine serum albumin, 
polyethylene glycol, and protein A as the primary stabi-
lizers and polyethylene glycol and/or bovine serum al-
bumin as secondary and tertiary stabilizers, in differ-
ent combinations. The probes were analyzed by 
isoelectric focusing in agarose gels, which allow the mi-
gration of particles in the size range 3-20 nm. (P. 
Sewer and S. J. Hayes, 1986, Anal. Biochem. 158,72-
78). Isoelectric focusing revealed that the surface 
charge of colloidal gold probes is dependent upon the 
size of the gold particle, the reduction method used, the 
primary ligand, and the pH at which this is adsorbed, 
as well as upon the secondary and tertiary stabilizers 
used. It is proposed that such differences in surface 
charge may underlie the different results which may 
sometimes be observed in colloidal gold labeling, es-
pecially when novel ligands are used. © 1990 Academi~ 
Press, Inc. 
Colloidal gold particles, commonly with a diameter of 
about 3-30 nm, to which suitable ligands are adsorbed, 
may be used as probes, typically for determining the ul· 
trastructural distribution of target molecules of interest 
(1,2), although they also find application in the analysis 
of Western blots (3), for example. Most commonly, im-
munoglobulins are adsorbed to the gold particles, 
thereby forming immunogold probes (1,4), but other Ii· 
gands such as protein A (5), lectins (6), peptide hor-
mones (7), etc, have also been successfully used. When 
)ptimally adsorbed, the ligand also protects the colloid 
19ainst salt-induced aggregation and thus constitutes 
;he primary stabilizer (8). 
I To whom correspondence should be addressed. 
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Optimal irreversible attachment of the ligand to the 
gold particle is thought to require multipoint contacts, 
which are favored by the use ofthe minimum concentra-
tion of ligand which will nevertheless stabilize the colloi-
dal gold against an electrolyte challenge (8). At this min-
imum concentration, the ligand might not coat the 
entire surface of the gold particles and a further protein, 
such as BSA,2 or a polymer such as polyethylene glycol, 
is required to additionally stabilize the colloid. If they 
were not quenched3 by the secondary stabilizing agent, 
exposed portions of the gold surface might also bind non-
specifically to components of the sample being probed. 
Finally, to prevent aggregation of coated particles, espe-
cially during centrifugation, the probes are normally 
stored in a tertiary stabilizing solution, usually of 1 % 
BSA or polyethylene glycol (8). 
Although colloidal gold probes have been successfully 
prepared with ligands of relatively large molecular 
weight, such as immuno'globulins (Mr 160,000) or pro-
tein A (Mr 42,000), we have encountered unexpected 
difficulties in our (unpublished) efforts to make probes 
for tissue proteinases, using relatively small proteinase 
inhibitors (Mr ca. 12,000) as ligands. The proteinase in-
hibitors successfully stabilized the colloids against an 
electrolyte challenge, but we were unable to prepare 
functional, specific probes. On Western blots and dot 
blots, blocked with different agents, probes prepared in 
different ways either targeted both the proteinase and 
certain standard proteins (lysozyme and carbonic anhy-
drase) or failed to target any proteins. The former obser-
vation suggested that residual binding sites may be inad-
2 Abbreviations used: BSA, bovine serum albumin; PEG, polyethyl-
ene glycol; SaR, sheep IgG anti·rabbit IgG; PBS, phosphate-buffered 
saline; TBS, Tris·buffered saline; IEF, isoelectric focusing; TA, tannic 
acid. 
3 Colloidal gold probes may be used to analyze dot blots and Western 
blots, for example, and the term "quenching" (9), in reference to sec-
ondary stabilization of the colloidal part;icies, is preferred to the term 
"blocking." which may be confused with blocking of sites on the blot-
ting membrane. 
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equately quenched, while the latter suggested that, by 
steric hindrance, the primary ligand may be masked or 
the ligand may be displaced from the gold particle. It 
must be realized that the stabilizing and quenching pro-
teins are of about the same size as the gold particles (10) 
and the numbers of each bound may be a function of 
particle size. In some cases this may lead to inadequate 
quenching. The relative sizes of the ligand and quench-
ing agents may also be relevant in masking. 
In an attempt to explore these obseryations further, 
we were motivated to find a way of analyzing differences 
in the surface properties of colloidal gold probes of 
different size, prepared and stabilized in different ways, 
with the ultimate objective of ascertaining whether the 
conditions of adsorption, stabilization, and storage could 
be manipulated to produce functional probes with a 
greater specificity. 
Electrophoretic studies on proteins in solution, and 
bound to colloids, indicate that the charge on a colloid is 
usually obscured by the adsorbed layer of protein (11-
13). Electrophoretic mobility is a function of the charge 
exposed in the shear layer of adsorbed protein (11) . The 
charge on the underlying colloid may, however, have an 
indirect influence on electrophoretic mobility by influ-
encing the orientation in which proteins are adsorbed. 
Isoelectric focusing is a technique commonly used to an-
alyze the surface charge properties of proteins and we 
report here on an extension of this technique to a study 
of the surface charge properties of protein -coated colloi-
dal gold probes. 
MATERIALS AND METHODS 
Chemicals. Protein A (Catalog No. P6031) was ob-
tained from Sigma (St. Louis, MO), chloroauric acid 
(Catalog No. 1582) and Coomassie blue R-250 from 
Merck (Darmstadt, West Germany), general chemicals 
(AR Grade) and polyethylene glycol (PEG 6000 and 
20,000) from BDH Chemicals (Poole, u.K.), and bovine 
serum albumin (BSA, fraction V preparation) from 
Boehringer (West Germany). Unless otherwise stated, 
all reagents were made up using water purified by reverse 
osmosis in a Millipore R/Q water purifier; this is referred 
to as "distilled H 20." 
Reagents. For the 10% BSA quenching solution, 1 g 
BSA was dissolved in 20 mM Tris (10 ml), adjusted to 
pH 8.2 with NaOH, and filtered through a 0.22-J-Lm filter. 
For the 1 % PEG 20,000 quenching solution, 0.1 g PEG 
was dissolved in distilled H 20 (10 m!) and pressure fil-
tered through a 0.22-J-Lm filter. 
IgG was isolated from a sheep anti-rabbit IgG antise-
rum by a modification of the method of Polson et al. 
(14): PEG 6000 was added, to 15% (w/v), to a mixture of 
equal volumes of antiserum and pH 8.6 bora~e bu~er. 
The IgG precipitate was collected by centnfugatIOn 
(7740g, 10 min, 4°C), redissolved in an equal volume of 
0.1 M phosphate buffer, pH 7.0, and reprecipitated with 
PEG 6000 (15% w/ v). The IgG precipitate was dissolved 
in 10 mM Na-phosphate buffer, pH 6.8, and a total of 39 
mg IgG was applied to a hydroxyapatite column (11.0 
X 1.5 cm) and eluted with a gradient of 10-300 mM Na-
phosphate, pH 6.8. The major eluted peak was collected, 
extensively dialyzed against distilled H 20 (4°C) , and 
used for the production of sheep anti-rabbit IgG-gold 
probes (Sa R probes). The absence of PEG in the eluted 
peak was established using Nessler's reagent (14) . 
A total of 32 probes were prepared, as listed in Table 
1. Gold particles 3.5 nm (2- 3.8 nm), 5 nm (4-5 nm), and 
10 nm (10- 12 nm) in diameter were prepared by the tan-
nic acid- citrate method (15) and particles of 10 nm (8-
10 nm), 15 nm (13-18 nm) , and 20 nm (20-22 nm) were 
produced by the modified citrate method (16); these are 
referred to below as T A probes and Cit probes, respec-
tively. 
The titration method of Zsigmondy, as described by 
De Mey (8) , was used to determine the dilution of pro-
tein required for probe production. Endpoints of stabili-
zation against salt aggregation were judged visually (17), 
and were assessed for all probes in one batch procedure. 
Adsorption of the sheep IgG anti-rabbit IgG (SaR) 
fraction to gold particles was effected at pH 7.0 (18), the 
pH of the colloid being adjusted with K 2C03 (25 mM) . 
The determined amount of SaR for probe production 
was added slowly to the relevant colloid, while mixing. 
The IgG and colloid were allowed to interact for 2 min 
and residual protein binding sites on the colloid were 
quenched with either BSA or PEG 20,000 quenching so-
lutions, added to a final concentration of lor 0.05% (wi 
v), respectively (8) . Probes were washed twice in 20 mM 
Tris, pH 8.2, containing either 1 % BSA or 0.05% PEG 
20000 and stored at 4°C (8). Probes 32 and 34 were 
w~shed in 0.01 M phosphate buffer, pH 7.2, containing 
1 % BSA (15) , instead ofthe Tris buffer. "Probes" were 
also prepared omitting the primary ligand. 
Probes were similarly prepared by adsorption of whole 
Sa R serum or BSA (as a primary stabilizing protein) to 
variously sized particles at pH 7.0 and pH 5.5, respec-
tively. Protein A- gold probes were prepared at pH 7.0 
(15). Particles used in the production of protein A probes 
were washed and size-fractionated in a glycerol gradient 
using PBS or TBS buffers, containing 1 % BSA, pH 7.2. 
Isoelectric focusing. Isoelectric focusing was per-
formed using an LKB 2117 Multiphor system. A 1 % aga-
rose (Pharmacia IEF) gel (115 X 250 X 1.0 mm) contain-
ing Pharmalyte pH 3-10 and 12% sorbitol was cast, 
according to the manufacturer's instructions, onto a 
sheet of GelBond, using a sealed mold. The set gel was 
positioned in the Multiphor apparatus and blotted, and 
gold probe samples (20 J-LI) were pipetted into slots (8 
X 5 mm) in an acetate sheet template placed on the sur-
face of the gel, parallel to the cathode wick and about 20 
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TABLE 1 
Immunoprobes Produced" 
SaR (TA-AuJ.s) PEG:PEG 
2 Sa R (TA- Aus) PEG:PEG 
3 SaR (TA-Au lO) PEG:PEG 19 SaR (TA- Au lO) PEG:BSA 
SaR (C it- Au lO) PEG: PEG 20 SaR (Cit- Au IO) PEG:BSA -1 
5 Sa R (Cit- Au ls) PEG: PEG 21 SaR (C it- Au ls) PEG:BSA 
6 SaR (Cit- Au2o) PEG:PEG 22 SaR (Cit-Au2Q) PEG:BSA 
I SaR (TA- AuJs) BSA:BSA 
8 Sa R (TA-Aus) BSA:BSA 
9 Sa R (TA- AulO) BSA:BSA 34 PA (TA-Aulo)p BSA:BSA 
10 S" R (Cit- Au lO) BSA:BSA 32 PA (Cit- Au lO )P BSA:BSA 
11 SaR (Cit- Au,, ) BS.-\:BSA 33 PA (Cit-Au lO ) BSA:BSA 
12 SaR (Cit- Au2o) BSA:BSA 
31 PA (Control) 
35 PA (TA- AulO) BSA:BSA 
13 BSA (TA-AulO) PEG:PEG 
14 BSA (Cit- Auls ) PEG:PEG 
15 PEG (TA- Aulo) PEG:BSA 
16 PEG (Cit- AuIS) PEG:BSA 
17 Nil (TA- Aulo) PEG:BSA 23 Nil (TA- Aulo) BSA:BSA 
18 Nil (Cit- AulO) PEG:BSA 24 Nil (Cit- AulO) BSA:BSA 
25 Sa R..",m (TA- Au lO ) BSA:BSA 
26 Sa R (Control) 
27 Sa R..",m (Control) 
28 SaR".",m (TA-AulO) PEG:PEG 30 Sa R .. ",m (Cit- AulO) PEG:PEG 
29 Sa R .. ",m (Cit-Au lO ) BSA:BSA 
a Abbreviated notation: Probe number-ligand (colloid) quencher:tert iary stabilizer. The notation of Goodman et al. (18) is used to denote the 
gold particle size. Thus Aulo indicates gold particles with a diameter of 10 nm. PA = protein A; Sa R (and Sa R .. ",m) = sheep IgG (or serum) 
anti-rabbit IgG. Probes 32 and 34, marked with a subscript P , were made in phosphate buffer (15); all other probes were made in Tris buffer 
(8) . 
mm from it. Electrofocusing was effected using 10 W at 
10· C, and was completed in about 5- 6 h. The template 
was removed after 35 min. The gels were fixed, washed, 
dried, photographed, stained with Coomassie blue R-
250, and photographed again. Before staining, stable 
probes appear red while destabilized probes appear a 
light blue. After staining, proteins not adsorbed to 
probes appear deep blue, while the stable probes re-
main red. 
RESULTS 
"Naked" gold colloids (to which no stabilizing pro-
teins were adsorbed) rapidly become destabilized on ex-
posure to agarose, containing ampholytes. Stabilized 
gold colloids, however, could be successfully evaluated 
by agarose IEF and yielded reproducible results for each 
probe, although the results changes slightly with the age 
of the probe. The results suggest that the apparent 
charge on the stabilized probes is influenced by the 
methods of preparation, stabilization, quenching, and 
storage of the probes, as well as by the size of the gold 
particles. 
Effect of the size of gold particles. Particle size ap-
pears to have a marked effect on the electrophoretic 
properties of otherwise comparable probes. Smaller gold 
probes (3.5 and 5.0 nm) generally focused to a lesser ex-
tent (Fig. 1, tracks 2, 3, 11, and 12). Although there are 
differences between probes prepared by different meth-
ods, probes 4-6 (Fig. 1, tracks 7-9) and probes 7- 9 (Fig. 
1, tracks 11-13) show a trend of greater anodal migration 
with smaller particle size. 
Effect of method of colloid production. The effect of 
the reduction method used in producing the colloid is 
shown by comparing probes of a similar size, i.e., probe 
3 (Fig. 1, track 4) with 4 (Fig. 1, track 7) and probe 9 (Fig. 
1, track 13) with 10 (Fig. 1, track 16). These comparisons 
reveal some marked differences and that, in general, for 
10-nm particles, TA probes give more and more clearly 
defined bands than the equivalent Cit probes. 
The SaR (TA-AulO) probe, quenched and stored in 
PEG (probe 3; Fig. 1, Track 4), exhibits a definite band 
at approximately pH 5.8, close to the position of the 
main band in the SaR IgG fraction used in production of 
the probe (Fig. 1, arrowheads). Although the equivalent 
citric acid probe (probe 4; Fig. 1, track 7) gives a very 
different overall result, a similar, faint band is neverthe-
less discernible. The electro focusing patterns for differ-
ently produced BSA-quenched probes (probes 9 and 10) 
(Fig. 1, tracks 13 and 16), however, appear generally sim-
ilar to each other. 
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FIG. 1. Effect of particle size, quenching, and stabilizing agents upon agarose gel isoelectric focusing of gold probes. Particles of different size 
(3.5-20 nm) , quenched and stored in either 0.05 <C PEG 20,000 or 1 % BSA, are shown in tracks 2- 4 and 7- 9 and tracks 11- 13 and 16-18 
re~pectively . Protein bands were revealed by subsequent staining with Coomassie blue R-250: for clarity the gel is shown before staining. I~ 
this and subsequent figures, the approximate focused positions of standard marker proteins, myoglobin (pI 6.8), carbonic anhydrase (pI 6.0) , 
and ovalbumin (pI 4.5-4.9) are indicated by arrows and the position of the main band of unbound SaR IgG is indicated by arrowheads. Numbers 
above each figure represent "track" numbers and those below indicate the identity of the probes (Table 1). 
Effect of ligand and secondary and tertiary stabilizing 
agents. SaR-gold probes quenched with PEG 20,000 
and stored in 0.05% PEG 20,000 in Tris (Fig. 1, tracks 
2-4 and 7-9), show fewer focused bands than those 
quenched and stored in 1 % BSA in Tris (Fig. 1, tracks 
11-13 and 16-18). SaR-goldprobes quenched with BSA 
show well-defined bands at approximately pH 6.0 and 
5.5 and a faint band at pH 5.8, a band that seems to be 
common to most of the SaR-gold probes (Figs. 1, 2 and 
3). A large diffuse band also occurs on the alkaline side 
of pH 6.8 in these probes. This band is more defined in 
the 10-nm TA probes (Fig. 1, tracks 4 and 13) than in 
the 10- to 20-nm citric acid probes (Fig. 1, tracks 7-9,16, 
17, and 18). 
Used as a quenching agent, BSA is usually added at a 
pH of 9.0, after the adsorption of the primary protein. 
To gain some insight into the interaction of BSA with 
gold probes at higher pH, it was added at pH 8.2 to "na-
ked" colloidal gold. The resultant probes (probes 23 and 
24) were washed and stored in BSA. The IEF results 
(Fig. 2, tracks 18 and 14) may be compared to those from 
the equivalent SaR probes (probes 9 and 10; Fig. 2, 
tracks 11 and 12). Similar focusing patterns were ob-
served, except that the band in the pH 5.8 region is less 
dominant than in the SaR-gold probes. 
In an attempt to identify the level of influence of the 
tertiary stabilizers, the IEF patterns of SaR probes (Fig. 
2, tracks 3, 4, 5, 6, 7 and 8) and probes without a primary 
protein adsorbed (Fig. 2, tracks 13 and 14), quenched, 
washed, and stored with either BSA or PEG, were com-
pared. The substitution of PEG with BSA, as a "stor-
age" or tertiary stabilizer, results in movement of the 
main group of diffusely focused bands to a more acidic 
position (Fig. 2, tracks 3-8)_ Substitution of BSA for 
PEG as a secondary stabilizer in the BSA-stored probes, 
in which no primary protein has been adsorbed, has the 
opposite effect (Fig. 2, tracks 13 and 14). 
The effect of BSA, added as the primary stabilizer, 
may be assessed by comparing probes 13 and 14. In pro-
ducing these probes, the BSA was adsorbed at pH 5.5, 
i.e., 0.5 pH unit above its pI, and the probes were 
quenched and stored in PEG. These probes produced 
bands focused in the pH 4.5-4.7 region (Fig. 3, tracks 2 
and 3), corresponding to the region where the unbound 
BSA protein focused (Fig. 3, track 1). This was markedly 
different from the pattern produced when the BSA was 
added to a naked gold probe, at pH 8.2, as a secondary 
stabilizing agent (Fig. 2, tracks 14 and 18). 
Generally, IgG and "serum" probes produce similar 
patterns. Probes produced from whole SaR serum, (Fig. 
3, tracks 8-11) appear to give focusing pattern similar to 
those produced by the SaR IgG equivalents (Fig. 1, 
tracks 4, 7, 13, and 16). A different pattern is, however, 
observed in the focusing of the protein A-gold probes. 
Though only BSA -quenched and stored probes were 
made with this protein, the main focused bands (Fig. 3, 
tracks 13-15) were different from that of the unbound 
protein A (Fig. 3, track 7). In the citric acid probes only 
(Fig. 3, track 13 and 14) diffuse bands occurred in the 
more acidic region. A more dense, diffuse band occurred 
in the probes in which Tris buffer was used in the final 
washing steps (Fig. 3, track 14) than observed when PBS 
was used (Fig. 3, track 13). The tannic acid equivalent, 
however, shows a large diffuse band alkaline to pH 6.0 
(Fig. 3, track 15). These results suggest that both the 
method of colloid production and the buffers commonly 
used in the production of gold probes could affect the 
surface characteristics and hence, possibly, also the 
binding properties of gold probes. 
DISCUSSION 
The structure and stability of gold colloids and colloi-
dal gold probes have been discussed by De Mey (8) and 
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FIG. 2. Agarose ge l isoelectric focusing of SaR-gold probes. The effect of the storage conditions (tertiary stabilization) of 10- and 15- nm 
PEG-quenched probes is shown in Tracks 3-8. The effect of the method of preparation of the colloidal gold (10 nm) is shown in tracks 11 and 
12. The effect of secondary stabilizers, PEG vs BSA, applied to ··naked" gold probes is shown in tracks 13, 14, and 17-20. Tracks 11 and 12 
show the patterns given by probes 9 and 10 when these were 2 months old: comparable patterns, for the same probes at 1 week old, are shown 
in Fig. 1, tracks 13 and 16. The sample application template was repositioned on the gel before it was photographed, in this case. 
Horisberger (19)_ As demonstrated in this study, isoelec-
tric focusing of colloidal gold probes is able to reveal 
differences in the interaction of proteins with colloids of 
different size, and with colloids produced using different 
methods, at different pH, and in combination with 
different quenching agents. A knowledge of these 
differences could provide insight into differences in the 
labeling behavior of the different probes. 
Why do probes focus isoelectrically and what does this 
indicate? If the interaction of the adsorbed protein with 
the gold particle was totally random, in terms of the ori-
entation of the adsorbed proteins, it would be antici-
pated that no focusing would occur. If the number ofpos-
sible orientations was limited and the number of 
proteins adsorbed was very small (e.g., one protein mole-
4 6 7 8 9 10 11 12 13 14 15 
13 14 15 16 31 28 30 25 29 32 33 35 
FIG. 3. Agarose gel isoelectric focusing of BSA probes, serum 
probes, and protein A probes. Tracks 2 and 3 illustrate the effect of 
BSA adsorbed (at its pI) to gold colloid as a primary stabilizing pro-
tein. This may be compared to "naked" colloid, blocked with PEG and 
stored in BSA (tracks 4 and 5). Results from probes made with whole 
SaR",rum are shown in tracks 8- 11, and from protein A probes in tracks 
13-15. Leakage of proteins from SaR",rum gold probes and BSA gold 
probes was revealed by subsequent staining of gels with Coomassie 
blue R-250. Tailless arrowhead indicates focused position of unbound 
BSA. 
cule per particle), then focusing into a finite number of 
bands might be anticipated. On the other hand, if the 
number of molecules adsorbed was small, the charge of 
the underlying colloid might predominate and give rise 
to a general anodal drift, without focusing. The exposed 
parts of the colloidal particles might also adsorb various 
ampholyte molecules which would cause focusing over a 
spectrum. If a larger number of protein molecules were 
adsorbed, focused bands might also be expected if the 
number of orientations of adsorbed proteins were lim-
ited and if all molecules adsorbed to a given gold particle 
had the same orientation. An interesting question which 
arises from this is whether all bands would represent 
functional probes or whether, on some, the ligands might 
be inappropriately orientated. 
In this study, adsorption of proteins to the negative 
gold colloid seemed to decrease, or leave unaltered, the 
observed isoelectric point of protein adsorbed at its pI or 
about 0.5 unit above. The BSA probes show focused 
bands corresponding to the pI values of the free protein, 
whereas the pI of adsorbed SaR (IgG) appears slightly 
decreased. This suggests that most of the charge on the 
adsorbed proteins is exposed in the shear layer. Experi-
ments with nonionic and ionic surfactants of similar 
chain length have shown that the compound least solu-
ble and nonionic was bound to colloidal gold in greater 
proportion (20). If hydrophobic interactions predomi-
nate in this way, the bound proteins may be orientated 
in such a way as to expose their hydrophilic, ionic resi-
dues in the shear layer, creating the observed pI. This 
would explain why the observed pI's of the adsorbed pro-
teins agree with those of unbound proteins in these 
cases. In cases where a different pI is obtained upon ad-
sorption, this could be due to a different orientation of 
the bound protein. Ribonuclease, adsorbed to various 
negatively charged colloid systems, such as glass, Dowex 
resins, and Nujol, manifests a pI higher than when un-
bound (21) . Similarly, orientation differences may ex-
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plain the different bands produced when BSA is ad-
sorbed at its pI or at pH 8.2. 
Small gold probes (3.5 and 5 nm) generally focused 
more diffusely than larger probes. On average, an esti-
mated 1.6 antibody molecules [3.6 nm in diameter 
(10,11)] may be adsorbed onto the surface of a 3.5-nm 
gold probe (22). This number of protein molecules may 
be too small to focus the probe adequately. The presence 
of BSA, as a quenching agent, also failed to produce the 
usual distinctive pattern, suggesting that the probes may 
also be inadequately quenched.4 Because of the equiva-
lent size of the small gold particles and the ligand and 
quenching proteins (10), perhaps only a very few of the 
latter can bind. Exposed residual binding sites on the 
colloid surface may interact, with the ampholytes or aga-
rose, giving the diffuse patterns. Such interactions could 
explain the observed nonspecific interaction of small 
gold probes with cytoskeletal entities (23). Perhaps the 
use of smaller quenching molecules may be advanta-
geous with smaller gold particles. 
The way in which the gold colloids are produced may 
affect their surface character and the subsequent focus-
ing of probes. Equivalent probes, with the same protein 
ligand, made from differently produced colloids, focus 
differently.4 This may explain reports of variations in 
the nonspecific binding (23) and labeling affinities (19) 
of gold probes made from differently produced colloids. 
The surface structure of gold particles may also be rel-
evant. Colloidal gold particles are roughly spherical, but 
have surface aberrations thought to result in van der 
Waal's forces that favor protein adsorption (8). Stepwise 
irregularities in shape are larger in larger colloids, which 
may result in greater, and more specific, adsorption of 
protein to these specific sites. Specifically oriented ad-
sorption, via specific amino acid residues or sequences, 
may result in more dominant focused bands. The diffuse 
focusing of smaller probes may, similarly, be explained 
by their more uniform surface charge, a consequence of 
their more regular shape. Random adsorption to the reg-
ular colloid surface may lead to more diffusely focused 
bands. 
Certain bands seem to recur in the electrofocusing 
patterns of probes of different size to which different 
proteins have been adsorbed, suggesting the existence 
of a common surface feature, expressed more or less in 
probes of different size. The use of PEG to quench 
probes, however, seems to obscure differences and re-
sults in a smearing of bands. How this correlates with 
the specificity and labeling characteristics of PEG-
, A referee has suggested that the different behavior of colloids pro-
duced by the citrate-tannic acid method may be due to the adsorption 
of residual TA polymers to the gold surface (15). It is suggested that 
these should be removed by treatment with H. O. before adsorption of 
the ligand. 
quenched probes, relative to BSA-quenched probes, re-
mains to be established. 
It may be difficult to assess which focused bands arise 
from the adsorption of the primary adsorbed protein and 
which are the result of interactions of the quenching 
molecules, either with the colloid itself or with the pri-
mary layer of adsorbed protein. When BSA is added as 
a quenching agent, it seems that it binds directly to re -
sidual protein binding sites on the gold probe. BSA, 
added at pH 8.2, in the presence or absence of the pri-
mary adsorbed protein, focuses similarly, suggesting 
that the BSA binding sites are independent of the pri-
mary ligand protein. Interactions of the storage or terti-
ary stabilization molecule, with the primary and quench-
ing agents, seem to take place in certain instances. BSA, 
introduced at a tertiary level, seems to change the sur-
face characteristics of PEG-quenched probes and hence 
may alter their labeling activity. It may therefore, be un-
wise to dilute PEG-stabilized probes in buffer contain-
ingBSA. 
There is evidence that -SH and -S-S- groups react 
with gold surfaces (24). BSA has three main domains 
containing 9 loops (25) in which 17 disulfide bridges and 
a free cystine occur (26). BSA has a more extended struc-
ture at high pH than at its pI (27), and the many bands 
produced by probes with BSA adsorbed at pH 8.2 
(probes 7-12, 23, 24, 28, and 29) may be a reflection of 
the different ways in which the extended protein may be 
adsorbed via sulfur-containing residues. A hypothetical, 
ideal IEF result would have a single, strong band corre-
sponding to the specific ligand and representing an ac-
tive probe. Such a result may be possible only with non-
protein quenching and stabilizing agents specifically 
engineered for the task. 
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